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Driven by the lack of literature on the potential of functionalized isoindigos as anti-
proliferative agents, the aim of this thesis was to investigate medicinal chemistry approaches 
towards the design and synthesis of functionalized isoindigos with enhanced potency and 
pharmaceutically friendly profiles. Six series of compounds comprising of 93 isoindigo 
analogues have been synthesized in this project. 
Initially, it was hypothesized that a structure-based approach based on the reported 
CDK inhibitory activity of meisoindigo would be a meaningful way of designing analogs with 
improved anti-proliferative activity. However, an unexpected finding in the early stage of the 
project was that meisoindigo failed to inhibit CDK2.  A similar result was obtained by an in 
silico molecular dynamics study. Hence, a phenotypic approach was adopted for biological 
evaluation. The synthesized compounds were evaluated for growth inhibitory activities on a 
chronic myelogenous leukemia cell line (K562).  
The key features of the potent analogues associated with growth inhibitory properties 
are (i) intact exocyclic double bond; (ii) presence of at least one amidic NH group; (iii) 
substitution at position 6 /6’ with methoxy group; (iv) a 1-(phenpropyl) or 1-(4-
methoxyphenpropyl) side chain if ring A or B of the scaffold is not substituted and (v) a 1-(4-
methoxyphenethyl) side chain if ring B is substituted with 6’-methoxy. 4-5 (IC50 = 0.50µM) 
which is more than 15 fold more potent that meisoindigo (IC50 = 7.75µM) was identified as 
the most potent analogue from the library. 4-5 has outstanding selectivity profiles which 
exceeds that of meisoindigo. However it is hampered by its high lipophilicity (ClogP = 4.8) 
and poor aqueous solubility (22 µM). 
 An important modification undertaken in Series F is the introduction of polar 
features that would improve the poor solubility of the scaffold. Compound 6-4 was observed 
to have excellent solubility (≥ 400 µM) while achieving significant improvement in 
antiproliferative activity (IC50 3.97 µM). 
 xiii 
In the subsequent mechanistic studies, 4-5 caused G2 arrest and apoptosis of K562 
cells at its IC50 concentration. Meisoindigo on the other hand was not found to cause cell 
cycle arrest at its IC50 concentration but apoptosis was observed. The soluble analogue 6-4 
was observed to behave like meisoindigo. 
 Given significant advances in potency for 4-5 and aqueous solubility for 6-4, the two 
compounds were evaluated on nude mice bearing K562 xenografts. The results indicated that 
in spite of its potent in vitro activity, 4-5 failed to extend survival times of the xenograft 
bearing mice or significantly reduced the tumour volume In contrast, the analog with 
improved aqueous solubility 6-4 resulted in significant improvements in both survival times 
and tumor size. In line with the objectives of this thesis, structural modifications of 
meisoindigo has led to 6-4 with improved in vitro / in vivo activity as well as a more desirable 
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Chapter 1: Introduction 
1.1. Indigoids 
Indigoids are a class of compounds with the bisindole framework. There are three 
isomeric bisindoles – indigo, indirubin and isoindigo which are of pharmaceutical and 


















Indigo Indirubin Isoindigo  
Figure 1-1: Structures of Indigo, Indirubin and Isoindigo 
 
Indigo and its di-bromo derivatives are unique dyes that have been used since 
antiquity. They are extracted from plants of various genus such as Indigofera and snails 
(“blue snails”) of the family Muricidae.  In contrast to indigo, indirubin is not used as a textile 
dye, in part due to its propensity to convert to indigo during processing.1 It has, however, been 
found to be a pharmacologically active scaffold associated with anti-cancer activity.  Several 
functionalized indirubins have been investigated for their effects on key pathways involved in 
tumorigenesis.2  The serendipitous discovery of the anticancer properties of indirubin is well 
documented in the literature.2-4 Briefly, it is the outcome of a detailed investigation initiated 
by the Chinese Academy of Medical Sciences on the efficacy of a traditional Chinese herbal 
prescription, Danggui LongHui Wan
for chronic myelogenous leukemia 
(CML). Analysis of the complex herbal mixture narrowed activity to one ingredient – a blue 
powder (Qing Dai, indigo naturalis) which contained a large amount of indigo. Unusually, 
anti-leukemic activity was not due to indigo but its isomer indirubin (“red indigo”) which is a 
minor constituent of the mixture. Indirubin and its derivatives were subsequently found to be 
potent inhibitors of cyclin-dependent kinases and to block cell proliferation by arresting the 
cell cycle.2  Notably, indirubin derivatives such as 5-chloroindirubin, indirubin-5-sulfonate 
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and indirubin-3’-oxime (Figure 1-2) are potent inhibitors of CDK1, CDK2 and CDK5.2, 5-7  In 
other reports, derivatives of indirubin-3’-oxime were found to target CDK5 and GSK3β.6, 8  
They also induced apoptosis9, caspase independent cell death10 and activate the aryl 
hydrocarbon receptor (AhR) pathway11. These properties triggered strong interest in the anti-
cancer potential of indirubins and led to the initiation of clinical trials on the efficacy of 
indirubin for the treatment of CML.12 These trials, which were carried out in the People’s 
Republic of China, highlighted several shortcomings of indirubin, notably its poor water 
solubility which significantly affected bioavailability when given at high doses.3, 13  It also 
caused gastrointestinal effects such as severe and persistent nausea, vomiting, abdominal pain, 
diarrhoea and gastric hemorrhage.12, 13 In view of these adverse effects, indirubin is no longer 
































Figure 1-2: Structures of selected indirubins with kinase inhibitory properties.  
 
1.2. Structural modifications to improve the aqueous solubility profile of indirubins 
The poor water solubility of indirubin is traced to the extensive array of hydrogen 
bonds that exist in its solid state. The crystal structure of indirubin revealed that the two 
halves of the molecule deviated only slightly (4o) from planarity, thus giving the whole 
molecule the conformation of a flat V. 15 Intramolecular hydrogen (H) bonding occurs 
between NH and C=O groups (distance of 2.70 Å between O2 and N1’ -H). (Figure 1-3) There 
is also a non-H bonding interaction between the non-amide carbonyl O (O3’) and C4 –H due to 
their close proximity (3.01 Å).  Together, these forces serve to lock the molecule in a planar Z 
configuration. The E configuration of indirubin has not been observed.  
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Figure 1-3: Intramolecular hydrogen bonding in indirubin15 drawn using MOE software.  
 
The crystal structure of indirubin also reveals extensive intermolecular H bonding 
between the carbonyl oxygen atoms and hydrogen atoms of NH groups not involved in 
intramolecular H bonding. Hydrophobic interactions between the aromatic rings further 
cement the molecules in the crystal structure and contribute in no small measure to the high 
melting point and poor aqueous solubility of indirubin.  Lipinski described compounds such 
as these which are insoluble due to tight crystal packing as “brick-dust”.16   
Recognizing that the poor solubility of indirubins is a major obstacle to the further 
development of the scaffold, considerable efforts were directed towards developing analogs 
with increased (but not excessive) water solubility that would permit optimal cell 
permeation.17, 18 One approach was to introduce polar groups like 5-methoxy or 5-
dimethylsulfonylamino to the core scaffold. Another was to convert the non-amide carbonyl 
to the more polar oxime which can be further functionalized by appropriate O-substitution 
with polar moieties. A novel idea by Jautelat and co-workers was to introduce a quaternary 
centre at the 3’ position in an effort to disrupt the planarity (and hence reduce intermolecular 
interactions) of the indirubins.18 Figure 1-4 shows some of the more successful analogs that 
combine moderate to good aqueous solubility with potent CDK2 inhibitory activities and anti-









Solubility in water: 42 mg/L 17
IC50 (MCF-7) 1.2 µM







Solubility in water: 1.6 mg/L 17
IC50 (MCF-7) 0.1 µM









Solubility in water: 520 mg/L 19











Solubility in water: > 40 mg/L 18
IC50 CDK 2: 0.07 µM  
Figure 1-4: Selected indirubins with potent CDK2 inhibition. 17-19 
 
1.3. Meisoindigo 
To address the poor solubility of indirubin, scientists in the People’s Republic of 
China sought new indirubin-like agents.  They found meisoindigo (1-methylisoindigo, 
	) (Figure 1-5) to be a suitable substitute with higher efficacy and lower toxicity than 
indirubin in patients with CML.3, 20 However, meisoindigo is still poorly soluble in water and 
it is questionable if its reported efficacy stemmed from better bioavailability. There is more 
evidence to support the tolerability of meisoindigo in patients. Side effects encountered with 
its use are mild and limiting.12 Chen and co-workers noted that a CML patient was treated 
with meisoindigo (50 mg daily) for nearly 15 years with no overt side effects.21 The drug 
however failed to bring about a complete cytogenic response in the patient which was 
achieved only when he was given imatinib.21 
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Figure 1-5: Structure of Meisoindigo (1-methylisoindigo, 1-2) 
 
1.4. Structural modifications to improve the aqueous solubility profile of isoindigos 
1.4.1. The isoindigo scaffold 
 
As in the case of indirubin, the poor solubility of isoindigo is attributed to the tight 
packing in the crystal structure due to strong intermolecular forces between the molecules.  
Before discussing the intermolecular interactions in isoindigo, stereochemical aspects of the 
molecule are briefly discussed. 
Isoindigo [3,3’–bisindole or (E)-(3,3'-bisindolinylidene)-2,2'-dione] has C2h rotational 
symmetry due to the double bond linking the two oxindole rings. (Figure 1-6A) In view of 
rotational symmetry, S1 and S2 (Figure 1-6B) are similar – they are both 5-chloroisoindigo. 
In meisoindigo, the methyl group is attached to N1. S3 (Figure 1-6C) is 5-chloro-1-

















































The crystal structure of isoindigo was published in 1960 22  and it shows that the 
molecule is planar.  More recently, the planarity of 1,1’-dibutylisoindigo was established from 
its crystal structure.23 Both reports confirmed the E configuration of the central C=C bond in 
isoindigo. No intramolecular H bonds are evident in isoindigo but there is intermolecular H 
bonding, involving the carbonyl oxygen atoms and the amide H atoms of adjacent molecules. 
The C=O…H-N distance was reported to be 2.81 Å.22 Intermolecular H bonding is absent in 
1,1’-dibutyl isoindigo but the authors noted a weak intramolecular interaction between C4 –H 
and the oxygen atom O2’ of the carbonyl group, as well as C4’–H and O2. (Figure 1-7). The 
distance was found to be 2.05 Å with a subtended angle of 137°.23 The authors proposed that 
these interactions serve to preserve the planar conformation of 1,1’-dibutylisoindigo.23 Very 




Figure 1-7: Structure of 1,1’-dibutylisoindigo drawn using MOE-2008 software 
 
 It is possible that isoindigo is more soluble than indirubin because none of the 
carbonyl and NH moieties in isoindigo are involved in intramolecular H bonding. Thus they 
would be accessible to solvation by water molecules. A preliminary assessment of the 
predicted aqueous solubilities of indirubin and isoindigo suggests that this may be the case 
(Table 1-1) 
 
Table 1-1:  Aqueous solubilities of indirubin and isoindigo (pH 7.4) estimated by ACD/Labs 
Version 12.  
 Aqueous solubility, pH 7.4 
 Moles per L Milligram per mL 
Indirubin 3.4 x 10 -5 0.0089 
Isoindigo 6.2 x 10 -5 0.016 
 
When the geometry of isoindigo was investigated using a commercial molecular 
modeling software (Molecular Operating Environment, version 2008.10; MOE), our own 
experience showed that the energy minimized configuration of isoindigo was not planar but 
skewed (Figure 1-8). A skewed conformation would imply the presence of a chiral axis at the 
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central double bond and accordingly, the presence of enantiomers (atropisomers).  The non-
planarity of the isoindigo scaffold has also been noted by other investigators using density 
functional theory measurements. 24, 25  They proposed that the small energy difference 
between the configurations was possibly due to a shallow energy minimum.25 Consequently, 
the configurations are dynamically interchangeable when the molecule vibrates, reducing the 
likelihood of enantiomers.25  Moreover, the crystal packing effect would force the slightly 
skewed molecules to become planar in the solid state24 and this would explain the planar 
isoindigo scaffolds observed by others. 22,23 
  
 
Figure 1-8: Planar and skewed configurations of the isoindigo 
 
 
Figure 1-9: Geometric isomers of isoindigo (A) E isomer: distance between C4-H and C4’–H = 
5.88 Å. (B) Z isomer. Distance between C4-H and C4’–H = 0.76 Å.  Distances were 
determined from energy minimized conformers of isoindigo on MOE-2008. 
 







As mentioned earlier, both isoindigo and 1,1’-dibutylisoindigo exist as E isomers.  No 
Z isomer has been isolated and this is to be anticipated given the likely steric clash between  
the C4–H and C4’–H protons and the electrostatic repulsion between the electron rich oxygen 
atoms of the adjacent carbonyl groups in the Z isomer (Figure 1-9). In the 1H NMR spectrum, 
the chemical shifts of the C4-H /C4’-H protons are found at approximately 9.00 ppm, due to 
their proximity to the electronegative oxygen of the carbonyl moiety. The characteristic 
downfield shift of the C4–H protons serves as a convenient means of confirming the E 
configuration of the synthesized isoindigos described in Chapter 3.  The proximity of C4-H 
and C4’-H protons to the neighbouring carbonyl oxygen atoms may also imply that 
introducing substituent groups at position 4 / 4’ would cause the oxindole rings in isoindigo to 
rotate away from each other to avoid a steric clash. As a result, a loss of planarity can be 
anticipated and this is likely to reduce crystal packing, leading to greater aqueous solubility. 
However, no 4/4’-substituted isoindigos have been reported to date, suggesting that the 
synthesis of these analogs may be difficult. 
 
1.4.2. Analogs of isoindigo designed to overcome the poor water solubility of the scaffold 
Unlike the indirubins, there are relatively few reports on structural modification of the 
isoindigo scaffold, and even fewer that specifically focus on addressing its poor 











Figure 1-10: Structure of Natura® 
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One of the earliest isoindigo analogs to be reported is 1-(β-D-O-
triacetylxylopyranosyl)-isoindigo), also known as Natura ® (Figure 1-10). 26, 27  Natura is an 
N-glycosyl isoindigo and it was designed to increase the bioavailability and bioactivity of 
meisoindigo.26, 27 The patents filed by Wang and co-workers26, 27 showed that the 
antiproliferative activity of Natura slightly exceeded that of meisoindigo in a battery of cancer 
cell lines.  Like meisoindigo, it induced apoptosis, inhibited cyclin dependent kinases and 
effectively arrested tumor growth in mice transplanted with Walker 256 cancer cells.26, 27  
Unusually, Natura was stated to be “almost insoluble in water” 26, 27, which meant that the 
reported improvements in activity were not the result of a more drug-like profile.  Its poor 
solubility is not surprising as all the hydroxyl (OH) groups on the sugar (xylose) are 
acetylated.  Curiously, the deacetylated analog of Natura was inactive, as were analogs where 
other sugars (glucose, arabinose, mannose, ribose) were introduced in place of xylose.26, 27  
A large number of N-glycosylisoindigos were reported by Sassatelli and co-
workers.28, 29  Their compounds have the following features:  
(i) Only one sugar moiety (β-D-glucopyranose) is attached to N1 of the isoindigo scaffold;  
(ii) The OH groups on the sugar are acetylated, benzylated or left unmodified;  
(iii) Substitution at position 5 or 5’.   
The compounds were tested for antiproliferative activities on a panel of cancer cells 
and non-malignant cells to establish selectivity.28, 29 They were also investigated for kinase 
inhibitory activities,29 motivated in part by the association of the dihydroindol-2-one scaffold  
(present in both indirubin and isoindigo) with kinase inhibitory activity.  Their findings are 
summarized as follows:  
(i) The OH groups on the sugar must be benzylated or acetylated in order to display kinase 
inhibitory activity.  
(ii) Analogs with benzylated OH groups on the sugar are generally strong kinase inhibitors (at 
10 µM) but devoid of antiproliferative activity. In contrast, one member (Compound 1, Figure 
1-11)29 with an oxobutanoic side chain at position 5’ weakly inhibited kinases but 
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demonstrated outstanding antiproliferative activity (IC50 < 10 µM). Unfortunately, its potent 
activity also extended to non-malignant cells (murine cell line L929, and a human fibroblast 
primary culture).  The polar oxobutanoic acid side chain of compound 1 may have served to 
counterbalance the lipophilicity associated with the benzylated groups, leading to enhanced 
cell penetration and growth inhibitory activity.29 
     
Figure 1-11: Compound 1 from Sassatelli and co-workers 
 
(iii) The activities of analogs with acetylated OH groups on the sugar vary according to the 
substituent present at position 5. No definite conclusion can be drawn as only a limited 
number of substituents (two) were investigated.29 The 5-bromo analog emerged as the most 
promising (ca 70% kinase inhibitory activity at 10 µM, with selective cytotoxicity against 
cancer cell lines) followed by the compound with no substituent at position 5 (slightly 
cytotoxic but no kinase inhibitory activity). (Figure 1-12) The 5-nitro analog had no effect on  
cell viability or kinase inhibitory activity. 
 
Figure 1-12: Compounds 2, 3 & 4 from Sassatelli and co-workers.29  
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Taken together, the strategy of introducing sugar moieties as substituents on the 
isoindigo core is a logical approach that should serve to enhance solubility. Unfortunately, 
this was achieved at the expense of biological activity. Analogs with protected OH groups 
(benzylated or acetylated) were active but the problem of poor solubility has not been solved 
and may even be aggravated in these analogs. 
The synthesis of functionalized azaisoindigos is another approach to enhance the 
polarity of the isoindigo scaffold. Introduction of an azomethine N into the scaffold enhances 
H bond acceptor capability.  Estimated solubilities and log D7.4 (D = distribution coefficient at 
pH 7.4) of isoindigo and azaisoindigo are given in Table 1-2. The presence of the azomethine 
N reduces lipophilicity (Log D7.4) by almost 2-fold and aqueous solubility is increased by 
approximately 5 fold.  
 
Table 1-2:  Aqueous solubilities of isoindigo and azaisoindigo (pH7.4) determined by 
ACD/Labs Version 12. 
 Aqueous solubility at  
pH 7.4, Moles per L 
LogD at pH 7.4 
Isoindigo 6.2x 10 -5 1.03 
Azaisoindigo 3.3 x 10 -4 0.6 
 
Bouchikhi and co-workers30 synthesized 7’-azaisoindigos bearing a glucose moiety 
with acetylated OH groups at position 1.  They reported enhanced growth inhibitory activity 
for the azaisoindigo 6 as compared to its isoindigo analog 5 (Figure 1-13). 
      
Figure 1-13: Compounds 5 & 6 from Bouchikhi and co-workers.30 
 13 
    
A follow up investigation on compounds with the same scaffold as 6 was less 
encouraging. (Figure 1-14) For example the isoindigo 7 had greater growth inhibitory activity 
than its azaisoindigo analog 8, but the reverse was observed for the isoindigo 9 (less potent) 
and its azaisoindigo analog 10 (more potent).31 Clearly, the structural features influencing 
activity of azaisoindigos require further investigation. 
 
 Figure 1-14: Compounds 7, 8, 9 & 10 from Bouchikhi and co-workers31 
 
 Wang and co-workers32 prepared a small series of azaisoindigos with the general 
structure depicted in Figure 1-15.  Unlike the earlier azaisoindigos, these compounds are 
substituted with short alkyl groups (not sugars) at position 1. Halogen substituents were 
introduced at position 5’.  The compounds were tested for growth inhibitory activities on the 
prostate cancer cell line DU-145 and CDK2/cyclin A.  Meisoindigo is a weak inhibitor of 
both activities (IC50 DU 145 = 17.4 µM; IC50 CDK2 = 89 µM). More potent azaisoindigos were 
identified but there was no correlation between growth inhibitory and CDK2/cyclin A 
inhibitory activities. The authors proposed compound 11 as the most promising. It had an IC50 
DU 145 of 10.5 µM and inhibited CDK2/cyclin A with an IC50 of 27 µM. 
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R = methyl, ethyl, isopropyl, n-butyl
















Figure 1-15: Compounds from Wang and co-workers32 
 
Based on the few reports available, functionalized azaisoindigos like those reported 
by Wang and co-workers32 are potential lead structures to address the physicochemical 
limitations of isoindigos without compromising biological activity.  
 
1.5. Biological properties of functionalized isoindigos 
1.5.1. Mode of action of meisoindigo 
 Meisoindigo is the most widely investigated of the reported isoindigos in the 
literature.3, 12, 33 It was introduced to replace indirubin for the treatment of chronic myeloid 
leukemia (CML) in the People’s Republic of China. Clinical trials carried out in the 1980s -
1990s12 confirmed meisoindigo as a well tolerated drug that was as effective as busulfan and 
hydroxyurea, which were commonly used drugs for CML.  A synergistic effect was reported 
when meisoindigo was used together with hydroxyurea.20, 34   
Chronic myeloid leukemia is characterized by unregulated growth of predominantly 
myeloid cells in the bone marrow and the accumulation of these cells in the blood.  It is 
associated with a characteristic chromosomal translocation that results in the Philadelphia 
chromosome.35 The Philadelphia chromosome arises from the reciprocal translocation of the 
long arms of chromosome 9 and 22.36 Two new genes are created : BCR-ABL on 
chromosome 22q- and ABL-BCR on chromosome 9q-.36 The BCR-ABL fusion protein is a 
constitutively active tyrosine kinase and its deregulated activity in CML causes activation of 
mitogenic signalling37, inhibition of apoptosis38 and altered adhesion properties39, all of which 
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contribute to the pathogenesis of CML.  Several tyrosine kinase inhibitors (imatinib, dasatinib, 
nilotinib)40-43 target the BCR-ABL fusion protein to bring about remission of CML.  
Meisoindigo does not target the BCR-ABL fusion protein in CML.12, 20  
  Meisoindigo has been evaluated in vitro on other hematological cancers 
(promyelocytic leukemia44, myeloblastic leukemia45, acute myeloid leukemia33) and a solid 
tumor (colorectal HT29 cells46). In spite of different experimental conditions and test 
concentrations, meisoindigo has been shown to consistently induce apoptosis. 33, 46-48  Its 
effects on the cell cycle are more varied, with disruptions at G133,45 or G2 46 phase reported in 
the literature. It induces cell differentiation in myeloblastic leukemia45 and acute myeloblastic 
leukemic cells33, possibly induced by down-regulation of c-Myb45.  There is evidence that 
meisoindigo inhibits the synthesis of DNA and RNA in acute myeloid leukemic cells.49  
There are many reports linking meisoindigo to the inhibition of phosphorylation 
mediated by cyclin dependent kinases (CDK). Wang and co-workers reported that 
meisoindigo suppressed cyclin D mediated CDK4/6 activity in LNCaP prostate cancer cells at 
5 µM (ca 40% inhibition) and 15 µM (> 90% inhibition).26, 27  These results were obtained by 
monitoring the reduction in protein levels by western blotting. In another investigation where 
kinase activity was monitored in a fluorescence resonance energy transfer (FRET)-based 
assay, only weak inhibitory activity was found for meisoindigo (IC50 CDK2/cyclin A 89 µM,).32 
The contrasting results may be attributed to the different assay protocols. 
In spite of extensive investigations on the mode of action of meisoindigo in CML and 
other malignancies, there are still gaps in our understanding of its mode of action. Unlike 
indirubins where CDK and other kinases are known targets, the protein targets of meisoindigo 
remain elusive.  
 
1.5.2. Mode of action of functionalized isoindigos 
The early reports on the potent CDK inhibitory activity of meisoindigo have 
encouraged investigators to propose CDK as a possible target for other functionalized 
isoindigos with growth inhibitory activities.  The N-glycosyl isoindigo Natura was reported to 
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suppress CDK2 activity with an IC50 of 1.6 µM. Using ATP competing assays, the authors 
showed that Natura had a higher affinity for the CDK2 enzyme than ATP.26, 27  As mentioned 
earlier, the N-glycosyl isoindigos reported by Sassatelli and co-workers were inhibitors of 
CDK2/cyclin A as well as other kinases.29 Compound 1 (Figure 1-11) is one such compound. 
Along with other benzylated analogs, strong kinase inhibitory activities were detected at 10 
µM, but only compound 1 showed growth inhibitory activities (IC50 < 15 µM) which 
unfortunately, was observed on both cancer and non-malignant cells.  Among the acetylated 
analogs, only the 5-bromo derivative (compound 5, Figure 1-13) combined kinase inhibitory 
activity with selective antiproliferative activity on cancer cells.   
The azaisoindigos listed in Figure 1-14 (compound 8, 10) were also evaluated for 
inhibition of CDK5/p25 and other kinases but none of them were active towards these 
kinases.30 On the other hand, azaisoindigos with 1-alkyl substituents in place of the sugar 
moiety, demonstrated CDK2/cyclinA inhibitory activity.32 Compound 11 (Figure 1-15) is one 
such example. The authors also showed (but not with compound 11) that inhibition was 
linked to the up-regulation of the endogenous CDK inhibitor p27 and suggested that this may 
be the consequence of the ability of the compounds to activate the AhR receptor pathways. 
 
1.5.3. Isoindigos as ligands of the Arylhydrocarbon Receptor (AhR) 
The AhR is a ligand dependent transcription factor that regulates the expression of a 
large number of genes.50 It is found in the cytosol where it exists as a complex with a heat 
shock protein (hsp90), an AhR-associated protein (AIP, XAP2) and p23.  When a ligand 
binds to AhR, it is transformed to a DNA binding form via the following processes:  
conformational change in the receptor protein, translocation into the nucleus, dissociation of 
hsp90, binding to a closely related nuclear protein called Arnt (AhR nuclear translocator), 
formation of the high affinity DNA binding form which binds to a dioxin response element 
found in the regulatory regions of dioxin responsive genes.  These genes encode phase 1 and 
phase 2 metabolizing enzymes such as cytochrome P450, glutathione S-transferase, UDP-
glucuronosyltransferase and NAD(P)H-quinone oxidoreductase (NQO1 or QR). 
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 AhR ligands are typically planar and hydrophobic molecules such as halogenated 
aromatic hydrocarbons and polycyclic aromatic hydrocarbons.  One of the best known AhR 
ligands is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental pollutant and 
cancer-causing substance. TCDD is metabolically stable and induces persistent AhR-
dependent gene expression.  Not all AhR ligands are as toxic as TCDD primarily because they 
undergo rapid metabolic degradation. Thus only transient AhR dependent gene activation is 
induced.51 
Indirubin and indigo were first identified as potent endogenous ligands of AhR on a 
yeast based AhR reporter system.11  In that study, indirubin was cited to be 50 times more 
potent than TCDD whereas indigo was equipotent to TCDD. However, these indigoids are 
metabolically labile and thus do not come close to the toxicity of TCDD.52  
An interesting report by Nishiumi and co-workers compared the AhR transforming 
properties of indirubin, indigo and isoindigo.53 They showed that the indigoids have agonistic 
effects on AhR transformation in a cell-free system using rat hepatic cytosol. All three 
indigoids were significantly less potent than TCDD (ED50 0.55 nM) and among them, 
agonistic potency was of the order indigo (most potent, ED50 2.3 nM) > indirubin (ED50 45 
nM) > isoindigo (300 nM). Unusually, the indigoids also blocked the binding of TCDD to 
AhR at a much lower concentration of 1 nM. Thus, the indigoids demonstrated a biphasic 
response that was dependent on concentration. At low concentrations, the compounds 
antagonized AhR transformation by other ligands while at higher concentrations, they 
functioned as agonists to promote transformation.   The agonistic effects of the indigoids were 
also evident in a cultured mice hepatoma cells but could not be demonstrated in vivo.  The 
antagonistic activity of isoindigo (but not indirubin and indigo) could not be demonstrated in 
a cell-based system.  
It is difficult to comment on the role of AhR as an anti-cancer target because it 
influences a complex network of signaling pathways.51 An antagonist of AhR may be 
desirable because it would inhibit the CYP-mediated activation of pro-carcinogens.  There is 
also merit in promoting AhR agonists if the induction of enzyme activity results in an active 
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metabolite. This is observed for the phytochemical indole-3-carbinol found in cruciferous 
vegetables. Its agonist activity results in the generation of active metabolites that have direct 
effects on apoptosis and the cell cycle, besides affecting oestrogen metabolism.54 Knockaert 
and co-workers showed that independent actions on CDKs and the AhR were involved in the 
antiproliferative effects of indirubins.55 Indirubin-3’-oxime and 6-bromo-indirubin-3’-oxime 
were potent kinase inhibitors but weak AhR agonists, whereas their 1-methyl analogs (1-
methyl-indirubin-3’-oxime and 1-methyl-6-bromo-indirubin-3’-oxime) were weak kinase 
inhibitors and potent AhR agonists.  The 1-methylated analogs induced G1 cell cycle arrest in 
an AhR-dependent manner and induced the expression of the CDK2 inhibitor p27kip1.  It was 
proposed that the cytostatic activity of indirubins is mediated by activation of the AhR 
signaling pathway, while the cytotoxic effects arise primarily from their kinase inhibitory 
activity.       
 
1.6. Statement of Purpose 
From the preceding sections, it is evident that isoindigos are a significantly under-
investigated class of compounds when compared to indirubins.  A comparison of the 
scientific literature on these closely related scaffolds revealed a yawning disparity in the level 
of research attention paid to these structurally related entitites.   Ironically, an isoindigo 
(meisoindigo) has been used since 1992 for the treatment of chronic myeloid leukemia (CML) 
in the People’s Republic of China whereas no indirubin analog has emerged as a clinical 
candidate for oncology.   
Notwithstanding its status as an approved drug, there are several problems associated 
with meisoindigo, namely its moderate potency (100-150 mg daily) and poor bioavailabilty 
due to limited aqueous solubility. Efforts to increase the potency of meisoindigo would 
require detailed information on structure-activity relationships but a review of the literature 
shows that this aspect is woefully inadequate.  There have been some attempts to address the 
poor physicochemical profile of the isoindigo scaffold though structural modifications, 
namely through the syntheses of 1-glycosylisoindigos and azaisoindigos.  Unfortunately, 
 19 
attempts to reconcile anti-proliferative activity with improved aqueous solubility have not 
been encouraging.  This is particularly true for the 1-glycosylisoindigos. In spite of claims 
that Natura has better bioavailability, it is difficult to see how this has been achieved in a 
molecule where the polar OH groups on the sugar moiety are masked by acetylation. 
Azaisoindigos may be more promising but the few reported to date are hampered by weak cell 
based potencies.  
 Several functionalized isoindigos (including meisoindigo and Natura) have 
demonstrated CDK inhibitory activity. The targeting of CDK is anticipated given the 
structural similarity between isoindigo and indirubin, an established scaffold with CDK 
inhibitory activity.  The ability of isoindigos to target CDKs would greatly enhance its 
attractiveness from the medicinal chemistry perspective. Even though solved crystal 
structures of functionalized isoindigos co-crystallized with CDKs are not available, those with 
indirubins are known.  With the availability of X-ray structures of several isoindigos, it is 
tempting to adopt a structure-based approach aimed at designing isoindigo analogs with 
enhanced affinities for CDKs.  
In the light of the available information, it is hypothesized that structural 
modifications of the isoindigo scaffold, guided in part by the likelihood of CDK as the 
intended target, is a viable means of obtaining potent and drug-like anti-cancer agents.  To 
examine this hypothesis, a systematic investigation is proposed with the aim of establishing 
the core structural features associated with potency. Modifications will be guided by 
structure-based design, based on the assumption that CDK2 is the intended target.  This 
aspect will be confirmed early in the study by determining the in vitro CDK inhibitory assays 
and anti-proliferative activities of a pilot series of synthesized compounds. Noting that 
meisoindigo is clinically used to treat CML, viability of hemapoietic cell lines will be 
assessed.   Another objective of structural modifications is to improve the physicochemical 
profile of the functionalized isoindigos and to achieve this without overt loss of potency.  This 
is a major challenge as seen from available literature.  Taken together, the investigations 
presented in this thesis aim to enhance our current understanding of the isoindigo scaffold and 
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to provide an objective assessment of its potential as a source of potent and drug-like 
compounds.  
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Chapter 2:  Functionalized isoindigos as cyclin-dependent kinase (CDK) inhibitors: 
Structure-based design and in vitro evaluation.  
 
2.1. Introduction 
 Several functionalized isoindigos have been reported to be cyclin dependent kinase 
(CDK) inhibitors.26, 27, 29, 31  This led to the hypothesis that isoindigo, like its isomer indirubin, 
is a scaffold that is readily accommodated at the ATP binding site of CDKs.  Hence, a 
structure-based approach offers a means of identifying functionalized isoindigos with good 
affinities for CDK. This chapter describes the investigations carried out to address this 
hypothesis. The overview of the chapter is as follows: 
(i) Molecular docking of functionalized isoindigos into the ATP binding site of CDK2 (PDB 
entry 2BHE). 
(iii) Evaluation of CDK inhibitory activity of test compounds by the Immobilized Metal Ion 
Affinity-based Fluorescence Polarization (IMAP) assay. 
(iv) Evaluation of selected isoindigos for inhibition of different kinases by a commercial 
service provider. 
(v) Re-evaluation of molecular docking results for selected isoindigos by molecular dynamics. 
(vi) Evaluation of growth inhibitory activities of synthesized isoindigos on human chronic 
myelogenous leukemia lymphoblast cells (K562) using the microculture tetrazolium (MTT) 
assay.  
The workflow is schematically depicted in Figure 2-1.  
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Figure 2-1: Workflow for structure-based drug design. 
 
2.2. Results 
2.2.1. Docking of isoindigos into the ATP binding site of CDK2 
An entry (2BHE) was found in the Protein Data Bank which comprised a co-
crystalized complex of 5-bromoindirubin (5BI) and CDK2.18  It was used as a starting point 
for the docking experiments described in this chapter in view of the absence of CDK-
isoindigo co-crystallized structures in the literature. The ligand 5BI was removed from the 
complex and re-docked to the apo-protein using AutoDock version 4.0 (AutoDock4).  The 
pose of the re-docked 5BI was found to be similar to its original pose in 2BHE, thus 
confirming the validity of the docking protocol.  In 2BHE, the ligand (5BI) occupies the ATP 
binding site of CDK2 and is held in position by 3 hydrogen (H) bonds.  As depicted in Figure 
2-2, these are H bonding between N1 H of 5BI to C=O of Glu 81, C2 =O of 5BI to NH of Leu 
83 and N1’ -H of 5BI to C=O of Leu 83.  Glu81 and Leu 83 are also known as gk+1 and gk+3 
amino acid residues respectively because they are 1 and 3 amino acids removed from the 
“gate-keeper” (gk) residue,  which in CDK2 is Phe 80.  The latter is so called because it 
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initiates a conformational change in the protein when ATP binds to the active site.56 This 
change directs the catalytic residues to perform the phosphorylation reaction.56  The gate 
keeper (usually a hydrophobic amino acid) is the landmark residue by which the active sites 
of different kinases are compared.56  
 
Figure 2-2: Interaction of 5BI with the “hinge” amino acid residues gk+1 and gk+3 at the 
ATP binding site of CDK2 as observed in 2BHE, visualized on MOE software. 
 
The docking score of 5BI was found to be -7.07 kcal/mol. A ligand with a more 
negative score would be considered to have a better affinity for the active site.   
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Figure 2-3: Docked pose of BIO as seen on Autodock4. 
 
Next, 6-bromoindirubin-3’-oxime (BIO) was docked onto the 2BHE apoprotein. 
Indirubin-3’-oxime (IC50 0.18 µM) is reported to be a more potent CDK1/cyclin B inhibitor 
than indirubin (IC50 10 µM), in part due to a 4th H bond between the OH of the oxime and 
carbonyl O of lle10 in the CDK active site.2   This was also observed in the docked pose of 
BIO in the apoprotein of 2BHE and the tighter binding was duly reflected in the higher score 
obtained with BIO (-7.51 kcal/mol).    
Having established the docked poses of 5BI and BIO, the docking of several 
functionalized isoindigos were attempted. Table 2-1 gives the structures and docking scores 
of the test compounds.   
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Table 2-1: Docking scores (kcal/mol) obtained from Autodock4 for 1-alkyl-isoindigo series. 




    
    
 
Some interesting observations were made with regards to the docking poses of the 
listed compounds at the CDK2 active site.  Notably, the isoindigo scaffold has only 2 H 
bonding interactions with the active site and this involved only one of the two 
dihydroindolone rings. The interactions were N1H with C=O of Glu81, and C2=O with HN of 
Leu83 (Figure 2-4).  Both isoindigo (1-1) and meisoindigo (1-2) assumed similar poses and 
 26 
had comparable docking scores (-7.45 and -7.51 kcal/mol respectively). Surprisingly, the 
docking scores of isoindigo and meisoindigo were higher than that of 5BI (-7.07 kcal/mol), 
implying a stronger affinity for the binding pocket in spite of the reduced number of H bonds 
(2 H bonds versus 3 H bonds for the indirubin scaffold).  When both N atoms of isoindigo 
were methylated, as in 1,1’-dimethylisoindigo (1-3), only 1 H bond was observed in the 
complex, and accordingly, the docking score fell to -6.47 kcal/mol.  The docking of 1-
methylindirubin (7-2) was also investigated. Not unexpectedly, 7-2 had a low score (-6.21 
kcal/mol) compared to 5BI, due to one less H bond (2 instead of 3) in the complex arising 
from the methylation of the amide NH. 
 
Figure 2-4: Docked pose of meisoindigo (1-2) as visualized on Autodock4. 
 
The pose of meisoindigo (1-2) in the CDK2 binding site showed that its 1- methyl 
group projected into a fairly spacious cavity that normally accommodates the polar sugar 
residue of ATP. Very likely, substituting 1-methyl with larger and preferably polar residues 
might lead to improved binding affinities. Hence, docking of several N 1 substituted analogs 
were attempted, namely isoindigos bearing 1-phenyl (2-1), 1-benzyl (2-2), 1-phenethyl (2-3) 
and 1-phenpropyl (2-13) substituents. As seen from Table 2-1, higher scores were obtained 
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with the 1-phenethyl (2-3) and 1-phenpropyl (2-13) analogs, supporting the view that larger 
N1 -substituents are accommodated in this cavity, in spite of their non-polar nature. Figures 2-
5 and 2-6 depict the poses of 2-3 and 2-13 at the CDK2 active site. 
 
Figure 2-5: Pose of 2-3 in the CDK2 active site (2BHE), as visualized on Autodock4. 
 
 
Figure 2-6: Pose of 2-13 in CDK2 active site (2BHE), as visualized on Autodock4. 
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 Further inspection of the poses of 2-3 and 2-13 showed that their side chains 
projected into a region of the cavity that was lined by hydrophilic amino acid residues. Thus, 
introducing H bonding groups on the phenyl ring of 2-3 or 2-13 would further enhance 
affinity. Noting that the estimated lipophilicity (ClogP) of 2-13 exceeded 5, it was decided 
that substitutions would be introduced to the less lipophilic 2-3 (ClogP 4.81).  The 
substituents were p-methoxy (2-6), p-methyl (2-7), p-hydroxyl (2-8), p-nitro (2-9) and p-
acetylamino (2-11). Indeed, higher docking scores were observed with 2-8, 2-9 and 2-11. The 
docking pose of 2-11 (Figure 2-7) showed an additional H-bond between the acetylamino NH 
and C=O of Asp 145 located in the distal end of the cavity. 2-11 had an impressive docking 
score of -9.33  kcal/mol. 
 
Figure 2-7: Docked pose of 2-11 seen on Autodock4. 
 
To determine if the isoindigos were indeed strong CDK2 inhibitors as predicted by 
the docking scores, the compounds listed in Table 2-1 were synthesized and evaluated for 
CDK2 inhibitory activity. The syntheses of the compounds are described in Chapter 3, 
together with the other compounds investigated in this report. 
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2.2.2. Evaluation of CDK inhibitory activity of test compounds by the Immobilized Metal Ion 
Affinity-based Fluorescence Polarization (IMAP) assay. 
In order to validate the in silico docking scores reported in 2.2.1, the compounds were 
synthesized and evaluated for in vitro CDK inhibition using the Immobilized Metal Ion 
Affinity-based Fluorescence Polarization (IMAP) assay. 57-59  Briefly, this assay measures the 
change in the fluorescence polarization of a peptide substrate of CDK2 on phosphorylation.  
The phosphorylated peptide substrate binds to the IMAP binding reagent and experiences a 
loss in molecular motion which translates to an increase in florescence polarization (Figure 2-
8). 58, 59  In the presence of a CDK2 inhibitor, phosphorylation of the substrate is interrupted, 
leading to a concomitant decrease in fluorescence polarization.   
 
Figure 2-8: Working principle of the IMAP Assay 
 
 The test compounds were evaluated at a single concentration (10 µM) on the IMAP 
assay. Indirubin-3’-oximes I30 and BIO which are known inhibitors of CDK2 2 were included 
as positive controls.  Also included were 1-methylindirubin (7-2) and 1,1’-dimethylisoindigo 
(1-3) which had low docking scores and were expected to demonstrate weak inhibitory 
activities. The remaining compounds were isoindigo (1-1), meisoindigo (1-2), the 1-phenyl / 
1-phenylalkyl analogs 2-1 to 2-3, 2-13, and analogs of the 1-phenylethyl analog 2-3 bearing 
p-methoxy (2-6), p-methyl (2-7), p-hydroxyl (2-8), p-nitro (2-9) and p-acetylamino (2-11) 
groups.  The results are presented in Figure 2-9.  The indirubin-3’-oximes I3O and BIO 
inhibited CDK2 by more than 80% at 10 µM whereas no inhibitory activity was detected for 
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7-1 and 1-3. These results were broadly in line with their docking scores. Disappointingly, the 
remaining compounds exhibited negligible inhibitory activity. Notably 2-9 and 2-11 which 
had scores that exceeded that of the indirubin-3’-oximes, had dismal inhibitory activities. 
Thus it is clear that there is no correlation between the predicted in silico scores and the 
experimental binding affinities of the isoindigos for CDK2.   
 
Figure 2-9: % Inhibition of CDK2 at 10 µM of test compounds as evaluated by the IMAP 
assay.  
 
2.2.3. Evaluation of selected isoindigos for inhibition of different kinases 
To confirm the results obtained with the IMAP assay, two compounds (meisoindigo 
and its 1-phenpropyl analog 2-13) were selected for screening at a single concentration of 10 
µM, against a panel of 96 representative kinases. The evaluation was carried out by 
DiscoveRx (formerly Ambit Biosciences) (San Diego, CA) on a broad panel of kinases which  
included serine/threonine kinases like CDK2, GSK3β, receptor tyrosine kinases and non-
receptor tyrosine kinases.  A complete listing of the kinases is given in Appendix 2-1.  
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Table 2-2: Percentage Inhibition of 96 kinases by meisoindigo (1-2) and 2-13 at 10 µM.  
 ABL1 ACVR 1B ADCK3 AKT1 AKT2 ALK AURKA 
AURK
B AXL 
1-2 5 0 0 27 0 0 0 0 0 
2-13 46 2 2 45 2 14 35 0 16 0 0 
 
 BMPR2 BRAF BTK CDK11 CDK2 CDK3 CDK7 CDK9 CHEK1 
1-2 0 0 0 0 4 0 56 3 0 0 
2-13 7 0 13 0 0 0 28 3 0 35 
 






1B EGFR EPHA2 ERBB2 ERBB4 
1-2 0 0 0 4 0 16 13 0 0 
2-13 11 0 0 0 0 0 45 2 3 16 
 
 ERK1 FAK FGFR2 FGFR3 FLT3 GSK3β IGF1R IKK-α IKK-β 
1-2 0 7 0 4 2 0 0 31 43 1 
2-13 18 0 42 2 32 0 5 20 0 0 
 
 INSR JAK2 JAK3 JNK1 JNK2 JNK3 KIT LKB1 MAP3K4 
1-2 10 4 0 14 11 0 8 19 0 
2-13 0 25 38 0 2 6 49 2 29 37 
 
 MAPKAPK2 MARK3 MEK1 MEK2 MET MKNK1 MKNK2 MLK1 
p38-
alpha 
1-2 0 0 16 0 0 0 0 0 0 
2-13 0 0 0 9 0 25 0 23 4 
 
 p38-beta PAK1 PAK2 PAK4 PCTK1 PDGFRA PDGFRB PDPK1 
PIK3C2
B 
1-2 0 0 0 1 0 0 15 3 12 
2-13 32 1 0 0 40 0 49 2 7 0 
 
 PIK3CA PIK3CG PIM1 PIM2 PIM3 PKAC-alpha PLK1 PLK3 PLK4 
1-2 18 0 3 2 7 0 5 0 12 
2-13 40 19 0 23 0 12 0 0 39 
 
 PRKCE RAF1 RET RIOK2 ROCK2 RPS6KA3 SNARK SRC SRPK3 
1-2 16 0 0 0 0 0 30 15 0 
2-13 24 9 0 37 52 2 11 3 15 7 
 
 TGFBR1 TIE2 TRKA TSSK1B TYK2 ULK2 VEGFR2 
YANK
3 ZAP70 
1-2 0 6 20 28 8 15 0 5 0 
2-13 0 0 23 52 2  0 22 0 40 2 44 2 
1 Kinases that were selectively inhibited by meisoindigo (1-2). 
2 Kinases that were selectively inhibited by 2-13. 
3 Kinases that were inhibited to a greater extent by both compounds compared to other kinases. 
 
Table 2-2 gives the % inhibition obtained for the 2 compounds at 10 µM. None of the 
kinsases were inhibited by more than 70%. There was neglible CDK2 inhibition, which 
agreed with the IMAP assay results.  Meisoindigo has been reported to inhibit GSK3β46 and 
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VEGFR60 but these were not evident from the screening results. Notwithstanding the 
generally weak kinase inhibitory profiles of both compounds, some differences were noted 
between them (Table 2-2). Notably, some kinases were inhibited by 2-13 at levels of 40-52% 
but only weakly by meisoindigo (0-28% inhibition).  Interestingly, most of these kinases are  
tyrosine kinases (Figure 2-10).  Only one kinase (CDK7) was inhibited to approximately the 
same degree by both compounds (56% and 27% respectively). Meisoindigo also selectively 
inhibited IKK-β (43%) which was not inhibited by 2-13. Thus, the results showed that neither 
meisoindigo nor 2-13 inhibited a varied family of kinases to any significant extent. 
Notwithstanding the weak kinase inhibitory profiles, there were differences in the degree to 
which different kinases were inhibited by meisoindigo and 2-13, implying that relatively 
minor changes to substitution on the scaffold affected inhibitory activity.  
 
Figure 2-10: Location of kinases inhibited by 40-52% by 2-13 (10 µM) on the Kinome tree.  
Abbreviations: CMGC (CDK, MAPK, GSK3, CLK kinase family), TK (Tyrosine kinases family), TKL 
(Tyrosine kinase-like family), STE (Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases family), 
CK1 (Caesein kinase 1 family), AGC (PKA, PKG, PKC kinase family), CAMK (calcium/calmodulin-
dependent protein kinases family). 
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2.2.4. Re-evaluation of molecular docking results of selected isoindigos by molecular 
dynamics (MD) 
 
The absence of CDK2 inhibitory activities (Sections 2.2.2 and 2.2.3) prompted a re-
investigation of the docking approach described in Section 2.2.1.  Here, the more robust 
molecular dynamics (MD) simulation is reported for meisoindigo as a representative 
isoindigo, and for comparative purposes, on indirubin-3’-oxime (I3O), a known inhibitor of 
CDK2.2 Dr Zhang Bing, formerly of the Department of Mechanical Engineering, NUS, 
carried out the simulations and helped in the interpretation of the results.  
Figure 2-11 shows the root mean square deviations (RMSD) in the positions of the 
backbone carbon atoms of meisoindigo and I3O from their initial positions over the 
simulation period (2 nanoseconds).  No large fluctuations were observed as the RMSD values 
remained relatively constant at approximately 0.7 Å for meisoindigo and 0.3 Å for I3O.  This 
indicated that the compounds were in stable equilibrium with CDK2 and neither compound 
was displaced from their original locations in the complex during the simulation period.  
  
 
Figure 2-11: RMSD fluctuations of CDK2/CyclinA protein and its respective ligands: (A) 
Meisoindigo (1-2) (B) Indirubin-3’-oxime (I3O). Top line indicates RMSD of CDK2 protein; 
bottom line indicates RMSD of ligand (1-2 or I3O). 
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The H bonding interactions between the ligand and the hinge amino acid residues Glu 
81 and Leu 83 in the CDK2 active site were analyzed (Table 2-3). I3O formed 3 H bonds 
with the hinge amino acids, namely the lactam amide N1H of I3O with the backbone carbonyl 
oxygen of Glu 81,  the lactam carbonyl oxygen (C2=O) with backbone NH of Leu 83, and the 
non-lactam N1’ H with the carbonyl oxygen of Leu 83. The arrangement of the H bonds was 
similar to that observed for other indirubins (5BI, BIO) in Section 2.2.1. The distances of the 
H bonds measured between heavy atoms in the time-averaged structure of the complex ranged 
from 2.81Ǻ to 3.09 Ǻ, which is within the range for H bonding.  The duration of the H bonds, 
measured as a percentage of the equilibration simulation time, exceeded 90%, indicating that 
the H bonds were not transient.   
 
Table 2-3: Hydrogen bonds and binding free energies of meisoindigo (1-2) and indirubin 3’-
oxime (I3O) bounded CDK2 obtained from MD simulations.  
Complex Hydrogen bond %  Duration 1 
Mean 
distance 2 /Å 





N1-H…O(Glu 81) 98.95 2.99 
-38.95 -32.38 C2=O…N(Leu83) 99.95 2.81 
N1’ -H…O(Leu83) 93.15 3.09 
CDK2/ 
1-2 
N1-H..O(Glu 81) 99.80 2.91 
-17.23 -26.08 
C2=O…N(Leu83) 74.15 3.17 
1 Percentage of equilibration simulation time. 
2 Hydrogen bond length obtained by measuring distances between heavy atoms.  
 
In the case of meisoindigo, only 2 H bonds were formed and these involved its lactam 
N1H and carbonyl oxygen (C2=O) with Glu 81 (carbonyl oxygen) and Leu 83 (amide NH) 
respectively.  Of the two H bonds, the bond to Glu 81 was more robust as seen from its 
shorter distance (2.91 Ǻ) and duration (99.8% of equilibration simulation time). The other H 
bond to Leu 83 was longer (3.17 Ǻ) and relatively transient (74.15%) (Table 2-3).  The free 
binding energies of the ligand-CDK2 complexes were calculated by two methods (MM/PBSA 
and MM/GBSA).  In both instances, lower free energy (Δ G) values were obtained for I3O 
(Table 2-3), indicating a more stable complex.  
 35 
Taken together, these results showed that although both meisoindigo and I3O formed 
H bonded complexes with CDK2, there were differences in their stabilities. Meisoindigo has a 
weaker affinity for CDK2 compared to I3O because only two H bonds of unequal strengths 
are involved in the interaction. On the other hand, I3O established 3 H bonds of equal 
strength with CDK2, thus establishing a tighter complex and greater CDK inhibitory activity 
as compared to meisoindigo.  
 
2.2.5. Evaluation of growth inhibitory activities of synthesized isoindigos on human chronic 
myelogenous leukemia lymphoblast cells (K562) using the microculture tetrazolium (MTT) 
assay.  
 While direct inhibition of CDK or other kinases may not be the intended mode of 
action of meisoindigo, there is no doubt that it has therapeutic efficacy in CML. 
Meisoindigo26, 45, 46, 60 and other functionalized isoindigos28-32 are reported to inhibit the 
proliferation of several cancer cells. It is thus of interest to determine if the compounds that 
were investigated for docking onto CDK2 (Table 2-1) and subsequently for inhibition of 
CDK2 by the IMAP assay (some not all as depicted in Figure 2-9) affected cell viability, and 
if so, the extent of their effects compared to meisoindigo. 
   The compounds evaluated for activity are listed in Table 2-4. The syntheses and 
characterization of these compounds are given in Chapter 3.  The compounds were evaluated 
for growth inhibition of a human chronic myelogenous cell line K562 using the microculture 
tetrazolium assay (MTT). 61, 62  Briefly, this assay is based on the ability of viable cells to 
convert a yellow tetrazolium dye (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to a dark violet product (formazan).  The formation of formazan is quantified 
spectrophotometrically.  It is formed in substantial amounts in viable cells via the activity of 
mitochondrial reductases but diminished in cells that are dead or not growing. 
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Table 2-4: Compounds evaluated for cell viability effects on K562 cells by the MTT assay 
and their IC50 values.   
    






   
 
1 IC50 values could not be determined due to limited solubility of test compound.  
   Standard deviation (SD) for n > 3 determinations are indicated in brackets.  
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The half maximal growth inhibitory concentrations (IC50) of the test compounds are 
listed in Table 2-4. The results showed that isoindigo (1-1) is significantly more potent than 
indirubin (7-1).  Interestingly, meisoindigo (1-2) is also more potent than 1-methylindirubin 
(7-2). The poor growth inhibitory profiles of the indirubins (7-1, 7-2) may be traced in part to 
their poor solubilities. It is noted that both 7-1 and 7-2 could not be tested beyond 20 µM 
without precipitation occurring in the test wells, in spite of the presence of DMSO (0.4% v/v) 
in the media.  On the other hand, derivatizing the non-amide carbonyl of indirubin to an 
oxime overcomes the poor solubility, but only for 6-bromoindirubin-3-oxime (BIO, 7-4), not 
indirubin-3-oxime (I3O, 7-3).  6-Bromoindirubin-3-oxime (BIO /7-4) is in fact the most 
potent compound in Table 2-4, in keeping with literature reports. 2   
Figure 2-12 shows the concentration versus viability curve for meisoindigo. 
Meisoindigo is almost as potent as isoindigo (1-1) on the K562 cells. Introducing another 
methyl group on to the other amide NH of meisoindigo (to give 1-3) significantly diminished 
activity, as did the reduction of the central double bond to give 1-4. Clearly, antiproliferative 
activity depends on the presence of at least one free NH and an intact exocyclic double bond.   
 
Figure 2-12: Viability curve of meisoindigo (1-2). Standard deviation indicated by error bars. 
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Replacing the 1-methyl of meisoindigo with 1-phenyl (2-1) or 1-benzyl (2-2) resulted 
in a slight reduction in activity, but this was reversed by further lengthening the side chain to 
1-phenethyl (2-3) and 1-phenpropyl (2-13). 2-13 (IC50 = 1.70 µM) (Figure 2-13) was in fact 
as potent as BIO (IC50 = 1.31 µM) on K562 cells. 
 
Figure 2-13: Viability curve of 2-13. Standard deviation indicated by error bars. 
 
In spite of its potency, 2-13 was not investigated further for its structure-activity 
relationship because of its lipophilic nature (ClogP 5.19). Instead, more attention was paid to 
the less lipophilic 1-phenethyl analog 2-3 (IC50 7.57 µM, ClogP 4.81). It is seen that growth 
inhibitory activity was significantly improved by replacing the aromatic ring of 2-3 with 
cyclohexyl (2-12, IC50= 3.79µM) and to a lesser degree by introducing a p-methoxy group to 
the phenylethyl side chain (2-6, IC50= 6.09µM). Substituents like p-methyl (2-7) and p-nitro 
(2-9) were clearly not favored, whereas others like p-hydroxyl (2-8) and p-acetylamino (2-11) 




A key finding in this chapter is the poor correlation between in silico docking results 
obtained with AutoDock4 and in vitro CDK2 inhibitory activities of the test compounds.  
Several isoindigos that had good docking scores suggestive of inhibition of CDK2 were found 
to be inactive on in vitro CDK assays. The discrepancy may be traced to several factors. First, 
molecular docking was carried out with a CDK2 protein (2BHE) that was co-crystallized with 
an indirubin and not an isoindigo derivative.  Verdonk and co-workers reported that when 
compounds were docked onto protein structures derived from complexes co-crystallized with 
a different ligand (“non-native” conformation of the protein), the results were less reliable .63  
On the hand, when docking was carried out using an apoprotein derived from a complex co-
crystalized with a structurally similar ligand, docking performance improved significantly.63  
Second, the docking model (2BHE) does not contain the cyclin counterpart (cyclin E) of 
CDK2, and its absence may have adversely affected the quality of the protein conformation.  
Thirdly, AutoDock4 adopts a rigid docking protocol, which means that the structure of the 
protein is kept rigid and does not accommodate the induced fit of a ligand to the binding 
pocket. These problems may be minimized if a flexible docking protocol is applied to an 
apoprotein derived from a co-crystallized isoindigo-CDK2-cyclin E complex of good 
resolution, which unfortunately is not available as yet. In the absence of this option, the 
interaction of meisoindigo and indirubin-3’-oxime (I3O) with CDK2 was investigated by 
molecular dynamics (MD) simulation. The results were more in keeping with the in vitro 
experimental data. Meisoindigo formed a weak and transient H bonding complex with CDK2. 
Its binding energy was considerably smaller than that of the oxime I3O which established 
stronger interactions with the enzyme consistent with its strong CDK2 inhibitory activity.2 
Thus, the more rigorous MD simulation reflected the weak CDK2 inhibitory activity of 
meisoindigo more accurately than molecular docking. 
The weak kinase inhibitory activity of meisoindigo reported in this chapter stood in 
contrast with literature reports that have reported otherwise.26, 27 One factor that may account 
for this discrepancy is that these reports monitored protein levels of the kinases from cell 
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lysates, and not direct inhibition of kinases. The reduction in kinase expression may arise 
from modulatory effects on signalling pathways that affect kinase levels. For example, 
stimulation of AhR signalling induces the expression of the CDK2 inhibitor p27 which in turn, 
reduces CDK2 protein expression and activity.  Thus the growth inhibitory effect of 
meisoindigo on the leukemic cells K562 (Section 2.2.5) may arise from intervention of 
several pathways45, 60, 64, some of which may be similarly affected by the test compounds. 
In spite of the small number of compounds screened in this chapter, initial deductions 
of key structural features for the antiproliferative activity of the isoindigo scaffold are evident. 
These  are the presence of at least one free amide NH on the scaffold and an intact exocyclic 
double bond, possibly to preserve the planarity of the ring. Replacing the 1-methyl group of 
meisoindigo with other substituents is permissible, with good activity associated with the 1-
phenpropyl and 1-cyclohexyl side chains of 2-13 and 2-12 respectively.  
 
2.4. Summary 
 The main findings of this chapter are summarized:  
(i) Molecular docking of functionalized isoindigos on a non-native CDK2 protein 
conformation (protein structure which does not have isoindigo as a co-crystallized ligand) is a 
poor predictor of in vitro CDK2 inhibitory activity.  
(ii) Meisoindigo and several related isoindigos are poor inhibitors of CDK2. Meisoindigo and 
2-13 are also poor inhibitors of several other kinases, although the degree of inhibition of 
various kinases differ for the two compounds. 
(iii) Meisoindigo has moderate growth inhibitory activity on leukemic cells K562 with an IC50 
of 7.75 µM. A preliminary assessement of structure-activity relationships (SAR) point to the 
importance of maintaining at least one free NH on the scaffold and its planarity. 
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2.5. Experimental methods  
2.5.1. Docking of isoindigos onto the ATP binding site of CDK2 
The LigX module in Molecular Operating Environment (MOE, version 2008.10, 
Chemical Computing Group, Montreal, Canada) was used to refine the CDK2 active site of 
2BHE (Protein Data Bank, Research for collaboratory structural bioinformatics, San Diego). 
The ligand (5BI) at the monomeric active site was verified, labeled, H atoms added and 
protonation of the protein was carried out. The H atoms were force field minimized and 
unbound water molecules were deleted. Force field minimization was not carried out on the 
heavy atoms in order not to alter the crystal structure. 5BI was then removed from the holo 
structure to give the apo-structure which was used for docking.  
The test compounds (Table 2-1) were drawn and geometry minimized with SYBYL 
Version 8.0 (Tripos Inc, St Louis, MO), after which Gasteiger Hückel partial charges were 
added. Each compound was docked onto the apo-protein prepared from 2BHE using 
AutoDock 4 (Scripps Research Institute, SD, CA) using default settings in the AutoDock4 
protocol manual.65 The grid parameters used in the grid parameter file (gpf) for CDK2 
docking are given in Table 2-5(A).  The Lamarckian Genetic Algorithm settings for the 
docking parameter file (dpf) are tabulated in Table 2-5(B).   
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Table 2-5: Settings for the (A) grid parameter file and (B) docking parameter file.  
(A) 
Protein PDB code Ligand 
Grid Size/ Å Grid Center Grid 
Spacing/ Å X Y Z X Y Z 












 The docked poses were analyzed with AutoDockTools and a score (kcal/mol) was 
assigned to the highest ranked conformation. Docked poses (Figures 2-2 to 2-7) were 
presented without modifications.  
A wrapper script was written to automate the docking process without manual 
intervention.  Three pre-prepared python scripts from The Scripts Research Institute 
(prepare_ligand4.py, prepare_gpf4.py, prepare_dpf4.py)65 were used for this purpose. Details 
of the written script are given in Appendix 2-2. The automated docking procedure repeated 
the docking process for every test compound in the folder until docking was completed. The 
Atlas3 server at the NUS Supercomputing & Visualization Unit (SVU) was used for this 
purpose. To ensure that docking scores from manual and automated processes were 
compatible, manual docking was initially carried out on a small number of compounds. 
Scores were then compared with those obtained by the automated method. A correlation R2 
value of 0.924 was obtained suggesting that the automated and manual processes gave 
comparable scores.  
 
 43 
2.5.2. Evaluation of CDK inhibitory activity of test compounds by the Immobilized Metal Ion 
Affinity-based Fluorescence Polarization (IMAP) assay  
 
The assay was carried out on the IMAP 800-tp kit (Molecular Devices, cat no.  R8155, 
USA). The EC70 value of CDK2/cyclinA (Millipore, cat no: #14-448, Dundee, UK) was 
initially determined following the protocol described in the kit.  Aliquots of complete reaction 
buffer (5 µL), CDK2/cyclinA (5 µL) enzyme at concentrations varying from 4.0 – 0.005 
unit/mL), ATP (5 uL, 120 µM) and lyophilized FAM-Histone H1-derived peptide (5FAM-
GGGPATPKKAKKL-COOH, 5 µL, 400 nM) (Molecular Devices) were added in sequence 
into a 384-well black microplate (Sigma CLS3571) such that the final concentrations of ATP 
and peptide substrate per well were 30 µM and 100 nM respectively. The mixture was 
incubated for 1h for phosphorlyation to take place, after which 60 µL of progressive binding 
solution (1/400 dilution of binding reagent) was added and incubated for another hour.  
Fluorescent polarization (FP) readings were taken on a microplate reader (MDC Spectramax 
M5) at λ Excitation 485 nm and  λ Emission 530 nm. Other settings were auto cut-off = 515 nm, 
readings per well = 100, PMT sensitivity = High, Auto-calibrate = On, Automix = Off and 
Settling time = Off.  The EC70 of CDK2/cyclin A was determined from the sigmoidal curve 
obtained by plotting FP versus logarithmic enzyme concentration (GraphPad Prism 4, San 
Diego, CA).   
The assay was repeated in the presence of 10 µM test compound. Briefly, 5 µL 
aliquots of the test compound (40 µM in 4%v/v DMSO), CDK2 / cyclin A at 4x EC70, 120 
µM ATP and 400nM lyophilized FAM-Histone H1-derived peptide were added to each well. 
The final concentration of DMSO in the well was maintained at 1% v/v. Control wells 
contained complete reaction buffer (5 µL) in place of the same volume of enzyme solution 
and the vehicle control wells had other reagents but not the test compound. The enzyme 
inhibition activity of test compound at 10 µM was calculated using the following equation: 
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Percentage Inhibition = (FP vehicle – FP drug / FP vehicle  – FP control) x 100 , 
 
where FP is the fluorescent polarization units (mP) measured for the test compound, vehicle 
and control, as indicted by the subscripts.  Each test compound was evaluated at least twice on 
separate occasions. 
 
2.5.3. Evaluation of selected isoindigos for inhibition of different kinases 
Meisoindigo and 2-13 were tested at a single concentration of 10 µM for inhibition of 
96 kinases (ScanEdge ™) by a commercial service provider (DiscoveRx, formerly Ambit 
Biosciences, San Diego, CA).  The assay quantified the ability of the test compound to 
compete with an immobilized active site directed ligand.27 Two determinations of each 
compound in 1% v/v DMSO vehicle were made for each kinase and the results were reported 
as % inhibition.  Inhibition levels > 70% were considered to be significant. The list of kinases 
tested in ScanEdge ™ is listed in Appendix 2-1B. 
 
2.5.4. Molecular Dynamics simulation of the binding of meisoindigo and I3O with CDK2 
The simulations were carried out by Dr Zhang Bing, then of the Department of 
Mechanical Engineering, NUS. The protocol is given in Appendix 2-3.  
 
2.5.5. Growth Inhibitory Assay on K562 cells 
K562 (human chronic myelogenous leukemia lymphoblast) cell line was purchased 
from American Type Culture Collection (Rockville, MD) and cultured in Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 10% v/v FBS, 100 mg/L penicillin G and 
100mg/L streptomycin.  The cells were sub-cultured by a ratio of 1:10 when cell density of 
106 cells/mL was attained and passages 4–12 were used for viability experiments. Stock 
solutions of test compounds (10 mM) were prepared in DMSO. 90µL of K562 cells and 10µL 
of test compound (appropriately diluted from stock solution) were added to each well to give 
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a seeding density of 10,000 cells per well and a final concentration of 0.4% v/v DMSO per 
well. The test compounds were incubated with the K562 cells for 72 h at 37°C, 5% CO2. After 
the incubation period, a solution of MTT (25 µL) was added in media to give a final 
concentration of 0.5 mg/mL in the well. The plate was gently agitated and incubated for 3 h at 
37°C, after which it was centrifuged (1200 g, 10 min), the supernatant removed by aspiration 
and DMSO (100 µL) added to dissolve the formazan crystals.  Vehicle controls were wells 
with cells grown in 0.4% v/v DMSO/Media (no drug) while blank controls were empty wells 
with 100 µL DMSO added just before measurements were taken.  
Absorbances were measured within 30 min at 595 nm on a microplate reader (Tecan, 
Infinite M200 or F200).  Similar control wells were maintained as described earlier.  The 
viability of cells at a given concentration of test compound is determined from the following 
expression: 
 
Percentage Viability = (A test compound – A blank / A vehicle   – A blank) x 100 
 
where A test compound = absorbance of wells with cells exposed to test compound in media,  
A vehicle = absorbance of wells with cells in the same media composition, and A blank = 
absorbance of wells with DMSO only.   
Each concentration of test compound was evaluated at least 4 times on separate 
occasions. The IC50 value (concentration that reduced growth by 50% compared to untreated 
cells) was determined from the sigmoidal curve obtained by plotting percentage viability 
versus logarithmic concentration of test compound using GraphPad Prism 4 (San Diego, 
USA). 
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Chapter 3: Design and Synthesis of Target Compounds 
 
3.1. Introduction 
This chapter describes the design and synthesis of the functionalized isoindigos 
reported in this thesis. A total of 93 isoindigos were synthesized, of which 16 were 
contributed by an undergraduate student and 1 by a postdoctoral fellow. In this chapter, the 
rationale of design, chemical considerations and experimental details are presented. It should 
be mentioned that the compounds were not synthesized on a single occasion but in an iterative 
manner, with chemical synthesis alternating with biological evaluation.  
 
3.2. Rationale of drug design 
 The impetus for structurally modifying the isoindigo template is to address two key 
issues relating to the antiproliferative activity of meisoindigo.  As described in Section 1-6, 
these are its moderate potency as an antileukemic agent and its limited aqueous solubility.  
The modifications described in this chapter are meant to address these shortcomings.  The 
isoindigos are divided into six classes (series 1-6) based on modifiations made to the scaffold. 
In the following paragraphs, each series is discussed in turn to highlight the rationale 
underlying its design.  
 
3.2.1. Series 1 
Series 1 comprise 4 compounds (1-1 to 1-4, Table 3-1), including isoindigo (1-1) and 
meisoindigo (1-2).  The dimethyl analog 1-3 serves to interrogate the importance of 
maintaining at least one free amide NH in the scaffold while the dehydro analog 1-4 
investigates the importance of a planar scaffold for activity.  The insoluble nature of isoindigo 
is due to intermolecular H bonding between the planar structures (Section 1.4.1). Disruption 
of H bonding should reduce the stacking of the molecules and so improve solubility. Table 3-
1 also gives the estimated lipophilicities (CLogP derived from ChemDraw 7.0) and 
solubilities (pH 7.4, ACD Labs 12.0) of 1-1 to 1-4. The ClogP values point to an increase in 
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lipophilicity with progressive methylation of the amide NH: 1-3 > 1-2 > 1-1.  Interestingly, 
solubility improves on methylation (1-2 > 1-1) but tapers off when both NH groups are 
methylated (1-3 < 1-2). Possibly, the loss of the H bonding NH on methylation and 
consequently a reduction in solvation by water results in diminished solubility. On the other 
hand, methylation of NH would reduce the brick-dust character of the scaffold by interfering 
with intermolecular H bonding and molecular stacking. The final effect on solubility would 
presumably depend on the balance of these two counteracting effects. Molecular stacking 
would be diminished in the non-planar dihydroanalog 1-4. Indeed, the estimated solubility of 
1-4 is remarkably high. 
 Both 1-3 and 1-4 did not exhibit antiproliferative activity as described in Section 
2.2.5. In fact, they were also not as soluble as anticipated from their estimated solubilities, 
highlighting the need to retain some skepticism when dealing with estimated values.  
  
Table 3-1: Series 1 compounds (1-1 to 1-4). 
Compoun
d 
    
ClogP 1 2.04 2.71 3.39 1.07 
Solubility 
2 61.0 673 589 43,800 
1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated from ACD/Labs 12.0. 
 
 
3.2.2. Series 2 
Series 2 comprise compounds (2-1 to 2-21) which have a variety of substituents in 
place of the 1-methyl of meisoindigo (Table 3-2).  Meisoindigo is essentially under-
functionalized. With a ClogP of 2.71, there is an option to increase its lipophilicity by 1-2 
units without overstepping the constraints mentioned by the Lipinski’s Rule of Five66 for 
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drug-like compounds with oral bioavailability. Undoubtedly, introduction of lipophilic 
residues will decrease aqueous solubility but at this stage of the investigation, the intention is 
to explore broad structure activity trends affecting potency.   







No. R1 ClogP1 
Solubility 


















































4.55 4.9 2-20  1.86 666.0 
2-10 
 
4.95 5.2 2-21 
 
2.76 172.2 
1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated by ACD/Labs 12. 
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The following series 2 compounds have been mentioned in Section 2.2.5: 1-phenyl 
(2-1), 1-benzyl (2-2), 1-phenethyl (2-3), 1-cyclohexylethyl (2-12) and 1-phenpropyl (2-13).  
The ClogP and estimated solubility values indicate that these are lipophilic and poorly soluble 
compounds. However, inspection of the energy minimized structures of these compounds 
suggests that the orientation of the substituent at position 1 may actually disrupt the stacking 
of the molecules (Figure 3-1) and if this is indeed so, they may not be as insoluble as 
anticipated from the estimated values.  
 
 
Figure 3-1: Energy minimized structures of meisoindigo (1-2) and 1-substituted analogs 2-1 
to 2-3, 2-12 and 2-13, showing the orientations of the 1-side chains.  Structures were drawn 
and minimized with MOE.  
 
2-3 (IC50 = 6.09 µM), 2-12 (IC50 = 3.79 µM) and 2-13 (IC50 = 1.70 µM) have been 
identified to be more potent than meisoindigo (IC50 = 7.75 µM) in K562 cells (Section 2.2.5). 
Accordingly, follow up modifications were made on 2-3 and 2-13, but not 2-12. This is 
because 2-12 is deemed to be too lipophilic (ClogP 5.89) and substitutions on the cyclohexyl 
ring will result in enantiomeric /diastereomeric mixtures that would complicate separation of 
synthesized analogs.   
The phenyl ring of 2-3 was substituted with representative groups drawn from  
different quadrants of the Craig Plot67, 68 :  electron donating, lipophilic (methyl 2-7), electron 
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donating, hydrophilic (methoxy 2-6, hydroxyl 2-8), electron withdrawing, lipophilic (nitro 2-9, 
fluoro 2-10), electron withdrawing, hydrophilic (acetylamino 2-11). These groups were 
introduced at the p-position of the ring but the methoxy group was also investigated at the 
ortho- (2-4) and meta- (2-5) positions when the methoxy analog 2-6 was found to be more 
promising than the other compounds. Modifications to 2-13 included rigidification of the 3-
carbon linker by introducing unsaturation (2-14, 2-15), introducing an oxygen atom in the 
side chain to reduce lipophilicity (2-16) and inclusion of a p-methoxy group (2-17) in view of 
the favorable activity associated with this group.  
H bonding side chains were also introduced at position 1: propanenitrile (2-18), 
butanenitrile (2-19), hydroxyethyl (2-20) and its acetylated derivative (2-21). These side 
chains are H bond acceptors and/or donors and are anticipated to increase solubility. 
 
3.2.3. Series 3 
 Series 3 investigates the substitution of rings A and B of meisoindigo (Table 3-3).   1-
Glycosylisoindigos bearing substitutions on either ring A or B of the scaffold are widely 
reported28-31 but similar modifications on meisoindigo are lacking. Therefore series 3 
compounds were designed to investigate the effects on activity brought about by substitution 
on ring A at positions 5, 6 or 7 on activity and to compare the results with those derived from 
substitution at the same positions (5’, 6’, 7’) on ring B.  The substitutents investigated were 
the halogens (F, Cl, Br) and methoxy. These groups were selected in part because of the 
availability of the starting reactants (isatins or oxindoles) and for the bromo substituent, its 
association with antiproliferative activity when attached to the indirubin scaffold. 10, 69  
In Section 1.4.1, it was mentioned that introducing groups at position 4 or 4’ would 
cause steric clash and result in a loss of planarity of the scaffold.  An improvement in 
solubility is anticipated but the compound may not be synthesizable.  There is in fact no 
reference in the literature of isoindigos with groups at this position. Hence, only positions 5, 6 
and 7 on rings A and B are considered in Series 3. Table 3-3 lists the Series 3 compounds 
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along with their ClogP (ChemDraw, Version 7.0) and estimated solubility (pH 7.4, estimated, 
ACD/Labs 12) values.   
 
Table 3-3: Series 3 compounds – Mono-substitution on ring A or B  
 
No. R2  ClogP1 
Solubility 
(µM) 2 No. R3 ClogP
1 Solubility (µM) 2 
3-1 5-F 2.86 642.2 3-13 5’-F 3.11 713.6 
3-2 5-Cl 3.43 209.2 3-14 5’-Cl 3.68 231.7 
3-3 5-Br 3.58 259.0 3-15 5’-Br 3.83 287.2 
3-4 5-OMe 2.63 692.1 3-16 5’-OMe 2.79 656.2 
 
3-5 6-F 2.86 339.8 3-17 6’-F 3.11 951.5 
3-6 6-Cl 3.43 157.7 3-18 6’-Cl 3.68 238.1 
3-7 6-Br 3.58 166.1 3-19 6’-Br 3.83 191.4 
3-8 6-OMe 2.63 297.1 3-20 6’-OMe 2.79 470.1 
 
3-9 7-F 2.86 727.2 3-21 7’-F 3.11 744.2 
3-10 7-Cl 3.43 234.9 3-22 7’-Cl 3.68 241.4 
3-11 7-Br 3.58 284.4 3-23 7’-Br 3.83 292.8 
3-12 7-OMe 2.63 639.9 3-24 7’-OMe 2.79 669.2 
 
 
3-25 6’-NMe2 2.89 269.3 
3-26 6’-CF3 4.05 52.3 
3-27 6’-CN 2.74 189.2 
3-28 6’-SO2CH3 1.72 747.8 
3-29 6’-NHCOCH3 1.73 363.0 
3-30 6’-NHSO2CH3 1.52 276.1 
1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated by ACD/Labs 12. 
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3-1 to 3-24 were first synthesized and evaluated for growth inhibitory activity on 
K562 cells. It was found that 3-20, which has a 6’-methoxy (on ring B) gave the best result. 
Accordingly, different substituents were introduced at this position, namely dimethylamino, 
trifluoromethyl, cyano, methylsulfonyl, acetylamino and methylsulphonylamino (3-25 to      
3-30). As before, these substituents are drawn from different quadrants of the Craig Plot. 
 
3.2.4. Series 4 
Series 4 comprise 5 compounds bearing ‘optimal’ substituents on ring B and position 
1.  These optimal substituents have been identified from the growth inhibitory activities of 
Series 2 and 3.  The objective of designing these compounds is to determine if the combined 
presence of these optimal groups in a single compound will result in even greater activity.  As 
seen from Table 3-4, the compounds are substituted at 6’ with methoxy and bear side chains 
present in the more potent series 2 compounds. However, estimated solubilities and 
lipophilicities of Series 4 compounds are not encouraging.  
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1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated by ACD/Labs 12. 
 
3.2.5. Series 5 
The design approach of Series 5 is similar to that of Series 4. In Series 4, the optimal 
6’-methoxy group is retained, while different 1-substituents are investigated. In Series 5, the 
optimal 1-substituent is retained while different groups on rings A and B are investigated.  
The optimal 1-substitutent was identified to be p-methoxyphenyethyl (side chain of 4-5) and 
the objective is to determine if replacing 6’-methoxy (present in 4-5) with other groups and at 
different positions of rings A/B will result in a more active compound than 4-5.  Like Series 4, 
the estimated solubilities and lipophilicities of Series 5 compounds are not encouraging.  
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Table 3-5. Series 5 compounds (5-1 to 5-25): Analogues of 4-5 
 
No. R2  ClogP1 
Solubility 
(µM) 2 No. R3 ClogP
1 Solubility (µM) 2 
5-1 5-F 4.87 7.2 5-12 5’-F 5.13 9.7 
5-2 5-Cl 5.44 2.3 5-13 5’-Cl 5.70 2.3 
5-3 5-Br 5.59 4.2 5-14 5’-Br 5.85 4.2 
5-4 5-OMe 4.65 9.4  
 
5-5 6-F 4.87 4.8 5-15 6’-F 5.13 12.0 
5-6 6-Cl 5.44 2.3 5-16 6’-Cl 5.70 2.3 
5-7 6-Br 5.59 2.1 5-17 6’-Br 5.85 2.1 
5-8 6-OMe 4.65 4.7 4-5 6’-OMe 4.80 7.0 
  
5-9 7-F 4.87 9.7 5-18 7’-F 5.13 9.7 
5-10 7-Cl 5.44 2.3 5-19 7’-Cl 5.70 2.3 
5-11 7-Br 5.59 4.2 5-20 7’-Br 5.85 4.2 
  
 
5-21 6’-NMe2 4.89 4.6 
5-22 6’-CF3 6.06 <1.0 
5-23 6’-CN 4.76 2.4 
5-24 6’-SO2CH3 3.73 12.6 
5-25 6’-NHCOCH3 3.75 6.6 
1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated by ACD Labs 12.0. 
 
3.2.6. Series 6 
 Series 6 compounds are designed to specifically address solubility issues associated 
with the isoindigo scaffold.  Two approaches were adopted to achieve this end: first, 
introducing an ionizable basic moiety at position 1 (6-1 to 6-6) and second, inserting an 
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azomethine nitrogen to the isoindigo ring to give aza-isoindigos (6-7, 6-8) (Table 3-6).  The 
ionizable basic groups are part of nitrogen containing heterocyclic rings – morpholine, 
thiomorpholine, piperidine, piperazine and 4-methylpiperazine, and they are attached to 
position 1 of the isoindigo scaffold via an ethyl linker.  Therefore, they mimic 2-12 except 
that the cyclohexyl ring of 2-12 has been replaced by a heterocyclic ring. 6-5 and 6-6 have 6’-
methoxy on ring B besides the basic side chain at position 1.   
The polarity of the azaisoindigo scaffold has been alluded to in Section 1.4.2.  Several 
azaisoindigos have been reported to have good antiproliferative activity.31, 32  6-7 is the 
azaisoindigo equivalent of meisoindigo. Its estimated aqueous solubility is in the millimolar 
range (1.6 mM) and at least twice greater than that of meisoindigo.  6-8 is the azaisoindigo 
equivalent of 2-6. Its estimated solubility is also about 2 fold that of 2-6.  The azomethine N 
of azaisoindigo is a weak base (estimated pKa 3.4) and the majority of 6-8 would not be 
protonated at pH 7.4.  However, it can function as a H bond acceptor in its non-protonated 
state and this feature may enhance the solvation of the scaffold in an aqueous medium.   
  
 56 
Table 3-6. Series 6 compounds (6-1 to 6-8): Analogues with improved water solubility 
 
No. R1 R3 LogD7.4 1 Solubility 1 
6-1 
 
H 1.13 258.4 
6-2 
 
H 1.87 81.7 
6-3 
 
H 1.47 720.3 
6-4 
 
H 0.88 602.4 
6-5 
 
6’-OMe 1.15 192.7 
6-6 
 
6’-OMe 0.90 456.4 
6-7 CH3 - 0.85 1644.5 
6-8 
 
- 3.03 20.1 
1 LogD7.4 and estimated solubility in µM, calculated by ACD/Labs 12. 
 
3.2.7. Series 7.  
Series 7 comprise functionalized induribins. 7-1 (indirubin) and 7-2 (1-
methylindirubin) are analogous to isoiindigo and meisoindigo and were included to allow   
comparisons with the isoindigos. The indirubin oximes 7-3 (indirubin-3’-oxime) and 7-4 (6-
bromoindirubin-3’-oxime) are known CDK inhibitors with growth inhibitory properties on 




Table 3-7. Series 7.compounds (7-1 to 7-4) : Functionalized Indirubins 
 
Compound R5 R6 ClogP1 Solubility2 
7-1 H H 3.17 33.8 
7-2 CH3 H 3.84 538.3 
7-3 - H 2.40 4.9 
7-4 - 6-Br 3.52 1.3 
1 ClogP calculated from ChemDraw 7.0. 
2 Estimated solubility in µM, calculated by ACD/Labs 12. 
 
 
3.3. Chemical considerations 
3.3.1. Disconnection approach to the synthesis of functionalized isoindigos 
 From the preceding sections, it is seen that the present series of compounds are 
substituted at three positions on the isoindigo ring (Scheme 3-1): Position 1 (R1), position 5, 6 
or 7 on ring A (R2) or position 5’, 6’ or 7’ on ring B (R3).  A general approach to the synthesis 
of isoindigos is the aldol condensation reaction between an appropriately substituted isatin 
(1H-Indole-2,3-dione) and substituted oxindole (1,3-dihydro-indol-2-one). Due to the C2 
symmetry of the isoindigo scaffold, there are two ways to disconnect the molecule at the 3-3’ 
position (Scheme 3-1).  The 1st approach is to react a di-substituted (at R1 and R2) isatin with 
an R3 substituted oxindole (Route 1).  The 2nd approach is to react an R3 substituted isatin with 















































Route 2 Route 1
Scheme 3-1: Disconnection approaches to the syntheses of functionalized isoindigos 
 
Route 1 is depicted in Scheme 3-2.  The alkylation of the NH of isatin is widely 
reported in the literature.71-75   The mechanism of base catalyzed N-alkylation of isatin is 
given in Figure 3-2. Different bases have been used to catalyze the reaction  – potassium 
carbonate71, 74, caesium carbonate75 , calcium hydride73.  In this report, potassium carbonate 
and calcium hydride were found to give satisfactory yields when the reaction was carried out 
in dimethylformamide (DMF) at 80°C for 4-16hrs.74  Microwave heating instead of 




























Scheme 3-2. Reagents and conditions: (a) Alkyl halide R1X, DMF, (K2CO3, 80°C, or CaH2, 
















Figure 3-2. Mechanism for base catalyzed N-alkylation of isatin. 
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The N-alkylated isatin was then reacted with the substituted oxindole in an acid-
catalyzed aldol condensation which involves an overnight reflux in acetic acid with catalytic 
amounts of hydrocholoric acid.76, 77 The reaction time may be shortened by microwave 
heating, generally with comparable yields. Figure 3-3 illustrates the mechanism of acid 






















































Figure 3-3 Mechanism for acid catalyzed aldol condensation 
 
In Route 2, 1-methyloxindole is reacted with an isatin (Scheme 3-3).  There are not 
many reports on the alkylation of oxindole in the literature. Yields are also generally lower.78  
One reason may be the occurrence of tautomerism (lactam-lactim) in the oxindole which may 
react to give other side products.  Bordwell and Fried described the methylation of 2-oxindole 
by heating (50°C) with dimethyl sulfate in the presence of sodium hydride in xylene (68% 
yield).79 This method may be applicable to the synthesis of R2-substituted 1-methyl-2-
oxindole as illustrated by Route 2. The 1-methylated oxindole is condensed with the isatin by 
the usual acid catalyzed aldol condensation. The mechanism of N-methylation of oxindole is 




















Scheme 3-3. Reagents and conditions: (a) NaH, Me2SO4, xylene, 50°C, 3hrs, (b) AcOH, HCl, 
















Figure 3-4 Mechanism for N-methylation of 2-oxindole. 
 
 
3.3.2. Synthesis of Series 1 
Isoindigo 1-1 was readily synthesized by reacting isatin and 2-oxindole via either 
conventional heating (acetic acid/HCl, reflux, 16 h) or in a microwave assisted reaction 
(acetic acid/HCl, 200 deg, 30 min). Yields did not differ significantly for the 2 methods (87% 
versus 91%). 
Meisoindigo (1-2) was synthesized by either N-methylation of isatin followed by 
condensation with oxindole (Route 1) or reacting commercially available 1-methyl-2-
oxindole with isatin (Route 2) (Scheme 3-4).  The methylation of isatin proceeded with 
quantitative yield but Route 2 was preferred for its economy (1 step reaction). Interestingly, 
the condensation between 1-methyl-2-oxindole and isatin by conventional heating gave 
slightly better yield (56%) than the microwave assisted procedure (40%).  The same was true 
for the reaction between 1-methylisatin and 2-oxindole where conventional heating gave 72% 
yield as compared to 63% by microwave heating.   
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Scheme 3-4. Reagents and conditions: (a) MeI, K2CO3, 0°C to RT, DMF, 3hrs, (b) AcOH, 
HCl, reflux, 16hrs; or AcOH, HCl, MW, 200°C, 30min. 
 
The dimethylated analog 1-3 was synthesized by reacting isoindigo (1-1) with excess 
methyl iodide in a microwave assisted reaction (Scheme 3-5). It was obtained in near 
quantitative yield (95%).  The dihydroisoindigo 1-4 was obtained by a palladium catalyzed 
hydrogenation of isoindigo at atmospheric conditions (Scheme 3-5). 1-4 was likely obtained 
as a mixture of isomers (2 enantiomers and a meso compound) but no attempt was made to 
separate the stereoisomers for evaluation of growth inhibitory activity.  
 
Scheme 3-5. Reagents and conditions: (a) MeI, K2CO3, DMF, MW, 150°C,10min (b) Pd/C, 
H2, RT, 2hrs, atmospheric pressure  
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3.3.3. Synthesis of Series 2 
The Series 2 compounds 2-1 to 2-7, 2-10, 2-12, 2-14 to 2-15, and 2-17 to 2-21 were 
prepared by reacting an N-alkylated isatin with an oxindole in an acid catalyzed aldol reaction 
(Route 1). Except for 1-phenylisatin which was commercially available, the other N-alkylated 
isatins were synthesized and obtained in reasonable yields (34-97%).   
Special mention is made of 1-(2-hydroxyethyl)indolin-2,3-dione (B-20) which is the 
common isatin intermediate for the 2-20 and 2-21.  As shown in Scheme 3-6, B-20 was 
prepared by reacting isatin with 2-bromoethanol followed by condensation with 2-oxindole in 
ethanol (2-20) or acetic acid (2-21). Acetic acid concurrently acetylates the OH group to give 
2-21.   
  
Scheme 3-6. Reagents and conditions: (a) 2-Bromoethanol, K2CO3, DMF, MW, 150°C, 
20min, (b) 2-oxindole, AcOH, HCl, reflux, 16hrs, (c) 2-oxindole, EtOH, HCl, reflux, 16hrs. 
 
The remaining Series 2 compounds (2-8, 2-9, 2-11, 2-13, 2-16) were not synthesized 
by Route 1 but by a direct alkylation of isoindigo in DMF and K2CO3 with microwave heating 
(150°C, 30 min) (Route 3, Scheme 3-7).  It is a shorter and more convenient synthetic method 
but could not be widely applied to the Series 2 compounds due to the difficulty encountered 
in separating the unreacted isoindigo from the desired product by column chromatography. 
The difficulty is due to the elution of the desired product after isoindigo from the column.  
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Thus it is difficult to obtain it without traces of isoindigo due to tailing.  Furthermore, the 
latter could not be removed by re-crystallization. Thus, Route 3 was applied only to those 
compounds for which Route 1 or 2 gave extremely poor yields or was not feasible.  For 
example, the syntheses of 2-9 and 2-13 by Route 1 gave yields of 9% and 21% (2 step), 
mainly due to the poor yields of the final aldol condensation step. In contrast, they were 
obtained in 33% and 42% yields by Route 3.  
 
 
Scheme 3-7: Reagents and conditions: (a) K2CO3, R1 halide, DMF, MW, 150°C, 30min. 
  
2-8 was synthesized by Route 3 (Scheme 3-8).  The phenolic OH of 4-(2-
bromoethyl)phenol was protected from deprotonation by reaction with tetrahydropyran. The 
protecting group was then removed by reaction with pyridinium p-toluenesulfonate (PPTS) in 
ethanol after the alkylation reaction.   
 
Scheme 3-8: Reagents and conditions: (a) DHP, PPTS, DCM, RT, 16hrs, (b) Isoindigo, 
K2CO3, DMF, MW, 150°C, 30min, (c) PPTS, EtOH, 60°C, 3hrs. 
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In the case of 2-11 (Scheme 3-9), the amino group was obtained by metal-acid 
reduction of the nitro group of 4-(2-bromoethyl)nitrobenzene and then acetylation to give the 
intermediate B-11, followed by reaction with isoindigo.80 The alternative route (Route 1) of 
alkylating isatin with B-11 was achievable but the subsequent aldol condensation proceeded 
in extremely low yields.  The option of not reducing the nitro group until after the side chain 
has been attached to isoindigo was considered but not found to be successful as reduction 
affected both the nitro group and the 3,3’ double bond of the isoindigo ring.  
 
Scheme 3-9. Reagents and conditions: (a) AcOH, Fe, MeOH, reflux, 2hrs, (b) AcCl, TEA, dry 
DCM, reflux, 1hr, (c) Isoindigo, K2CO3, DMF, MW, 150°C, 30min. 
  
2-16 was synthesized by reacting (2-chloroethoxy)benzene (B-16) with isoindigo. 
(Scheme 3-10) B-16 was prepared by the microwave-assisted alkylation of phenol with 1,2-
dicholoroethane.81  
 
Scheme 3-10. Reagents and conditions: (a) 1,2-dicholoroethane, K2CO3, MeOH, MW, 140°C, 
30min, (b) K2CO3, DMF, MW, 150°C, 30min. 
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3.3.4. Synthesis of Series 3 
The Series 3 compounds are ring A or ring B substituted analogs of meisoindigo. 
They were synthesized by reacting 1-methylisatin (substituted on ring A or otherwise) with an 
oxindole (substituted on ring B or otherwise) as shown in Route 1, Scheme 3-11. 
Alternatively, the compound is obtained by reacting 1-methyl-2-oxindole (substituted on Ring 
A or otherwise) with an isatin (substituted on ring B or otherwise) as shown in Route 2, 
Scheme 3-12.  The choice of either route was determined primarily by the availability of the 
starting reactants. 
 
Scheme 3-11. Reagents and conditions: (a) MeI, K2CO3, 0°C to rt, DMF, 3hrs, (b) 2-oxindole, 




Scheme 3-12. Reagents and conditions: (a) NaH, Me2SO4, xylene, 50°C, 3hrs, (b) isatin, 
AcOH, HCl, reflux, 16hrs, (c) AcOH, HCl, reflux, 16hrs. 
 
3-1 to 3-12 are substituted (R2) on ring A which is also the ring with the 1-methyl 
group.  Except for 3-8 and 3-12, these compounds were synthesized by reacting commercially 
available substituted isatins with methyl iodide in the presence of K2CO3 to give intermediates 
(C-1 to C-7, C-9 to C-11) which were then condensed with oxindole (Route 1, Scheme 3-11).   
For 3-8 and 3-12,   Route 2 (Scheme 3-12) was followed because of the availability of 
R2 substituted oxindoles. The substituted oxindole was methylated by dimethylsulfate in the 
presence of sodium hydride and xylene as solvent79 to give intermediates (C-8, C-12) which 
were then condensed with isatin.  
3-13 to 3-30 are substituted (R3) on ring B which is not the ring with the 1-methyl 
group.  3-13 to 3-19 and 3-21 to 3-23 were conveniently synthesized by Route 2, using 
commercially available 1-methyl-2-oxindole and the substituted (R3) isatin. On the other hand, 
3-20, 3-24 to 3-30 were synthesized by Route 1 because of the availability of the substituted 
(R3) oxindole.  
3-25, 3-29 and 3-30 were also prepared by Route 1. These compounds require a 
common oxindole intermediate (6-amino-2-oxindole, C-25) which was synthesized following 
a reported method by Marfat and Carta.82 The method involved catalytic reduction of the nitro 
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groups in 2,4-dinitrophenylacetic acid, followed by acid catalyzed intramolecular cyclization 
of the adjacent amino and carboxylic acid functionalities to give the oxindole ring of C-25.  
Reductive amination of the amino group in C-25 with formaldehyde in the presence of 
cyanoborohydride in acetic acid gave the 6-dimethylamino-2-oxindole C-26 (Scheme 3-13).   
Acetylation of the amino group of C-25 with acetic anhydride gave the amide C-29 and 
reacting C-25 with methanesulfonyl chloride yielded the sulfonamide C-30.  The oxindole 




 Scheme 3-13. Reagents and conditions: (a) Pd/C, H2, MeOH, 45psi, rt, 2.5hrs, (b) 5N HCl, 
reflux, 16hrs, (c) NaBH3CN, formaldehyde, AcOH, rt, 24hrs, (d) Ac2O, H2SO4, rt, 2hrs, (e) 
MeSO2Cl, ACN, 0°C to rt, 3hrs, (f) AcOH, HCl, reflux, 16hrs, or EtOH, HCl, reflux, 7hrs. 
 
3.3.5. Synthesis of Series 4 
The series 4 compounds (4-1 to 4-5) were prepared by reacting synthesized 
intermediates B-13, B-17, B-4, B-5 and B-6 (Section 3.5.3.1) with commercially available 6-
methoxy-2-oxindole in an acid catalyzed aldol condensation. 
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Scheme 3-14. Reagents and conditions: (a) 6-Methoxy-2-oxindole, AcOH, HCl, reflux, 16hrs. 
 
3.3.6. Synthesis of Series 5 
 Series 5 compounds are characterized by the presence of the side chain p-
methoxyphenethyl at position 1.  Route 1 was employed for their syntheses. (Scheme 3-15)  
For 5-1 to 5-11, appropriately substituted isatins were alkylated by reaction with p-
methoxyphenethyl bromide in the presence of calcium hydride and DMF as solvent to yield 
the intermediates E-1 to E-11 (41-87%). This was followed by aldol condensation with 2-
oxindole in acetic acid.   
For 5-12 to 5-25 which are substituted on ring B, isatin was alkylated with p-
methoxyphenethyl bromide under similar conditions to give B-6 and then condensed with 
substituted 2-oxindoles to give the desired isoindigos.  The substituted 2-oxindoles were 
either commercially available or synthesized as described in Section 3.3.4.  
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Scheme 3-15. Reagents and conditions: (a) p-methoxy-phenethyl bromide, K2CO3, 80°C, 
DMF, 3hrs, (b) 2-oxindole, AcOH, HCl, reflux, 16hrs, (c) AcOH, HCl, reflux, 16hrs 
 
3.3.7. Synthesis of Series 6 
Series 6 comprise compounds with an ionizable basic heterocyclic ring at position 1 
(6-1 to 6-6) and azaisoindigo analogs (6-7, 6-8) Several approaches were investigated for the 
syntheses of 6-1 to 6-6. The first approach was based on Route 3, namely direct alkylation at 
position 1 of isoindigo with the alkyl halide (F-1 to F-4). The alkyl halides (F-1 to F-4) were 
synthesized by reacting 2-bromoethanol with the basic heterocycle (morpholine, 
thiomorpholine, piperidine, N-methylpiperazine) 83 followed by displacement of OH (a poor 
leaving group) by Cl from thionyl chloride. The resulting intermediate (F-1 to F-4) was then 
reacted with isoindigo in the final alkylation step (K2CO3, DMF) to give the desired product 
(Scheme 3-16).   
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Scheme 3-16: Reagents and conditions: (a) Toluene, triethylamine, reflux, 4hrs, (b) thionyl 
chloride, 0°C-80°C, 2hrs, (c) isoindigo, K2CO3, DMF, 80°C, 4h. 
 
The main problem with this reaction sequence was the instability of the intermediates 
F-1 to F-4.  The instability was attributed to the formation of quaternary aziridinium cations 







X= O, C, NCH3, CH2  
Figure 3-5: Formation of quaternary aziridinium cations. 
 
In view of the electronegative character of chlorine in the side chain of these 
intermediates, the carbon atom to which it is attached is electrophilic and would in turn be 
attacked by the lone pair of electrons on the N of the heterocyclic ring, thus giving rise to an 
aziridinium cation.  
It was observed that F-1 to F-4 were obtained as liquids after reaction with thionyl 
chloride. They were soluble in chloroform but on standing at room temperature in an inert 
atmosphere, solidification occurred and the resulting solids were soluble in water and not 
chloroform.   In the case of F-4 which was left to stand for a week, the aziridinium species 
was detected as the major molecular ion peak in the mass spectrometry spectrum while F-4 
was present as a minor peak. Fortunately, the intermediates varied in their stabilities. Based 




Figure 3-6: Time taken for intermediates F-1 to F-4 to solidify under room temperature 
conditions in an atmosphere of argon. 
 
The apparent stability of F-1 is attributed to the presence of the electron withdrawing 
O atom in morpholine which serves to reduce the nucleophilicity of the basic N atom.  The 
pKa values of the basic heterocycles are of the order piperidine (most basic, pKa 11.2) > N-
methylpiperazine (pKa 9.65) > thiomorpholine (pKa 9.1) > morpholine (pka 9.0) (ACD labs 
12.0), which broadly reflects the proposed sequence of reactivity of the intermediates F-1 to 
F-4.    
To circumvent the instabilities of the intermediates F-1 to F-4, they were immediately 
characterized (NMR, MS) after synthesis and reacted with isoindigo on confirmation.  The 
desired compounds were purified by column chromatography and at this stage it was found 
that 6-1 and 6-4 eluted out of the column after isoindigo. As mentioned in Section 3.3.3 
(Route 3), it is difficult to achieve adequate purification under these circumstances. Thus, the 
syntheses of 6-1 and 6-4 by this route (Scheme 3-16) were abandoned. On the other hand, 6-2 
and 6-3 eluted out of the column before isoindigo and these compounds could be adequately 
purified.  However, the alkylation yields of 6-2 and 6-3 were relatively low (16-20%).  
The synthesis of 6-1 and 6-4 was next attempted by reacting F-1 and F-4 with isatin 
to give the N-alkylated isatins F-5 and F-6, which were then reacted with 2-oxindole in the 
usual way (Scheme 3-17).  Two technical problems were encountered with this route.  First, 
during the work-up of the N-alkylated isatins F-5 and F-6, it was necessary to adjust the pH 
to 9-10 to ensure that the intermediate was present as the free base and available for extraction 
into the organic solvent.  However, the pH adjustment had to be done carefully (preferably < 
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pH 10) because the isatin ring is prone to hydrolysis in an alkaline pH, presumably due to ring 
opening of the amide containing 5-membered ring.83, 84  Thus, some decomposition invariably 
occurred during the extraction of the alkylated isatins, contributing to their low yields.  The 
other problem pertains to the purification of F-5 and F-6 by column chromatography. In view 
of their polar nature, they eluted very slowly from the column although the process was 
hastened by the addition of triethylamine (up to 5%) to the mobile phase.  Both 6-1 and 6-4 
were successfully synthesize by this route but in low overall yields (28%, 29%, 3 steps).  F-5 
was also reacted with 6-methoxy-2-oxindole to give 6-5 in 27% yield. 
 
Scheme 3-17. Synthesis of 6-1 and 6-4 Reagents and conditions: (a) isatin, K2CO3, DMF, 
80°C, 4hrs, (b) 2-oxindole, AcOH, HCl, reflux, 16hrs. 
 
Although several of the Series 6 compounds could be synthesized by the preceding 
methods, they were obtained in generally low yields. This led to a re-examination of the 
reaction route in the light of the problems encountered with stability and purification of the 
intermediates.  It was decided that to avoid the formation of polar /unstable intermediates, the 
heterocyclic ring should be introduced at the final stage of the synthetic scheme.  Thus, the 
following reaction sequence was proposed (Scheme 3-18).  It involved the alkylation of isatin 
with dibromoethane to give 1-(2-bromoethyl)indolin-2,3-dione (F-7).20 The latter was reacted 
with 2-oxindole to give the corresponding isoindigo (F-8) after which the bromine atom in the 
side chain was displaced by the incoming basic heterocycle. Scheme 3-18 illustrates the 
reaction sequence for the synthesis of 6-4. 6-6 was also synthesized by reacting F-7 with 6-
methoxy-2-oxindole to give F-9, followed by displacement of bromine by N-
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methylpiperazine.   The intermediates F-7, F-8 and F-9 were less polar and more readily 
purified by column chromatography. The relative ease of purification and the presence of the 
common intermediate F-7 make the reaction sequences illustrated in Scheme 3-18 an 
attractive and convenient means for the synthesis of 6-1 to 6-3 as well.  
 
Scheme 3-18. Reagents and conditions: (a) 1,2-dibromoethane, K2CO3, DMF, rt, 4hrs, (b) 2-
oxindole, AcOH, HCl, reflux, 16hrs, (c) N-methylpiperazine, triethylamine, DMF, 80°C, 
16hrs, (d) 6-methoxy-2-oxindole, AcOH, HCl, reflux, 16hrs. 
 
The remaining Series 6 compounds (6-7, 6-8) are functionalized azaisoindigos.  The 
azomethine N is present in Ring B while Ring A of the scaffold is substituted at position 1 
with 1-methyl (6-7) or 1-(p-methoxyphenethyl) (6-8).  1H-Pyrrolo[2,3-b]pyridine-2(3H)-one 
(7-aza-2-oxindole) (F-11) is the common intermediate for both 6-7 and 6-8. It was 
synthesized by a reported method 82 starting from 7-azaindole which was reacted with 
pyridinium bromide perbromide (PBPB), a brominating and oxidizing agent, to give 3,3-
dibromo-1H-pyrrolo[2,3-b]pyridine-2(3H)-one (F-10). (Scheme 3-19, Figure 3-7) 
Debromination of F-10 by hydrogenation gave F-11 which was then condensed with 1-
methylisatin (A-2) or 1-(p-methoxyphenethyl)isatin (B-6) to give the desired products.  The 
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acid catalyzed aldol condensation was carried out in ethanol and not acetic acid as solvent to 
prevent unwanted acetylation of the pyridine N in the final product. 
  
Scheme 3-19. Synthesis of 6-7 & 6-8. Reagents and conditions: (a) PBPB, t-BuOH, rt, 6hrs, 
(b) Pd/C, H2, 50psi, rt, 4hrs, (c) A-2 or B-6, EtOH, HCl, reflux, 4hrs. 
 
 
Figure 3-7: Proposed mechanism for the formation of F-10.  
 
3.3.8. Synthesis of Series 7 
 The synthesis of 7-1 and 7-2 was achieved by reacting 3-acetoxyindole with either 
isatin or 1-methylisatin (A-2) in the presence of sodium carbonate as a base.85 The reaction 
mechanism involves base catalyzed hydrolysis of the acetoxy ester to the enolic intermediate 
which then reacts in an aldol condensation with the isatin to give the indirubin after 
dehydration. (Figure 3-8) 7-1 and 7-2 were obtained in good yields (ca. 80% ). 
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Figure 3-8: Mechanism of based-catalyzed hydrolysis and aldol condensation of 3-
acetoxyindole to give indirubins 7-1 and 7-2. 
 
3.4. Summary 
The syntheses of 93 functionalized isoindigos were successfully achieved. Of these 
compounds, 83 have not been cited in the SciFinder Scholar when checked on 12th July 2011, 
which may indicate that they are novel compounds.  The final compounds were at least 95% 
pure when evaluated by elemental analysis or reversed phase HPLC on 2 different mobile 
phases.  
 
3.5. Experimental methods 
3.5.1. General Details 
ClogP values were calculated using ChemDraw 7.0 software (Cambridgesoft, UK). 
Estimated solubilities were predicted by ACD/Labs 12 software (Physicochemical & 
ADMET prediction suite)(Canada). Reagents (synthesis grade or better) were purchased from 
Sigma-Aldrich Chemical Company Inc (Singapore) or Alfa Aesar (Regent Chemicals Pte Ltd, 
Singapore) unless otherwise specified and used without purification.  
1H NMR spectra were determined on a Bruker Spectrospin 300 Ultrashield 
spectrometer and referenced to residual solvent peaks (CDCl3 at δ 7.26, DMSO-d6 at δ 2.50) 
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as internal standard. Analysis of the peaks was performed on the MesRec version 4.9.9 
software (Spain). 13C NMR spectra (75MHz) were determined on the same instrument and 
reported in ppm (δ) relative to residual CDCl3 (δ 77.0) and DMSO-d6 (δ 39.5). Coupling 
constants (J) were reported in Hertz (Hz). Proton (1H) NMR spectral information is reported 
in the following format: multiplicity, coupling constant, number of protons. Multiplicities are 
reported as follows: s (singlet), brs (broad singlet), d (doublet), t (triplet), q (quadruplet), m 
(multiplet), dd (doublet of doublet), dt (doublet of triplet), td (triplet of doublet).  Spectral 
assignments are given in Appendix 3-1. 
Melting points were determined on a Gallenkamp melting point apparatus and 
reported as uncorrected values. Mass spectra were captured on LCQ Finnigan MAT 
equipment with a chemical ionization (APCI) probe and m/z values for the molecular ion 
were reported. Microwave assisted reactions were carried out on Biotage Initiator ® 
instrument. Merck silica 60 F254 sheets and Merck 45 silica gel (0.040-0.063) were used for 
thin layer chromatography (TLC) and flash chromatography respectively.  Spectroscopic data, 
melting points and purities of target compounds and their corresponding intermediates are 
given in Appendix 3-1.  Briefly, purities of final compounds are verified either by combustion 
analysis or by reversed phase HPLC. Combustion analysis (C, H) was performed on a Perkin 
Elmer PRE-2400 Elemental Analyzer. Criteria for purity were no more than 5% deviation of 
found % C and %H values as compared to theoretical values, and peak areas ≥ 95% in 
chromatograms obtained from 2 different solvent systems. Details are given in Appendix 3-2.  
 
3.5.2. Series 1  
3.5.2.1. (E)-[3,3'-biindolinylidene]-2,2'-dione (1-1) 
To a solution of isatin (2 g, 13.6 mmol) and 2-oxindole (1.81 g, 13.6 mmol) dissolved 
in 15ml glacial acetic acid in a 20ml microwave vessel was added 2 drops of conc HCl. The 
vessel was sealed and subjected to microwave irradiation at 200°C for 30 min. The resultant 
crude mixture was concentrated in vacuo, ethyl acetate (30 mL) was added to the residue and 
vigorously stirred. After 1 h at 4°C, the suspension was filtered under reduced pressure, rinsed 
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with chilled ethyl acetate and dried in the oven. 1-1 was obtained as a dark violet powder. 
Yield: 91% 
1-1 was also obtained by refluxing isatin (2 g, 13.6 mmol) and 2-oxindole (1.81 g, 
13.6 mmol) in 15 ml glacial acetic acid to which was added 2 drops of conc HCl.  The 
solution was refluxed at 140°C for 16hrs, and worked up as described above. Yield: 96% 
 
3.5.2.2. 1-Methylindoline-2,3-dione (A-2) 
To a solution of isatin (294 mg, 2 mmol) dissolved in anhydrous DMF (1.5 mL) in a 
5ml microwave vessel was added anhydrous K2CO3 (400 mg). The vessel was sealed and the 
contents allowed to stir at room temperature (RT, 30°C) for 15min. Methyl iodide (3 eqv) was 
injected into the vessel, stirred for 5 min and heated in a microwave reactor at 150°C for 
15min.  Deionized water (5 mL) was added to quench the reaction and the suspension was 
extracted with ethyl acetate. The organic layer was dried using anhydrous Na2SO4, 
concentrated, and purified either by recrystallization with ethanol or by flash chromatography 
(isocratic 3:1 hexane / ethyl acetate as eluting solvent). Orange crystals. Yield: 92.9% 
A-2 was also obtained by a non-microwave heating reaction.  To a solution of isatin 
(2 mmol) dissolved in anhydrous DMF (1.5 mL) in a 10mL flask was added either anhydrous 
K2CO3 (400 mg) or anhydrous CaH2 (2.2mmol). The solution was stirred at RT for 15min, 
cooled to 0 °C after which was added methyl iodide (1.1 eqv) dropwise. The mixture was 
stirred for another 5 min on ice, then warmed up to RT and stirred for 3hr.  It was worked up 
as described earlier. Yield: 95.1% (K2CO3), 99.5% (CaH2) 
 
3.5.2.3. (E)-1-Methyl-[3,3'-biindolinylidene]-2,2'-dione /meisoindigo (2-2)  
2-2 was obtained by reacting equimolar quantities (2 mmol) of A-2 and 2-oxindole in 
15 mL glacial acetic acid spiked with 2 drops of conc HCl. The mixture was subjected by 
microwave heating or reflux as described for the synthesis of 1-1. A similar workup 
procedure was followed and the crude mixture was purified by column chromatography 
(DCM).  1-2 was obtained as a dark violet powder. Yield: 41% 
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Alternatively, 1-2 was obtained by reacting equimolar quantities (2 mmol) of isatin 
and 1-methyl-2-oxindole can under similar conditions as the microwave /normal reflux 
method. A similar workup protocol was followed.  1-2 was obtained as a dark violet powder 
in 49% yield.  
 
3.5.2.4. (E)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione (1-3) 
To a solution of isoindigo (265 mg, 1 mmol) dissolved in 2.5ml anhydrous DMF in a 
5 ml microwave vessel was added dry K2CO3 (400 mg, 2.9 mmol) and allowed to stir at RT 
for 15 min. Methyl iodide (624 µL, 10mmol) was added to the mixture, stirred for another 
5min and heated in a microwave reactor (150°C, 10min). 5ml of water was added to quench 
the reaction. The suspension was shaken vigorously and left to stand in the refrigerator (4°C) 
for 1hr. The suspension was filtered under reduced pressure, rinsed with excess water and 
dried in the oven. Recrystallization with ethanol gave 1-3 as dark violet powder. Yield: 95% 
 
3.5.2.5. [3,3'-biindoline]-2,2'-dione (1-4) 
To a solution of isoindigo (1-1, 350 mg, 1.3 mmol) dissolved in 20ml of ethanol in a 
50ml flask was added 35 mg of 10% Pd/C. Hydrogen gas was bubble into the solution and 
stirred at RT for 2hrs. The suspension was filtered under reduced pressure and rinsed with 
cold ethanol to give a pale yellow powder. Yield: 93%. 
 
3.5.3. Series 2 analogues 
3.5.3.1. General method for the preparation of 1-alkylated isatin intermediates (B-2, B-3, B-4, 
B-5, B-6, B-7, B-12, B-13, B-17, B-20) 
Isatin (1 equivalent), anhydrous K2CO3 (1.2eqv) and anhydrous DMF (2-4mL) were 
added to a 5ml microwave vessel which was sealed and the contents stirred at RT for 15min. 
The alkyl halide (1.1 eqv) was injected into the vessel and stirring was continued for another 
5 min before reaction in a microwave reactor at 150°C for 15-30min.  At the end of the 
reaction, water was added to the mixture. Depending on the solubility, the compound was 
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either filtered and rinsed with deionized water or extracted with ethyl acetate / 
dichloromethane (DCM). For the latter, the organic layer was dried with anhydrous Na2SO4 
and the organic solvent was removed in vacuo. Purification by column chromatography (see 
appendix 3-1 for details) followed by recrystallization with ethanol gave the desired product. 
   
3.5.3.2. General method for the preparation of 1-alkylated isatin intermediates (B-10, B-14, 
B-15, B-18, B-19)  
Isatin (1 equivalent), anhydrous CaH2 (1.2eqv) and anhydrous DMF (2-4mL) were 
stirred together in a flask for 15 min at RT.  The alkyl halide (1.1eqv) was added and the 
mixture heated to 80°C for 2-4hrs.  Extraction was performed using either ethyl acetate or 
DCM with brine. The organic layer was dried (anhydrous Na2SO4), concentrated in vacuo and 
purified by column chromatography (see appendix 3-1 for details) and recrystallization with 
ethanol.  
 
3.5.3.3. N-(4-(2-chloroethyl)phenyl)acetamide (B-11) 
A solution of 4-nitrophenethyl bromide (1 g, 4.3 mmol) in 16ml glacial acetic acid / 
7.5ml methanol was heated to 65°C in an oil bath. Iron powder (870 mg, x2) was added in 2 
portions, 30min apart. The mixture was stirred for 2.5hrs, 65°C, concentrated in vacuo. 
Extraction with DCM/ brine was performed after pH was adjusted to 10 with ammonia 
solution.  The organic layer was dried (anhydrous Na2SO4) and concentrated in vacuo to give 
a colourless liquid. The latter was dissolved in dry DCM (4 ml) to which was added 
triethylamine (600 µL, 2.2eqv) followed by acetyl chloride (300 µL, 2.2eqv), after which the 
mixture was refluxed for 1 h. The reaction was quenched with aqueous NaOH (0.1 M), 
extracted with DCM/ brine and washed successively with 0.1M NaHCO3 (aq) and 0.1M HCl. 
The organic layer was dried (anhydrous Na2SO4), concentrated in vacuo and purified by 
column chromatography (isocratic 2:1 hexane/ethyl acetate as eluant) to give B-11, as a beige 
powder.  31% yield. 
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3.5.3.4. (2-chloroethoxy)benzene (B-16) 
Phenol (10 mmol), anhydrous K2CO3 (15 mmol) and methanol (8 mL) were stirred in 
a sealed microwave vessel (20 mL) at RT, 15 min before heating in a microwave reactor at 
140°C for 30min. The mixture was extracted with DCM and the DCM layer was washed with 
aqueous K2CO3 solution before drying (anhydrous Na2SO4). The solvent was removed in 
vacuo and residue purified by column chromatography (isocratic 100% hexane as eluant) to 
give B-16 as a colourless oil. Yield 43%. 
 
3.5.3.5. General method for the preparation of 1-alkylated isoindigos (2-2, 2-3, 2-4, 2-5, 2-7, 
2-12) by aldol condensation  
The alkylated isatin (B-2, B-3, B-4, B-5, B-7 or B-12) (1 equivalent) and 2-oxindole 
(1.1 equivalent) were dissolved in acetic acid (1-3 mL) containing conc HCl (2 drops) in a 
sealed vessel and stirred at RT for 5 min. It was then heated in a microwave reactor at 200°C 
for 20-30min. The mixture was cooled, concentrated in vacuo and extracted with DCM/brine 
or ethyl acetate/ brine. The organic fraction was dried (anhydrous Na2SO4), concentrated and 
purified by column chromatography (see appendix 3-1 for details) to give the desired product.  
 
3.5.3.6. General method for the preparation of 1-alkylated isoindigos (2-1, 2-6, 2-10, 2-14,   
2-15, 2-17, 2-18, 2-19, 2-20, 2-21) by aldol condensation  
The alkylated isatin (1-phenylisatin, B-6, B-10, B-14, B-15, B-17 to B-19, B-21) (1 
equivalent), 2-oxindole (1.1 equiv) were dissolved in acetic acid containing 2 drops conc HCl 
and refluxed for 12-14 h. The mixture was worked up as described in Section 3.5.3.5. 2-20 
was prepared in a similar way by refluxing the same starting as 2-21 in ethanol instead of 
acetic acid. 
 
3.5.3.7. General method for the preparation of 1-alkylated isoindigo via direct alkylation onto 
isoindigo (2-9, 2-11, 2-13, 2-16) 
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Isoindigo 1-1 (1 equivalent) and anhydrous K2CO3 (1.1 eqv) were dissolved in 
anhydrous DMF (2-4mL) in a sealed microwave vessel and stirred at room temperature for 
15min. The appropriate alkyl halide (1.1 eqv) was added and the mixture heated in a 
microwave reactor 150°C for 30min. Extraction was performed using either DCM/brine or 
ethyl acetate/brine and the organic fraction was dried (anhydrous Na2SO4), concentrated in 
vacuo and purified by column chromatography (see appendix 3-1 for details) to give the 
desired product.  
 
3.5.3.8. (E)-1-(4-hydroxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione (2-8) 
To a solution of p-hydroxyphenethyl bromide (600 mg, 3 mmol) and dihydro-2H-
pyran (411 µL, 4.5mmol) in 5ml DCM was added pyridinium p-toluenesulfonate (PPTS, 75 
mg, 0.3 mmol) and the mixture was stirred for 16 h at RT. It was then concentrated in vacuo, 
extracted with DCM/brine and the organic fraction was dried (anhydrous Na2SO4), 
concentrated and purified by column chromatography (isocratic 20:1 hexane/ethyl acetate as 
eluting solvent). The tetrahydropyranyl ether was obtained as a colorless liquid in 80% yield 
and reacted with isoindigo (390 mg, 1.5 mmol) and K2CO3 (310 mg, 2.25 mmol) in 2mL 
anhydrous DMF as described in Section 3.5.3.7. After workup, the residue from the column 
(155 mg) was reacted with PPTS (20 mg) in refluxing ethanol for 3 h. The solvent was 
removed in vacuo, the residue extracted with ethyl acetate/brine. The organic layer was dried 
(anhydrous Na2SO4), concentrated, and purified by recrystallization in ethanol to give the 
desired product as red solid in 34% yield. 
 
3.5.4. Series 3 
3.5.4.1. General method for the preparation of 1-methylated substituted isatins (C-1, C-2, C-3, 
C-4, C-5, C-6, C-7, C-9, C-10, C-11) 
The 1-methylated isatins were prepared by reacting the corresponding substituted 
isatin with methyl iodide as described in Section 3.5.2.2 using reflux method. (See Appendix 
3-1 for details) 
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3.5.4.2. General method for the preparation of 1-methylated substituted 2-oxindoles (C-8,    
C-12) 
To a solution of substituted 2-oxindole (2 mmol) in xylene (4 mL) was added NaH (2 
mmol) followed by dimethylsulfate (2 mmol) and allowed to stir at RT for 15min, after which 
the mixture was stirred at 50°C for 3h. The mixture was concentrated in vacuo and extracted 
with ethyl acetate/ brine. The organic layer was dried (anhydrous Na2SO4), concentrated, and 
purified by column chromatography (isocratic 4:1 hexane / ethyl acetate as eluting solvent) to 
give the desired product.  
 
3.5.4.3. 6-aminoindolin-2-one (C-25) 
The method of Khanwelkar and co-workers was followed.86 Briefly, a solution of 2,4-
dinitrophenylacetic acid (10 mmol) in methanol (100 mL) was hydrogenated in a Parr 
hydrogenator with 10%Pd/C (500 mg) as catalyst, RT, 2.5 h. After the reaction, more 
methanol (100 mL) was added. The mixture was sonicated (50°C, 5 min) to dissolve the 
product and was filtered through celite under reduced pressure. The filtrate was concentrated 
to 30mL, 6 mL of 2.5N HCl was added and the solution was refluxed  for 16 h.  The pH of the 
solution was adjusted to pH 10 with K2CO3 and then extracted with ethyl acetate/ brine. The 
organic fraction was dried (anhydrous Na2SO4) and concentrated in vacuo to give the desired 
product in a sufficiently pure state, yield 53%. (lit. 65%) C-25 is a pale brown powder which 
darkened rapidly on exposure to air and light.  
 
3.5.4.4. 6-(dimethylamino)indolin-2-one (C-26) 
Sodium cyanoborohydride (4.5 mmol) was added to a solution of C-26 (2 mmol) in 
glacial acetic acid (3 mL) followed by formaldehyde (4.5 mmol) and the mixture was stirred 
at RT for 24 h. The suspension was concentrated in vacuo and extracted with ethyl acetate/ 
brine. The organic layer was dried (anhydrous Na2SO4), concentrated and purified by column 
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chromatography (gradient elution from DCM to DCM + 2% ethanol) to give the desired 
product as an off white powder. Yield: 84%. 
 
3.5.4.5. N-(2-oxoindolin-6-yl)acetamide (C-29) 
A solution of C-25 (2 mmol) in acetic anhydride (4 mmol) to which was added 2 
drops of conc H2SO4  and was stirred at RT for 2 h. The solution was concentrated in vacuo 
and extracted with  ethyl acetate/ brine. The organic fraction was dried (anhydrous Na2SO4) 
and concentrated to give the desired product (light brown solid) in 69% yield.  
 
3.5.4.6. N-(2-oxoindolin-6-yl)methanesulfonamide (C-30) 
Methanesulfonyl chloride (1.2 mmol) was added dropwise to a stirred solution of    
C-25 (1 mmol) in anhydrous acetonitrile (5 ml) at 0°C. When effervescence had subsided, the 
solution was warmed to RT and stirred for 3hrs. The solution was concentrated in vacuo and 
extracted with ethyl acetate/ brine. The organic layer was dried (anhydrous Na2SO4), 
concentrated and purified by column chromatography (isocratic DCM + 1% ethanol) to give 
the desired product as a beige powder (yield 60%) which darkened rapidly on exposure to 
light and air.  
 
 
3.5.4.7. General method for the preparation of Series 3 compounds (3-1 to 3-7, 3-9 to 3-11) 
Equivalent amounts of the substituted 1-methyl isatin (C-1 to C-7, C-9 to C-11) and 
2-oxindole were dissolved in acetic acid containing 2 drops of conc HCl. The mixture was 
refluxed for 16 h. If the desired product precipated from the reaction mixture on cooling, it 
was removed by filtration under reduced pressure, rinsed with chilled acetic acid and 
recrystallized in ethanol.  If no precipitation was observed, the solution was concentrated in 
vacuo and extracted with DCM/brine or ethyl acetate/ brine. The organic fraction was dried 
(anhydrous Na2SO4), concentrated, and purified by column chromatography to give the 
desired product in a sufficiently pure state. (See Appendix 3-1 for details). 
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3.5.4.8. General method for the preparation Series 3 compounds (3-8, 3-12) 
Equivalent amounts of the substituted 1-methyl-2-oxindole (C-8, C-12) and isatin 
were reacted in acetic acid as described in Section 3.5.4.7. The product was obtained by the 
workup procedures described in the same section.  
 
3.5.4.9. General method for the preparation of Series 3 compounds (3-20, 3-24 to 3-30) 
Equivalent amounts of the appropriate ring substituted 2-oxindole and 1-methylisatin 
were reacted in acetic acid as described in Section 3.5.4.7. The product was obtained by the 
workup procedures described in the same section.  
 
3.5.4.10. General method for the preparation of Series 3 compounds (3-13 to 3-19, 3-21 to    
3-23) 
Equivalent amounts of 1-methyl-2-oxindole and ring substituted isatin were reacted in 
acetic acid as described in Section 3.5.4.7. The product was obtained by the workup 
procedures described in the same section.  
 
3.5.5. General method for synthesis of Series 4 compounds (4-1 to 4-5) 
 The method described in Section 3.5.3.6 was followed. Briefly, the alkylated isatin 
(B-13, B-17, B-4, B-5, B-6) were reacted with 6-methoxy-2-oxindole in refluxing acetic acid 
to give the desired product on workup (Section 3.5.3.5).  
 
3.5.6. Series 5 
3.5.6.1. General method for the preparation of Series 5 compounds (E-1 to E-11) 
The method described in Section 3.5.3.2 was followed. Briefly, the substituted isatin 
was reacted with 4-methoxyphenethyl bromide in the presence of CaH2 in DMF by refluxing 




3.5.6.2. General method for the preparation of Series 5 compounds (5-1 to 5-11) 
The method described in Section 3.5.3.6 was followed. Briefly, the substituted 1-(p-
methoxyphenethyl)isatin (E-1 to E-11) was reacted with 2-oxindole in refluxing acetic acid to 
give the desired product.  The product was obtained by the work-up procedure described in 
Section 3.5.3.5.  
 
3.5.6.3. General method for the preparation of Series 5 compounds (5-12 to 5-25) 
5-12 to 5-25 were prepared following the method described in Section 3.5.4.7. Briefly, 
1-(p-methoxyphenethyl)isatin (B-6) was reacted with appropriate ring substituted 2-oxindole 
in refluxing acetic acid.  The product was obtained by the workup procedures described in the 
same section.  
 
3.5.7. Series 6 
3.5.7.1. General method for the preparation of F-1 to F-4. 
The basic heterocycle (morpholine, thiomorpholine, piperidine or N-methylpiperazine) 
(10 mmol), triethylamine (12 mmol) and 2-bromoethanol (12 mmol) were dissolved in 
toluene (5 mL) and stirred at 80°C for 4h. The reaction mixture was concentrated in vacuo 
and DCM (5mL) added. The solution was cooled to 0°C and SOCl2 (30 mmol) was added 
dropwise. After effervescence has subsided, the mixture was heated to 80°C and reacted for 2 
h. The crude mixture was adjusted to pH 10 with K2CO3 and extracted using DCM/ brine. The 
product was obtained by column chromatography (See Appendix 3-1 for details) as oils which 
solidified on standing.  
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3.5.7.2. General method for the preparation of F-5 and F-6. 
Isatin (1 equivalent) and anhydrous K2CO3 (1.1 eqv) were dissolved in anhydrous 
DMF and stirred at room temperature for 15min. F-1 or F-4 (1.1 eqv) was added and the 
reaction was continued at 80°C for 4h. After this time, the pH was carefully adjusted to 8-9 
and the mixture was extracted with DCM/brine. The organic fraction was dried (anhydrous 
Na2SO4), concentrated and purified by column chromatography (See Appendix 3-1 for details) 
to give the desired product.  
 
3.5.7.3. General method for the preparation of 6-1 and 6-4. 
F-5 or F-6 (1 equivalent) and 2-oxindole (1.1 equivalent) were dissolved in acetic 
acid containing 2 drops of conc HCl. The mixture was refluxed at 140°C for 12-16h. It was 
then concentrated in vacuo and the pH was carefully adjusted to 10 before extraction with 
DCM/brine. The organic fraction was dried (anhydrous Na2SO4), concentrated in vacuo and 
purified by column chromatography (See Appendix 3-1 for details) to give the desired 
product. 
 
3.5.7.4. (E)-6'-methoxy-1-(2-morpholinoethyl)-[3,3'-biindolinylidene]-2,2'-dione (6-5) 
6-5 was prepared in a similar method as 6-4 (Section 3.5.7.3) using 6’-methoxy-2-
oxindole in place of 2-oxindole. 
 
3.5.7.5. General method for the preparation of 6-2 and 6-3. 
Isoindigo 1-1 (1 equivalent) and anhydrous K2CO3 (1.1 eqv) were dissolved in 
anhydrous DMF (4-8 mL) and stirred at RT for 15 min. F-2 or F-3 (1.1 eqv) was added to the 
mixture which was then heated at 80°C for 3 h. The mixture was extracted with DCM/brine, 
with pH adjusted to 14. The organic fraction was dried (anhydrous Na2SO4), concentrated and 




3.5.7.6. 1-(2-bromoethyl)indoline-2,3-dione (F-7) 
Isatin (10 mmol) and anhydrous K2CO3 (20 mmol) were dissolved in anhydrous DMF 
(12 mL) and stirred at RT for 15 min. 1,2-Dibromoethane (12 mmol) was added to the 
solution and stirring was continued at RT for 16 h. The suspension was filtered under reduced 
pressure and the residue rinsed with DMF to give the desired compound. The filtrate was 
concentrated in vacuo and water (20 mL) was added. A precipitate was obtained which was 
removed by filtration under reduced pressure, washed with water, combined with the earlier 
obtained material and dried in an oven (100°C). F-7 was obtained as a red solid. Yield 67%.  
 
3.5.7.7. General method for the syntheses of F-8 & F-9 
F-8 and F-9 were prepared by reacting F-7 with 2-oxindole or 6-methoxy-2-oxindole 
respectively in a refluxing acetic acid as described in Section 3.5.4.7. 
 
3.5.7.8. General procedure for synthesis of 6-4 and 6-6 from F-8 and F-9. 
A solution of morpholine or N-methylpiperazine (1 mmol) and triethylamine (2 eqv) 
was stirred in anhydrous DMF (4 mL) at RT for 15min. F-8 or F-9 (1 mmol) was added and 
the mixture was heated at 80°C for 16 h. The reaction mixture was extracted with DCM/ brine 
at pH 10, the organic layer dried (anhydrous Na2SO4) and concentrated in vacuo. The product 
was purifed by column chromatography and obtained in 52% (4-4) and 27% (4-6) yields. 
 
3.5.7.9. 3,3-Dibromo-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (F-10) 
The method of Marfat and Carta82 was followed.  Briefly, to a stirred solution of 7-
aza-2-oxindole (10 mmol) dissolved in t-butanol (70 mL) at room temperature was added 4 
equivalents of pyridinium bromide perbromide (PBPB) in small portions over 6hrs. The 
solvent was removed in vacuo and the residue extracted with ethyl acetate/ brine. The organic 
fraction was dried (anhydrous Na2SO4) and concentrated to give the crude residue which was 
dissolved in DCM, sonicated for 2 min, and filtered under reduced pressure. Recrystallization 
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of the product in toluene gave the desired compound as a light brown solid which darkens on 
standing. Yield: 80% (Lit. 86%) 
 
3.5.7.10. 1H-pyrrolo[2,3-b]pyridin-2(3H)-one (F-11) 
The method of Marfat and co-worker was followed.82 To a solution of F-10 (1 mmol) 
in ethanol was added 10% Pd/C (200 mg). Hydrogenation was carried out at 50 psi H2, RT, 4 
h in a Parr hydrogenator.  At the end of the reaction, the mixture was filtered over celite, 
solvent was removed in vacuo and the residue was used for the next step of reaction without 
further purification. Yield: 72% (Lit. 75%) 
 
3.5.7.11. General method for the preparation of 6-7 and 6-8. 
 F-11 (1 equivalent) was reacted with either 1-methylisatin A-2 (1 equivalent) or 1-(p-
methoxyphenethyl)isatin (B-6) as described in 3.5.4.7. The reaction was carried out in ethanol 
as solvent, with refluxing, 16 h. The precipitated product was filtered under reduced pressure 
and rinsed with ice-cold ethanol to give desired product.  
 
3.5.8. General method for the preparation of 7-1-7-2 
7-1 and 7-2 were synthesized by the method reported by Ferandin and co-workers.85 
Briefly, a solution of 3-acetoxyindole (1 mmol), isatin or 2-methylisatin (A-2) (1.5 mmol).in 
methanol (25 mL) was stirred at room temperature for 5min. Na2CO3 (2.5 mmol) was added 
and stirring continued for another 3 h. The suspension was filtered and washed with 50% 
aqueous methanol (20 mL) to give the 7-1 and 7-2 in 81% and 80% yield respectively.  
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Chapter 4: Cell-based growth inhibitory activities of functionalized isoindigos and 




 This chapter discusses the growth inhibitory activities of the series 1-7 compounds.  It 
is organized in two sections: the 1st section focuses on the structure-activity relationships 
established for Series 1-7 on the human chronic myelogenous leukemic cells K562. In the 2nd 
section, attention is paid to selected compounds that have demonstrated potent activity on 
K562 cells (IC50 K562 < 5 µM).  These compounds were tested across a panel of cancer cells, 
namely another leukemic cell line (acute promyelocytic leukemia, NB4) and three non-
hematological malignant cells (liver HuH7, colon HCT-116, renal RCC-786). The compounds 
were also evaluated on non-malignant lung fibroblast cells (IMR-90) to determine if these 
compounds selectively target malignant cells.  Growth inhibitory activity was determined by 
the microculture tetrazolium (MTT) assay 61, 62 and activity was expressed in terms of half 
maximal growth inhibitory concentration (IC50).  
 
4.2. Experimental 
4.2.1 Cell lines 
 Human chronic myelogenous leukemic cells K562, human normal lung fibroblast 
cells IMR-90 and human colon carcinoma cells HCT-116 were purchased from American 
Type Culture Collection (Rockville, MD). Human acute promyelocytic leukemia cells NB4, 
human liver carcinoma cells HuH7 and human renal carcinoma cells RCC-786 were obtained 
from Dr Matiullah Khan (National University of Singapore), Dr Ho Han-Kiat (National 
University of Singapore) and Dr John Yuen (Singapore General Hospital) respectively.  
 Iscove’s modified Dulbecco’s medium (IMDM, catalog no. I7633), high glucose 
Dulbecco modified eagle’s medium (DMEM, catalog no. D1152) and Eagle’s minimum 
essential medium (EMEM, catalog no. M0268) were purchased from Sigma Aldrich in 
powder form and reconstituted according to manufacturer’s instructions.  RPMI-1640 
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(Hyclone) and phosphate buffered saline (PBS) were purchased from NUMI (National 
University Medical Institutes) Laboratory Supplies, National University of Singapore.  Fetal 
bovine serum (FBS) was obtained from Gibco, South America.  3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) was purchased from Duchefa Biochemie, 
Netherlands. All other chemicals were purchased from local suppliers and were of molecular 
biology or cell culture grade. 
 
4.2.2 Propagation of cells 
The propagation of K562 cells was described in Section 2.5.5. NB4 cells were grown 
in RPMI-1640 supplemented with 10% v/v FBS, 100mg/L penicillin-G and 100mg/L 
streptomycin.  The cells were sub-cultured at a split ratio of 1:8 when cell density reached 106 
cells/mL. Only cells of passages 8–14 were used for experiments.  HuH7 cells were 
propagated in high glucose DMEM supplemented with 10% v/v FBS, 1 mM sodium pyruvate, 
100 mg/L penicillin-G and 100mg/L streptomycin. The cells were subcultured when 90% 
confluent (ratio of 1:4) and used within passages 8-16 for experiments. RCC-786 cells were 
cultured in high glucose DMEM supplemented with 10% v/v FBS, 100mg/L penicillin-G and 
100mg/L streptomycin. The cells were subcultured when 90% confluent (ratio of 1:4) and 
used within passages 9-16 for experiments. HCT116 cells were cultured in RPMI-1640 
supplemented with 10% v/v FBS, 100mg/L penicillin-G and 100mg/L streptomycin. The cells 
were subcultured when 90% confluent (ratio of 1:5) and used within passages 9-18 for 
experiments. IMR-90 cells were grown in EMEM supplemented with 10% v/v FBS, 100mg/L 
penicillin-G and 100mg/L streptomycin. The cells were subcultured when 90% confluent 
(ratio of 1:3) and used within passages 6-13 for viability experiments. 
 
4.2.3 MTT assay for determination of cell viability 
The MTT assay for K562 cells was described in Section 2.5.5.  The same method was 
applied to NB4 cells except that cells were seeded at a lower density of 4000 cells per well.  
For the non-adherent cells (HuH7, HCT116, RCC-786, IMR90), the MTT assay was modified 
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as follows: The cells in their respective media were seeded at densities of 6000 (HuH7), 2500 
(HCT116), 10,000 (RCC-786) and 4000 (IMR90) cells per well. Cells adhered to the base of 
the wells after 16-18 h incubation at 37°C, 5% CO2.  The media was removed by aspiration 
and replaced by fresh media containing the test compound at varying concentrations. The 
final concentration of DMSO vehicle was kept at 0.4% v/v per well for all cell lines. The cells 
were incubated for 72hrs at 37°C, 5% CO2, after which time the media was removed by 
aspiration and the cells gently rinsed with PBS to remove residual compound. 100 µL of MTT 
(0.5mg/ml in PBS) was added to each well and incubated for 4 h at 37°C. The MTT solution 
was removed gently by aspiration and the formazan crystals dissolved in 100 µL of DMSO. 
Absorbances were measured within 30 min at 595 nm on a microplate reader as described 
earlier. Cell viability at a given concentration is determined from the following expression: 
 
Percentage Viability = (A test compound – A blank / A vehicle   – A blank) x 100 
 
where A test compound = absorbance of wells with cells exposed to test compound in media;  A 
vehicle = absorbance of wells with cells in media and A blank = absorbance of wells with DMSO 
only. Each concentration was tested at least 3 times on separate occasions, using two different 
stock solutions, and on cells of different passage numbers. The IC50 value (concentration 
required to reduce growth by 50% compared to untreated cells) was determined from the 
sigmoidal curve obtained by plotting percentage viability versus logarithmic concentration of 
test compound using GraphPad Prism 5.0 (San Diego, USA). 
 
4.2.4 Statistical analysis 
 Data was analyzed for statistical significance by one-way ANOVA followed by 
Dunnett (2-sided) post-hoc test on SPSS 18.0 for Windows, Chicago, IL. p < 0.05 was taken 
as a criterion for significance.  
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4.3 Results  
4.3.1 Growth inhibitory activity on human chronic myelogenous leukemic cells K562. 
 
4.3.1.1. Series 1 
The growth inhibitory activity of Series 1 compounds (1-1 to1-4) (Figure 4-1) have 
been discussed in Section 2.2.5.  Briefly, the findings highlighted the importance of at least 
one available NH group, and an intact exocyclic double bond for activity.  The NH group may 
be required as a H bond donor and the intact double bond serves to ensure planarity of the 
scaffold.   
 
Figure 4-1: IC50 K562  values of Series 1 compounds.   
 
4.3.1.2. Series 2 
The series 2 compounds are characterized by the presence of different substituents in 
place of the 1-methyl group found in meisoindigo. The results are given in Table 4-1.   
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Table 4-1: IC50 K562 and Clog P values of Series 2 compounds 
 
No. R1 ClogP 4 
IC50 
(µM)1 No. R1 ClogP
4 IC50 (µM)1 
























4.73 5.30 (0.97) 2-15  




















5.31 >30 3 2-18 
 
2.15 24.21 (2.20) 
2-8 
 

















1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3  Could not be determined due to limited solubility. >50% viability was observed at the stated concentration. 




The following structure-activity trends are deduced: 
(i) Replacing 1-methyl (1-2) with 1-phenyl (2-1) or 1-phenalkyl homologs (2-2, 2-3, 2-13) 
generally did not adversely affect activity. The 1-phenpropyl analog 2-13 is in fact more 
active than meisoindigo (1-2), and the most potent analog identified in Series 2. It is also one 
of the more lipophilic compounds in the series. Interestingly, activity was not correlated to 
lipophilicity as revealed by the absence of a significant correlation (p > 0.05) between IC50 
and ClogP of Series 2 compounds when tested by Spearman Bivariate Correlation.  
(ii) Substitution of the phenyl ring of the phenethyl analog 2-3 shows that the p-methoxy 
group is favored over groups like F, NO2, OH and CH3. The p-methoxyphenethyl analog 2-6 
is equipotent to meisoindigo, but the m-methoxy analog 2-5 is significantly more active. It is 
noted that only the methoxy occupies the -π, -σ  quadrant of the Craig Plot unlike the other 
groups. 
(iii) Replacing the phenethyl ring of the 2-3 with cyclohexyl resulted in a significant 
improvement in activity but at the expense of a steep increase in lipophilicity (ClogP 4.81  
5.89).  
(iv) Rigidifying the propyl side chain of 2-13 with a double or triple bond either decreased 
activity (2-15) or left it unchanged (2-14). A slight decline is noted when an ether linkage was 
inserted in the propyl side chain (2-16).  On the other hand, 2-17 which has a p-methoxy 
group on the phenyl ring is as active as 2-13. In the same way, inserting a p-methoxy group 
onto the phenethyl side chain of 2-3 gave 2-6 which is equipotent to 2-3. 
(v) Replacing 1-methyl of meisoindigo with alkyl side chains containing polar CN and OH 
groups (2-18 to 2-20) had mixed effects on activity. Only the longer chain butanenitrile 
analog (2-19) was more active, not the shorter propanenitrile (2-18) and hydroxyethyl (2-20) 
side chains. Acetylation of the OH group in 2-20 improved activity, possibly due to a 
concurrent reduction in polarity, increase in size or change in the H bond status of the side 




4.3.1.3. Series 3 
 Series 3 was explored with the aim of understanding the effect of substituting ring A 
or ring B of meisoindigo. 3-1 to 3-12 are substituted on ring A with halogen (F, Cl or Br) or 
methoxy at position 5, 6 or 7.   Position 6 appears to be the more favored position as 6-
halogen (3-5 to 3-7) or 6-methoxy (3-8) analogs were comparable to meisoindigo in terms of 
IC50. (Table 4-2) Substitution at other positions (5 and 7) resulted in diminished activity. The 
exceptions are the 5-methoxy and 7-methoxy analogs, both of which retained comparable 
activities to meisoindigo.   
3-13 to 3-24 are analogous to the ring A substituted analogs 3-1 to 3-12, except that 
the substitutents are now attached on ring B. The privilege position of 6 (6’ on ring B) is less 
evident here, with good activity observed for only 6’-Br (3-19) and 6’-methoxy (3-20). 
Notably, the 6’-methoxy analog (3-20) is significantly more potent than meisoindigo but not 
the 5’-methoxy (3-16) or 7’-methoxy (3-24) analogs. Position 7’ appears to be the least 
favored position on ring B, even more so than position 7 on ring A.  
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Table 4-2 IC50 K562 values of compounds 3-1 to 3-26. 
 
No. R2  ClogP 4 
IC50 
(µM)1 No. R3 ClogP 
4 IC50 
(µM)1 
3-1 5-F 2.86 19.24 (1.30) 3-13 5’-F 3.11 
18.20 
(0.89) 
3-2 5-Cl 3.43 32.23 (2.46) 3-14 5’-Cl 3.68 
21.85 
(3.55) 
3-3 5-Br 3.58 >30 3-15 5’-Br 3.83 14.41 (1.88) 




3-5 6-F 2.86 10.87 (0.93) 3-17 6’-F 3.11 
14.82 
(1.65) 
3-6 6-Cl 3.43 11.08 (1.27) 3-18 6’-Cl 3.68 
18.45 
(2.40)  
3-7 6-Br 3.58 9.84 (0.69) 3-19 6’-Br 3.83 
6.71 
(1.03) 




3-9 7-F 2.86 13.45 (1.38) 3-21 7’-F 3.11 
32.89 
(2.67) 
3-10 7-Cl 3.43 17.12 (0.96) 3-22 7’-Cl 3.68 >30 
3 
3-11 7-Br 3.58 20.82 (0.65) 3-23 7’-Br 3.83 >30 
3 




3-25 6’NMe2 2.89 >30 3 
3-26 6’CF3 4.05 >30 3 
3-27 6’CN 2.74 >30 3 
3-28 6’SO2CH3 1.72 >30 
3-29 6’NHCOCH3 1.73 7.04 (0.51) 
3-30 6’NHSO2CH3 1.52 7.96 (0.25) 
1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3  Could not be determined due to limited solubility. >50% viability was observed at the stated concentration. 
4 ClogP values were determined from ChemDraw 7.0.  
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To test if methoxy is indeed a favored substituent at 6’, groups with different 
electronic and lipophilicity properties were introduced at this position (Table 4-2, 3-25 to      
3-30). These groups are drawn from different quadrants of the Craig Plot, as described in 
Section 3.2.3.  Only 6’-acetylamino (3-29) and 6’-methylsulfonylamino (3-30) (+σ, -π groups) 
were found to have IC50 values <10 µM, but they were still less potent than 6’-methoxy (-σ, -
π). There appears to be a preference for less lipophilic (-π) groups but the σ status of the 
substituent may not be critical.  
 
4.3.1.4. Series 4 
 
Table 4-3 IC50 K562 values of compounds 4-1 to 4-5. 
 
 
No. R1 ClogP 6 IC50 (µM)1 
Corresponding 
compound in Series 2 

















4.80 >20 5 2-4 5.30 (0.97) 
4-4 
 










1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3 Significantly lower than 3-20 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
4 Significantly lower than it corresponding Series 2 analogue (p < 0.05, 1-way ANNOVA, Dunnett post hoc). 
5  Could not be determined due to limited solubility. >50% viability was observed at the stated concentration. 




Several promising 1-substituents were identified in Series 2. These are 1-phenpropyl 
(2-13), 1-(p-methoxyphenpropyl) (2-17), and the isomeric 1-(methoxyphenethyl) (2-4 to 2-6) 
analogs.  In Series 4, these side chains are “combined” with the favored 6’-methoxy to give  
4-1 to 4-5 (Table 4-3). Based on the IC50 values, it is seen that only one compound 4-5 (IC50= 
0.50 µM) was more potent than its corresponding Series 2 analog (2-6, IC50= 6.09µM). Its 
dose response curve is depicted in Figure 4-2.  4-5 is also more potent than meisoindigo 
(IC50= 7.75 µM) and 3-20 (IC50= 3.18 µM). Of the remaining series 4 compounds, only 4-1 is 
almost as potent as its Series 2 analog 2-13.  
 




The IC50 values of 4-1 to 4-5 were also compared with 3-20 with the aim of 
establishing the importance of 1-methyl (in 3-20) versus the different  side chains present in 
Series 4. It is noted that only the phenpropyl (4-1) and p-methoxyphenethyl (4-5) analogs 
were more potent than 3-20, indicating that the presence of 6’-methoxy does not always result 
in improved activity. More likely, activity is influenced by the interplay between 6’-methoxy 
and the position 1 side chain.  Another observation is that the inclusion of 6’-methoxy widens 
the range of activity, which spans 0.5µM to > 20µM in Series 4 (with 6’ methoxy) as 
compared to 1.7µM to 6.1µM in series 2 (without 6’ methoxy).   
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4.3.1.5. Series 5 
Having shown that the greatest activity is associated with 6’-methoxy and 1-(p-
methoxyphenethyl) side chain in 4-5, the next step was to determine if other ring A or B 
substituents coupled with 1-(p-methoxyphenethyl) would lead to a more potent compound. 
Series 5 was designed with this purpose in mind. As seen from Table 4-4, the structure 
activity trends in Series 5 are closely aligned to that observed in Series 3.  Firstly, the 6’ 
position is clearly superior to other positions on rings A and B. Secondly, 6’-methoxy remains 
the most favored substituent. On ring A, 6-methoxy (5-8) outperformed other substituents 
(halogens) but is still 10 times less potent than its 6’-methoxy counterpart (4-5). Interestingly,  
the 6’-halogen analogs 5-15 to 5-17 have good activity which was just slightly less than 6’-
methoxy 4-5. 5-15 to 5-17 are also significantly more potent than 2-6, suggesting an 
important contribution to activity by occupancy of the 6’ position by halogens or methoxy. 
Thus, Series 5 differs from Series 3 in the type of groups at position 6’ which promoted 
activity.  In Series 3, a 6’-methoxy is clearly preferred whereas in Series 5, a 6’-methoxy has 
only a slight edge over some 6’-halogens. 
  Estimated solubilities indicate that the Series 5 compounds are generally 100 fold 
less soluble than Series 3 compounds (Section 3.2.5, Table 3-5), which is anticipated given 
the greater molecular mass and lipophilicities of these compounds. Indeed, many of the Series 
5 compounds, notably the 7’-F and 7’ Br analogs, could not be tested at concentrations >10 
µM because of their poor solubilities. 
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Table 4-4 IC50 K562 values of compounds 5-1 to 5-20. 
 
 
No. R2 ClogP 5 IC50 (µM)1 No. R3 ClogP 5 IC50 (µM)1 
5-1 5-F 4.87 18.58 
(0.82) 
5-12 5’-F 5.13 14.03 
(1.53) 
5-2 5-Cl 5.44 >30 4 5-13 5’-Cl 5.70 12.01 (0.51) 
5-3 5-Br 5.59 >30 4 5-14 5’-Br 5.85 12.04 (0.60) 
5-4 5-OMe 4.65 >30 4  
 
5-5 6-F 4.87 >30 4 5-15 6’-F 5.13 2.42 
2,3 
(0.28) 
5-6 6-Cl 5.44 >30 4 5-16 6’-Cl 5.70 1.05 
2,3 
(0.10) 
5-7 6-Br 5.59 10.75 
(1.62) 
5-17 6’-Br 5.85 1.06 
2,3 
(0.17) 
5-8 6-OMe 4.65 5.15 
2 
(0.90) 




5-9 7-F 4.87 22.24 (2.51) 5-18 7’-F 5.13 >10 
4 
5-10 7-Cl 5.44 >30 4 5-19 7’-Cl 5.70 >30 4 
5-11 7-Br 5.59 >30 4 5-20 7’-Br 5.85 >10 4 
  
 
5-21 6’-NMe2 4.89 >30 4 
5-22 6’-CF3 6.06 9.81 (1.21) 
5-23 6’-CN 4.76 13.82 (0.14) 
5-24 6’-SO2CH3 3.73 10.30 (0.54) 
5-25 6’-NHCOCH3 3.75 9.79 (1.54) 
1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3 Significantly lower than 2-6 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
4 Could not be determined due to limited solubility. >50% viability was observed at the stated concentration. 
5 ClogP values were determined from ChemDraw 7.0.  
 
 Besides investigating halogens at position 6’, other groups drawn from different 
quadrants of the Craig Plot were investigated in 5-21 to 5-25.  As seen from Table 4-4, none 
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of these substituents are better than the 6’-methoxy analog 4-5. A similar observation was 
made for the Series 3 compounds 3-25 to 3-30 (Table 4-2) where not one of the 6’-substituted 
analogs (including halogens) proved to be better than 6’methoxy analog 3-20.  
 
4.3.1.6. Series 6 
Table 4-5: IC50 K562 values of compounds 6-1 to 6-8 
 
 
No. R1 R3 ClogP 4 IC50 ( µM) 1 
6-1 
 
H 2.67 6.81 (0.14) 
6-2 
 
H 3.40 7.91 (0.51) 
6-3 
 
H 3.88 7.70 (0.74) 
6-4 
 










6’-OMe 1.81 5.89 
2 
(0.67) 





- 4.06 >20 3 
1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3 Could not be determined due to limited solubility. >50% viability was observed at the stated concentration. 
4 ClogP values were determined from ChemDraw 7.0.  
 
The Series 6 compounds were designed to address the poor solubility profiles of the 
Series 1-5 compounds. 6-1 to 6-4 bear basic sidechains that are ionized at pH 7.4.  Only the 2-
(4-methyl-1-piperazinyl)ethyl analog 6-4 was found to be more potent than meisoindigo. 
(Figure 4-3) whereas the other analogs 6-1 to 6-3 were comparable to meisoindigo. Next, the 
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favored 6’-methoxy was introduced to 6-1 and 6-4 to give 6-5 and 6-6 respectively. This 
modification improved the activity of the 2-morpholinylethyl analog (6-5) but did not 
improve the activity of the 2-(4-methyl-1-piperazinyl)ethyl analog (6-6). Thus, there is 
additional support for the observation made in Series 4, namely that the close interplay 
between 6’-methoxy and the 1-substituent, and that 6’-methoxy works well when present 
together with  some (5-5, 6-5) but not all (5-1, 6-6) 1-substituents. Nonetheless both 6-5 and 
6-6 were more potent than meisoindigo. 
 
Figure 4-3: Dose response curve of 6-4 on K562 MTT assay. Error bars indicates standard 
deviation 
 
The synthesis of the azaisoindigos 6-7 and 6-8 was another approach at improving 
solubility. 6-7 is the azaisoindigo analog of meisoindigo, while 6-8 is the azaisoindigo analog 
of 2-6.  Both compounds were poorly active with IC50 values > 15 µM. In spite of their high 
estimated solubilities (1.6 mM for 6-7, 20 µM for 6-8), practical handling of 6-7 and 6-8 
suggest ed that their actual solubilities may be equivalent or lower than that of meisoindigo 
and 2-6 respectively. 
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4.3.1.7 Series 7 
 Series 7 comprise functionalized induribins which were tested in the IMAP assay 
(Section 2.2.2.).  Table 4-6 lists the IC50 values of these compounds.  Indirubin (7-1) and 1-
methylindirubin (7-2) have poor activity (IC50 >20 µM) compared to their isoindigo analogs 
(1-1, 1-2), besides having poor solubilities.  The oximes 7-3 and 7-4 are more soluble but only  
the 6-bromo-3’oxime analog 7-4 exhibited good activity.  It is significantly more active than 
meisoindigo but not 4-5, the most potent analog identified in this study. 
 
Table 4-6: IC50 K562 values of compounds 7-1-7-4 
 
 
No. R5 R6 ClogP 3 IC50 (µM) 1 
7-1 H - 3.17 >20 2 
7-2 CH3 - 3.84 >20 2 
7-3 - H 3.52 21.83 
(1.86) 
7-4 - 6-Br 2.40 1.26 
(0.05) 
1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Could not be determined due to limited solubility. >50% viability was observed at the stated 
concentration. 
3 ClogP values were determined from ChemDraw 7.0. 
 
 
4.3.2. Growth inhibitory activity of selected compounds on other cell lines 
 Thirteen compounds were selected for further evaluation of growth inhibitory 
activities on a panel of malignant cells. These are compounds that are more potent than 
meisoindigo on K562 cells, although 3-28 is included as a representative inactive compound.  
Their structures and IC50 K562 are presented in Figure 4-4.   
As described in 4.3.1, several compounds in Series 2 were found to be more potent 
than meisoindigo but only three compounds  – 2-13, 2-14, 2-17 – were shortlisted for further 
evaluation.   2-6 which is equipotent to meisoindigo was also included because it is the lead 
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compound for 4-5 and 5-15 to 5-17.  In Series 6, only 6-4 was selected because of its better 
solubility profile. Other compounds included were 3-20 and 4-1. 
 
 
Figure 4-4: Structures and IC50 K562 of compounds shortlisted for further evaluation of cell 
viability effects on other cell lines.  
 
 
Table 4-7 lists the IC50 values of the compounds on solid tumor cells: liver HuH7, 
renal RCC-786 and colon HCT-116.  The key observations are as follows: 
(i)  The growth inhibitory effects of meisoindigo (1-2) on the solid tumor cells vary according 
to the type of cells.  Activity was low for HuH7 and HCT-116 (IC50 > 20 µM) but improved 
for RCC-786 where its activity was comparable to K562 (IC50 K562 7.75 µM versus IC50 RCC-786 
5.53 µM). These observations broadly agree with those reported in the literature. Wang and 
co-workers32 reported an IC50 of 17.4 µM for meisoindigo on DU145 (hormone independent 
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prostate carcinoma cells)32  while Zuo and co-workers reported an IC50 value of 4.3 µM for 
meisoindigo against colorectal HT29 cells.46 
(ii) The test compounds are generally less potent on the non-leukemic cells (HuH7, RCC-786, 
HCT-116) as compared to the leukemic cells (K562).  
(iii) There is a general trend whereby compounds that are more potent than meisoindigo on 
K562 cells are also more potent than meisoindigo on HuH7 and HCT-116 cells. An exception 
is 2-6 which was potent on HuH7 and HCT116 cells, in spite of being equipotent to 
meisoindigo on K562 cells.  3-28 remained inactive across all the test cell lines.  4-5 did not 
retain its “most active” status on HuH7 and HCT 116 cells.   Instead, the most active 
compounds were 5-17 (HuH7) and 4-1 (HCT116).  
(iv) More variation in growth inhibitory activity is observed in RCC-786 cells.  Most of the 
test compounds were as potent as meisoindigo but there were some with more (6-4) or less  
(3-20, 5-15) growth inhibitory activities. The good activity of 6-4 on RCC-786 stands in 
contrast to its moderate activity on HCT116 and HuH7. 
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Table 4-7: IC50 values of compounds listed in Figure 4-4 on K562, HuH7, RCC786 and HCT 
116 cells. 
 
 IC50 (µM)  1 
Compound K562 HuH7 RCC-786 HCT-116 








































































































1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 on the specified cell line (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3 Could not be determined due to limited solubility. >50% viability was observed at the stated 
concentration. 
 
 The results in Table 4-7 point to a possible selective activity of the test compounds on 
leukemic cells. So, they were tested on another human leukemic cell line NB4 which differs 
from K562 in being of promyelocytic origin. In addition to the selected compounds in Figure 
4-4, several water soluble Series 6 compounds (6-1 to 6-3, 6-5 to 6-6) were included.  Besides 
NB4, the compounds were also tested against a non-malignant cell line (lung fibroblast IMR-




Table 4-8: IC50 values of selected compounds on NB4 and IMR-90 cells 
 
Compound 
IC50 /µM 1 Selectivity ratio 
K562 NB4 IMR-90 IMR90/K562 IMR90/NB4 




(0.27) 1.55 5.04 
































3 >6 >8 
3-28 >30 15.90 (0.75) >30 
3 n/a n/a 


































(0.24) 5.33 8.67 





































(0.70) 4.93 3.29 
1  Mean (standard deviation) for n ≥ 3 determinations. 
2 Significantly lower than 1-2 on the specified cell line (p < 0.05, 1-way ANOVA, Dunnett post hoc). 
3 Could not be determined due to limited solubility. >50% viability was observed at the stated 
concentration. 
 
 The results show that meisoindigo has greater growth inhibitory activity on NB4 cells 
(IC50 NB4 = 2.38 µM versus IC50 K562 = 7.75 µM).  The same is true for the test compounds, 
although the Series 6 compounds are marginally less active (1.1 – 1.6 times) on NB4 cells.   
4-5 is again the most active compound on NB4 cells, with an even lower IC50 than on K562 
cells (IC50 NB4 = 0.18 µM versus IC50 K562 = 0.50 µM).  
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 Meisoindigo and the test compounds were found to be less potent on the non-
malignant cells IMR-90 than on the leukemic cells. The difference in activity is particularly 
marked for NB4 versus IMR90 cells, where fold difference ranged from 1.6 to 27 times, as 
compared to K562 versus IMR-90 cells (1.3 to 9.6 fold difference).   Special mention should 
be made of 4-5 which combines exceptional potencies on K562 and NB4 (IC50 <1 µM) with 
excellent selectivity (9.6 – 27 fold difference).  The Series 6 compounds are somewhat 
disappointing in that they were less potent on the leukemic cells than the other compounds 
and had only modest selectivities (no more than 5 fold) for the leukemic cells.   
 
4.4. Discussion 
 The results presented in this chapter provide a useful insight into the structure activity 
requirements for growth inhibition of the K562 leukemic cells by functionalized isoindigos. It 
is evident that the isoindigo scaffold (Series 1) is superior to the indirubin scaffold (Series 7) 
One can only speculate on the reasons for this difference between these isomeric scaffolds. 
Possible factors may be the presence of two amide (lactam) moieties in isoindigo, as 
compared to only one in indirubin and the role of intramolecular H bonding which is possible 
only in indirubin.   
 Turning to the isoindigo scaffold, activity depends on the presence of at least 1 
unsubstituted amide NH. The planarity of this scaffold is also critical, but it should be noted 
that indirubin is inactive notwithstanding its planarity.  As for substitution on the amide NH, 
it is telling that many of the groups explored in Series 2 are actually no better than indirubin 
or meisoindigo. The more active side chains (phenpropyl 2-16, p-methoxyphenpropyl 2-17, 
phenylprop-1-enyl 2-14) are usually lipophilic and bulky but there is apparently no significant 
correlation between the lipophilicities of the Series 2 compounds and their growth inhibitory 
activities.   
 As for substitution on ring A or B of meisoindigo, the results point to a preference for 
the methoxy group over halogens (less marked in Series 5 but more so in Series 3) and 
position 6 on ring A / 6’ on ring B over other positions. The 6’-methoxy has emerged as the 
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optimal group but including it into those Series 2 compounds with good activity profiles (2-4 
to 2-6, 2-13, 2-17) to give Series 4 did not always improve activity. Notably, pairing of 2 
optimal groups (6’-methoxy from 3-20 and 1-phenpropyl from 2-13) did not give a more 
potent compound (4-1). Rather, combining 6’-methoxy and the moderately active (p-
methoxyphenethyl) side chain (from 2-6) gave 4-5, which is the only compound with a 
submicromolar IC50 on K562 cells.  That the 6’-methoxy in 4-5 is optimal is reinforced from 
investigations on Series 5, which showed that notwithstanding some differences, position 6’ 
and the methoxy group retain their favored status.   
Series 2-5 have yielded several potent analogs with greater activity than meisoindigo 
but activity was achieved at the expense of an increase in lipophilicity and decrease in 
aqueous solubility (based on estimated values). Two modifications were explored in Series 6 
to address this problem. The azaisoindigos 6-7 and 6-8 proved disappointing (IC50 >15 µM).  
It is worth noting that the azaisoindigos explored by Wang and co-workers32 are isomeric to 
6-7 and 6-8 in that the azomethine N in Wang’s compounds is located at ring A at position 7, 
and not position 7’ of ring B, as in 6-7 and 6-8. The more promising azaindigos from that 
investigation had IC50 values of 8-10µM on prostate cancer cells DU143.32 It may be 
worthwhile exploring a similar modification in follow-up investigations.   
Among the Series 6 compounds which have basic side chains that are ionized at pH 
7.4, 6-4 to 6-6 are more potent than meisoindigo.  6-5 and 6-6 are substituted at 6’ position 
with methoxy and it is again evident that the potency enhancing effect of 6’-methoxy is 
contingent on its combination with certain side chains. In this case it is the 2-morpholinoethyl 
side chain to give 6-5 (IC50= 3.78µM).  It is worth noting that this side chain is not 
particularly outstanding when present by itself in 6-1. Thus activity is influenced by a critical 
but poorly understood interplay between the 6’-methoxy and 1-substitutent, as observed in   
4-5 and 6-5.  
Figure 4-5 summarizes the structural features that affect the activity of functionalized 
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Figure 4-5: Summary of structural features of functionalized isoindigos that are critical for 
growth inhibitory activity on K562 cells. 
 
The screening of meisoindigo and selected potent compounds on various malignant 
cell types highlighted their selectivity for leukemic cells (K562, NB4) as compared to 
malignant cells of non-hematological origin.  The test compounds also exhibited desirable 
selective growth inhibitory activities on the leukemic cells as compared to non-malignant 
IMR-90 cells. Mention should be made of 4-5 as it is the most potent analog identified in this 
study. 4-5 has submicromolar potencies on the leukemic cells and outstanding selective 
activity exceeding that of meisoindigo. However it is disadvantaged by its high lipophilicity 
(ClogP = 4.8) and poor aqueous solubility (estimated at 7 µM). The polar isoindigos 6-4 and 
6-5 are disappointing in that they have only moderate potencies on the leukemic cells (IC50 ~ 
5µM) and modest selectivity (2-4 fold). However, both 6-4 and 6-5 are less lipophilic (ClogP 
1.8, 2.7) and are anticipated to be more soluble (estimated at 600µM and 192µM respectively) 





The main findings of this chapter are (i) elucidation of the structural features that 
determine activity of functionalized isoindigos on K562 cells (Figure 4-5) ; (ii) evidence of 
the selective activity of meisoindigo and selected isoindigos on leukemic malignant cells; (iii) 
evidence of the modest anti-proliferative activity and selectivity of 6-1 to 6-6 which are 
designed to address the poor solubility of functionalized isoindigos; and (v) identification of 
4-5 as a potent analog with selective growth inhibitory activity on leukemic cells.  
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Chapter 5: Investigations into the physicochemical properties and effects on cell cycle & 
apoptosis of meisoindigo and selected potent analogs. 
  
5.1 Introduction  
The structural modifications described in Chapter 3 were undertaken with the aim of 
improving the drug-like profile of the functionalized isoindigos and to achieve this end 
without an overt loss of potency. The results in Chapter 4 suggest that selected Series 6 
compounds (notably 6-4 and 6-5) may have met these requirements.  Thus far, only estimated 
solubilities and lipophilicities have been collated for these compounds. Hence, 
experimentation is required to confirm these estimated values.  
A key proposal of this thesis is that growth inhibitory properties of functionalized 
isoindigos involve CDK as a target protein. The findings presented in Chapter 2 have shown 
that inhibition of CDK does not contribute to the anti-proliferative properties of the isoindigos, 
notwithstanding the potent and selective growth inhibitory effects of several members on 
leukemic cells (Chapter 4).  In particular, 4-5 has emerged as the most potent compound 
identified in this investigation, with submicromolar potencies and impressive selective 
activity exceeding that of meisoindigo.  As direct inhibition of CDK has been discounted, it is 
of interest to gain a better understanding of the processes involved in the growth inhibitory 
effects of these potent analogs.   
With this background in mind, there are 2 main objectives in this chapter: 
(i) To determine if the design strategies described in Chapter 3 have resulted in drug-like 
analogs that combine potency with desirable physicochemical profiles.  For this purpose, 
aqueous solubilities and aggregation tendencies of selected potent analogs are determined. 
(ii) To investigate some aspects of the growth inhibitory effects of selected potent analogs, in 
particular, effects on the cell cycle of leukemic K562 cells and the involvement of apoptosis. 
Interruption of the G11 and G22 phases of the cell cycle and induction of apoptosis2-4  have 
been widely reported for meisoindigo.  It is of interest to determine if these processes also 
contribute to the growth inhibitory effects of the structurally modified analogs.  
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5.2 Experimental section 
5.2.1. Determination of aqueous solubility 
 Determination of aqueous solubility was carried out on Multiscreen ® Solubility filter 
plates (Millipore-MSSLBPC10) from Millipore Corporation (MA, USA).  The protocol 
(PC2445EN00, Millipore Corporation) was followed and applied to the following compounds: 
meisoindigo (1-2), 2-6, 2-13, 3-20, 4-5 and 6-1 to 6-6.  Briefly, various concentrations of the 
test compound were prepared in Universal buffer (pH 7.4) / acetonitrile / DMSO.  The UV 
absorbances of these solutions were obtained at a pre-determined wavelength and used to 
construct a calibration curve for the test compound.  Next, a stock solution of the test 
compound in DMSO was prepared at a known concentration, diluted with Universal buffer 
(pH 7.4), dispensed into wells of the Multiscreen Solubility filter plate, and agitated for a 
period of time. The suspension was then filtered, the filtrate collected and diluted with 
acetonitrile to give the same solvent composition used to prepare the calibration solutions.  
The absorbance of the diluted filtrate was then read at the pre-determined wavelength and the 
concentration of the filtrate (taken here to be equivalent to the solubility of the test compound) 
was determined from the calibration curve. A detailed description of the method is given as 
follows. 
The test compound was dissolved in DMSO and diluted with a solution of 8 parts 
Universal buffer (45 mM potassium dihydrogen phosphate, 45 mM potassium acetate, 45mM 
ethanolamine, 0.15 M potassium chloride in MilliQ water, pH 7.4) and 2 parts acetonitrile to 
give a final concentration of 400 µM or 100 µM, with DMSO maintained at 1% v/v.  An 
aliquot (300 mL) of the solution was dispensed into a well of a UV compatible plate (Costar-
3635 96 well plate, Corning) and scanned from 230 nm to 600 nm in 2nm increments on a 
Tecan (Infinite M200) microplate reader to identify the optimal wavelength (found to be 396 
nm) (Appendix 5-1).  
Next, solutions the test compound were prepared with the following concentrations: 
400µM, 200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM and 3.13 µM in the same 
solvent system (Universal buffer-acetonitrile-DMSO) described in the preceding paragraph. If 
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the compound precipitated at 400 µM and 200 µM, these concentrations were omitted.  The 
absorbances of the solutions were determined at 396 nm and the readings were used to 
construct a calibration curve of absorbance versus concentration.  Representative calibration 
curves are given in Appendix 5-2.   
To determine the solubility of the test compound, the stock solution of the test 
compound in DMSO was diluted with Universal buffer (pH 7.4) to give a final concentration 
of 400 µM or 100 µM in 300 uL per well in the Multiscreen ® Solubility filter plate. Final 
concentration of DMSO was kept at 1% v/v. Triplicate determinations were made for each 
compound. Control wells containing Universal buffer and DMSO (1% v/v) but without test 
compound were similarly prepared The plate was gently shaken (200 rpm) at room 
temperature on a plate shaker for either 30 min or 24 h. The suspension was then filtered 
under reduced pressure on a vacuum manifold (Millipore-MAVM0960R). 240 µL of the 
filtrate was transferred to a 96 well UV/Vis analysis plate (Costar-3635, Corning), 60 µL of 
acetonitrile was added and the absorbance of the resulting solution was measured at 396 nm. 
Aqueous solubility was calculated using the following equation: 
 
Aqueous solubility (µM) = 1.25 x (A FILTRATE – A VEHICLE) / g , 
 
where A FILTRATE is the absorbance of the test compound, A VEHICLE is the absorbance of the 
control well and g represents the gradient of the standard curve. 
 
5.2.2. Assessment of aggregation tendency by dynamic light scattering (DLS) 
 Stock solutions (10 mM) of test compounds were prepared in DMSO and serially 
diluted with potassium phosphate buffer (5 mM, pH 7.4, pre-filtered before use) to give final 
concentrations of 0.5 µM, 1 µM, 5 µM and 10 µM. Concentration of DMSO was maintained 
at 1% v/v in the final solutions. DSL measurements were carried out using a Malvern 
Instrument Zetasizer Nano ZS system equipped with a 4 mW He-Ne laser at 633 nm. The 
detector angle was 90 deg. Three or more independent measurements of derived count rates 
(in kilocounts per second, kcps) were made for each concentration of test compound, using at 
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least two separately prepared solutions. Results are represented as mean ± standard deviation. 
Size of particles were also collated at each concentration. Data collection and quality 
assessment were carried out using the software supplied with the instrument.  
 
5.2.3. Cell cycle analysis by flow cytometry 
Human chronic myelogenous leukemia K562 cells were propagated as described in 
Section 2.5.5. Cells were seeded at a density of 2.0x105 cells/mL in each well of a 6-well 
plate and treated with a known concentration of test compound for 24 h at 37°C, 5% CO2.  
The cells were then harvested, centrifuged at 200 g for 10min and rinsed once with chilled 
PBS.  106 cells were suspended in 300 µL of PBS and ice cold absolute ethanol (700 uL) was 
added dropwise to the cell suspension with intermittent vortexing between additions. The cell 
sample was kept at 4°C overnight and subsequently stored at -20°C prior to analysis. For 
analysis, the sample was centrifuged at 200 g for 10min to remove the fixing solution, the cell 
pellet was rinsed with chilled PBS and re-suspended in 1mL of staining solution which 
contained  0.2 mg/ml RNase A (MP Biomedicals, France) and 20 µg/ml PI (propidium iodide) 
(Sigma-Aldrich, catalog P-4170) in PBS. The cell suspension was then kept for 15min in the 
dark at room temperature, after which it was immediately analyzed for cell cycle distribution 
on a Dako Cytomation Cyan LX instrument (Dako Colorado, Fort Collins, CO, USA) 
equipped with argon solid state laser (488 nm) using Summit (Version 4.3) software. 20,000 
cells were read for each determination. Each test compound was evaluated at 5 concentrations 
with at least 3 repeats per concentration. 
 
5.2.4 Apoptotic cell determination by Annexin V/ propidium iodide (PI) staining 
The Annexin V-FITC Apoptosis Detection Kit from Sigma-Aldrich (Catalog  
APOAF) was used. K562 cells were seeded at a density of 2.0x105 cells/mL in each well of a 
6-well plate and treated with a known concentration of test compound for 24 h (or 48 h) at 
37°C, 5% CO2. Cells were harvested, centrifuged (200 g , 10min),  the cell pellet rinsed with 
chilled PBS and re-suspended in 1x binding buffer at a density of 106 cells/mL.  Annexin V-
 116 
FITC conjugate protein (5 µL) and propidium iodide solution (10 µL) were added to an 
aliquot (500 µL) of cell suspension and incubated at room temperature, 10min in the dark, 
after which flow cytometric analysis was immediately carried out on the Dako Cytomation 
Cyan LX instrument (Dako Colorado, Fort Collins, CO, USA) using the Summit (Version 4.8) 
software. Unstained treated cells, treated cells stained with Annexin V-FITC only and treated 
cells stained with PI only were used for calibration and compensation. 20,000 cells were read 
for each sample determination. Each test compound was evaluated at 5 concentrations with at 
least 3 repeats for those concentrations that were associated with apoptosis.  
 
5.2.5 Statistical analysis 
 Data was analyzed for statistical significance by one-way ANOVA followed by 
Dunnett post-hoc test on SPSS 18.0 for Windows, Chicago, IL. p < 0.05 was taken as the 
criterion for significance. Spearman bivariate correlation analysis was carried out using the 
same software.   
 
5.3 Results 
5.3.1. Aqueous solubilities of test compounds 
The aqueous solubilities of meisoindigo (1-2) and selected compounds are given in 
Table 5-1.  Compounds were selected based on their potencies in the cell viability assays     
(2-13, 3-20, 4-5 are the most active compounds in their respective series), their status as lead 
compounds (1-2, 2-6) or their intended design as water soluble analogs (6-1 to 6-6). (Figure 




Figure 5-1: Structures of isoindigos selected for solubility determination 
 
The method of solubility determination used here provides estimates of kinetic, not 
thermodynamic, solubility.  For this reason, determinations were made at 2 time points (30 
min which was recommended by the protocol and 24 h) to determine if a longer period of 
agitation would give a more stable reading. It was noted that the solubilities of some 
compounds (2-13, 6-5) significantly decreased after 24 h of agitation but most compounds 
showed only incremental decreases (< 3-fold) or no change in solubility after 24h. Solubilities 
at both time points were significantly correlated (Spearman ρ = 0.782, p = 0.004) but for 
discussion purposes, reference will be made to values obtained after 24 hours of agitation.  
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Table 5.1 Solubility of Test Compounds determined at room temperature (28°C) in Universal 
buffer (pH 7.4) containing 1% v/v DMSO.  
 
 Concentration of test compound in filtrate (µM)1 





1-2 3 1.53 - 7.92 (0.81) 
8.34 
(1.48) 
2-6 3 3.64 - 11.68 (1.35) 
9.49 
(3.78) 
2-13 3 4.16 - 59.05 (3.64) 
14.98 
(2.10) 
3-20 3 1.82 - 37.77 (3.18) 
23.87 
(1.33) 
4-5 3 3.93 - 22.33 (1.58) 
22.36 
(3.65) 
6-1 4 1.16 6.94 34.30 (2.99) 
34.59 
(0.90) 
6-2 4 2.20 6.71 13.82 (0.86) 
8.95 
(0.66) 
6-3 4 1.57 8.76 13.98 (1.82) 
5.29 
(0.55) 
6-4 4 0.51 7.65 399.52 
5 
(1.97) 
348.38 5  
(3.23) 
6-5 4 1.47 6.88 88.56 (1.57) 
13.64 
(2.65) 





1  Corresponds to solubility of test compound given as mean (standard deviation) of n = 3 independent 
determinations. 
2  Log D pH 7.4  and pKa values were estimated from ACD Labs Version 6.0. 
3 Concentration of initial solution from which filtrate was derived :100 µM. 
4 Concentration of initial solution from which filtrate was derived: 400 µM. 
5 Solubility may exceed reported values because no precipitate was observed in the starting solutions (400 µM).  
 
Based on solubility estimates made after 24 h, there is an indication that the presence 
of a methoxy substituent improves solubility. Notably, introducing 6’-methoxy on rings B of 
meisoindigo (1-2) and the p-methoxyphenethyl analog 2-6 resulted in analogs (3-20 and 4-5 
respectively) which were at least 2 times more soluble. 6-1 to 6-6 are anticipated to have 
improved solubilities in view of the ionizable basic side chains in these compounds, but as 
can be seen from Table 5-1, this is not always the case.  The N-containing heterocycle plays 
an important role in modulating solubility.  Poor solubilities were associated with the 
thiomorpholine (6-2) and piperidine (6-3) analogs whereas 6-4 and 6-6 which have N-
methylipiperazinyl side chains were significantly more soluble.  The basicity of the 
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heterocyclic nitrogen as reflected in the pKa of the compound, determines the proportion of 
ionized species present at pH 7.4. However, pKa values of 6-1 to 6-6 per se are not correlated 
to solubility. Rather it is logD pH 7.4  (estimated, Table 5-1) that is significantly and inversely 
correlated to solubility (Spearman ρ =  -0.943, p = 0.005). Thus, greater solubilities are 
associated with compounds that are less lipophilic at physiological pH (smaller log D values).  
6-4 and 6-6 which have the N-methylpiperazinyl side chains (pKa 7.6) have the lowest 
estimated logD pH 7.4 values and are the most soluble members in Series 6. On the other hand, 
the thiomorpholinyl analog 6-2 and the piperidinyl analog 6-3 have higher estimated logD pH 
7.4 values and accordingly, lower solubilities.  Log D is determined by both the partition 
coefficient (logP) and pKa as given by the following equation (for bases): 
 
log D = log P + log [ 1 / (1+ 10 pKa – pH)] 
 
Thus, both the basicity of the side chain (which will determine the proportion of polar 
ionized species present at the stated pH) and the lipophilicity of the non-ionized compound 
contribute to the final log D value.  This is nicely illustrated for the N-methylpiperazinyl 
analogs 6-4 and 6-6 whose low log D values are likely due to their intrinsically low 
lipophilicities (Table 4.5, clogP 1.76, 1.81) while for the thiomorpholinyl analog 6-2, its 
comparatively high log D (2.20) is the result of its lipophilic character (Table 4.5, clogP 3.40) 
and the relatively small proportion of polar ionized species at pH 7.4.  
 
5.3.2. Formation of colloidal aggregates  
 Indirubin and indigo have been reported to form colloid-like aggregates in aqueous 
solutions.87 The tendency of compounds to form such aggregates (“aggregators”) has been 
widely investigated.87-93 Aggregators may inhibit proteins in a non-specific manner and lead 
to misinterpretation of biological data. They are well represented among “false positives” in 
high thorough-put screens88 and may adversely affect pharmacokinetics by delaying 
absorption and altering distribution sites.93 They also share characteristic physical chemical 
features like low solubility, high lipophilicity and extended conjugation.90 As these features 
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are characteristic of the present series of compounds and, in view of the known aggregate 
forming ability of indigo and indirubins,87 there is concern that aggregate formation may be a 
shared property of the synthesized compounds, in particular those listed in Table 5-1 which 
have been identified for their potent growth inhibitory effects.  
Various experimental approaches have been used to identify compounds that form 
aggregates.  These include investigating the time dependence of enzyme inhibition, sensitivity 
to non-ionic detergents, sensitivity to enzyme concentration and formation of light scattering 
particles.89 The latter is used here to investigate aggregate formation.  Briefly, the method 
involves measuring the light scattering capacity of a known concentration of test compound in 
aqueous buffer (containing 1% v/v DMSO). The presence of light scattering particles in 
solution will result in a high count rate (measured in kilocounts per sec, kcps). The mean 
particle size of the solution is also monitored. Aggregators have been reported to form 
particles of 30-1000 nm in diameter.90 The test compounds were evaluated at various 
concentrations (0.5 µM – 10 µM).   Benzyl benzoate (at 250 µM), a known aggregator94, 95, 
was used as a positive control.  The results of the light scattering measurements are given in 
Table 5-2. 
Negligible scattering was detected for phosphate buffer with or without 1% DMSO.  
The known aggregator benzyl benzoate at 250 µM had a high light scattering count (680 
kcps), with particle size averaging 373 nm. Thompson and co-workers reported ca. 6500 
kcps94 for benzyl benzoate at 250 µM (particle size 540 nm95) using the same instrument 
whereas Seidler and co-workers reported a lower value of 30 kcps90 for 250 µM benzyl 
benzoate and particle size of 893nm90 using a different instrument. Both these investigators 
used 50 mM phosphate buffer as vehicle. A buffer of higher ionic strength has been reported 
to increase the particle size of aggregates.88 A comparison of the present values and those 
reported in the literature clearly shows that light scattering is highly dependent on the 
experimental conditions.  
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Table 5-2. Dynamic light scattering (kilocount per sec) and particle size measurements of test 
compounds.  
 
 Light scattering count  (kcps) 3 
Particle size 
(nm) 3 
Buffer1 only 9 (0) 0 
Buffer1 containing 
1% v/v DMSO 2 9 (0) 0 
Benzyl benzoate 
(250µM) 680 (4) 373 (8) 
 
1-2 
10 µM 480 (15) 981 (86) 
5 µM 200 (20) 1238 (66) 
1 µM 11 (1) 1518 (162) 
 
2-6 
10 µM 460 (20) 569 (69) 
5 µM 199 (5) 673 (26) 
1 µM 13 (1) 836 (58) 
 
2-13 
10 µM 409 (14) 244 (19) 
5 µM 189 (17) 306 (10) 
1µM 11 (1) 803 (68) 
 
3-20 
10µM 408 (14) 294 (20) 
5 µM 185 (8) 359 (40) 
1 µM 11 (1) 722 (43) 
 
4-5 
10 µM 455 (14) 241 (22) 
5 µM 204 (7) 268 (61) 
1 µM 14 (2) 545 (71) 
0.5 µM 4 (1) 1151 (52) 
 
6-1 10 µM 12 (0) 55 (9) 5 µM 10 (0) 0 
 
6-2 10 µM 17 (1) 108 (12) 5 µM 12 (0) 3 (6) 
 
6-3 10 µM 16 (1) 692 (88) 5µM 12 (0) 279 (20) 
 
6-4 10 µM 11 (0) 0 5 µM 10 (1) 0 
 
6-5 10 µM 10 (0) 0 5 µM 9 (0) 0 
 
6-6 10 µM 11 (0) 0 5µM 10 (0) 0 
1 Potassium phosphate buffer (5 mM, pH 7.4). 
2 Test compounds were dissolved in potassium phosphate buffer (5 mM, pH 7.4) containing 1% v/v 
DMSO for light scattering measurements.  
3  Mean (standard deviation) for  n ≥3 determinations. 
 
It can be seen from Table 5-2 that meisoindigo, 2-6, 2-13, 3-20 and 4-5 were 
associated with significant light scattering at the highest concentration tested (10 µM). The 
degree of scattering was almost comparable to that of benzyl benzoate, which was tested at a 
higher concentration (250 µM). The degree of light scattering decreased at lower 
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concentrations as anticipated, but particle size showed an unexpected increase at low 
concentrations. It may be that the instrument is unable to report accurate size measurements at 
low scattering counts.  Thus, the readings at 5 µM and lower may be inaccurate. Nonetheless, 
the degree of light scattering and particle size range obtained at 10 µM of meisoindigo, 2-6,  
2-13, 3-20 and 4-5 point to the potential for aggregate formation among these compounds. 
In the case of the Series 6 compounds, it is heartening to note that these compounds 
had negligible scattering counts and significantly smaller particle sizes (except 6-3) compared 
to meisoindigo, 2-6, 2-13, 3-20 and 4-5. Thus, 6-1 to 6-6 demonstrated limited aggregation 
tendencies and this may be linked to their improved solubilities (6-4, 6-6) or their lower 
lipophilicities (logD values < 2.5).  
 
5.3.3. Effects of meisoindigo (1-2), 4-5 and 6-4 on the cell cycle distribution of K562 cells 
 In view of the ability of meisoindigo (1-2), 4-5 and 6-4 to inhibit proliferation of 
K562 cells at low to submicromolar concentrations (IC50 values of 1-2, 4-5 and 6-4 are 7.75 
µM, 0.50 µM and 3.97 µM respectively), it is of interest to determine if cell-cycle arrest 
contributed to their growth inhibitory properties.  The effects of these compounds on the cell 
cycle were investigated by fluorescence activated cell sorter analysis (FACS) using flow 
cytometry.  Briefly, K562 cells were incubated with the test compound for 24 h, after which 
cellular DNA content was analyzed to determine the proportion of cells in the different phases 
of the cell cycle. 
  Meisoindigo (1-2) was investigated at 1, 5, 10, 15 and 20 µM. The results are given in 
Table 5-3 and depicted in a representative diagram (Figure 5-2).  The cells were not 
synchronized in this analysis and control cells (untreated) showed a higher proportion of cells 
in the G1 phase (“growth phase” characterized by synthesis of enzymes required for DNA 
replication) and about equal amounts of cells in the S (replication of DNA) and G2 
(preparation for mitosis) phases. Negligible number of cells were detected in sub-G1 phase 
which is associated with cellular debris arising from necrotic or apoptotic cells.  As seen from 
Table 5-3, meisoindigo did not disrupt the distribution of cells in the various phases at 
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concentrations of 1-10 µM. At 15µM and 20 µM, a small but significant decrease in the 
proportion of cells in the G2 phase was observed.  This was accompanied by an increase in 
the S phase but only in cells treated with 20 µM meisoindigo.  Overall, meisoindigo exhibited 
negligible effects on cell cycle progression, even at concentrations that are associated with its 
effects on cell viability. 
Table 5-3. Effect of Meisoindigo on the different phases of the cell cycle of K562 cells. 
 
Meisoindigo % Sub-G1 % G1 % S % G2 N 

















































1  Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 




Figure 5-2:  Representative figure showing the DNA content analysis of K562 cells after 24 h 
incubation with vehicle (media + 0.4% v/v DMSO) and meisoindigo (1-2) at stated 
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concentrations.  Sub-G1, G1, S and G2 phases are arbitrary identified by the following colors: 
red (sub-G1), yellow (G1), green (S), blue (G2).  
 
 6-4 was evaluated at the same concentrations as meisoindigo.  As seen from the 
results (Table 5-4, Figure 5-3), 6-4 had no effect on cell cycle progression at concentrations of 
1-10 µM, which correspond to the concentration range of its growth inhibitory effects (IC50= 
3.97µM).  At higher concentrations of 15 µM and 20 µM,   6-4 significantly increased the 
proportion of cells in the sub G1 phase. At 15 µM, 6-4 increased the proportion of cells in G1 
and reduced the proportion of cells in G2, which is indicative of an arrest of cells at the G1 
phase. However at 20 µM, the opposite was observed with more cells in G2 and fewer cells in 
G1, suggesting arrest of cells at the G2 phase.  The contrasting results may reflect non-
specific disruption of the cell cycle at these high concentrations, which is more than 5 times 
its IC50 on K562 cells. The significant increases in the subG1 phase further point to a non-
specific cell-killing effect at these concentrations of 6-4.   
 
Table 5-4. Effect of 6-4 on the different phases of the cell cycle of K562 cells. 
6-4 % Sub-G1 % G1 % S % G2 N 




















































1  Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 





Figure 5-3:  Representative figure showing the DNA content analysis of K562 cells after 24 h 
incubation with vehicle (media + 0.4% v/v DMSO) and 6-4 at stated concentrations. Sub-G1, 
G1, S and G2 phases are arbitrary identified by the following colors: red (sub-G1), yellow 
(G1), green (S), blue (G2).   
 
In view of its potency on K562 cells (IC50= 0.5 µM), 4-5 was investigated at lower 
concentrations (0.1 µM – 10 µM) than meisoindigo and 6-4.  Unlike the latter compounds,   
4-5 had significant effects on the cell cycle at a concentration of 0.5 µM and higher (Table 5-
5, Figure 5-4).  Notably, it caused a concentration-dependent decrease in the proportion of 
cells in G1 which was accompanied by a corresponding increase in % cells in the G2 phase.  
Such a trend is indicative of a G2 arrest.  Significant increases in the sub-G1 phase were also 
evident at 1-10 µM 4-5.  
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Table 5-5. Effect of 4-5 on the different phases of the cell cycle of K562 cells. 
4-5 % Sub-G1 % G1 % S % G2 N 
























































1 Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 




Figure 5-4:  Representative figure showing the DNA content analysis of K562 cells after 24 h 
incubation with vehicle (media + 0.4% v/v DMSO) and 4-5 at stated concentrations.  Sub-G1, 
G1, S and G2 phases are arbitrary identified by the following colors: red (sub-G1), yellow 
(G1),  green (S), blue (G2).   
 
5.3.4. Effects of meisoindigo (1-2), 4-5 and 6-4 on the induction of apoptosis in K562 cells.   
Deregulation of the cell cycle is normally associated with the induction of apoptosis. 
In the preceding section, significant increases in the proportion of cells in the sub-G1 phase 
were detected for meisoindigo, 6-4 and 4-5 at different concentration ranges.  Thus, it is of 
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interest to determine if these increases are linked to the induction of apoptosis.   A 
commercial kit based on dual staining by Annexin V and propidium iodide was used for this 
purpose. Briefly, the method is based on the translocation of phosphatidylserine from the 
inner surface to the outer leaflet of the plasma membrane during apoptosis.96, 97 The exposed 
phosphatidylserine molecules bind specifically to Annexin V in the presence of calcium.98 By 
conjugating Annexin V with a fluorescent tag (fluorescein isothiocyanate, FITC), the binding 
of Annexin V to the membrane surface can be monitored. The kit includes propidium iodide 
(PI) which binds to cellular DNA of necrotic cells (whose cell membranes have been totally 
disrupted and thus permeable to PI).  The combination of Annexin V-FITC and PI allows 
differentiation of cells into 3 phases: normal cells (Annexin V -, PI -), early apoptosis 
(Annexin V +, PI -), and late apoptosis /necrosis (Annexin V +, PI +). These phases are 
depicted in Figure 5-5.   
 
Figure 5-5: Double staining of cells by Annexin V and PI and their relationship to normal, 
apoptotic and necrotic cells.  
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Normal cells which are not stained by either Annexin V-FITC or PI are found in the 
lower left quadrant. The lower right quadrant represents cells that are in the early apoptotic 
stage. They are stained by Annexin V but not by PI because the cell membranes are still intact. 
Cells in late apoptosis or undergoing necrosis are found in the upper right quadrant. They are 
stained by both Annexin V and PI due to permeabilization of the cell membranes.  The 
proportion of cells in each quadrant was monitored by FACS analysis using cell cytometry.  
Meisoindigo, 6-4 and 4-5 were investigated at the same concentrations used for the cell cycle 
analysis (Section 5.3.3). 
Meisoindigo did not affect the distribution of normal, apoptotic and necrotic cells at 
1-10 µM. (Table 5-6) At 15 µM and 20 µM, it significantly increased the proportion of 
apoptotic and necrotic cells at the expense of normal cells. These are the same concentrations 
of meisoindigo that increased the sub-G1 phase of K562 cells.  It is noted that the increases in 
proportion of apoptotic and necrotic cells were closely matched and that these increases are 
observed at concentrations of meisoindigo that were at least 2- 3 fold greater than its growth 
inhibitory IC50.  Figure 5-6 shows a typical FACS analysis obtained with cells treated with 
different concentrations of meisoindigo.  
 
Table 5-6:  Distribution of normal, apoptotic and necrotic K562 cells treated with varying 
concentrations of 1-2 (24 h)  
 
1-2 % Normal % Apoptotic % Necrotic N 







1 µM 93.25 3.70 2.42 2 
5 µM 93.36 3.48 2.51 2 
10 µM 93.58 3.77 2.07 2 














1 Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 





Figure 5-6:  Representative figure showing FACS analysis of normal, apoptotic and necrotic 
K562 cells after 24 h incubation with vehicle (media + 0.4% v/v DMSO) and Meisoindigo (1-
2) at stated concentrations.  
 
 6-4 was evaluated at the same concentrations as those used for cell cycle analysis. 
The results (Table 5-7, Figure 5-7) show that 6-4 induced apoptosis and necrosis only at 
concentrations of 15 µM and 20 µM, with a higher proportion of cells undergoing late 
apoptosis/ necrosis at 20 µM 6-4.  These are also the same concentrations of 6-4 that 
significantly increased the sub G1 phase of K562 cells. Thus, 6-4 (like meisoindigo) induces 
apoptosis and necrosis at concentrations that exceed its growth inhibitory IC50 values.  
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Table 5-7:  Distribution of normal, apoptotic and necrotic K562 cells treated with varying 
concentrations of 6-4 (24 h)  
 
6-4 % Normal % Apoptotic % Necrotic n 





1 µM 92.72 3.74 2.63 2 
5 µM 93.29 3.43 2.42 2 
10 µM 94.02 3.73 1.59 2 














1 Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 




Figure 5-7:  Representative figure showing FACS analysis of normal, apoptotic and necrotic 




 In the case of 4-5, it was found to significantly increase the proportion of apoptotic 
cells at a relatively low concentration of 0.5 µM which is equivalent to its growth inhibitory 
IC50 (Table 5-8, Figure 5-8). The proportion of apoptotic cells increased with increasing 
concentrations of 4-5.  Interestingly, the proportion of necrotic cells was significantly 
increased only at 5 µM 4-5 and higher, and even then, the fold increase in necrotic cells was 
only 2 fold compared to untreated cells (at the highest concentration of 4-5) as compared to 5 
fold for apoptotic cells.  These findings suggest a specific apoptotic effect in the growth 
inhibitory profile of 4-5.  There is also broad agreement between the present findings and the 
earlier observations pertaining to the effect of 4-5 on the sub G1 phase of K562 cells (Section 
5.3.3.).  A representative figure depicting the FACS analysis of apoptotic cells in the presence 
of 4-5 is given in Figure 5-6.  
 
Table 5-8:  Distribution of normal, apoptotic and necrotic K562 cells treated with varying 
concentrations of 4-5 (24 h)  
4-5 % Normal % Apoptotic % Necrotic N 








































1 Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 






Figure 5-8:  Representative figure showing FACS analysis of normal, apoptotic and necrotic 
K562 cells after 24 h incubation with vehicle (media + 0.4% v/v DMSO) and 4-5 at stated 
concentrations.  
 
Noting that the growth inhibitory effects of meisoindigo and 6-4 on K562 cells were 
determined after 72 hours of incubation, the question was asked if monitoring the apoptotic 
effects of these compounds after 24 hours would adequately reflect their effects on cell 
proliferation. Thus, the FACS analysis was repeated after a longer period (48 h) of incubation 
with meisoindigo and 6-4 at 5 µM and 10 µM.  The results are given in Table 5-9.  The longer 
incubation period did indeed increase the proportion of apoptotic cells at 10 µM (but not 5 
µM) meisoindigo and 6-4. However, it was accompanied by a concurrent increase in necrotic 
cells, the fold increase of which was greater (6-4) or equivalent (meisoindigo) to that of 
apoptotic cells.  The effect of a longer incubation time was also investigated for 4-5 at 5 µM 
and 10 µM.  As anticipated, there was an increase in the % apoptotic cells but the fold 
increase in apoptotic cells exceeded that of necrotic cells.  Representative figures showing 




Table 5-9:  Distribution of normal, apoptotic and necrotic K562 cells treated with 
mesioindigo (1-2), 6-4 and 4-5 at 5 µM and 10 µM after an incubation period of 48 h.  
 
 % Normal % Apoptotic % Necrotic N 





1-2 – 5 µM 93.53 3.93 1.90 2 







6-4 – 5 µM 92.68 4.92 1.60 2 





















1 Cells treated with media (0.4% v/v DMSO) in the absence of test compound. 




 The objectives of this chapter are two fold: first, to determine if the design strategies 
adopted for the synthesis of the present series of compounds have yielded analogs that 
combine potency with drug-like physicochemical profiles, and second, to have a better 
understanding of the mechanisms involved in the antiproliferative activity of meisoindigo and 
selected potent analogs (4-5, 6-4) identified in Chapter 4. 
 With regards to the first objective, it is heartening that two analogs 6-4 and 6-6 which 
have ionizable N-methylpiperazinyl side chains, demonstrated exceptionally favourable 
solubility profiles.  6-4 is the most potent analog in its series (IC50 ca 4 µM for K562 and NB4) 
and has a modest two fold selectivity for leukemic cells compared to normal fibroblast cells 
(Table 4-8).  As for 6-6, it is not as potent on leukemic cells as 6-4 but has better selectivity.  
Both 6-4 and 6-6 may be deemed comparable to meisoindigo in terms of its antiproliferative 
activity on leukemic cells, but with significantly improved solubilities.  The solubilities of 6-4 
and 6-6 also exceed that of 4-5 which is the most potent analog identified in this study.  Thus, 
the inclusion of the ionizable N-methylpiperazinyl side chain in 6-4 and 6-6 has significantly 
improved solubilities while retaining acceptable antiproliferative potencies /selectivities. 
Unfortunately, other Series 6 compounds bearing ionizable basic side chains failed to 
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demonstrate the expected improvement in solubility. Notably, analogs with thiomorpholinyl 
(6-2) and piperidinyl (6-3) side chains were no more soluble than meisoindigo.  Thus, 
inclusion of an ionizable moiety does not always translate into better solubility. Attention 
must be paid to the pKa of the basic moiety which determines the proportion of polar ionized 
species at pH 7.4, the lipophilicity of the remaining non-ionized species, and the intrinsic 
brick-dust character of the isoindigo scaffold which favors strong intermolecular interactions.  
Indeed, the experimental solubilities of 6-1 to 6-6 are significantly correlated to their 
estimated logD 7.4 values, reinforcing the roles of pKa and lipophilicity (logP) in determining 
solubility.   
In line with their improved solubilities, aqueous solutions of 6-4 and 6-6 
demonstrated limited light scattering properties. Similar observations were made for the other 
Series 6 compounds, in stark contrast to meisoindigo and the other isoindigoids which 
demonstrated strong scattering.  These findings imply limited aggregation for the more 
soluble isoindigoids of Series 6 and potentially strong aggregating potential for the remaining 
isoindigoids (including meisoindigo).  Aggregators are of concern in drug discovery because 
they may be non-specific / promiscuous inhibitors of enzymes. The adverse effects of 
aggregators are due to their ability to reversibly sequester proteins onto their surfaces by 
adsorption or absorption, thereby resulting in apparent loss of activity or function. In the 
present context, the compounds have been evaluated on cell-based assays and one may 
question if aggregation affects these assays in the same way as enzyme-based assays.  If it 
does, this would negate the growth inhibitory effects of a large number of potent isoindigoids 
like meisoindigo, 4-5 and 2-13 Even if aggregation does not compromise the growth 
inhibitory effects of the isoindigoids, it can potentially affect the pharmacokinetics of these 
compounds.93  
It is appropriate to mention several caveats regarding the solubility and aggregation 
determinations reported in this chapter. Solubility determinations were made in the presence 
of DMSO (1%) and were obtained at definite time points rather than at equilibrium.  
Aggregation tendencies of the compounds were more apparent from light scattering counts 
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than from particle size range which failed to show concentration dependency.  These caveats, 
while important, do not diminish confidence in the main findings of this section, which show 
that isoindigoids with improved drug-like profiles (better solubility, lower aggregation 
potential) and reasonable growth inhibitory potencies have been identified. 
 The antiproliferative properties of meisoindigo have been widely investigated.33, 45, 46, 
60   It is reported to interfere with cell cycle progression by either arresting the G1 or G2 phase. 
G1 arrest was reported by Lee and co-workers for leukemic HL60 cells33 (5, 10 µM 
meisoindigo) and Liu and co-workers for leukemic ML-1 cells45 (2.6 µM meisoindigo). G2 
arrest was reported by Zuo and co-workers for colorectal HT29 cells46 at 5 µM meisoindigo.  
Meisoindigo (2-15 µM) was found to induce apoptosis in multiple leukemic cell lines.33 It 
downregulated anti-apoptotic Bcl-2 and upregulated pro-apoptotic Bak and Bax and cell cycle 
related proteins p21 and p27.33  The antiproliferative properties of meisoindigo has been 
linked to the inhibition of several CDKs, specifically CDK4/6 and CDK2.26, 27 
 In the light of these findings, it is troubling to note that the current results did not 
demonstrate an effect on cell cycle progression at concentrations corresponding to the growth 
inhibitory concentration of meisoindigo.  Meisoindigo was found, however to induce 
apoptosis at 10-20 µM, in agreement with the findings of others.33  The results in Chapter 2 
have shown that meisoindigo is not an inhibitor of CDK2 (or other kinases), corroborating the  
absence of interference with cell cycle progression observed here.  There are still wide gaps in 
our understanding of the antiproliferative activity of meisoindigo.  Noting that isoindigo has 
been reported as an AhR agonist, one possibility is that it exerts its antiproliferative activity 
via AhR signalling pathways, like that reported for 1-methylated indirubins.55   
6-4 and 4-5 were also investigated for their effects on the cell cycle and apoptosis. 
The results showed that relatively minor changes to functional groups attached to the 
isoindigo scaffold significantly affected these processes. Notably, the potent analog 4-5 
demonstrated a clear cut effect on the cell cycle at concentrations corresponding to its IC50 
value.  G2 arrest and induction of apoptosis were observed for 4-5. Interestingly, 4-5 was also 
evaluated for kinase inhibition (ScanEdge KinomeScan, DiscoveRx, US) but like meisoindigo, 
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did not inhibit CDKs (Appendix 2-1A). Thus its ability to disrupt G2 progression may be due 
to other factors, such as an increase in the production of endogenous cell cycle inhibitors (KIP, 
INK4 proteins), down regulation of cyclins required for CDK activation, or activation of AhR 
signalling pathways leading to cell cycle arrest. In contrast, 6-4 has no discernible effects on 
the cell cycle. On the other hand, both 6-4 and 4-5 increased the proportion of apoptotic cells 
but with some striking differences.  The induction of apoptosis was not observed at the IC50 of 
6-4 but at higher concentrations of 10 µM and 20 µM.  This was not the case for 4-5. In 
addition, 6-4 increased the proportion of both apoptotic and necrotic cells at these higher 
concentrations, which suggest a non-specific cell killing effect. Again, this was not observed 
with 4-5 which increased the proportion of apoptotic cells to a greater extent.  Like 4-5, 6-4 
did not exhibit kinase inhibition when evaluated against a panel of 96 kinases (Appendix 2-
1A).   
Taken together, these findings have not cast sufficient light on the mechanisms 
involved in the antiproliferative properties of meisoindigo, except to highlight the fact that 
cell cycle arrest and direct inhibition of CDKs are not involved.  There is however evidence to 
support the involvement of apoptosis but the mechanisms (intrinsic or extrinsic) underlying 
this process remains to be investigated.  These findings also apply to 6-4.  In the case of 4-5, 
there is a strong likelihood that G2 arrest and apoptosis contribute to its antiproliferative 
activity on leukemic cells.   
 
5.5. Summary 
The main findings in this chapter are summarized as follows: 
(i) 6-4 and 6-6 have been identified as analogs with good solubilities and minimal aggregation 
potential. In view of their moderately potent and selective activity on leukemic cells, these 
properties serve to enhance their drug-like profiles and potential for further development.  
(ii) Meisoindigo has no effect on the cell cycle progression of K562 cells at its half maximal 
growth inhibitory concentration (IC50= 7.75 µM). However it does induce apoptosis at 
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equivalent concentrations. The water soluble analog 6-4 behaves like meisoindigo in this 
respect. The mode of actions of these compounds require further investigation. 
(iii) 4-5 causes G2 arrest and apoptosis of K562 cells at its IC50 concentration. These 
processes are likely to contribute to its potent effects on cell viability.  
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Chapter 6: In vivo evaluation of meisoindigo, 4-5 and 6-4 in mice bearing human 
myeloid chronic leukemia cells (K562) xenografts 
 
6.1 Introduction 
 This chapter describes the in vivo evaluation of meisoindigo, 4-5 and 6-4 on 
xenografts induced by human myeloid chronic leukemia K562 cells in immuno-compromised 
mice. The investigations are carried out with two objectives. Firstly, to confirm that the in 
vitro growth inhibitory activities of these compounds would be observed when they are 
administered to xenograft-bearing animals. Secondly, to determine if differences in growth 
inhibitory potencies (4-5 is more potent and selective than meisoindigo and 6-4, based on IC50 
values) and solubilities (6-4 is more soluble than meisoindigo and 4-5) would affect the 
outcome of the in vivo tests.  Figure 6-1 summarizes the IC50 K562 and aqueous solubilities of 
meisoindigo, 4-5 and 6-4 reported in earlier chapters. 
 
 
Figure 6-1: In vitro IC50 K562 and solubilities of meisoindigo, 4-5 and 6-4.  
 
6.2 Experimental  
6.2.1 Materials 
 Dimethyl sulfoxide (pharmaceutical grade) was purchased from Sigma Aldrich 
(Singapore). Isofurane (USP grade) was purchased from Halocarbon (NJ, USA).  
Meisoindigo, 4-5 and 6-4 were synthesized, characterized and purified to > 95% as described 
in Chapter 3 (Section 3.3) and Appendix 3-1.  Human chronic myelogenous leukemia K562 
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cells from ATCC were cultured as described in Chapter 2 (section 2.5.5). K562 cells were 
assessed to be pathogen-free by Laboratory Animal Center of the National University of 
Singapore (NUS). 
 
6.2.2 In vivo studies 
 Experimental protocols for the in vivo study were approved by the NUS Institutional 
Animal Care and Use Committee [IACUC, 112/10] and were in compliance with guidelines 
for the care and use of animals for scientific purposes issued by the National Advisory 
Committee for Laboratory Animal Research, Republic of Singapore. Balb/c female nude 
athymic nude mice (16-20g body weight, 5-8 weeks old) were obtained from the Biological 
Resource Center (Singapore). Animals were kept under controlled environmental conditions 
(19-26°C, relative humidity <70%, 12h dark-light cycle) at the Center for Life Science 
vivarium, NUS. They were given free access to water and standard feed. They were also 
randomly assigned into one of 4 groups, namely control animals to be treated with vehicle 
(1% DMSO v/v saline), and treated animals earmarked to receive either 1-2, 4-5 or 6-4. Each 
group comprises 5-8 mice.  
 To establish the xenograft, K562 cells (2.0x107 in 150µL in saline) were injected 
subcutaneously on the right dorsal flank of the animal previously sedated with gaseous 
isoflurane (5% v/v in oxygen for induction of anaesthesia and 2-3% v/v in oxygen for 
maintenance).  Tumor formation at the site was monitored carefully and treatment was 
initiated when a palpable tumor of approximately 150mm3 was evident (Day 0).  The test 
compound (10 µM in 100 µL saline containing 1% v/v DMSO) was injected into the tumor on 
3 separate occasions – Day 0, Day 3 and Day 10.  Animals in the control group were similarly 
treated with saline containing 1% v/v DMSO on Days 0, 3 and 10. Solutions of test 
compounds were freshly prepared prior to injection and sterilized by filtration using a 0.22 
micron size DMSO-safe Acrodisc syringe filter.  
 The animals were monitored daily for changes in body weight, tumor volume and 
signs of distress. Tumor volume was calculated using the formula for the volume of an 
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ellipsoid:  V= (π x L x W2 ) /6.  Length (L) and width (W) of the tumor was measured with 
electronic vernier calipers and reported to 2 decimal places.  The mice were monitored for 28 
days after the 1st intratumoral injection of test compound or vehicle (Day 0), after which they 
were euthanized with CO2. Animals were also euthanized (before Day 28) if they complied 
with the following criteria : (i) tumor diameter >1.5cm, (ii) tumor ulceration, infection or 
inflammation, (iii) ruffled fur, hunched back appearance or inappetent state, (iv) 10% or more 
body weight loss over 24 h or 20% body weight loss relative to control group, or (v) 
moribund or pre-moribund state. 
For the purpose of analyzing the results using the Kaplan-Meier survival analysis, 
censored events were recorded. These are events in which the period of survival of the animal 
could not be determined due to the following: (i) animal was still alive when the study period 
(28 days) had lapsed, (ii) death of animal due to unrelated causes such as sudden death or 
infection and (iii) conditions which warrants euthanasia due to unrelated disease pathology or 
infection (for example, pin-worm infestation in animal).   
 
6.2.3 Statistical Analysis 
Survival data were analyzed by Kaplan-Meier (with log rank test, pairwise 
comparison) on IBM SPSS Statistics Version 19.0 (Chicago, IL) following the protocol 
described by Chan.99 Tumour size data were analyzed by One-way ANOVA with Dunnet 
post-hoc test on the same software. p-values <0.05 were considered significant for both tests. 
Graphical representations were plotted on Prism 5.0 (San Diego, USA). 
 
6.3 Results 
 Table 6-1 summarizes the mean and median survival times (in days) of xenograft 
bearing mice in the control and different treatment arms.  
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Table 6-1: Kaplan-Meier analysis1 for comparison between treatment groups in xenograft-




Control Meisoindigo 4-5 6-4 
Sample size 8 5 5 6 
No. survived after 28 days 2 1 0 5 
Median Survival time (days) 19 26 16 >28 2 
Mean Survival time in days  









ILS 3 - + 21.3% - 0.1% + 35.9% 
1 Kaplan-Meier analysis was carried out on IBM SPSS Statistics Version 19.0 (Chicago, IL). 
2 Median could not be determined because 5 of the 6 animals in this group survived beyond 28 days.  
3 ILS (Percentage increase in mean life span) = [(mean survival time of treated group – mean survival time of 
control group) / mean survival time of control group ] x 100%. 
 
Mice in the control group (treated with saline-DMSO) had a mean survival of 19.6 
days. This was increased to 23.8 days for those treated with meisoindigo, which is equivalent 
to a 21.3% increase in the mean life span (ILS).  There was no apparent change in the mean 
survival time of mice treated with 4-5, whereas those treated with 6-4 showed a 35.9% 
increase in mean life span. The changes in mean life span were compared for statistical 
significance using the log rank test (pair-wise) comparison statistic p in the Kaplan Meier 
Analysis.  As seen from Table 6-2, only mice treated with 6-4 had significantly longer mean 
life spans compared to control animals (p = 0.028).  In the case of mice treated with 
meisoindigo or 4-5, their mean life spans were not significantly lengthened compared to 
control animals. However, neither meisoindigo nor 4-5 shortened the life-spans of the treated 
animals, which suggests that they are relatively nontoxic at the given doses.  Life spans of 
mice treated with 6-4 were also significantly longer than those treated with meisoindigo or   
6-5. 
Table 6-2: Log rank test1 (pairwise comparison) p-values of different treatment groups. 
 
 Control Meisoindigo 4-5 6-4 
Control - 0.631 0.658 0.028 2 
Meisoindigo 0.631 - 0.287 0.048 2 
4-5 0.658 0.287 - 0.006 2 
6-4 0.028 2 0.048 2 0.006 2 - 
1 Log rank test from Kaplan-Meier analysis was carried out on IBM SPSS Statistics Version 19.0.  
2 Significantly different (p-value <0.05). 
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The survival curves of control and treated animals are depicted in Figure 6-2.  Each 
“step” in the plot indicates the demise of an animal because it fulfilled the criteria for 
euthanasia specified in Section 6.2.2. The only censored event encountered in this study was 
the survival of the animal beyond 28 days. It was observed in 2 of the 8 control animals, 1 of 
the 5 animals treated with meisoindigo and 5 of the 6 animals treated with 6-4.  
 
 
Figure 6-2: Survival plots of Balb/c nude mice bearing K562 xenografts : Control (vehicle 
only) animals, animals dosed with 10 µM meisoindigo, 10 µM 4-5 or 10 µM 6-4. Test 
compound or saline /DMSO (for control animals) were administered intratumorally on Days 0, 
3 and 10, after tumor volume has reached approximately 150mm3 (Day 0). 
 
 
 The body weights of the treated animals were monitored throughout the study period 
and shown in Figure 6-3.  Body weights remained fairly constant throughout the period of 
study. The decrease in weight observed on Day 23 for animals treated with 4-5 was due to the 
death of 1 of the 2 remaining animals. The absence of an obvious decline in body weight 
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during the study period lend support to the apparent lack of toxicity of the test compounds at 
the given doses.  
 
 
Figure 6-3: Changes in body weight (grams) of xenograft-bearing mice treated with vehicle 
(Control) and test compounds (meisoindigo, 4-5, 6-4). Error bars indicate standard error of 
mean (SEM) 
 
The tumor volumes of the mice were monitored daily throughout the study period. 
Figure 6-4 shows changes in tumor volumes during the first 14 days of the study. During this 
period, all the animals were alive and none have been euthanized.   Days 0, 3 and 10 are 
indicated as orange dots on the x-axis. On these days, animals were dosed with test compound 
(or saline-DMSO for control animals).   
It is seen that tumor volumes of control animals increased steadily from Day 0 to Day 
14. A similar trend was observed for animals treated with 4-5.  In the case of meisoindigo, a 
gradual increase in tumor volume was evident whereas for 6-4, there was a decrease in tumor 
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volume from Day 0 to Day 10, followed thereafter by an increase. The changes in tumor 
volumes of treated animals were analyzed for statistical difference from control animals by 
one-way ANOVA (Dunnett post hoc). Only animals treated with 6-4 between Day 6 (p 
=0.026) to Day 14 (p = 0.036) had tumor volumes that were statistically smaller than that of 
control animals over the same period.   
Of the 6 mice treated with 6-4, it was encouraging to note that tumors of 2 mice 
completely regressed and remained as such until Day 28. In the case of another animal, the 
tumor regressed during the first 10 days but reappeared and increased in size thereafter.  It 
may be that continued dosing after Day 10 could have prevented tumor growth. The tumors of 
another 2 animals steadily increased but did not meet the criteria for euthanasia (tumor 
diameter > 1.5cm).  
 
 
Figure 6-4: Changes in tumour size (mm3) of xenograft-bearing mice treated with vehicle 
(Control) and test compounds (meisoindigo, 4-5, 6-4). * Indicates administration of test 




 There are several reports on the in vivo efficacy of mesioindigo on xenografts induced 
by cancer cells in test animals.  Ji and co-workers noted the efficacy of multiple dosing of 
meisoindigo (106 mg/kg at 9-12 doses) on the growth of Lewis lung carcinoma and Walker-
256 carcinocarcoma cells.100 Zuo and co-workers showed that daily 50mg/kg oral 
administration of  meisoindigo (for 25 days) led to a significant decrease in the size of HT-29 
colon carcinoma induced xenografts in immunocompromised mice.46 They observed that a 
lower dose of 25 mg /kg meisoindigo was not effective.  Lee and co-workers reported that 
meisoindigo administered at 100 mg/kg for 14 days by intraperitoneal injection significantly 
reduced the spleen size of NOD/SCID mice that were injected with HL60 (acute myeloid 
leukemia, AML) cells into the peritoneal cavity at the beginning of the study.33 The reduction 
in spleen size was indicative of in vivo efficacy.33 No reference could be found in the 
literature pertaining to the in vivo evaluation of meisoindigo on xenografts induced by chronic 
myelogenous leukemic cells, in spite of the widely publicized clinical use of meisoindigo in 
chronic myelogenous leukemia.  In this chapter, the method of Liu and co-workers101 was 
followed for the induction of K562 xenografts in nude mice, although the original objective of 
that paper was to investigate gene therapy with a peptide fragment.    
 Meisoindigo and the test compounds were injected directly into the tumor mass in 
this study as no pharmacokinetic data have been gathered for these compounds. Care was 
taken to ensure that the injection was made directly to the palpable tumor and that no damage 
was made on neighbouring tissues.  Dosing was carried out at 10 µM, a concentration that is 
close to the IC50 of meisoindigo and 6-4 but 20 times greater than the IC50 of 4-5 on K562 
cells on the antiproliferative assay.  They are equivalent to 13.8 µg/kg meisoindigo, 21.3 
µg/kg 4-5 and 19.4 µg/kg 6-4, which is considerably lower than the 50-100 mg/kg dose range 
used for meisoindigo. In addition, the compounds were administered three times (Days 0, 3 
and 10) which is relatively infrequent. 
 One objective of this chapter is to determine if the in vitro antiproliferative activities 
of meisoindigo, 4-5 and 6-4 will be observed in an in vivo environment. From the results, only 
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6-4 continued to demonstrate antiproliferative activity as seen from the significant increase in 
life span of xenograft-bearing animals. Meisoindigo and 4-5 failed to demonstrate in vivo 
efficacy. The comparatively low concentrations of meisoindigo used in this study compared 
to those reported in the literature may account for its apparent inactivity.  In the case of 4-5, 
its failure to translate its potent in vitro efficacy to the in vivo setting is disappointing, 
especially since it was administered at a concentration that is 20 fold higher than its IC50. 
These findings provide an answer to the 2nd objective of this chapter, which is to determine if 
differences in growth inhibitory potencies and solubilities of the test compounds would affect 
their in vivo activites. It is tempting to suggest that the greater solubility of 6-4 contributed to 
its in vivo activity whereas the less soluble 4-5 failed to bring about the desired in vivo 
activity, in spite of its potency. 
 
6.5. Summary 
The findings in this chapter showed that 6-4 demonstrated a significant in vivo effect 
on K562-induced xenograft bearing mice at a dose of 10 µM, administered over three days.   
Its in vivo efficacy was evident from the significant extension in lifespan of the treated 
animals and the reduction in tumor size during the early phase of the test period.  The good 
solubility of 6-4 is proposed to play a key role in its in vivo efficacy.  It is notable that 4-5 and 
meisoindigo which have poor solubilities failed to demonstrate in vivo efficacies under 
similar conditions. The poor showing of meisoindigo may also be due to the comparatively 
low dosage administered in this study. In fact, this makes the activity of 6-4 more compelling 
as it is given at the same concentration as meisoindigo. Notwithstanding the outcome of the in 
vivo tests, all compounds did not demonstrate overt toxic effects in the treated animals.  
. 
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Chapter 7:  Conclusions and Future Work 
 
 A key impetus driving the investigations described in this thesis is the limited 
information available in the literature on the potential of functionalized isoindigos as anti-
proliferative agents.  The apparent neglect of this scaffold stands in contrast with the generous 
attention paid to its structural isomer indirubin and its derivatives, many of which have been 
reported to be potent kinase inhibitors with anti-cancer activity.6-8, 10, 55, 102, 103 The irony is 
further compounded by the availability of an isoindigo analog (meisoindigo) for clinical 
treatment of chronic myeloid leukemia. Although meisoindigo has several shortcomings 
related to its modest in vivo potency and poor bioavailability, few attempts have been made to 
resolve these issues.   Hence the aim of this thesis is to investigate medicinal chemistry 
approaches directed towards the design and synthesis of functionalized isoindigos with 
enhanced potency and pharmaceutically friendly profiles.  With regards to potency, it was 
hypothesized that a structure-based approach based on the reported CDK inhibitory activity of 
meisoindigo would be a meaningful way of designing analogs with improved anti-
proliferative activity.  A key question would be if CDK inhibitory activity would still be 
retained in analogs with polar functionalities. This would be initially assessed by in silico 
docking and if results are positive, would be followed up by synthesis and in vitro evaluation.   
 An unexpected finding that emerged early in the investigations was the absence of 
CDK inhibitory activity for meisoindigo, isoindigo and several functionalized analogs when 
evaluated in vitro on a commercial kit based on metal ion affinity-based fluorescence 
polarization.   Not only was there no inhibition of CDK2 but meisoindigo (at 10 µM) also 
failed to inhibit a varied panel of tyrosine and serine-threonine kinases in vitro.  The absence 
of inhibition of these kinases was subsequently confirmed for other potent analogs (2-13, 4-5 
and 6-4). There are several reasons that could explain the disparity in results reported here and 
in the literature26, 27, 32 Firstly, some sources monitored indirect inhibition of CDK based on 
changes in the protein levels of the kinases from cell lysates. 26, 27 It is possible that the 
reduction in kinase expression may be due to the effect of meisoindigo on signalling 
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pathways that affect kinase levels. The involvement of AhR signalling may be relevant in this 
context because isoindigos are known to be AhR agonists.53 One consequence of activating 
AhR signalling is the greater expression of the CDK2 inhibitor p27 which would in turn 
disrupt the cell cycle progression by indirectly inhibiting CDKs.  Secondly, some 
investigators have used extremely high concentrations of meisoindigo to demonstrate its 
pharmacological activity. Notably, Wang and coworkers reported that meisoindigo inhibited 
CDK2/cyclin A with an IC50 of 89 µM. Meisoindigo has been shown to form colloid-like 
aggregates at 10 µM based on dynamic light scattering measurements (Chapter 5). 
Aggregation would be even more pronounced at 89 µM and it is possible that the observed 
inhibition is an artifact arising from the adsorption of the enzyme/protein onto meisoindigo 
aggregates. There is also the question regarding the solubility of meisoindigo at 
concentrations greater than 30 µM, even in the presence of DMSO (capped at 0.5%).   
In spite of the absence of CDK2 inhibition, in silico docking of meisoindigo and other 
isoindigos into the CDK2 active site (Protein Data Base entry 2BHE) pointed to reasonable 
affinities based on good docking scores. The apparent contradiction was resolved when more 
rigorous molecular dynamics simulation showed that meisoindigo formed a weak and 
transient complex with CDK2 that was held by two H bonds of unequal strengths.  These 
findings put to rest any attempt at structure based design of functionalized isoindigos. Thus 
conventional medicinal chemistry approaches, such as ring substitutions guided by Craig Plot, 
bioisosteric replacement, homologation and conformational restriction were used to design 
potential analogs. In all, 93 compounds in six series (Series 1-6) were synthesized, 
characterized and purified to ≥ 95%.  Having discounted CDK as a target protein of the 
functionalized isoindigos, a phenotypic approach was adopted for biological evaluation. In 
view of the reported efficacy of meisoindigo in chronic myeloid leukemia, the synthesized 
compounds were evaluated for growth inhibitory activities on a related cell line (K562).  A 
strength of phenotypic screening is that activity in such assays may be translated into 
therapeutic impact in a given disease stage more effectively than in target based assays.104 On 
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the other hand, phenotypic screens fail to provide sufficient chemical and molecular leads 
necessary for optimization of molecular properties of candidate compounds.  
An important outcome of the thesis is the elucidation of structure activity relationship 
for the isoindigo scaffold with respect to growth inhibition of K562 cells.  The findings are 
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Figure 7-1: Summary of structural features of functionalized isoindigos that are critical for 
growth inhibitory activity on K562 cells. 
 
 Briefly, the key features of the scaffold associated with growth inhibitory properties 
are (i) intact exocyclic double bond; (ii) presence of at least one amidic NH group; (iii) 
substitution at position 6 /6’ with methoxy group; (iv) a 1-(phenpropyl) or 1-(4-
methoxyphenpropyl) side chain if ring A or B of the scaffold is not substituted and (v) a 1-(4-
methoxyphenethyl) side chain if ring B is substituted with 6’-methoxy.  An important 
modification undertaken in Series 6 is the introduction of polar features that would improve 
the poor solubility of the scaffold that is largely due to its “brick-dust” character.  
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Unfortunately, the azaisoindigos (6-7, 6-8) were poorly active and preliminary observations 
suggest that they are no more soluble than meisoindigo. More headway was made with 6-1 to 
6-6 which have ionizable basic side chains at position 1.  These compounds were active as or 
modestly better than meisoindigo in terms of their IC50 K562 values.   
 Another notable finding was that meisoindigo and several potent functionalized 
analogs were more active on leukemic cell lines (K562, NB4) than on non-leukemic cells like 
HuH7 (liver) and HCT116 (colon). Selectivity for leukemic cells over non-cancerous 
fibroblast cells was less impressive and varied from 1.3 to ca 26 fold.  Nonetheless, the most 
active compound (4-5) identified in this study has submicromolar IC50 for leukemic cells (IC50 
K562 = 0.50 µM, IC50 NB4 = 0.18 µM) and outstanding selectivities for leukemic cells compared 
to non-cancerous cells (9.6 fold for K562 and 27 fold for NB4).  Unfortunately, 4-5 is 
hampered by poor solubility and a marked propensity for aggregate formation. These features 
may partly account for its failure to increase the survival of K562-induced xenograft-bearing 
mice. A similar observation was made for meisoindigo which also demonstrated poor 
solubility and a tendency to form aggregates. On the other hand, 6-4 which was the most 
potent analog identified from Series 6 demonstrated in vivo activity under similar test 
conditions. Dynamic light scattering measurements showed that 6-4 (as well as 6-1 to 6-3, 6-5 
to 6-6) has little or no tendency to form aggregates. Its solubility is tentatively assessed to be 
≥ 400 µM.  It is tempting to attribute the in vivo efficacy of 6-4 to its improved 
physicochemical profile and to further propose that modest potency (which is the case of 6-4) 
may be compensated or even overcome by addressing solubility or permeability limitations.  
On the other hand, the poor in vivo efficacies of meisoindigo and 4-5 may be due to the low 
doses administered (10-25 µg /kg) which fall far short of that used by others in related studies 
with meisoindigo.    
 Some attempt has been made to understand the mechanisms underlying the growth 
inhibitory activities of meisoindigo and selected potent analogs (4-5 and 6-4).    It is clear that 
none of the compounds directly inhibit CDKs, in spite of several reports claiming otherwise. 
Meisoindigo had minimal effects on cell cycle progression of K562 cells but induced 
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apoptosis at concentrations greater than 10 µM. The increase in the apoptotic cell population 
was accompanied by a similar increase in the proportion of cells undergoing necrosis, 
especially at 15 µM and 20 µM.  Similar observations were made for 6-4, suggesting that it 
may share similar targets as meisoindigo. On the other hand, 4-5 demonstrated a strikingly 
different profile, with arrest of the cell cycle at the G2 phase and the induction of apoptosis 
without concurrent increase in non-specific cell death.   
Taken together, the present findings have addressed, to some degree, the questions 
that have motivated the investigations undertaken in this thesis. Meisoindigo has been 
successfully modified to yield analogs with better growth inhibitory activity. Some but not all 
of these analogs possess a pharmaceutically “friendly” profile, in terms of improved aqueous 
solubility and diminished aggregation tendencies.  In vivo efficacy has been demonstrated for 
one such analog 6-4.   
  There are however several questions that remain unanswered or have surfaced 
during the course of the present work. Notably, limited headway has been made in 
understanding the molecular basis for the antiproliferative activities of meisoindigo and its 
potent analogs 4-5 and 6-4, and this should be addressed in future investigations. It is 
essential to establish if apoptosis involves an intrinsic (mitochondrial) or extrinsic (receptor-
related) mechanism, and if caspase dependent or independent pathways are responsible. 
Examining changes in the levels of apoptotic and anti-apoptosis proteins in the Bcl-2 family 
would also be helpful in providing insight into the process.  These considerations aside, a key 
question would be to determine the biological targets of this scaffold. A possible solution may 
be to carry out microarray-based gene expression profiling to determine which genes are up-
regulated or down-regulated in the presence of the test compound.  Knowledge of the affected 
genes would lead to identification of the proteins regulated by these genes and these may be 
the putative targets of the isoindigos.    
 It is noted that of the 93 analogs synthesized, only a handful (6-1 to 6-8) were 
designed to improve solubility, and of these, only 2 compounds (6-4, 6-6) were finally found 
to have better solubilities than meisoindigo. Clearly, more synthetic effort should be directed 
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towards this end and 6-4 would be a logical starting compound for this purpose.  6-4 has been 
shown to have a better solubility profile and a diminished tendency towards aggregate 
formation.  It should be further characterized for its permeability across cellular barriers, 
susceptibility to hepatic metabolism, binding to plasma proteins, affinity for ATP binding 
cassette transporters (notably p-glycoprotein) before it can be truly deemed to have a drug-
like physicochemical profile. 
Another area for further investigation pertains to the demonstration of in vivo efficacy 
of 6-4. In most studies, the preferred route of administration is intraperitoneal or intravenous 
rather than intratumoral which is adopted in this study. The intratumoral route is frequently 
criticized for its lack of real-life applicability and the potential to cause damage in normal 
tissues surrounding the tumor.  Nonetheless, it was employed in this study due to the absence 
of pharmacokinetic data on 6-4. Thus, basic pharmacokinetic parameters (half life, clearance) 
should be determined for 6-4 as well as 4-5 and meisoindigo. This would permit alternative 
routes of administration of the test compounds and hence more convincing evidence of their 
in vivo activities.  A more rational choice of dosing would also be possible with the 
availability of pharmacokinetic data, which may be particularly critical for meisoindigo and 
4-5 as there is a strong likelihood that they are given at sub-optimal doses.   
In conclusion, the results presented in this thesis have contributed to some degree to a 
better understanding of the antiproliferative activity of functionalized isoindigos. It has shown 
that several of the shortcomings associated with this scaffold are surmountable but there is 
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Appendix 2-1A: Summary of Kinome Screen Results. Percentage inhibition of 96 kinases 1-2, 
2-13, 4-5 and 6-4 at 10 µM.  
 
 ABL1 ACVR 1B ADCK3 AKT1 AKT2 ALK AURKA 
AURK
B AXL 
1-2 5 0 0 27 0 0 0 0 0 
2-13 46 2 45 14 35 0 16 0 0 
4-5 0 9 3 15 0 0 3 20 0 
6-4 27 3 0 0 0 36 25 0 8 
 
 BMPR2 BRAF BTK CDK11 CDK2 CDK3 CDK7 CDK9 CHEK1 
1-2 0 0 0 0 4 0 56 0 0 
2-13 7 0 13 0 0 0 28 0 35 
4-5 7 6 0 41 13 6 4 12 0 
6-4 0 0 0 0 24 10 0 12 0 
 






1B EGFR EPHA2 ERBB2 ERBB4 
1-2 0 0 0 4 0 16 13 0 0 
2-13 11 0 0 0 0 0 45 3 16 
4-5 23 22 0 0 16 4 11 15 0 
6-4 0 4 0 9 0 25 10 6 0 
 
 ERK1 FAK FGFR2 FGFR3 FLT3 GSK3B IGF1R IKK-α IKK-β 
1-2 0 7 0 4 2 0 0 31 43 
2-13 18 0 42 32 0 5 20 0 0 
4-5 0 22 0 10 31 4 0 0 0 
6-4 7 13 5 27 0 19 23 9 0 
 
 INSR JAK2 JAK3 JNK1 JNK2 JNK3 KIT LKB1 MAP3K4 
1-2 10 4 0 14 11 0 8 19 0 
2-13 0 25 38 0 2 6 49 29 37 
4-5 15 0 22 0 16 11 21 0 10 
6-4 39 8 3 3 0 0 21 0 3 
 
 MAPKAPK2 MARK3 MEK1 MEK2 MET MKNK1 MKNK2 MLK1 
p38-
alpha 
1-2 0 0 16 0 0 0 0 0 0 
2-13 0 0 0 9 0 25 0 23 4 
4-5 0 0 10 10 9 0 13 0 9 
6-4 21 18 0 5 23 0 0 8 29 
 
 p38-beta PAK1 PAK2 PAK4 PCTK1 PDGFRA PDGFRB PDPK1 
PIK3C2
B 
1-2 0 0 0 1 0 0 15 3 12 
2-13 32 1 0 0 40 0 49 7 0 
4-5 0 16 21 0 11 18 35 0 5 
6-4 1 23 0 5 14 0 36 0 0 
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Appendix 2-1A: Summary of Kinome Screen Results. Percentage inhibition of 96 kinases 1-2, 
2-13, 4-5 and 6-4 at 10 µM.  (Cont.) 
 
 PIK3CA PIK3CG PIM1 PIM2 PIM3 PKAC-alpha PLK1 PLK3 PLK4 
1-2 18 0 3 2 7 0 5 0 12 
2-13 40 19 0 23 0 12 0 0 39 
4-5 6 4 0 0 8 0 1 10 0 
6-4 0 0 0 6 18 23 0 24 8 
 
 PRKCE RAF1 RET RIOK2 ROCK2 RPS6KA3 SNARK SRC SRPK3 
1-2 16 0 0 0 0 0 30 15 0 
2-13 24 9 0 37 52 11 3 15 7 
4-5 19 19 0 13 0 18 4 0 0 
6-4 8 4 15 0 1 14 0 0 0 
 
 TGFBR1 TIE2 TRKA TSSK1B TYK2 ULK2 VEGFR2 
YANK
3 ZAP70 
1-2 0 6 20 28 8 15 0 5 0 
2-13 0 0 23 52 0 22 0 40 44 
4-5 15 17 14 0 0 0 0 0 24 





Appendix 2-1B: List of kinases screened in the ScanEdge Kinome screen. 
 
Kinase Official Name in Entrez Gene Kinase Official Name in Entrez Gene 
ABL1 c-abl oncogene 1 EPHA2 EPH receptor A2 
ACVR1B Activin A receptor, type 1b ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
ADCK3 chaperone, ABC1 activity of bc1 complex homolog (CABC1) ERBB4 
v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 4 
AKT1 v-akt murine thymoma viral oncogene homolog 1 ERK1 
mitogen-activated protein kinase 3 
(MAPK3) 
AKT2 v-akt murine thymoma viral oncogene homolog 2 FAK protein tyrosine kinase 2 (PTK2) 
ALK anaplastic lymphoma receptor tyrosine kinase FGFR2 fibroblast growth factor receptor 2 
AURKA aurora kinase A FLT3 fms-related tyrosine kinase 3 
AURKB aurora kinase B GSK3B glycogen synthase kinase 3 beta 
AXL AXL receptor tyrosine kinase IGF1R insulin-like growth factor 1 receptor 
BMPR2 bone morphogenetic protein receptor, type II IKK-alpha 
conserved helix-loop-helix 
ubiquitous kinase (CHUK) 
BRAF v-raf murine sarcoma viral oncogene homolog B1 IKK-beta 
inhibitor of kappa light 
polypeptide gene enhancer in B-
cells 
BTK Bruton agammaglobulinemia tyrosine kinase INSR insulin receptor 
CDK11 cyclin dependent kinase 11 JAK2 Janus kinase 2 
CDK2 cyclin dependent kinase 2 JAK3 Janus kinase 3 
CDK3 cyclin dependent kinase 3 JNK1 mitogen-activated protein kinase 8 (MAPK8) 
CDK7 cyclin dependent kinase 7 JNK2 mitogen-activated protein kinase 9 (MAPK9) 
CDK9 cyclin dependent kinase 9 JNK3 mitogen-activated protein kinase 10 (MAPK10) 
CHEK1 CHK1 checkpoint homolog KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
CSF1R colony stimulating factor 1 receptor LKB1 serine/threonine kinase 11 (STK11) 
CSNK1D casein kinase 1, delta MAP3K4 mitogen-activated protein kinase kinase kinase 4 
CSNK1G2 casein kinase 1, gamma 2 MAPKAPK2 
mitogen-activated protein kinase-
activated protein kinase 2 
DCAMKL1 doublecortin-like kinase 1 MARK3 MAP/microtubule affinity-regulating kinase 3 
DYRK1B 
dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 
1B 
MEK1 mitogen-activated protein kinase kinase 1 (MAP2K1) 
EGFR epidermal growth factor receptor MEK2 mitogen-activated protein kinase kinase 2 (MAP2K2) 
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Appendix 2-1B: List of kinases screened in the ScanEdge Kinome screen (Cont.) 
 
Kinase Official Name in Entrez Gene Kinase Official Name in Entrez Gene 
MET met proto-oncogene PLK3 polo-like kinase 3 
MKNK1 MAP kinase interacting serine/threonine kinase 1 PLK4 polo-like kinase 4 
MKNK2 MAP kinase interacting serine/threonine kinase 2 PRKCE protein kinase C, epsilon 
MLK1 mitogen-activated protein kinase kinase kinase 9 (MAP3K9) RAF1 
v-raf-1 murine leukemia viral 
oncogene homolog 1 
P38-alpha mitogen-activated protein kinase 14 (MAPK14) RET ret proto-oncogene 
P38-beta mitogen-activated protein kinase 11 (MAPK 11) RIOK2 RIO kinase 2 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 ROCK2 
Rho-associated, coiled-coil 
containing protein kinase 2 
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 RPS6KA3 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 3 
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 SNARK NUAK family, SNF1-like kinase, 2 
PCTK1 PCTAIRE protein kinase 1 SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
PDGFRA platelet-derived growth factor receptor, alpha SRPK3 SFRS protein kinase 3 
PDGFRB platelet-derived growth factor receptor, beta TGFBR1 
transforming growth factor, beta 
receptor 1 
PDPK1 3-phosphoinositide dependent protein kinase-1 TIE2 TEK tyrosine kinase, endothelial 
PIK3C2B phosphoinositide-3-kinase, class 2, beta TRKA 
neurotrophic tyrosine kinase, 
receptor, type 1 (NTRK1) 
PIK3CA phosphoinositide-3-kinase, catalytic, alpha TSSK1B testis-specific serine kinase 1B 
PIK3CG phosphoinositide-3-kinase, catalytic, gamma TYK2 tyrosine kinase 2 
PIM1 pim-1 oncogene ULK2 unc-51-like kinase 2 
PIM2 pim-2 oncogene VEGFR2 
kinase insert domain receptor 
(KDR) (a type III receptor tyrosine 
kinase) 
PIM3 pim-3 oncogene YANK3 serine/threonine kinase 32C (STK32C) 
PKAC-
alpha 
protein kinase, cAMP-dependent, 
catalytic, alpha ZAP70 
zeta-chain (TCR) associated protein 
kinase 70kDa 
PLK1 polo-like kinase 1   
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Appendix 2-2: Written script for docking process. 
 
#THE AUTOMATED AUTODOCK (VDOCK) SCRIPT 
 
# Scripted by Yeo Wee Kiang 
# Modified by Wee Xi Kai 
# Date Created: 30 July 2008, Wednesday 




# USAGE: nohup csh ./vdock.csh vdockgpf.txt vdockdpf.txt >& 
vdocklog.txt & 
# SVU USAGE: bsub -q linux64 -o testvdock.eo -m multicore 
"csh ./vdock.csh vdockgpf.txt vdockdpf.txt >& vdocklog.txt" 
# SVU Server recommended at NUS : atlas3. Activate vdock script at 
the folder containing n x ligand.mol2 and protein.pdbqt. 
 
# Prepares the ligands and receptor for docking by AutoDock. 
# Stores the prepared ligand files in the individual [ligandname] 
folders/directories. 
# Invokes the actual AutoDock 4 docking. 
# [Caution!] Please pre-process the receptor file manually using the 
AutoDock Tools graphical  
# user interface and save it as [receptorname].pdbqt file. 
 
# REQUIRED FILES TO WORK 
# Required input files: n number of [ligandname].mol2, 
[receptorname].pdbqt, [vdockgpf].txt, [vdockdpf].txt 




if (! -e $argv[1]) then 
 echo "Error: The parameter file $argv[1] does not exist." 
endif 
 
# define the name of the prepared receptor file 
echo "Setting parameters..." 
echo " " 
set receptor_filename = `grep -i receptor_filename $argv[2] | sed 
's/[a-zA-Z_]*\=//'` 
set receptorname = `basename $receptor_filename .pdbqt` 
 
echo "receptor_filename :" $receptor_filename 
echo "-------------------------" 
echo " " 
 
# for gpf, set parameters according to [gpf_parameters].txt 
echo "Setting gpf parameters..." 
echo "-------------------------" 
 
set gpf_parameters = `basename $argv[1] .txt` 
set gridcenter = `grep -i gridcenter $argv[1] | sed 's/[a-zA-
Z_]*\=//'` 
echo $gridcenter 
set spacing = `grep -i spacing $argv[1] | sed 's/[a-zA-Z_]*\=//'` 
echo $spacing 
set npts = (`grep -i npts $argv[1] | sed 's/[a-zA-Z_]*\=//'`) 
echo $npts 
echo " " 
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# for dpf, set parameters 
echo "Setting dpf parameters..." 
echo "-------------------------" 
 
set ga_num_evals = `grep -i ga_num_evals $argv[2] | sed 's/[a-zA-
Z_]*\=//'` 
echo "ga_num_evals :" $ga_num_evals 
set ga_pop_size = `grep -i ga_pop_size $argv[2] | sed 's/[a-zA-
Z_]*\=//'` 
echo "ga_pop_size :" $ga_pop_size 
set ga_run = `grep -i ga_run $argv[2] | sed 's/[a-zA-Z_]*\=//'` 
echo "ga_run :" $ga_run 
set ga_num_generations = `grep -i ga_num_generations $argv[2] | sed 
's/[a-zA-Z_]*\=//'` 
echo "ga_num_generations :" $ga_num_generations 
set ga_elitism = `grep -i ga_elitism $argv[2] | sed 's/[a-zA-
Z_]*\=//'` 
echo "ga_elitism :" $ga_elitism 
set ga_mutation_rate = `grep -i ga_mutation_rate $argv[2] | sed 
's/[a-zA-Z_]*\=//'` 
echo "ga_mutation_rate :" $ga_mutation_rate 
set ga_crossover_rate = `grep -i ga_crossover_rate $argv[2] | sed 
's/[a-zA-Z_]*\=//'` 
echo "ga_crossover_rate :" $ga_crossover_rate 
echo " " 




#processes every ligand, loops through all ligands 
foreach filename (`ls *.mol2`) 
 echo " " 
 echo "Processing... " $filename  
 set ligandname = `basename $filename .mol2` 
 mkdir "$ligandname" 
 
 # checks whether that particular ligand directory exists 
 if (! -d "$ligandname") then 
         mkdir ./"$ligandname"; 
 endif 
 
 ./pythonsh ./prepare_ligand4.py -l $filename -
o ./"$ligandname"/"$ligandname".pdbqt -d ligand_dict.py 
 echo "Ok, converted" $filename" to "$ligandname".pdbqt" 
 
 cd "$ligandname" # change to directory of that particular 
ligand 




 ../pythonsh ../prepare_gpf4.py -l "$ligandname".pdbqt -r 
"$receptor_filename" -o "$ligandname".gpf -i ../"$gpf_parameters".txt 
 
 echo "Ok, created" $ligandname".gpf" 
 autogrid4 -p "$ligandname".gpf -l "$ligandname".glg 
 echo "Ok, created" $ligandname".glg" 
 
 ../pythonsh ../prepare_dpf4.py -l "$ligandname".pdbqt -r 
$receptor_filename -p ga_num_evals=$ga_num_evals -p 
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ga_pop_size=$ga_pop_size -p ga_run=$ga_run -o 
"$receptorname"_"$ligandname".dpf 
 echo "Ok, created" $receptorname"_"$ligandname".dpf" 
 echo "Now attempting to dock" $ligandname 
 autodock4 -p "$receptorname"_"$ligandname".dpf -l 
"$receptorname"_"$ligandname".dlg 
# 
#Compiling dock results from all dlg files from the ligand subfolders 
and writes a new summary #file called "docking results.txt" inside 
each protein folder. 
# 
 echo " " >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo "RESULTS FOR " $ligandname >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo " " >> ../docking_results.txt 
 sed -n '/LOWEST ENERGY DOCKED CONFORMATION from EACH 
CLUSTER/,/USER    Estimated Inhibition 
Constant/p' ./"$receptorname"_"$ligandname".dlg >> ../docking_results
.txt 
 echo " " >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo " " >> ../docking_results.txt 
 sed -n '/CLUSTERING HISTOGRAM/,/LOWEST ENERGY DOCKED 
CONFORMATION/p' ./"$receptorname"_"$ligandname".dlg >> ../docking_res
ults.txt 
 echo " " >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo 
"********************************************************************
***" >> ../docking_results.txt 
 echo " " >> ../docking_results.txt 
 echo "Available docking results for" $ligandname" printed to 
docking_results.txt." 
 echo "Docking for" $ligandname" over." 
 echo "------------------------------------------------------" 
 echo "------------------------------------------------------" 
 echo " " 
 cd .. 
end 
 
# End of script 
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Appendix 2-3: Molecular Dynamics 
 
Molecular dynamics simulations were carried out using the SANDER module of 
AMBER 9.0 with the all-atom force field described by Cornell et al.A1 Prior to the MD 
simulations, the values of some of the force field parameters for the ligands had to be 
developed due to the lack of reported data. Optimization of meisoindigo was first achieved 
with the Gaussian98 package at the HF/6-31G* theoretical level. Electrostatic potentials (ESP) 
were generated with Merz-Singh-Kollman van der Waals parameters. A2 Fitting of the charges 
to the ESP was performed with the RESP program A3 of the AMBER package. GAFF A4 force 
fields parameters and RESP partial charges were assigned using the ANTECHAMBER 
module. 
The protein-ligand structure complex of the CDK2/cyclinA/meisoindigo was derived 
from Section 2.2.1 using Autodock4. The heavy atom RMSD score that compared the docked 
poses of meisoindigo/CDK2 generated by Autodock 4 and Gold 4 was 0.328 Ǻ, which 
indicated that the poses generated by either docking software were comparable.  The best 
docked pose of meisoindigo in complex with CDK2/cyclinA was saved as a pdb file for MD 
simulation. All simulations were performed at neutral pH. Lys and Arg residues were 
positively charged and Asp and Glu residues were negatively charged.  The default His 
protonation state in Amber9 was adopted. Counter ions were added to maintain the electro-
neutrality of the system. Each system was immersed in a 10Å layer truncated octahedron 
periodic water box. The layer of water molecule in all cases contained around 11,000 TIP3P 
A5 water molecules in each of the complexes. A two femtoseconds time step was used in all 
the simulations and long-range electrostatic interactions were treated with the particle mesh 
Ewald (PME) procedure A6 using a cubic B-spline interpolation and a 10-5 tolerance for the 
direct-space and with a 12Å non-bonded cutoff. Bond lengths involving hydrogen atoms were 
constrained using the SHAKE algorithm.A7 All systems were minimized prior to the 
production run. The minimization, performed with the SANDER module under constant 
volume conditions, consisted of 7 steps. All heavy atoms in both proteins and ligands were 
restrained with degressive forces of 500, 200, 100, 50, 5, 1kcal/mol, respectively. In the first 3 
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steps, minimization of the solvent molecules and hydrogen atoms of the systems involved 250 
cycles of steepest descent followed by 250 cycles of conjugate gradient minimization. In the 
next 3 steps, 100 cycles of steepest descent minimization were performed followed by 500 
cycles of conjugate gradient minimization. All systems were then relaxed by 500 cycles of 
steepest descent and 1000 cycles of conjugate gradient minimization. After the relaxation, the 
systems were heated to 300K. The production run spanned two nanoseconds. 
Binding free energies of both the systems, were analyzed using both the MM/PBSA 
(Molecular Mechanics-Possion-Boltzmann/Surface Area) A8 and MM/GBSA (Molecular 
Mechanics-Generalized Born/Surface Area) A9 approach to highlight the electrostatic and van 
der Waal contributions in the binding of the inhibitors and the proteins. The previous MD 
trajectory file of CDK2/cyclinA/indirubin-3-oxime was taken as the reference system for the 
current CDK2/cyclinA/MeIS simulations to compare the binding patterns and affinities of the 
ligands with the proteins.  
  The binding free energies (ΔGbind ) are computed as: 
ΔGbind    =  ΔG (complex) – [ΔG (protein) + ΔG (ligand) ]      (1) 
ΔGbind    =  ΔEgas + ΔGsolv – TΔS                          (2) 
ΔEgas      =  ΔEint + ΔEele + ΔEvdw                               (3) 
ΔGsolv   =  ΔGP(G)B + ΔGnonpolar                                 (4) 
 ΔGnonpolar   = γA+b                   (5) 
 
The sum of molecular mechanical energies, ΔEgas, were divided into contributions from 
internal energy (ΔEint), electrostatic potential (ΔEele) and van der Waals (ΔEvdw) potential. The 
solvation free energy (ΔGsolv) was composed of two parts - polar solvation free energy 
(ΔGP(G)B) and nonpolar salvation free energy (ΔGnonpolar). All energies are averaged along the 
MD trajectories. The snapshots were sampled from the 500-1500ps single trajectory with an 
interval of 20ps. The single trajectory approach was applied to estimate the energies. 
Estimation of energies in this manner had proven successful in previous studies. A10 Part of the 
reason for the success of this approach was the cancellation of errors that hid the effect of 
 10 
incomplete sampling. Egas was obtained using SANDER and estimation of ΔGP(G)B was 
conducted with a built-in module, PBSA in AMBER.  Gnonpolar was determined from equation 
(5), where A was the solvent-accessible surface area estimated using Sanner’s algorithm A11 
with a solvent probe radius of 1.4Å and the PARSE atomic radii parameters A12. γ and b were 
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Appendix 3-1: Analytical and spectral data of synthesized compounds. 
 
[1-1] (E)-[3,3'-biindolinylidene]-2,2'-dione 
1-1 was prepared from isatin and 2-oxindole as described in section 
3.5.2.1. Yield: 91% (microwave), 96% (reflux).  
mp: >350°C. 1H NMR (300MHz, DMSO-d6): δ= 10.87 (s, 2H), 9.04 
(d, J= 8.1Hz, 2H), 7.33 (t, J= 7.5Hz, 2H), 6.95 (t, J= 7.8Hz, 2H), 
6.84 (d, J= 7.8Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 170.0, 
145.1, 134.4, 133.7, 130.3, 122.7, 122.2, 110.6; MS(APCI) m/z: 
263.4 [(M+H+) calculated for C16H10N2O2, 263.3]. Anal. Calcd. for C16H10N2O2 (262.26): C, 
73.27; H, 3.84. Found: C, 73.29; H, 4.01. 
 
[1-2] (E)-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
1-2 was prepared from either A-2 with 2-oxindole or isatin with 1-
methyl-2-oxindole as described in section 3.5.2.3 Yield: 41% 
(microwave), 49% (reflux).  
mp: 231-232°C. 1H NMR (300MHz, DMSO-d6): δ= 10.92 (s, 1H), 
9.10 (dd, J1= 7.8, J2= 2.1 Hz, 2H), 7.44 (t, J= 7.5Hz, 1H), 7.36 (t, J= 
7.5Hz, 1H), 7.05 (t, J= 8.4Hz, 1H), 7.03 (d, J= 8.1, 1H), 6.98 (t, J= 
7.8Hz, 1H), 6.85 (d, J= 7.8Hz, 1H), 3.23 (s, 3H); 13C NMR (75MHz, 
DMSO-d6): δ= 169.9, 168.3, 146.0, 145.3, 134.8, 133.9, 133.6, 133.2, 130.4, 130.0, 122.8, 
122.6, 122.2, 121.9, 110.7, 109.5; MS(APCI) m/z: 277.7 [(M+H+) calculated for C17H12N2O2, 
277.3]. Anal. Calcd. for C17H12N2O2 (276.29): C, 73.90; H, 4.38. Found: C, 73.52; H, 4.43.  
 
[1-3] (E)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione 
1-3 was prepared from 1-1 and methyl iodide as described in section 
3.5.2.4. Yield: 95%  
mp: 274-275°C. 1H NMR (300MHz, DMSO-d6): δ= 9.20 (d, J= 
8.1Hz, 2H), 7.37 (t, J= 7.8Hz, 2H), 7.07 (t, J= 8.1Hz, 2H), 6.78 (d, 
J= 7.8Hz, 2H), 3.29 (s, 6H); 13C NMR (75MHz, DMSO-d6): δ= 
164.8, 146.2, 133.9, 130.1, 122.9, 121.8, 109.6, 100.6;MS(APCI) m/z: 
291.7 [(M+H+) calculated for C18H14N2O2, 291.3]. Anal. Calcd. for C18H14N2O2 (291.32): C, 



















1-4 was prepared from 1-1 as described in section 3.5.2.5. The 
methyl protons at 3 and 3’ positions were detected at 4.16 (major 
isomer) and 4.07 (minor isomer) in the ratio of 2:1 in the 1H NMR 
(300MHz). Yield: 93%  
13C NMR (75MHz, DMSO-d6): δ= 177.2, 176.1, 143.2, 142.7, 
128.19, 128.12, 127.4, 125.9, 123.3, 122.9, 121.3, 121.2, 109.4, 
109.3, 45.7, 45.6; MS(APCI) m/z 265.5 [(M+H+) calculated for C16H12N2O2, 265.3]. Anal. 
Calcd.for C16H12N2O2 (264.28): C, 72.72; H, 4.58. Found: C, 72.78; H, 4.61. A4 was tested as 
a mixture of steroisomers. 
 
[2-1] (E)-1-phenyl-[3,3'-biindolinylidene]-2,2'-dione 
 2-1 was prepared from 1-phenylisatin (1mmol) and 2-oxindole 
(1mmol) as described in section 3.5.3.6. Extraction was performed 
using DCM/brine and purification by flash chromatography with 
DCM as eluant gave the desired product as red solid. Yield: 54%  
mp: 273-274°C. 1H NMR (300MHz, DMSO-d6): δ= 10.95 (s, 1H), 
9.17 (d, J= 7.8Hz, 1H), 8.97 (d, J= 8.1Hz, 1H), 7.64-7.59 (m,2H), 
7.53-7.50 (m, 3H), 7.38-7.33 (m, 2H), 7.10 (t, J= 7.8Hz, 1H), 6.95 
(t, J= 7.8Hz, 1H), 6.86 (d, J= 7.8Hz, 1H), 6.68 (d, J= 8.1Hz, 1H); 13C NMR (75MHz, DMSO-
d6): δ= 168.8, 166.7, 144.8, 144.4, 134.4, 133.9, 133.1, 132.6, 131.9, 129.6, 129.5, 129.2, 
128.4, 127.3, 122.3, 121.6, 121.2, 121.0, 109.7, 108.8; MS(APCI) m/z: 339.5 [(M+H+) 
calculated for C22H14N2O2, 339.4]. Anal. Calcd. for C22H14N2O2 (338.35): C, 78.09; H, 4.17. 
Found: C, 78.07; H, 4.14 
 
[2-2] (E)-1-benzyl-[3,3'-biindolinylidene]-2,2'-dione 
2-2 was prepared from B-2 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant. Recrystallization in ethanol gave red wool. Yield: 43%  
mp: 238-241°C. 1H NMR (300MHz, DMSO-d6): δ= 10.94 (s, 1H), 
9.10 (dd, J1= 7.8Hz, J2= 3.3Hz, 2H), 7.36-7.27 (m, 7H), 7.06-6.95 (m, 
3H), 6.86 (d, J= 7.8Hz, 1H), 5.02 (s, 2H); 13C NMR (75MHz, 
DMSO-d6): δ= 169.9, 168.4, 145.4, 145.0, 137.3, 135.4, 134.1, 133.5, 132.9, 130.6, 130.2, 
129.8, 128.5, 128.3, 123.0, 122.7, 122.3, 122.0, 110.7, 110.0, 43.8; MS(APCI) m/z: 353.7 
[(M+H+) calculated for C23H16N2O2, 353.4]. Anal. Calcd. for C23H16N2O2 (352.28): C, 78.39; 





















2-3 was prepared from B-3 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant. Recrystallization in ethanol gave the desired product as red 
wool. Yield: 49%  
mp: 216-217°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 1H), 9.09 
(d, J= 7.8Hz, 1H), 8.98 (d, J= 7.8Hz, 1H), 7.40 (t, J= 7.5Hz, 1H), 7.35 
(t, J= 7.8Hz, 1H), 7.29-7.18 (m, 5H), 7.08 (d, J= 7.8Hz, 1H), 7.03 (t, 
J= 8.1Hz, 1H), 6.96 (t, J= 7.8Hz, 1H), 6.84 (d, J= 7.8Hz, 1H), 4.00 (t, J= 7.5Hz, 2H), 2.94 (t, 
J= 7.5Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 169.9, 168.1, 145.2, 145.1, 139.4, 134.9, 
134.0, 133.6, 133.1, 130.4, 130.1, 129.9, 129.4, 127.5, 122.7, 122.6, 122.2, 121.8, 110.7, 
109.7, 41.9, 34.0; MS(APCI) m/z 367.8 [(M+H+) calculated for C24H18N2O2, 367.4]. Anal. 
Calcd. for C24H18N2O2 (366.40): C, 78.67; H, 4.95. Found: C, 78.40; H, 4.95. 
 
[2-4] (E)-1-(2-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
2-4 was prepared from B-4 (0.5mmol) and 2-oxindole (0.55mmol) as 
described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant. Recrystallization in ethanol gave the desired product as red 
wool. Yield: 40%  
mp: 225-226°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.07 (d, J = 8.1, 1H), 8.98 (d, J = 8.1, 1H), 7.39 (t, J = 7.5, 1H), 7.34 
(t, J = 7.8, 1H), 7.20-7.14 (m, 2H), 7.03-6.90 (m, 4H), 6.86-6.81 (m, 
2H), 3.93 (t, J = 7.2, 2H), 3.75 (s, 1H), 2.90 (t, J = 7.2, 2H) ;  
13C NMR (75MHz, DMSO-d6): δ= 168.8, 166.9,157.3, 144.2, 144.1, 133.6, 132.8, 132.5, 
132.2, 130.3, 129.3, 128.9, 128.0, 126.1, 121.6, 121.5, 121.1, 120.8, 120.3, 110.5, 109.5, 
108.3, 55.2, 39.4 (from dept135), 27.9. MS(APCI) m/z: 397.1 [(M+H+) calculated for 
C25H20N2O3, 397.2]. HPLC: found 100% (retention time = 12.2 min, 80 MeOH : 20 H2O) and 















 2-5 was prepared from B-5 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant. Recrystallization in ethanol gave the desired product as red 
wool. Yield: 35%  
mp: 275-277°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 
1H), .9.08 (d, J = 7.8, 1H), 8.97 (d, J = 8.1, 1H), 7.40 (t, J = 7.5, 1H), 
7.34 (t, J = 7.5, 1H), 7.17 (t, J = 8.1, 1H), 7.08 (d, J = 7.8, 1H), 6.99 
(t, J = 8.1, 1H), 6.92 (t, J = 7.8, 1H), 6.85-6.83 (m, 3H), 6.74 (d, J = 7.5, 1H), 3.98 (t, J = 6.9, 
2H), 3.68 (s, 1H), 2.90 (t, J = 6.9, 2H); 13C NMR (75MHz, DMSO-d6): δ= 169.9, 168.0, 160.3, 
145.2, 145.1, 140.9, 134.9, 133.9, 133.6, 133.2, 130.45, 130.39, 130.0, 122.7, 122.6, 122.2, 
122.1, 121.9, 115.4, 113.1, 110.7, 109.8, 55.9, 41.8, 34.0. MS(APCI) m/z: 397.0 [(M+H+) 
calculated for C25H20N2O3, 397.2]. HPLC: found 99.7% (retention time = 9.3 min, 80 MeOH : 
20 H2O) and 97.2% (retention time = 4.0 min, 70 ACN: 30 H2O).  
 
[2-6] (E)-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
2-6 was prepared from B-6 (0.5mmol) and 2-oxindole (0.55mmol) as 
described in section 3.5.3.6. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant. Recrystallization in ethanol gave the desired product as red 
solid. Yield: 59% 
mp: 216-217°C. 1H NMR (300MHz, DMSO-d6): δ= 10.89 (s, 1H), 
9.09 (d, J= 8.1Hz, 1H), 8.97 (d, J= 8.1Hz, 1H), 7.41 (t, J= 7.5Hz, 
1H), 7.35 (t, J= 7.5Hz, 1H), 7.20 (d, J= 8.4Hz, 2H), 7.07 (d, J= 
7.8Hz, 1H), 7.03 (t, J= 7.8Hz, 1H), 6.96 (t, J= 7.8Hz, 1H,), 6.83-6.82 
(m, 3H), 3.95 (t, J= 7.2Hz, 2H), 3.69 (s, 3H), 2.87 (t, J= 7.5Hz, 2H);  
13C NMR (75MHz, DMSO-d6): δ= 169.9, 168.0, 158.9, 145.2, 145.1, 134.9, 133.9, 133.6, 
133.2, 131.2, 130.9, 130.4, 130.1, 122.7, 122.6, 122.2, 121.9, 114.9, 110.7, 109.7, 56.0, 42.2, 
33.1; MS(APCI) m/z: 397.4 [(M+H+) calculated for C25H20N2O3, 397.4]. Anal. Calcd.for 
















2-7 was prepared from B-7 (0.5mmol) and 2-oxindole (0.55mmol) as 
described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant gave the desired product as red solid. Yield: 20%  
mp: 242-243°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.08 (d, J= 7.8Hz, 1H), 8.94 (d, J= 8.1Hz, 1H), 7.41 (t, J= 7.5Hz, 
1H), 7.35 (t, J= 7.8Hz, 1H), 7.16-7.00 (m, 6H), 6.95 (t, J= 7.8Hz, 
1H), 6.84 (d, J= 7.5Hz, 1H), 3.96 (t, J= 7.2Hz, 2H), 2.88 (t, J= 7.5Hz, 
2H), 2.23 (s, 3H); 13C NMR (75MHz, DMSO-d6): δ= 169.9, 168.0, 
145.2, 145.1, 136.4, 136.3, 134.9, 134.0, 133.7, 133.1, 130.3, 130.0, 129.8, 122.7, 122.6, 
122.2, 121.9, 110.7, 109.7, 42.0, 33.5, 21.7; MS(APCI) m/z: 381.7 [(M+H+) calculated for 





2-8 was prepared as described in section 3.5.3.8. 3-step yield: 34% 
mp: 282-285°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.20 (brs, 1H), 9.08 (d, J= 8.1Hz, 1H), 9.00 (d, J= 7.8Hz, 1H), 7.39 
(t, J= 7.8Hz, 1H), 7.34 (t, J= 7.5Hz, 1H), 7.07-7.01 (m, 4H), 6.96 (t, 
J= 7.8Hz, 1H), 6.84 (d, J= 7.5Hz, 1H), 6.65 (d, J= 8.4, 2H), 3.91 (t, 
J= 7.2Hz, 2H), 2.80 (t, J= 7.5Hz, 2H); 13C NMR (75MHz, DMSO-
d6): δ= 168.8, 166.9, 155.8, 144.14, 144.08, 133.8, 132.8, 132.5, 
132.1, 129.7, 129.3, 129.0, 128.3, 121.6, 121.1, 120.8, 115.1, 109.6, 
108.6, 41.2, 32.0. MS(APCI) m/z: 383.4 [(M+H+) calculated for 
















2-9 was prepared from 1-1 (5mmol) and 4-nitrophenethyl (6mmol) 
as described in section 3.5.3.7. Extraction was performed using 
DCM/brine and purification by flash chromatography with gradient 
elution of DCM to DCM + 5% methanol gave the desired product as 
dark solid. Yield: 33% 
mp: 241-242°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.09 (d, J= 7.8Hz, 1H), 8.85 (d, J= 7.8Hz, 1H), 8.13 (d, J= 8.4Hz, 
2H), 7.55 (d, J= 8.4Hz, 2H), 7.41 (t, J= 7.5Hz, 1H), 7.33 (t, J= 7.5Hz, 
1H), 7.11 (d, J= 7.8Hz, 2H), 7.03 (t, J= 7.8Hz, 1H), 6.90 (t, J= 7.5Hz, 
1H), 6.83 (d, J= 7.5Hz, 1H), 4.07 (t, J= 6.9Hz, 2H), 3.10 (t, J= 6.9Hz, 2H); 13C NMR 
(75MHz, DMSO-d6): δ= 168.8, 167.0, 146.9, 146.2, 144.2, 143.8, 133.9, 132.9, 132.5, 131.9, 
130.3, 129.1, 129.0, 123.4, 121.8, 121.5, 121.1, 120.8, 109.6, 108.7, 42.0, 32.7; MS(APCI) 
m/z: 412.7 [(M+H+) calculated for C24H16N3O4, 412.4]. Anal. Calcd.for C24H16N3O4 (411.41): 
C, 70.07; H, 4.16. Found: C, 68.64; H, 4.46. HPLC: found 96.5% (retention time = 13.6 min, 
75 MeOH : 25 H2O) and 96.5% (retention time = 7.3 min, 70 ACN: 30 H2O).  
 
[2-10] (E)-1-(4-fluorophenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
2-10 was prepared from B-10 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.6. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant gave the desired product as red solid. Yield: 58%  
mp: 232-233°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.08 (d, J= 7.8Hz, 1H), 8.95 (d, J= 8.1Hz, 1H), 7.42-7.27 (m, 4H), 
7.11-7.00 (m, 4H), 6.95 (t, J= 7.8Hz, 1H), 6.84 (d, J= 7.8Hz, 1H), 
3.99 (t, J= 6.9Hz, 1H), 2.93 (t, J= 6.9Hz, 1H); 13C NMR (75MHz, 
DMSO-d6): δ= 168.8, 167.0,162.6, 159.3, 144.2, 144.0, 134.53, 
134.48, 133.8, 132.9, 132.5, 132.0, 130.7, 130.6, 129.2, 129.0, 121.7, 121.5, 121.1, 120.7, 
115.1, 114.9, 109.6, 108.6, 40.8, 32.0.MS(APCI) m/z: 385.0 [(M+H+) calculated for 
C24H17N2O2F, 385.13]. HPLC: found 95.1% (retention time = 9.1 min, 80 MeOH : 20 H2O) 















[2-11] (E)-N-(4-(2-(2,2'-dioxo-[3,3'-biindolinylidene]-1-yl)ethyl) phenyl)acetamide  
2-11 was prepared from 1-1 (1mmol) and B-11 (1.1mmol) as 
described in section 3.5.3.7. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM 
gave the desired product as red solid. Yield: 21% 
mp: 278-279°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.85 (s, 1H), 9.08 (d, J= 8.1Hz, 1H), 8.95 (d, J= 7.8Hz, 1H), 7.46 
(d, J= 8.4Hz, 2H), 7.41 (t, J= 8.1Hz, 1H), 7.35 (t, J= 7.8Hz, 1H), 
7.18 (d, J= 8.4Hz, 2H), 7.07 (d, J= 8.1Hz, 1H), 7.02 (t, J= 7.8Hz, 
1H), 6.95 (t, J= 7.5Hz, 1H), 6.84 (d, J= 7.8Hz, 1H), 3.96 (t, J= 
6.9Hz, 2H), 2.87 (t, J= 6.6Hz, 2H), 2.00 (s, 3H); 13C NMR 
(75MHz, DMSO-d6): δ= 168.9, 168.3, 167.0, 144.2, 137.7, 133.9, 133.0, 132.9, 132.7, 132.2, 
129.3, 129.1, 121.7, 121.6, 121.2, 120.8, 119.0, 109.7, 108.7, 41.0, 32.3, 20.0; MS(APCI) m/z 
424.4 [(M+H+) calculated for C26H21N3O3, 424.5]. Anal. Calcd.for C26H21N3O3 (423.45): C, 
73.74; H, 5.00. Found: C, 73.56; H, 5.20. 
 
[2-12] (E)-1-(2-cyclohexylethyl)-[3,3'-biindolinylidene]-2,2'-dione 
2-12 was prepared from B-12 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.5. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant gave the desired product as red solid. Yield: 38%  
mp: 188-189°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 1H), 
9.08 (t, J= 8.7Hz, 2H), 7.43 (t, J= 7.5Hz, 1H), 7.36 (t, J= 7.5Hz, 1H), 
7.06-6.95 (m, 3H), 6.85 (d, J= 7.8Hz, 1H), 3.79 (t, J= 6.9Hz, 2H), 
1.79 (d, J= 12.6Hz, 2H), 1.65-1.47 (m, 6H), 1.17-1.14 (m, 3H), 1.00-
0.89 (m, 2H); 13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.0,144.2, 144.1, 133.9, 132.9, 
132.7, 132.2, 129.4, 129.1, 121.7, 121.6, 121.2, 120.9, 109.7, 108.5, 37.3, 34.8, 34.2, 32.6, 
26.0, 25.7;MS(APCI) m/z: 373.0 [(M+H+) calculated for C24H24N2O2, 373.18]. HPLC: found 
99.3% (retention time = 6.6 min, 80 MeOH : 20 H2O) and 98.0% (retention time = 9.8 min, 
















2-13 was prepared from 1-1 (1mmol) and phenpropyl bromide 
(1.1mmol) as described in section 3.5.3.7. Extraction was 
performed using EA/brine and purification by flash 
chromatography (4:1 Hex/EA + 5% EtOH) gave the desired 
product as a dark solid. Yield: 42% 
mp: 173-174°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 
1H), 9.08 (t, J= 7.5Hz, 2H), 7.41 (t, J= 7.8Hz, 1H), 7.35 (t, J= 
7.5Hz, 1H), 7.29-7.17 (m, 5H), 7.01 (t, J= 6.6Hz, 2H), 6.97 (t, J= 
7.8Hz, 1H), 6.85 (d, J= 7.8Hz, 1H), 3.80 (t, J= 6.9Hz, 2H),  2.67 
(t, J= 7.5Hz, 2H), 1.93 (m, 2H); 13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.1, 144.2, 141.2, 
133.8, 132.9, 132.6, 132.2, 129.5, 129.1, 128.3, 128.2, 125.9, 121.7, 121.6, 121.2, 120.9, 
109.6, 108.5, 40.3, 32.5, 28.6; MS(APCI) m/z: 381.5 [(M+H+) calculated for C25H20N2O2, 
381.4]. Anal. Calcd.for C25H20N2O2 (380.43): C, 78.93; H, 5.30. Found: C, 78.75; H, 5.25. 
 
[2-14] (E)-1-cinnamyl-[3,3'-biindolinylidene]-2,2'-dione 
 2-14 was prepared from B-14 (1mmol) and 2-oxindole 
(1.1mmol) as described in section 3.5.3.6. Extraction was 
performed using DCM/brine and purification by flash 
chromatography with DCM as eluant gave the desired product as 
red solid. Yield: 62%  
mp: 249-250°C. 1H NMR (300MHz, DMSO-d6): δ= 10.93 (s, 
1H), 9.11 (t, J= 8.4Hz, 2H), 7.44-7.33 (m, 4H), 7.30 (t, J= 7.2Hz, 
2H), 7.23 (d, J= 6.9Hz, 1H), 7.09-7.02 (m, 2H), 6.98 (t, J= 7.8Hz, 
1H),  6.86 (d, J= 7.5Hz, 2H), 6.66 (d, J= 15.9Hz, 1H), 6.34 (dt, J1= 16.2Hz, J2= 5.4Hz, 1H), 
4.59 (d, J= 5.4Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 168.8, 166.9, 144.2, 144.0, 136.0, 
134.0, 1329, 132.5, 132.0, 131.9, 129.5, 129.1, 128.6, 127.7, 126.3, 123.4, 121.8, 121.6, 121.2, 
120.9, 109.6, 108.9, 41.2;MS(APCI) m/z: 379.0 [(M+H+) calculated for C25H18N2O2, 379.14]. 
HPLC: found 96.1% (retention time = 4.8 min, 90 MeOH : 10 H2O) and 98.0% (retention 














2-15 was prepared from B-15 (1mmol) and 2-oxindole 
(1.1mmol) as described in section 3.5.3.6. Extraction was 
performed using EA/brine and purification by flash 
chromatography with DCM as eluant gave the desired product 
as red solid. Yield: 55%  
mp: 260-262°C. 1H NMR (300MHz, DMSO-d6): δ= 10.94 (s, 
1H), 9.13 (d, J= 8.1Hz, 1H), 9.05 (d, J= 8.1Hz, 1H), 7.49 (t, J= 
7.5Hz, 1H), 7.42-7.34 (m, 6H), 7.22 (d, J= 7.8Hz, 1H), 7.10 (t, 
J= 7.8Hz, 1H), 6.98 (t, J= 7.8Hz, 1H), 6.85(d, J= 7.5Hz, 1H), 4.91 (s, 1H); 13C NMR (75MHz, 
DMSO-d6): δ= 168.7, 166.5, 144.4, 143.0, 134.5, 133.1, 132.5, 131.5, 131.4, 129.4, 129.1, 
128.9, 128.6, 122.1, 121.5, 121.2, 120.9, 109.7, 109.0, 83.6, 82.7, 29.5; MS(APCI) m/z: 377.0 
[(M+H+) calculated for C25H16N2O2, 377.12]. HPLC: found 95.4% (retention time = 12.1 min, 
80 MeOH : 20 H2O) and 98.5% (retention time = 7.0 min, 70 ACN: 30 H2O). 
 
[2-16] (E)-1-(2-phenoxyethyl)-[3,3'-biindolinylidene]-2,2'-dione 
 2-16 was prepared from 1-1 (1mmol) B-16 (1.1mmol) as 
described in section 3.5.3.7. Extraction was performed using 
DCM/brine and purification by flash chromatography (4:1 
Hex/EA) gave the desired product as a dark solid. Yield: 13% 
mp: 204-205°C. 1H NMR (300MHz, DMSO-d6): δ= 10.89 (s, 
1H), 9.04 (d, J= 8.7Hz, 1H), 8.95 (d, J= 8.1Hz, 1H), 7.42 (t, J= 
7.8Hz, 1H), 7.34 (t, J= 7.8Hz, 1H), 7.26-7.15 (m, 3H), 7.02 (t, J= 
7.5Hz, 1H), 6.93 (t, J= 8.1Hz, 1H), 6.89-6.83 (m, 4H), 4.20 (m, 
4H);  13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.5, 158.1, 144.5, 144.3, 134.0, 133.1, 
132.6, 132.1, 129.6, 129.5, 129.0, 121.8, 121.7, 121.3, 121.0, 120.9, 114.5, 109.8, 109.2, 65.0, 
56.2; MS(APCI) m/z: 383.4 [(M+H+) calculated for C24H18N2O3, 383.13]. HPLC: found 
98.6% (retention time = 9.3 min, 80 MeOH : 20 H2O) and 96.6% (retention time = 6.3 min, 















 2-17 was prepared from B-17 (1mmol) and 2-oxindole 
(1.1mmol) as described in section 3.5.3.6. Extraction was 
performed using DCM/brine and purification by flash 
chromatography with DCM as eluant gave the desired 
product as a dark solid. Yield: 41%  
mp: 181-182°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 
1H), 9.08 (t, J= 7.2Hz, 2H), 7.41 (t, J= 7.5Hz, 1H), 7.35 (t, 
J= 7.8Hz, 1H), 7.13 (d, J= 8.1Hz, 2H), 7.05-6.97 (m, 3H), 
6.94-6.80 (m, 3H), 3.78 (t, J= 6.6Hz, 2H), 3.70 (s, 3H), 2.60 (t, J= 7.5Hz, 2H), 1.89 (m, 2H); 
13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.1, 157.5, 144.2, 133.8, 133.0, 132.9, 132.6, 
132.2, 129.5, 129.2, 121.7, 121.2, 120.9, 113.7, 109.6, 108.5, 54.9, 40.1 (from dept135), 31.6, 
28.7;MS(APCI) m/z: 411.0 [(M+H+) calculated for C26H22N2O3, 411.16]. HPLC: found 96.9% 
(retention time = 12.8 min, 80 MeOH : 20 H2O) and 96.0% (retention time = 6.8 min, 70 
ACN: 30 H2O).  
 
[2-B18] (E)-3-(2,2'-dioxo-[3,3'-biindolinylidene]-1-yl)propanenitrile 
2-18 was prepared from B-18 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.6. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM as 
eluant gave the desired product as a dark solid. Yield: 41%  
mp: 258-260°C. 1H NMR (300MHz, DMSO-d6): δ= 10.92 (s, 1H), 
9.10 (d, J= 7.8Hz, 1H), 9.03 (d, J= 8.1Hz, 1H), 7.43 (t, J= 7.5Hz, 
1H), 7.35 (t, J= 7.5Hz, 1H), 7.19 (d, J= 7.8Hz, 1H), 7.06 (t, J= 7.8Hz, 
1H), 6.97 (t, J= 7.8Hz, 1H), 6.84 (d, J= 7.8Hz, 1H), 4.08 (t, J= 6.6Hz, 
2H), 2.95 (t, J= 6.3Hz, 2H) ; 13C NMR (75MHz, DMSO-d6): δ= 168.7, 167.1, 144.3, 143.3, 
134.2, 133.0, 132.5, 131.5, 129.4, 129.1, 122.0, 121.5, 121.1, 120.8, 118.6, 109.6, 108.7, 35.3, 
15.7; MS(APCI) m/z: 316.0 [(M+H+) calculated for C19H13N3O2, 316.10]. HPLC: found 
98.9% (retention time = 2.3 min, 90 MeOH : 10 H2O) and 98.4% (retention time = 3.0 min, 
















2-19 was prepared from B-19 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.3.6. Extraction was performed using 
DCM/brine and purification by flash chromatography with DCM 
as eluant gave the desired product as a dark solid. Yield: 32%  
mp: 201-203°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 1H), 
9.11 (d, J= 8.1Hz, 1H), 9.07 (d, J= 8.1Hz, 1H), 7.43 (t, J= 7.5Hz, 
1H), 7.35 (t, J= 7.5Hz, 1H), 7.11-7.02 (m, 2H), 6.97 (t, J= 7.8Hz, 
1H), 6.84 (d, J= 7.5Hz, 1H), 3.86 (t, J= 6.6Hz, 2H), 2.60 (t, J= 
6.9Hz, 2H), 1.94 (p, J= 6.6Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 169.0, 167.6, 144.3, 
144.1, 134.0, 133.1, 132.8, 132.3, 129.6, 129.3, 122.0, 121.8, 121.4, 121.2, 120.5, 109.8, 
108.6, 39.2 (from dept135), 23.2, 14.3; MS(APCI) m/z: 330.0 [(M+H+) calculated for 
C20H15N3O2, 330.12]. HPLC: found 97.3% (retention time = 3.1 min, 80 MeOH : 20 H2O) and 
99.3% (retention time = 2.9 min, 70 ACN: 30 H2O).  
 
[2-20] (E)-1-(2-hydroxyethyl)-[3,3'-biindolinylidene]-2,2'-dione 
 2-20 was prepared from B-20 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.3.6 with ethanol as the solvent. The 
precipitated was filtered and rinsed with EtOH and dried in the oven. 
Red solid. Yield: 85%  
mp: 254-256°C. 1H NMR (300MHz, DMSO-d6): δ= 10.88 (s, 1H), 
9.07 (dd, J1= 7.5Hz, J2= 2.4Hz, 2H), 7.39 (t, J= 7.8Hz, 1H), 7.34 (t, 
J= 7.5Hz, 1H), 7.06 (d, J= 7.8Hz, 1H), 7.00 (t, J= 7.8Hz, 1H), 6.96 (t, 
J= 7.8Hz, 1H), 6.84 (d, J= 7.5Hz, 1H), 4.87 (brs, 1H), 3.83 (t, J= 5.1Hz, 1H), 3.64 (t, J= 
5.1Hz, 1H); 13C NMR (75MHz, DMSO-d6): δ= 168.8, 167.3, 144.9, 144.1, 133.6, 132.7, 
132.4, 129.4, 128.9, 121.6, 121.4, 121.1, 120.8, 109.5, 108.9, 58.0, 42.2; MS(APCI) m/z: 
307.2 [(M+H+) calculated for C18H14N2O3, 307.2]. HPLC: found 100% (retention time = 3.1 















[2-21] (E)-2-(2,2'-dioxo-[3,3'-biindolinylidene]-1-yl)ethyl acetate 
2-20 was prepared from B-20 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.3.6. Extraction was performed using 
DCM/brine and purification by flash chromatography (DCM + 2% 
EtOH as eluant) gave the desired product as red solid. Yield: 41% 
mp: 195-196°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 1H), 
9.09 (d, J= 7.8Hz, 1H), 9.03 (d, J= 7.8Hz, 1H), 7.43 (t, J= 7.5Hz, 
1H), 7.35 (t, J= 7.5Hz, 1H), 7.10 (d, J= 7.8Hz, 1H), 7.04 (t, J= 
7.8Hz, 1H), 6.97 (t, J= 7.8Hz, 1H), 6.84 (d, J= 7.8Hz, 1H), 4.28 (t, 
J= 5.1Hz, 2H), 4.03 (t, J= 5.1Hz, 2H), 1.89 (s, 1H); 13C NMR (75MHz, DMSO-d6): δ= 170.2, 
168.8, 167.4, 144.3, 144.1, 134.0, 133.0, 132.5, 131.9, 129.3, 129.0, 121.8, 121.6, 121.2, 
120.8, 109.7, 108.6, 60.7, 40.3 (from dept135), 20.6; MS(APCI) m/z: 349.3 [(M+H+) 
calculated for C20H16N2O4, 349.3] HPLC: found 96.4% (retention time = 3.9 min, 80 MeOH : 
20 H2O) and 95.1% (retention time = 3.4 min, 70 ACN: 30 H2O).  
 
[3-1] (E)-5-fluoro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-1 was prepared from C-1 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.4.7. Extraction was performed using 
DCM/brine and purification by flash chromatography (3:1 
Hex/EA) gave the desired product as a dark solid. Yield: 41% 
mp: 269-271°C. 1H NMR (300MHz, DMSO-d6): δ= 10.95 (s, 
1H), 9.08 (d, J= 7.8Hz, 1H), 8.96 (dd, J1= 11.1Hz, J2= 
2.4Hz,1H), 7.35 (t, J= 7.5Hz, 1H), 8.96 (dt, J1= 8.7Hz, J2= 2.4Hz,1H), 7.00-6.93 (m, 2H), 
6.83 (d, J= 7.8Hz, 1H), 3.18 (s, 1H); 13C NMR (75MHz, DMSO-d6): δ= 168.9, 166.9, 159.0, 
155.9, 144.5, 141.3, 134.9, 133.3, 131.4, 129.7, 121.5, 121.35, 121.30, 118.6, 118.3, 116.0, 
115.6, 109.7, 109.0, 108.8, 26.1; MS(APCI) m/z: 294.9 [(M+H+) calculated for C17H12N2O2F, 
295.08]. HPLC: found 95.5% (retention time = 3.7 min, 80 MeOH : 20 H2O) and 95.9% 

















3-2 was prepared from C-2 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.4.7. Extraction was performed using 
DCM/brine and purification by flash chromatography (3:1 
Hex/EA) gave the desired product as a dark solid. Yield: 84% 
m.p. 268-270 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.98 (s, 
1H), 9.22 (d, J = 2.1 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 7.50 (dd, 
J = 8.4, 2.1 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H), 
6.86 (d, J = 7.8 Hz, 1H), 3.23 (s, 3 H); 13C NMR (75 MHz, DMSO-d6): δ 169.9, 167.9, 145.6, 
144.6, 136.2, 134.5, 132.6, 131.9, 130.8, 129.4, 126.7, 123.0, 122.4, 122.4, 110.8, 110.8, 27.2; 
MS (APCI) m/z: 310.9 [(M+H)+ calc for C17H12N2O2Cl, 311.05] HPLC: found 96.2% 




3-3 was prepared from C-3 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.4.7. Extraction was performed using 
DCM/brine and purification by flash chromatography (4:1 
Hex/EA) gave the desired product as a dark solid. Yield: 28% 
m.p. 304-306 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.91 (s, 
1H), 9.28 (d, J = 1.5 Hz, 1H), 9.04 (d, J = 7.8 Hz, 1H), 7.55 (dd, 
J = 8.4, 1.8 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 6.97-6.92 (m, 2H), 6.82 (d, J = 7.8 Hz, 1H), 
3.17 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 168.8, 166.7, 144.5, 143.9, 135.1, 134.3, 
133.3, 131.0, 131.0, 129.7, 122.4, 121.3, 121.3, 113.4, 110.1, 109.7, 26.1; MS (APCI) m/z: 
354.9, 357.1. [(M+H)+ calc for C17H12N2O2Br, 355.00 and 357.00] HPLC: found 96.3% 

















3-4 was prepared from C-4 (1mmol) and 2-oxindole (1.1mmol) 
as described in section 3.5.4.7. Extraction was performed using 
EA/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 62% 
mp: 243-244°C. 1H NMR (300MHz, DMSO-d6): δ= 10.88 (s, 
1H), 9.09 (d, J = 7.8Hz, 1H), 8.85 (d, J = 2.1 Hz, 1H), 7.34 (t, J 
= 7.5 Hz, 1H), 7.03-6.83 (m, 4H), 3.74 (s, 3H), 3.17 (s, 3H); 13C NMR (75MHz, DMSO-d6): 
δ= 169.0, 167.0,154.5, 144.2, 138.9, 134.0, 132.9 132.8, 129.5, 121.6, 121.5, 121.2, 117.6, 
115.6, 109.6, 108.5, 55.5, 26.1; MS(APCI) m/z: 307.0 [(M+H+) calculated for C18H14N2O3, 
307.10]. HPLC: found 98.1% (retention time = 5.6 min, 80 MeOH : 20 H2O) and 95.6% 
(retention time = 4.6 min, 70 ACN: 30 H2O).  
 
[3-5] (E)-6-fluoro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-5 was prepared from C-5 (0.5mmol) and 2-oxindole 
(0.55mmol) as described in section 3.5.4.7. Extraction was 
performed using EA/brine and purification was carried out by 
recrystallization in EtOH. Dark crystals. Yield: 63% 
mp: 256-258°C. 1H NMR (300MHz, DMSO-d6): δ= 10.93 (s, 
1H), 9.18 (dd, J1 = 8.1Hz, J2 = 6.6 Hz, 1H), 9.05 (d, J = 8.1 Hz, 
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.02-6.95 (m, 2H), 6.88-6.83 (m, 2H), 3.22 (s, 3 H); 13C NMR 
(75MHz, DMSO-d6): δ= 168.9, 167.6, 166.3, 163.0, 147.4, 147.3, 144.2, 133.20, 133.15, 
132.8, 131.4, 131.3, 131.0, 1294, 121.5, 121.3, 117.24, 117.20, 109.7, 108.0, 107.7, 97.2, 96.8, 
26.3; MS(APCI) m/z: 294.9 [(M+H+) calculated for C17H11N2O2F, 295.08]. HPLC: found 
100% (retention time = 6.3 min, 80 MeOH : 20 H2O) and 98.3% (retention time = 4.0 min, 70 
ACN: 30 H2O).  
 
[3-6] (E)-6-chloro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-6 was prepared from C-6 (0.5mmol) and 2-oxindole 
(0.55mmol) as described in section 3.5.4.7. Extraction was 
performed using EA/brine and purification was carried out by 
recrystallization in EtOH. Dark crystals. Yield: 72% 
mp: 282-284°C. 1H NMR (300MHz, DMSO-d6): δ= 10.93 (s, 
1H), 9.09 (d, J = 8.7Hz, 1H), 9.05 (d, J = 8.1 Hz, 1H), 7.35 (t, J 
= 7.5 Hz, 1H), 7.15 (d, J = 2.1 Hz, 1H), 7.08 (dd, J1 = 8.4Hz, J2 = 1.8 Hz, 1H), 6.97 (t, J = 7.5 
Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 3.22 (s, 3 H);  13C NMR (75MHz, DMSO-d6): δ= 168.6, 




















108.8, 26.2; MS(APCI) m/z: 310.9 [(M+H+) calculated for C17H11N2O2Cl, 311.05]. HPLC: 
found 99.6% (retention time = 7.3 min, 80 MeOH : 20 H2O) and 98.3% (retention time = 5.3 
min, 70 ACN: 30 H2O).  
 
[3-7] (E)-6-bromo-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-7 was prepared from C-7 (0.5mmol) and 2-oxindole 
(0.55mmol) as described in section 3.5.4.7. Extraction was 
performed using EA/brine and purification was carried out by 
recrystallization in EtOH. Dark crystals. Yield: 73% 
mp: 289-290°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 
1H), 9.03 (d, J = 7.8Hz, 1H), 8.97 (d, J = 8.4 Hz, 1H), 7.34 (t, J 
= 7.5 Hz, 1H), 7.22-7.17 (m, 2H), 6.94 (t, J = 7.8 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 3.18 (s, 3 
H);  13C NMR (75MHz, DMSO-d6): δ= 168.8, 167.1, 146.1, 144.3, 134.3, 133.1, 130.9, 130.2, 
129.5, 125.5, 124.2, 121.5, 121.2, 119.8, 111.5, 109.6, 26.2; MS(APCI) m/z: 354.9, 357.2 
[(M+H+) calculated for C17H11N2O2Br, 355.0, 357.0]. HPLC: found 99.0% (retention time = 
8.5 min, 80 MeOH : 20 H2O) and 98.4% (retention time = 5.7 min, 70 ACN: 30 H2O).  
 
[3-8] (E)-6-methoxy-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-8 was prepared from C-8 (0.5mmol) and isatin (0.55mmol) 
as described in section 3.5.4.8. Extraction was performed using 
EA/brine and purification by recrystallization in EtOH gave 
the desired product as dark crystals. Yield: 65% 
mp: 235-237°C. 1H NMR (300MHz, DMSO-d6): δ= 10.83 (s, 
1H), 9.10 (d, J = 9.0Hz, 1H), 9.03 (d, J = 8.1 Hz, 1H), 7.30 (t, 
J = 7.5 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H),  
6.59 (dd, J1 = 8.7Hz, J2 = 2.1 Hz, 1H), 3.88 (s, 3H), 3.22 (s, 3 H); 13C NMR (75MHz, DMSO-
d6): δ=169.1, 168.0, 163.3, 147.4, 143.5, 132.0, 131.8, 131.1, 130.1, 128.7, 121.8, 121.0, 
113.9, 109.4, 106.7, 95.3; MS(APCI) m/z: 307.0 [(M+H+) calculated for C18H14N2O3, 307.10]. 
HPLC: found 94.8% (retention time = 4.7 min, 80 MeOH : 20 H2O) and 96.4% (retention 
















3-9 was prepared from C-9 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.4.7. Extraction was performed using 
DCM/brine and purification by flash chromatography (3:1 Hex/EA) 
gave the desired product as a dark solid. Yield: 60% 
m.p. 251-252 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.91 (s, 1H), 
9.00 (d, J = 7.8 Hz, 1H), 8.91 (d, J = 7.8 Hz, 1H), 7.37-7.25 (m, 
2H), 7.02-6.92 (m, 2H), 6.82 (d, J = 7.8 Hz, 1H);13C NMR (75 MHz, DMSO-d6): δ 168.5, 
166.7, 148.1, 145.0, 144.4, 135.1, 133.3, 131.3, 131.2, 131.0, 131.0, 129.6, 125.0, 123.5, 
123.5, 121.9, 121.8, 121.4, 121.2, 119.8, 119.6, 109.6, 28.5, 28.4; MS (APCI) m/z: 294.9. 
[(M+H)+ calc for C17H11N2O2F, 295.08]; HPLC: found 98.5% (retention time = 6.8 min, 80 
MeOH : 20 H2O) and 98.7% (retention time = 4.6 min, 70 ACN: 30 H2O). 
 
[3-10] (E)-7-chloro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-10 was prepared from C-10 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.4.7. Extraction was performed using 
EA/brine and purification by flash chromatography (4:1 Hex/EA) 
gave the desired product as a dark solid. Yield: 16% 
m.p. 232-233 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.94 (s, 1 H), 
9.09 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.8 Hz, 
1H), 7.36 (t, J = 7.8 Hz, 1H), 7.06-6.94 (m, 2H), 6.83 (d, J = 7.5 Hz, 1H), 3.56 (s, 3H); 13C 
NMR (75 MHz, DMSO-d6): δ 168.5, 167.4, 144.4, 140.3, 135.2, 134.0, 133.4, 130.6, 129.5, 
127.4, 123.7, 122.6, 121.5, 121.2, 114.0, 109.7, 29.5; MS (APCI) m/z: 310.9. [(M+H)+ calc 
for C17H11N2O2Cl, 311.05]; HPLC: found 97.8% (retention time = 10.5 min, 80 MeOH : 20 
H2O) and 96.5% (retention time = 6.5 min, 70 ACN: 30 H2O). 
 
[3-11] (E)-7-bromo-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-11 was prepared from C-11 (1mmol) and 2-oxindole (1.1mmol) as 
described in section 3.5.4.7. Extraction was performed using EA/brine 
and purification by recrystallization in EtOH. Dark solid. Yield: 14% 
m.p. 264-266 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.94 (s, 1H), 
9.11 (d, J = 7.8 Hz, 1H), 8.95 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 8.1 Hz, 
1H), 7.36 (t, J = 7.5 Hz, 1H), 6.98-6.93 (m, 2H), 6.83 (d, J = 7.8 Hz, 
1H), 3.57 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 168.6, 167.7, 144.5, 141.7, 137.5, 135.2, 
133.5, 130.7, 129.6, 127.9, 124.1, 123.1, 121.6, 121.3, 109.8, 101.4, 29.8; MS (APCI) m/z: 




















(retention time = 11.7 min, 80 MeOH : 20 H2O) and 98.8% (retention time = 7.0 min, 70 
ACN: 30 H2O). 
 
[3-12] (E)-7-methoxy-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-12 was prepared from C-12 (0.5mmol) and isatin (0.55mmol) as 
described in section 3.5.4.8. Extraction was performed using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 56% 
mp: 276-277°C. 1H NMR (300MHz, DMSO-d6): δ= 10.87 (s, 1H), 
9.02 (d, J = 7.8 Hz, 1H), 8.72 (d, J = 8.1 Hz, 1H), 7.33 (t, J = 7.5 Hz, 
1H), 7.57 (d, J = 8.1 Hz, 1H), 6.98-6.93 (m, 2H), 6.83 (d, J = 7.8 Hz, 
1H), 3.84 (s, 3H), 3.44 (s, 3H);  13C NMR (75MHz, DMSO-d6): δ= 169.7, 168.4, 145.4, 145.2, 
135.2, 134.0, 133.9, 133.5, 130.4, 123.21, 123.15, 123.1, 122.7, 122.2, 118.5, 110.7, 57.5, 
30.5;MS(APCI) m/z: 307.1 [(M+H+) calculated for C18H14N2O3, 307.10]. HPLC: found 98.7% 
(retention time = 5.5 min, 80 MeOH : 20 H2O) and 96.2% (retention time = 4.4 min, 70 ACN: 
30 H2O).  
 
[3-13] (E)-5'-fluoro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-13 was prepared from 1-methyl-2-oxindole (1mmol) and 5-
fluoro-isatin (1.1mmol) as described in section 3.5.4.10. Extraction 
was performed using DCM/brine and purification by flash 
chromatography (DCM) gave the desired product as a dark solid. 
Yield: 48% 
m.p. 243-244 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.85 (s, 1H), 
9.04 (d, J = 7.8 Hz, 1H), 8.89 (dd, J = 11.7, 2.4 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.15 (td, J = 
8.7, 2.4 Hz, 1H), 7.01-6.91 (m, 2H), 6.76 (dd, J = 8.4, 4.8 Hz, 1H), 3.15 (s, 3H); 13C NMR (75 
MHz, DMSO-d6): δ 168.7, 167.1, 158.5, 155.4, 145.1, 140.5, 133.3, 132.9, 129.3, 122.3, 
122.2, 121.8, 120.5, 119.1, 118.8, 116.2, 115.9, 110.0, 109.9, 108.4, 25.9; MS (APCI) m/z: 
294.9. [(M+H)+ calc for C17H11N2O2F, 295.08]; HPLC: found 96.6% (retention time = 5.0 min, 
















3-14 was prepared from 1-methyl-2-oxindole (0.5mmol) and 5-
chloro-isatin (0.55mmol) as described in section 3.5.4.10. 
Extraction was performed using DCM/brine and purification by 
flash chromatography (DCM) gave the desired product as a dark 
solid. Yield: 57% 
m.p. 279-280 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.04 (s, 1H), 
9.20 (d, J = 1.5 Hz, 1H), 9.09 (d, J = 8.1 Hz, 1H), 7.45 (t, J = 7.8 Hz, 1H), 7.39 (dd, J = 8.4, 
1.8 Hz, 1H), 7.07-7.00 (m, 2H), 6.84 (d, J = 8.4 Hz, 1H), 3.22 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6): δ 168.5, 167.2, 145.3, 142.8, 133.7, 133.2, 132.4, 132.0, 129.3, 128.7, 125.0, 
122.8, 121.9, 120.6, 110.9, 108.6, 26.1; MS (APCI) m/z: 310.0. [(M+H)+ calc C17H11N2O2Cl, 
311.05]; HPLC: found 97.8% (retention time = 6.9 min, 80 MeOH : 20 H2O) and 97.3% 
(retention time = 5.1 min, 70 ACN: 30 H2O). 
 
[3-15] (E)-5'-bromo-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-15 was prepared from 1-methyl-2-oxindole (0.5mmol) and 5-
bromo-isatin (0.55mmol) as described in section 3.5.4.10. 
Extraction was performed using DCM/brine and purification by 
flash chromatography (DCM) gave the desired product as a dark 
solid. Yield: 52% 
m.p. 292-294 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.04 (s, 1H), 
9.33 (s, 1H), 9.09 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.06-
7.00 (m, 2H), 6.80 (d, J = 8.1 Hz, 1H), 3.22 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ 168.4, 
167.2, 145.3, 143.1, 134.7, 133.7, 133.2, 132.2, 131.4, 129.3, 123.3, 121.9, 120.6, 112.8, 
111.4, 108.6, 26.1; MS (APCI) m/z: 354.8, 356.8. [(M+H)+ calc for C17H11N2O2Br, 355.0 and 
357.0]; HPLC: found 97.3% (retention time = 7.4 min, 80 MeOH : 20 H2O) and 96.7% 
(retention time = 5.4 min, 70 ACN: 30 H2O). 
 
[3-16] (E)-5'-methoxy-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-16 was prepared from 1-methyl-2-oxindole (1mmol) and 5-
methoxy-isatin (1.1mmol) as described in section 3.5.4.10. 
Extraction was performed using EA/brine and purification by flash 
chromatography (DCM) gave the desired product as a dark solid. 
Yield: 57% 
mp: 244-246°C. 1H NMR (300MHz, DMSO-d6): δ= 10.71 (s, 1H), 
9.11 (d, J = 7.8 Hz, 1H), 8.87 (d, J = 2.4 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.06-6.95 (m, 3H), 




















167.2, 153.9, 144.9, 138.1, 134.3, 132.5, 132.4, 129.0, 122.2, 121.7, 120.7, 118.7, 115.1, 
109.7, 108.3, 55.4, 26.0;MS(APCI) m/z: 307.0 [(M+H+) calculated for C18H14N2O3, 307.10]. 
HPLC: found 97.0% (retention time = 4.3 min, 80 MeOH : 20 H2O) and 97.3% (retention 
time = 3.4 min, 70 ACN: 30 H2O).  
 
[3-17] (E)-6'-fluoro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-17 was prepared from 1-methyl-2-oxindole (0.5mmol) and 6-
fluoroisatin (0.55mmol) as described in section 3.5.4.10. 
Extraction was performed using EA/brine and purification by 
recrystallization in EtOH. Dark crystals. Yield: 66% 
mp: 293-294°C. 1H NMR (300MHz, DMSO-d6): δ= 11.07 (s, 1H), 
9.18 (d, J1 = 9.0 Hz, J2 = 6.0 Hz, 1H), 9.06 (d, J = 7.8 Hz, 1H), 
7.43 (t, J = 7.8 Hz, 1H), 7.06-7.00 (m, 2H), 6.79 (dt, J1 = 9.6 Hz, J2 = 2.7 Hz, 1H), 6.65 (dd, 
J1 = 9.0 Hz, J2 = 2.4 Hz, 1H), 3.22 (s, 3H); 13C NMR (75MHz, DMSO-d6): δ= 169.0, 167.2, 
166.0, 162.7, 146.4, 146.2, 144.8, 132.4, 132.32, 132.29, 131.9, 131.7, 131.61, 131.57, 128.8, 
121.7, 120.6, 118.09, 118.06, 108.4, 107.7, 107.4, 97.5, 97.1, 25.9; MS(APCI) m/z: 294.9 
[(M+H+) calculated for C17H11N2O2F, 295.08]. HPLC: found 98.3% (retention time = 5.3 min, 
80 MeOH : 20 H2O) and 95.6% (retention time = 3.9 min, 70 ACN: 30 H2O).  
 
[3-18] (E)-6'-chloro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-18 was prepared from 1-methyl-2-oxindole (0.5mmol) and 6-
chloroisatin (0.55mmol) as described in section 3.5.4.10. 
Extraction was performed using EA/brine and purification by 
recrystallization in EtOH. Dark crystals. Yield: 78% 
mp: 296-298°C. 1H NMR (300MHz, DMSO-d6): δ= 11.03 (s, 1H), 
9.05 (t, J = 8.4 Hz, 2H), 7.42 (t, J = 7.5 Hz, 1H), 7.04-6.97 (m, 3H), 
6.81 (d, J = 1.8 Hz, 1H), 3.19 (s, 3H);  13C NMR (75MHz, DMSO-d6): δ= 168.8, 167.1, 145.4, 
145.1, 136.6, 132.8, 132.7, 132.2, 130.8, 129.1, 121.8, 120.9, 120.6, 120.4, 109.4, 108.5, 26.0; 
MS(APCI) m/z: 310.9 [(M+H+) calculated for C17H11N2O2Cl, 311.05]. HPLC: found 99.3% 
(retention time = 8.2 min, 80 MeOH : 20 H2O) and 97.2% (retention time = 5.1 min, 70 ACN: 
















3-19 was prepared from 1-methyl-2-oxindole (0.5mmol) and 6-
bromoisatin (0.55mmol) as described in section 3.5.4.10. 
Extraction was performed using EA/brine and purification by 
recrystallization in EtOH. Dark crystals. Yield: 78% 
mp: 295-297°C. 1H NMR (300MHz, DMSO-d6): δ= 11.02 (s, 1H), 
9.05 (d, J = 7.8 Hz, 1H), 8.99 (d, J = 8.7 Hz, 1H), 7.40 (t, J = 7.2 
Hz, 1H), 7.13 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 1H), 7.04-6.95 (m, 3H), 3.19 (s, 3H);   13C NMR 
(75MHz, DMSO-d6): δ= 168.6, 167.1, 145.3, 145.0, 132.78, 132.75, 132.2, 130.8, 129.0, 
125.4, 123.7, 121.8, 120.7, 112.2, 108.4, 25.9; MS(APCI) m/z: 355.0, 357.2 [(M+H+) 
calculated for C17H11N2O2Br, 355.0, 357.0]. HPLC: found 98.7% (retention time = 9.2 min, 
80 MeOH : 20 H2O) and 98.4% (retention time = 5.8 min, 70 ACN: 30 H2O).  
 
[3-20] (E)-6'-methoxy-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-20 was prepared from A2a (0.5mmol) and 6-methoxy-2-oxindole 
(0.55mmol) as described in section 3.5.4.9. Extraction was 
performed using DCM/brine and purification by flash 
chromatography (4:1 Hex/EA) gave the desired product as a dark 
solid. Yield: 56% 
mp: 237-239°C. 1H NMR (300MHz, DMSO-d6): δ= 10.86 (s, 1H), 
9.08 (d, J = 9.0 Hz, 1H), 9.03 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.04-6.94 (m, 2H), 
6.53 (dd, J1 = 9.0 Hz, J2 = 2.4 Hz, 1H), 6.37 (d, J = 2.4 Hz, 1H), 3.183 (s, 3H), 3.22 (s, 3H);   
13C NMR (75MHz, DMSO-d6): δ= 169.6, 167.4, 163.2, 146.6, 144.2, 133.4, 131.52, 131.46, 
128.5, 128.3, 121.5, 120.9, 114.8, 108.2, 106.8, 95.5, 55.5, 25.9; MS(APCI) m/z: 307.0 
[(M+H+) calculated for C18H14N2O3, 307.10]. HPLC: found 96.3% (retention time = 3.3 min, 
90 MeOH : 10 H2O) and 94.6% (retention time = 2.5 min, 70 ACN: 30 H2O).  
 
[3-21] (E)-7'-fluoro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-21 was prepared from 1-methyl-2-oxindole (0.5mmol) and 7-
fluoroisatin (0.55mmol) as described in section 3.5.4.10 Extraction 
was performed using DCM/brine and purification by flash 
chromatography (DCM) gave the desired product as a dark solid. 
Yield: 24% 
m.p. 267-268 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.32 (s, 1H), 
8.99 (d, J = 7.8 Hz, 1H), 8.85 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.5 Hz, 
1H), 7.22 (t, J = 9.0 Hz, 1H), 7.00-6.91 (m, 3H), 3.14 (s, 3H); 13C NMR (75 MHz, DMSO-d6): 




















124.3, 124.2, 121.9, 121.4, 121.4, 120.6, 119.1, 118.9, 108.5, 26.0; MS (APCI) m/z: 294.9, 
[(M+H)+ calc for C17H11N2O2F, 295.08]; HPLC: found 97.9% (retention time = 5.1 min, 80 
MeOH : 20 H2O) and 97.0% (retention time = 4.0 min, 70 ACN: 30 H2O). 
 
[3-22] (E)-7'-chloro-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-22 was prepared from 1-methyl-2-oxindole (1mmol) and 7-
chloroisatin (1.1mmol) as described in section 3.5.4.10. Extraction 
was performed using DCM/brine and purification by recrystallization 
in MeOH. Dark solid. Yield: 58% 
m.p. 322-324 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.31 (s, 1H), 
9.07 (d, J = 8.1 Hz, 2H), 7.49-7.42 (m, 2H), 7.09-6.98 (m, 3H), 3.26 
(s, 3H); 13C NMR (75 MHz, DMSO-d6): Not performed due to poor solubility. MS (APCI) 
m/z: 310.9. [(M+H)+ calc for C17H12N2O2Cl, 311.05]; HPLC: found 100% (retention time = 
6.6 min, 80 MeOH : 20 H2O) and 100% (retention time = 5.1 min, 70 ACN: 30 H2O). Anal. 
Calcd. for (C17H11N2O2Cl): C, 65.54; H, 3.80. Found: C, 65.71; H, 3.57. 
 
[3-23] (E)-7'-bromo-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-23 was prepared from 1-methyl-2-oxindole (0.5mmol) and 7-
bromoisatin (0.55mmol) as described in section 3.5.4.10. Extraction 
was performed using DCM/brine and purification by recrystallization 
in DCM. Dark solid. Yield: 79% 
m.p. 332-334 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.15 (brs, 1H), 
9.10 (d, J = 7.8 Hz, 1H), 9.06 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 8.1 Hz, 
1H), 7.46 (t, J = 7.8 Hz, 1H), 7.09-7.02 (m, 2H), 6.95 (t, J = 8.1 Hz, 
1H), 3.22 (s, 3H); 13C NMR (75 MHz, DMSO-d6): Not performed due to poor solubility. MS 
(APCI) m/z: 354.8, 356.8. [(M+H)+ calc for C17H11N2O2Br, 355.0 and 357.0]; HPLC: found 
98.5% (retention time = 7.5 min, 80 MeOH : 20 H2O) and 100% (retention time = 5.6 min, 70 
ACN: 30 H2O). Anal. Calcd. for (C17H11N2O2Br): C, 57.62; H, 3.04. Found: C, 57.49; H, 3.12. 
 
[3-24] (E)-7'-methoxy-1-methyl-[3,3'-biindolinylidene]-2,2'-dione 
3-24 was prepared from A-2 (0.5mmol) and 7-methoxy-2-oxindole 
(0.55mmol) as described in section 3.5.4.9. The precipitated was 
filtered under reduced pressure and rinsed with glacial AcOH 
followed by chilled EtOH. Dark solid. Yield: 73% 
mp: 307-308°C. 1H NMR (300MHz, DMSO-d6): δ= 10.93 (s, 1H), 
9.09 (d, J = 7.8 Hz, 1H), 8.70 (d, J = 7.8 Hz, 1H), 7.43 (t, J = 7.5 Hz, 




















performed due to poor solubility MS(APCI) m/z: 307.2 [(M+H+) calculated for C18H14N2O3, 
307.2]. HPLC: found 99.5% (retention time = 4.7 min, 80 MeOH : 20 H2O) and 99.2% 




3-25 was prepared from A-2 (0.5mmol) and C-26 (0.55mmol) as 
described in section 3.5.4.9. Extraction was performed using 
EA/brine and purification by flash chromatography (DCM + 1% 
EtOH) gave the desired product as a dark solid. Yield: 43% 
mp: 299-300°C. 1H NMR (300MHz, DMSO-d6): δ= 10.63 (s, 
1H), 8.99 (d, J = 9.3 Hz, 1H), 8.95 (d, J = 7.8 Hz, 1H), 7.29 (t, J = 7.2 Hz, 1H), 7.00-6.95 (m, 
2H), 6.29 (dd, J1 = 9.3 Hz, J2 = 1.8 Hz, 1H), 6.09 (s, 1H), 3.22 (s, 3H), 3.07 (s, 6H); 13C NMR 
(75MHz, DMSO-d6): δ= 170.9, 168.2,153.9, 147.2, 143.3, 134.3, 131.8, 130.0, 127.3, 123.1, 
121.8, 121.5, 110.7, 108.1, 104.9, 92.6, 40.3, 26.1; MS(APCI) m/z: 320.2 [(M+H+) calculated 
for C19H17N3O2, 320.2]. HPLC: found 96.6% (retention time = 7.4 min, 80 MeOH : 20 H2O) 
and 100% (retention time = 4.0 min, 70 ACN: 30 H2O).  
 
[3-26] (E)-1-methyl-6'-(trifluoromethyl)-[3,3'-biindolinylidene]-2,2'-dione 
3-26 was prepared from A-2 (1mmol) and 6-trifluoromethyl-2-
oxindole (1.1mmol) as described in section 3.5.4.9. The crude 
sample was dissolved in EtOH, sonicated and left to stand at rt 
for 15min. The product was filtered under reduced pressure and 
residue rinsed with EtOH gave the desired product as a dark 
solid. Yield: 69% 
mp: 309-311°C. 1H NMR (300MHz, DMSO-d6): δ= 11.14 (s, 
1H), 9.21 (d, J = 8.4 Hz, 1H), 9.07 (d, J = 7.8 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.28 (d, J = 
8.1 Hz, 1H), 7.05-6.96 (m, 3H), 3.18 (s, 3H);    13C NMR (75MHz, DMSO-d6): δ= 168.4, 
166.8, 145.5, 144.2, 134.9, 133.4, 131.6, 131.4, 131.0, 129.7, 129.5, 125.5, 124.8, 121.9, 
120.5, 117.6, 108.5, 105.5, 105.4, 26.0; MS(APCI) m/z: 345.2 [(M+H+) calculated for 
C18H11N2O2F3, 345.2]. HPLC: found 100% (retention time = 7.9 min, 80 MeOH : 20 H2O) 
















3-27 was prepared from A-2 (1mmol) and 6-cyano-2-oxindole 
(1.1mmol) as described in section 3.5.4.9. The crude sample was 
dissolved in DCM, sonicated and left to stand at rt for 15min. 
The product was filtered under reduced pressure and residue 
rinsed with DCM. Purification by recrystallization in EtOH was 
performed. Dark solid. Yield: 72% 
mp: 334-336°C. 1H NMR (300MHz, DMSO-d6): δ= 11.23 (s, 1H), 9.18 (d, J = 8.4 Hz, 1H), 
9.07 (d, J = 8.1 Hz, 1H), 7.49-7.39 (m, 2H), 7.15 (s, 1H), 7.06-6.99 (m, 2H), 3.20 (s, 3H); 13C 
NMR (75MHz, DMSO-d6): δ= 169.3, 168.0, 146.8, 145.1, 136.7, 134.9, 132.5, 130.7, 130.6, 
126.6, 126.3, 123.1, 121.6, 119.7, 114.2, 112.9, 109.8, 27.2; MS(APCI) m/z: 302.2 [(M+H+) 
calculated for C18H11N3O2, 302.2]. HPLC: found 98.0% (retention time = 6.8 min, 80 MeOH : 
20 H2O) and 100% (retention time = 3.6 min, 70 ACN: 30 H2O).  
 
[3-28] (E)-1-methyl-6'-(methylsulfonyl)-[3,3'-biindolinylidene]-2,2'-dione 
3-28 was prepared from A-2 (1mmol) and 6-mesyl-2-oxindole 
(1.1mmol) as described in section 3.5.4.9. The product was 
allowed to stand for 15min at rt and filtered under reduced 
pressure and rinsed with AcOH. Dark grey solid. Yield: 85% 
mp: 286-287°C. 1H NMR (300MHz, DMSO-d6): δ= 11.25 (s, 
1H), 9.24 (d, J = 8.4 Hz, 1H), 9.08 (d, J = 8.1 Hz, 1H), 7.52-7.43 
(m, 2H), 7.25 (s, 1H), 7.06-6.99 (m, 2H), 3.26 (s, 3H), 3.20 (s, 
3H); 13C NMR (75MHz, DMSO-d6): δ= 168.42, 168.36, 166.83, 166.77, 145.65, 145.59, 
144.13, 144.09, 142.94, 142.87, 135.47, 135.40, 133.71, 133.65, 131.45, 131.38, 129.6. 125.6, 
121.96, 121.91, 120.51, 120.47, 119.57, 119.51, 108.66, 108.57, 107.20, 107.15, 43.3, 26.04, 
25.99; MS(APCI) m/z: 355.2 [(M+H+) calculated for C18H18N2O4S, 355.2]. HPLC: found 
100% (retention time = 3.2 min, 80 MeOH : 20 H2O) and 99.3% (retention time = 2.8 min, 70 

















3-29 was prepared from A-2 (0.5mmol) and C-29 
(0.55mmol) as described in section 3.5.4.9. Extraction was 
carried out using EA/brine and purification by flash 
chromatography (DCM + 5% EtOH) gave the desired 
product as a dark solid. Yield: 11% 
mp: 299-301°C. 1H NMR (300MHz, DMSO-d6): δ= 10.87 (s, 
1H), 10.27 (s, 1H), 9.07-9.02 (m, 2H), 7.49 (s, 1H), 7.40 (t, J 
= 7.2 Hz, 1H), 7.05-7.00 (m, 2H), 6.94 (dd, J1 = 9.0 Hz, J2 = 1.8 Hz, 2H), 3.23 (s, 3H), 2.08 (s, 
3H);  13C NMR (75MHz, DMSO-d6): δ= 169.4, 168.9, 167.4, 145.6, 144.4, 143.3, 133.4, 
131.6, 130.5, 129.2, 128.4, 121.6, 120.9, 116.4, 110.9, 108.2, 99.8, 25.9, 24.2 ; MS(APCI) 
m/z: 334.2 [(M+H+) calculated for C19H15N3O3, 334.2]. HPLC: found 98.4% (retention time = 
3.5 min, 80 MeOH : 20 H2O) and 99.5% (retention time = 4.6 min, 70 ACN: 30 H2O).  
 
[3-30] (E)-N-(1'-methyl-2,2'-dioxo-[3,3'-biindolinylidene]-6-yl)methanesulfonamide 
3-30 was prepared from A-2 (0.5mmol) and C-30 
(0.55mmol) as described in section 3.5.4.9. Extraction was 
carried out using EA/brine and purification by flash 
chromatography (gradient DCM to DCM + 2% EtOH)  gave 
the desired product as a dark solid. Yield: 20% 
mp: 313-314°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 
1H), 10.31 (s, 1H), 9.07-9.04 (m, 2H), 7.40 (t, J = 7.8 Hz, 
1H), 7.05-6.99 (m, 2H), 6.78-6.73 (m, 2H), 3.22 (s, 3H), 3.12 (s, 3H); 13C NMR (75MHz, 
DMSO-d6): δ= 169.3, 167.4, 145.9, 144.5, 142.6, 133.1, 131.9, 131.0, 129.7, 128.5, 121.6, 
120.9, 116.6, 110.2, 108.3, 98.9, 54.8, 26.0;MS(APCI) m/z: 370.2 [(M+H+) calculated for 
C18H15N3O4S, 370.2]. HPLC: found 100% (retention time = 3.2 min, 80 MeOH : 20 H2O) and 





















4-1 was prepared from B-13 (0.5mmol) and 6-methox-2-
oxindole (0.55mmol) as described in section 3.5.5. Extraction 
was carried out using DCM/brine and purification by flash 
chromatography (3:1 Hex/EA) gave the desired product as a dark 
solid. Yield: 20% 
mp: 182-184°C. 1H NMR (300MHz, DMSO-d6): δ= 10.86 (s, 
1H), 9.05 (t, J = 9.6 Hz, 2H), 7.36 (t, J = 7.5 Hz, 1H), 7.29-7.14 
(m, 5H), 7.03-6.98 (m, 2H), 6.53 (d, J = 9.3 Hz, 1H), 6.39 (s, 
1H), 3.83-3.77 (m, 5H), 2.66 (t, J = 7.5 Hz, 1H), 1.92 (p, J = 7.2 Hz, 1H); 13C NMR (75MHz, 
DMSO-d6): δ= 169.7, 167.5, 163.4, 146.7, 143.6, 141.3, 133.6, 131.7, 131.6, 128.6, 128.5, 
128.4, 128.3, 125.9, 121.6, 121.1, 114.9, 108.3, 107.0, 95.6, 55.6, 39.1 (from dept135), 32.5, 
28.7; MS(APCI) m/z: 411.3 [(M+H+) calculated for C26H22N2O3, 411.3]. HPLC: found 96.9% 
(retention time = 14.3 min, 80 MeOH : 20 H2O) and 97.8% (retention time = 9.5 min, 70 
ACN: 30 H2O).  
 
[4-2] (E)-6'-methoxy-1-(3-(4-methoxyphenyl)propyl)-[3,3'-biindolinylidene]-2,2'-dione 
4-2 was prepared from B-17 (1mmol) and 6-methox-2-
oxindole (1.1mmol) as described in section 3.5.5. Extraction 
was carried out using DCM/brine and purification by flash 
chromatography (4:1 Hex/EA) gave the desired product as a 
dark solid. Yield: 20% 
mp: 189-190°C. 1H NMR (300MHz, DMSO-d6): δ= 10.87 (s, 
1H), 9.09-9.02 (m, 2H), 7.37 (t, J = 7.8 Hz, 1H), 7.13 (d, J = 
8.7 Hz, 2H), 7.03-6.98 (m, 2H), 6.82 (d, J = 8.4 Hz, 1H), 
6.53 (dd, J1 = 9.0 Hz, J2 = 2.4 Hz, 2H),  6.38 (d, J = 2.4 Hz, 
1H), 3.83-3.76 (m, 5H), 3.70 (s, 3H), 2.60 (t, J = 7.5 Hz, 1H), 1.88 (p, J = 7.5 Hz, 1H); 13C 
NMR (75MHz, DMSO-d6): δ= 169.9, 167.7, 163.6, 157.7, 146.8, 143.8, 133.7, 133.3, 131.9, 
129.4, 128.9, 128.7, 121.8, 121.3, 115.1, 114.0, 108.6, 107.2, 95.9, 55.9, 55.2, 39.1, 31.8, 29.0; 
MS(APCI) m/z: 441.3 [(M+H+) calculated for C27H24N2O4, 441.2]. HPLC: found 98.7% 
(retention time = 12.6 min, 80 MeOH : 20 H2O) and 100% (retention time = 8.2 min, 70 ACN: 
















[4-3] (E)-6'-methoxy-1-(2-methoxyphenethyl)-[3,3'-biindolinylidene] -2,2'-dione 
4-3 was prepared from B-4 (0.5mmol) and 6-methox-2-oxindole 
(0.55mmol) as described in section 3.5.5. Extraction was carried 
out using DCM/brine and purification by flash chromatography 
(5:1 Hex/EA) gave the desired product as a dark solid. Yield: 
17% 
mp: 236-237°C. 1H NMR (300MHz, DMSO-d6): δ= 10.85 (s, 
1H), 9.01 (t, J = 6.3 Hz, 2H), 7.35 (t, J = 7.8 Hz, 1H), 7.21-7.14 
(m, 2H), 7.01-6.92 (m, 3H), 6.83 (t, J = 7.5 Hz, 1H), 6.52 (dd, J1 
= 9.0 Hz, J2 = 2.1 Hz, 1H), 6.38 (s, 1H), 3.92 (t, J = 6.6 Hz, 2H), 
3.83 (s, 3H), 3.76 (s, 3H), 2.89 (t, J = 6.9 Hz, 1H) ;  13C NMR (75MHz, DMSO-d6): δ= 169.6, 
167.2, 163.2, 157.3, 146.5, 143.5, 133.3, 131.5, 131.4, 130.3, 128.6, 128.3, 128.0, 126.2, 
121.3, 121.0, 120.3, 114.8, 110.6, 108.0, 106.8, 95.5, 55.5, 55.2, 39.3 (from DEPT 135), 28.0 ; 
MS(APCI) m/z: 427.4 [(M+H+) calculated for C26H22N2O4, 427.16]. HPLC: found 97.8% 
(retention time = 11.7 min, 80 MeOH : 20 H2O) and 99.7% (retention time = 8.1 min, 70 
ACN: 30 H2O).  
 
[4-4] (E)-6'-methoxy-1-(3-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
4-4 was prepared from B-5 (0.5mmol) and 6-methox-2-oxindole 
(0.55mmol) as described in section 3.5.5. Extraction was carried 
out using DCM/brine and purification by flash chromatography 
(4:1 Hex/EA) gave the desired product as a dark solid. Yield: 
15% 
mp: 190-191°C. 1H NMR (300MHz, DMSO-d6): δ= 10.85 (s, 
1H), 9.01 (t, J = 8.7 Hz, 2H), 7.35 (t, J = 7.5 Hz, 1H), 7.18 (t, J = 
8.1 Hz, 1H), 7.06 (d, J = 7.8 Hz, 1H), 7.00 (t, J = 7.8 Hz, 1H), 
6.84 (s, 2H), 6.75 (t, J = 8.1 Hz, 1H), 6.51 (dd, J1 = 9.0 Hz, J2 = 
2.4 Hz, 1H), 6.37 (d, J = 2.1 Hz, 1H), 3.98 (t, J = 7.2 Hz, 2H), 3.83 (s, 3H), 3.69 (s, 3H), 2.89 
(t, J = 7.5 Hz, 1H); 13C NMR (75MHz, DMSO-d6): δ= 169.7, 167.4, 163.4, 159.3, 146.7, 
143.4, 140.0, 133.6, 131.6, 129.5, 128.5, 128.4, 121.6, 121.13, 121.05, 114.8, 114.4, 112.1, 
108.6, 107.0, 95.6, 55.6, 54.9, 40.7, 33.0 ; MS(APCI) m/z: 427.3 [(M+H+) calculated for 
C26H22N2O4, 427.16]. HPLC: found 99.5% (retention time = 9.3 min, 80 MeOH : 20 H2O) and 


















4-5 was prepared from B-6 (1mmol) and 6-methoxy-2-oxindole 
(1.1mmol) as described in section 3.5.5. Extraction was carried 
out using DCM/brine and purification by flash chromatography 
(4:1 Hex/EA) gave the desired product as a dark solid. Yield: 
16% 
mp: 229-231°C. 1H NMR (300MHz, DMSO-d6): δ= 10.87 (s, 
1H), 9.03 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 9.0 Hz, 1H), 7.36 (t, J 
= 7.5 Hz, 1H), 7.18 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 7.8 Hz, 1H), 
7.00 (t, J = 8.1 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 6.51 (dd, J1 = 
9.0 Hz, J2 = 1.8 Hz, 1H), 6.37 (d, J = 2.1 Hz, 1H), 3.98 (t, J = 6.9 
Hz, 2H), 3.83 (s, 3H), 3.69 (s, 3H), 2.85 (t, J = 7.2 Hz, 1H); 13C NMR (75MHz, DMSO-d6): 
δ= 169.6, 167.2, 163.3, 157.8, 146.6, 143.4, 133.5, 131.5, 130.2, 129.8, 128.4, 128.3, 121.4, 
121.0, 114.7, 113.7, 108.4, 106.9, 95.4, 55.5, 54.9, 41.0, 32.0 ; MS(APCI) m/z: 427.0 [(M+H+) 
calculated for C26H22N2O4, 427.16]. HPLC: found 97.4% (retention time = 10.2 min, 80 
MeOH : 20 H2O) and 97.8% (retention time = 6.6 min, 70 ACN: 30 H2O).  
 
[5-1] (E)-5-fluoro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-1 was prepared from E-1 (0.5mmol) and 2-oxindole 
(0.55mmol) as described in section 3.5.6.2. Extraction was 
carried out using DCM/brine and purification by flash 
chromatography (DCM) gave the desired product as a dark solid. 
Yield: 73% 
m.p. 244-245 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.98 (s, 
1H), 9.02-8.98 (m, 2H), 7.37 (t, J = 7.8 Hz, 1H), 7.28 (td, J = 8.7, 
2.7 Hz, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.11-7.06 (m, 1H), 6.97 (t, 
J = 7.8 Hz, 1H), 6.86-6.81 (m, 3H), 3.95 (t, J = 7.2 Hz, 2H), 3.68 
(s, 1H), 2.85 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 169.0, 166.8, 159.0, 158.0, 
155.9, 144.5, 140.5, 135.1, 133.5, 131.4, 130.2, 129.9, 129.8, 121.7, 121.5, 121.4, 118.8, 
118.5, 116.1, 115.7, 113.9, 109.8, 109.3, 109.2, 55.0, 41.3, 32.0; MS (APCI) m/z: 414.9. 
[(M+H)+ calc for C25H19N2O3F, 415.14]; HPLC: found 97.8% (retention time = 9.4 min, 80 


















5-2 was prepared from E-2 (0.4mmol) and 2-oxindole 
(0.44mmol) as described in section 3.5.6.2. Extraction was 
carried out using DCM/brine and purification by flash 
chromatography (DCM) gave the desired product as a dark solid. 
Yield: 55% 
m.p. 272-274 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.97 (s, 
1H), 9.20 (s, 1H), 8.97 (d, J = 8.1 Hz, 1H), 7.45 (dd, J = 8.4, 1.5 
Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.09 
(d, J = 8.7, 1H), 6.96 (t, J = 7.8 Hz, 1H), 6.86-6.81 (m, 3H), 3.94 
(t, J = 7.5 Hz, 2H), 3.68 (s, 1H), 2.84 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 
168.8, 166.6, 157.9, 144.5, 142.7, 135.2, 133.5, 131.6, 130.7, 130.0, 129.8, 129.6, 128.3, 
125.5, 122.0, 121.3, 121.3, 113.8, 110.0, 110.0, 54.9, 41.2, 31.9; MS (APCI) m/z: 430.9. 
[(M+H)+ calc for C25H19N2O3Cl, 431.11]; HPLC: found 99.3% (retention time = 13.5 min, 80 
MeOH : 20 H2O) and 99.6% (retention time = 9.6 min, 70 ACN: 30 H2O). Anal. Calcd. for 
(C25H19N2O3Cl): C, 69.74; H, 4.44. Found: C, 69.69; H, 4.44. 
 
[5-3] (E)-5-bromo-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-3 was prepared from E-3 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 58% 
m.p. 284-286 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.96 (s, 1H), 
9.33 (d, J = 1.5 Hz, 1H), 8.97 (d, J = 8.1 Hz, 1H), 7.57 (dd, J = 8.4, 
1.8 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.4, 2H), 7.05 (d, 
J = 8.4 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.86-6.81 (m, 3H), 3.94 (t, 
J = 7.2 Hz, 2H), 3.68 (s, 1H), 2.84 (t, J = 7.5 Hz, 2H); 13C NMR 
(75 MHz, DMSO-d6): δ 169.9, 167.6, 159.0, 145.7, 144.2, 136.3, 135.5, 134.6, 132.1, 131.6, 
131.1, 130.9, 130.7, 123.6, 122.4, 122.4, 114.9, 114.4, 111.6, 110.8, 56.0, 42.3, 33.0; MS 
(APCI) m/z: 475.0, 477.0. [(M+H)+ calc for C25H19N2O3Br, 475.06 and 477.06]; HPLC: found 
99.1% (retention time = 15.4 min, 80 MeOH : 20 H2O) and 98.9% (retention time = 10.6 min, 



















5-4 was prepared from E-4 (0.4mmol) and 2-oxindole (0.44mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 40% 
mp: 242-243°C. 1H NMR (300MHz, DMSO-d6): δ= 10.88 (s, 1H), 
8.93 (d, J = 6.0 Hz, 1H), 8.83 (d, J = 2.1 Hz, 1H), 7.34 (t, J = 7.5 
Hz, 1H), 7.14 (d, J = 8.4, 2H), 7.01-6.91 (m, 3H), 6.85-6.79 (m, 
3H), 3.89 (t, J = 7.2 Hz, 2H), 3.74 (s, 3H), 3.66 (s, 3H), 2.83 (t, J = 
7.2 Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 168.8, 166.7, 
157.8, 154.3, 144.1, 137.9, 134.0, 132.8, 132.6, 130.1, 129.7, 129.3, 121.5, 121.1, 117.7, 
115.4, 113.7, 109.5, 108.8, 55.4, 54.9, 41.1, 31.9; MS(APCI) m/z: 427.0 [(M+H+) calculated 
for C26H22N2O4, 427.16]. HPLC: found 99.0% (retention time = 9.5 min, 80 MeOH : 20 H2O) 
and 98.6% (retention time = 6.4 min, 70 ACN: 30 H2O).  
 
[5-5] (E)-6-fluoro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-5 was prepared from E-5 (0.4mmol) and 2-oxindole (0.44mmol) 
as described in section 3.5.6.2. The product was filtered under 
reduced pressure and rinsed with AcOH. Dark solid. Yield: 72% 
mp: 244-246°C. 1H NMR (300MHz, DMSO-d6): δ= 10.89 (s, 1H), 
9.12 (dd, J1 = 8.7 Hz, J2 = 6.3 Hz, 1H), 8.89 (d, J = 8.1 Hz, 1H), 
7.33 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.4, 2H), 6.96-6.91 (m, 2H), 
6.84-6.76 (m, 4H), 3.92 (t, J = 7.2 Hz, 2H), 3.66 (s, 3H), 2.84 (t, J 
= 7.2 Hz, 2H) ; 13C NMR (75MHz, DMSO-d6): δ= 168.8, 167.3, 
166.2, 162.9, 157.8, 146.5, 146.3, 144.1, 133.2, 133.1, 132.7, 131.3, 
131.2, 130.8, 130.1, 129.8, 129.2, 121.4, 121.1, 117.12, 117.08, 113.7, 109.5, 107.8, 107.5, 
97.2, 96.9, 54.9, 41.3, 31.9 ; MS(APCI) m/z: 415.0 [(M+H+) calculated for C25H19N2O3F, 
415.14]. HPLC: found 96.6% (retention time = 10.5 min, 80 MeOH : 20 H2O) and 97.5% 


















5-6 was prepared from E-6 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 73% 
mp: 260-261°C. 1H NMR (300MHz, DMSO-d6): δ=  10.94 (s, 1H), 
9.09 (d, J = 8.7 Hz, 1H), 8.95 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.5 
Hz, 1H), 7.18 (d, J = 8.4, 2H), 7.13 (d, J = 1.5, 1H), 7.06 (dd, J1 = 
8.7 Hz, J2 = 1.5 Hz, 1H), 6.96 (t, J = 7.8 Hz, 1H), 6.85-6.81 (m, 
3H), 3.96 (t, J = 7.5 Hz, 2H), 3.68 (s, 3H), 2.85 (t, J = 6.9 Hz, 2H); 
13C NMR (75MHz, DMSO-d6): δ= 168.8, 167.1, 157.9, 145.4, 144.3, 136.7, 134.2, 133.2, 
130.7, 130.2, 129.9, 129.4, 121.5, 121.2, 119.5, 113.8, 109.7, 108.9, 55.0, 41.3, 32.1; 
MS(APCI) m/z: 431.0 [(M+H+) calculated for C25H19N2O3Cl, 431.11]. HPLC: found 100% 
(retention time = 16.7 min, 80 MeOH : 20 H2O) and 98.6% (retention time = 9.8 min, 70 




5-7 was prepared from E-7 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 71% 
mp: 240-241°C. 1H NMR (300MHz, DMSO-d6): δ= 10.94 (s, 1H), 
9.00 (d, J = 8.4 Hz, 1H), 8.95 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.5 
Hz, 1H), 7.22-7.16 (m ,4H), 6.95 (t, J = 7.8 Hz, 1H), 6.84-6.80 (m, 
3H), 3.96 (t, J = 6.9 Hz, 2H), 3.68 (s, 3H), 2.84 (t, J = 6.9 Hz, 2H) ;   
13C NMR (75MHz, DMSO-d6): δ= 169.1, 167.2, 158.1, 145.6, 
144.5, 134.6, 133.5, 131.1, 130.4, 130.2, 129.6, 125.9, 124.4, 121.7, 121.5, 119.9, 114.0, 
111.9, 110.0, 55.1, 41.6, 32.3; MS(APCI) m/z: 474.9, 476.9 [(M+H+) calculated for 
C25H19N2O3Br, 475.06, 477.06]. HPLC: found 97.2% (retention time = 18.3 min, 80 MeOH : 


















5-8 was prepared from E-8 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave 
the desired product as a dark solid. Yield: 59% 
mp: 215-217°C. 1H NMR (300MHz, DMSO-d6): δ= 10.83 (s, 1H), 
9.08 (d, J = 8.7 Hz, 1H), 8.91 (d, J = 7.8 Hz, 1H), 7.30 (t, J = 7.2 
Hz, 1H), 7.18 (d, J = 8.7 Hz, 2H), 6.93 (t, J = 7.8 Hz, 1H), 6.84-
6.81 (m, 3H), 6.58-6.54 (m, 2H), 3.95 (t, J = 6.9 Hz, 2H), 3.85 (s, 
3H), 3.68 (s, 3H), 2.86 (t, J = 6.9 Hz, 2H);  13C NMR (75MHz, 
DMSO-d6): δ= 169.2, 167.9, 163.3, 157.9, 146.6, 143.5, 132.0, 131.8, 131.1, 130.3, 130.2, 
129.9, 128.7, 121.8, 121.0, 113.9, 113.8, 109.4, 106.8, 95.4, 55.7, 55.0, 41.1, 32.2; MS(APCI) 
m/z: 427.2 [(M+H+) calculated for C26H22N2O4, 427.16]. HPLC: found 97.0% (retention time 
= 7.7 min, 80 MeOH : 20 H2O) and 95.8% (retention time = 6.0 min, 70 ACN: 30 H2O).  
 
[5-9] (E)-7-fluoro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-9 was prepared from E-9 (0.5mmol) and 2-oxindole (0.55mmol) as 
described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave the 
desired product as a dark solid. Yield: 58% 
m.p. 239-240 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.94 (s, 1H), 
8.96 (d, J = 8.1 Hz, 1H), 8.87 (d, J = 8.1 Hz, 1H), 7.38-7.32 (m, 2H), 
7.11 (d, J = 8.4 Hz, 2H), 7.08-7.00 (m, 1H), 6.94 (t, J = 7.5 Hz, 1H), 
6.83 (d, J = 8.1 Hz, 3H), 4.03 (t, J = 7.2 Hz, 2H), 3.67 (s, 3H), 2.86 (t, 
J = 7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ 168.6, 166.6, 158.0, 
148.0, 144.8, 144.5, 135.4, 133.5, 133.5, 131.0, 131.0, 130.5, 130.4, 129.9, 129.7, 129.6, 
125.2, 123.8, 123.7, 122.2, 122.1, 121.5, 121.2, 120.2, 119.9, 113.9, 109.8, 55.0, 43.3, 43.3, 
33.6; MS (APCI) m/z: 414.9. [(M+H)+ calc for C25H19N2O3F, 415.14]; HPLC: found 99.4% 
(retention time = 15.2 min, 80 MeOH : 20 H2O) and 98.6% (retention time = 9.1 min, 70 


















5-10 was prepared from E-10 (0.4mmol) and 2-oxindole (0.44mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine, purification by flash chromatography (DCM) and 
recrystallization in EtOH. Dark solid. Yield: 47% 
m.p. 251-252 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.95 (s, 1H), 
9.12 (d, J = 8.1 Hz, 1H), 8.83 (d, J = 8.1 Hz, 1H), 7.48 (d, J = 7.8 Hz, 
1H), 7.37 (t, J = 7.5 Hz, 1H), 7.15 (d, J = 8.7 Hz, 2H), 7.07 (t, J = 8.1 
Hz, 1H), 6.95 (t, J = 7.8 Hz, 1H), 6.87-6.82 (m, 3H), 4.28 (t, J = 7.5 Hz, 
2H), 3.69 (s, 3H), 2.89 (t, J = 7.8 Hz, 2H); 13C NMR (75 MHz, 
DMSO-d6): δ 168.4, 167.2, 157.9, 144.4, 139.3, 135.4, 134.2, 133.5, 130.4, 129.7, 129.6, 
129.4, 127.5, 124.0, 122.7, 121.5, 121.1, 113.9, 113.6, 109.6, 54.9, 42.9, 34.2; MS (APCI) 
m/z: 430.9. [(M+H)+ calc for C25H19N2O3Cl, 431.11]; HPLC: found 100% (retention time = 
23.8 min, 80 MeOH : 20 H2O) and 97.2% (retention time = 13.3 min, 70 ACN: 30 H2O). Anal. 
Calcd. for (C25H19N2O3Cl): C, 69.89; H, 4.37. Found: C, 69.69; H, 4.44. 
 
[5-11] (E)-7-bromo-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-11 was prepared from E-11 (0.5mmol) and 2-oxindole (0.55mmol) 
as described in section 3.5.6.2. Extraction was carried out using 
DCM/brine and purification by flash chromatography (DCM) gave the 
desired product as a dark solid. Yield: 63% 
m.p. 252-253 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.94 (s, 1H), 
9.14 (d, J = 8.1 Hz, 1H), 8.82 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 7.8 Hz, 
1H), 7.36 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 8.1, 2H), 6.99 (t, J = 7.8 Hz, 
1H), 6.95 (t, J = 7.5 Hz, 1H), 6.87-6.82 (m, 3H), 4.31 (t, J = 7.5 Hz, 
2H), 3.69 (s, 3H), 2.89 (t, J = 7.8 Hz, 2H); 13C NMR (75 MHz, 
DMSO-d6): δ 168.4, 167.5, 157.9, 144.4, 140.7, 137.5, 135.2, 133.5, 130.4, 129.7, 129.4, 
127.9, 124.4, 123.1, 121.5, 121.1, 113.9, 109.7, 101.1, 54.9, 42.6, 34.1; MS (APCI) m/z: 
474.8, 476.8. [(M+H)+ calc for C25H19N2O3Br, 475.06 and 477.06]; HPLC: found 98.2% 
(retention time = 25.7 min, 80 MeOH : 20 H2O) and 97.5% (retention time = 14.4 min, 70 


















5-12 was prepared from B-6 (0.5mmol) and 5-fluoro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. The product was filtered 
under reduced pressure and rinsed with AcOH. Dark solid. Yield: 
63% 
mp: 235-236°C. 1H NMR (300MHz, DMSO-d6): δ= 10.93 (s, 1H), 
9.11 (d, J = 7.8 Hz, 1H), 8.82 (dd, J1 = 11.4 Hz, J2 = 2.4 Hz, 1H), 
7.42 (d, J = 7.8 Hz, 1H), 7.25-7.19 (m, 3H), 7.16-7.00 (m, 2H), 6.82 
(d, J = 8.4 Hz, 3H), 3.94 (t, J = 6.9 Hz, 2H), 3.68 (s, 3H), 2.86 (t, J = 
7.2 Hz, 2H); 13C NMR (75MHz, DMSO-d6): δ= 169.0, 167.2, 158.7, 
158.1, 155.6, 144.5, 140.6, 133.6, 133.4, 133.30, 133.26, 130.3, 130.0, 129.5, 122.4, 122.3, 
122.0, 120.7, 119.5, 119.2, 116.1, 115.8, 113.9, 110.4, 110.3, 109.0, 55.1, 41.3, 32.1; 
MS(APCI) m/z: 415.0 [(M+H+) calculated for C25H19N2O3F, 415.14]. HPLC: found 100% 
(retention time = 10.1 min, 80 MeOH : 20 H2O) and 99.1% (retention time = 6.8 min, 70 
ACN: 30 H2O).  
 
[5-13] (E)-5’-chloro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-13 was prepared from B-6 (0.5mmol) and 5-chloro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. Extraction was carried 
out using EA/brine and purification by flash chromatography (DCM) 
gave the desired product as a dark solid. Yield: 73% 
mp: 252-253°C. 1H NMR (300MHz, DMSO-d6): δ= 11.05 (s, 1H), 
9.10 (d, J = 8.1 Hz, 1H), 9.07 (d, J = 2.1 Hz, 1H), 7.46-7.41 (m, 2H), 
7.39 (d, J = 8.4 Hz, 2H), 7.09-7.01 (m, 2H), 6.84 (t, J = 9.3 Hz, 3H), 
3.95 (t, J = 7.5 Hz, 2H), 3.68 (s, 3H), 2.86 (t, J = 7.2 Hz, 2H); 13C 
NMR (75MHz, DMSO-d6): δ= 169.0, 167.4, 158.2, 144.8, 143.0, 
134.1, 133.8, 132.7, 132.5, 130.5, 130.3, 129.6, 128.8, 125.6, 123.1, 122.3, 120.9, 114.1, 
111.4, 109.3, 55.3, 41.5, 32.2 ; MS(APCI) m/z: 431.0 [(M+H+) calculated for C25H19N2O3Cl, 
431.11]. HPLC: found 99.7% (retention time = 14.3 min, 80 MeOH : 20 H2O) and 99.4% 
(retention time = 9.2 min, 70 ACN: 30 H2O). Anal. Calcd.for C25H19N2O3Cl (431.11): C, 


















5-14 was prepared from B-6 (0.5mmol) and 5-bromo-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. Extraction was carried 
out using EA/brine and purification by flash chromatography (DCM) 
gave the desired product as a dark solid. Yield: 73% 
mp: 271-273°C. 1H NMR (300MHz, DMSO-d6): δ= 11.04 (s, 1H), 
9.19 (d, J = 1.5 Hz, 1H), 9.07 (d, J = 8.1 Hz, 1H), 7.51 (dd, J1 = 8.4 
Hz, J2 = 1.5 Hz, 1H), 7.41 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 8.4 Hz, 
2H), 7.07-6.99 (m, 2H), 6.83-6.78 (m, 3H), 3.96 (t, J = 7.2 Hz, 2H), 
3.68 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H); 13C NMR (75MHz, DMSO-d6): 
δ= 168.7, 167.3, 158.1, 144.7, 143.3, 135.1, 133.9, 133.6, 132.5, 131.5, 130.3, 130.1, 129.5, 
123.5, 122.1, 120.8, 114.0, 113.1, 111.8, 109.1, 55.2, 41.3, 32.1 ; MS(APCI) m/z: 474.9, 
476.9 [(M+H+) calculated for C25H19N2O3Br, 475.06, 477.06]. HPLC: found 96.2% (retention 
time = 15.7 min, 80 MeOH : 20 H2O) and 95.5% (retention time = 10.3 min, 70 ACN: 30 
H2O). Anal. Calcd.for C25H19N2O3Br (475.33): C, 63.30; H, 4.09.. Found: C, 63.30; H, 3.84. 
 
[5-15] (E)-6’-fluoro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-15 was prepared from B-6 (0.5mmol) and 6-fluoro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. Extraction was carried 
out using EA/brine and purification by flash chromatography (DCM) 
gave the desired product as a dark solid. Yield: 75% 
mp: 237-239°C. 1H NMR (300MHz, DMSO-d6): δ= 11.08 (s, 1H), 
9.09-9.04 (m, 2H), 7.40 (t, J = 7.5 Hz, 1H), 7.09-7.01 (m, 2H), 7.18 
(d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.1 Hz, 1H), 7.02 (t, J = 8.1 Hz, 1H), 
6.78-6.74 (m, 3H), 6.65 (dd, J1 = 8.7 Hz, J2 = 2.4 Hz, 1H), 3.94 (t, J 
= 7.2 Hz, 2H), 3.68 (s, 3H), 2.85 (t, J = 7.5 Hz, 2H); 13C NMR 
(75MHz, DMSO-d6): δ= 169.8, 168.0,159.6, 158.9, 156.5, 145.4, 141.5, 134.4, 134.2, 134.2, 
134.1, 131.2, 130.9, 130.3, 123.3, 123.2, 122.9, 121.6, 120.4, 120.0, 117.0, 116.6, 114.8, 
111.3, 111.2, 109.8, 56.0, 42.1, 32.9; MS(APCI) m/z: 415.0 [(M+H+) calculated for 
C25H19N2O3F, 415.14]. HPLC: found 100% (retention time = 12.1 min, 80 MeOH : 20 H2O) 


















5-16 was prepared from B-6 (0.5mmol) and 6-chloro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. Extraction was carried 
out using EA/brine and purification by flash chromatography (DCM) 
gave the desired product as a dark solid. Yield: 71% 
mp: 228-230°C. 1H NMR (300MHz, DMSO-d6): δ= 11.04 (s, 1H), 
9.07 (d, J = 8.1 Hz, 1H), 8.99 (d, J = 8.7 Hz, 1H), 7.41 (t, J = 7.8 Hz, 
1H), 7.18 (d, J = 8.7 Hz, 2H), 7.09-7.00 (m, 3H), 6.86-6.81 (m, 3H), 
3.93 (t, J = 7.5 Hz, 2H), 3.68 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H); 13C 
NMR (75MHz, DMSO-d6): δ= 168.8, 167.0, 157.9, 145.4, 144.2, 
136.6, 132.9, 132.7, 132.3, 130.7, 130.1, 129.8, 129.1, 121.7, 120.9, 120.7, 120.4, 113.8, 
109.5, 108.8, 54.9, 41.1, 32.0 ; MS(APCI) m/z: 431.0 [(M+H+) calculated for C25H19N2O3Cl, 
431.11]. HPLC: found 99.8% (retention time = 11.3 min, 80 MeOH : 20 H2O) and 98.4% 
(retention time = 7.4 min, 70 ACN: 30 H2O).  
 
[5-17] (E)-6’-bromo-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-17 was prepared from B-6 (0.5mmol) and 6-bromo-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. The product was filtered 
under reduced pressure and rinsed with AcOH. Dark solid. Yield: 
75% 
mp: 243-244°C. 1H NMR (300MHz, DMSO-d6): δ= 11.03 (s, 1H), 
9.07 (d, J = 7.8 Hz, 1H), 8.91 (d, J = 8.4 Hz, 1H), 7.41 (t, J = 7.8 Hz, 
1H), 7.19-7.13 (m, 3H), 7.07-6.98 (m, 3H), 6.82 (d, J = 8.4 Hz, 2H), 
3.92 (t, J = 7.2 Hz, 2H), 3.68 (s, 3H), 2.85 (t, J = 7.5 Hz, 2H); 13C 
NMR (75MHz, DMSO-d6): δ= 168.7, 167.0,157.9, 145.4, 144.3, 
133.0, 132.9, 132.4, 130.8, 130.1, 129.9, 129.2, 125.6, 123.9, 121.8, 120.7, 113.8, 112.3, 
108.8, 55.0, 41.1, 32.0; MS(APCI) m/z: 475.2, 477.2 [(M+H+) calculated for C25H19N2O3Br, 
475.2, 477.2]. HPLC: found 98.5% (retention time = 16.1 min, 80 MeOH : 20 H2O) and 


















5-18 was prepared from B-6 (0.5mmol) and 7-fluoro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. Extraction was carried 
out using DCM/brine and purification by flash chromatography (4:1 
Hex/EA) gave the desired product as a dark solid. Yield: 72% 
mp: 247-249°C. 1H NMR (300MHz, DMSO-d6): δ= 11.40 (s, 1H), 
9.06 (d, J = 7.8 Hz, 1H), 8.80 (d, J = 7.8 Hz, 1H), 7.41 (t, J = 7.5 Hz, 
1H), 7.27 (t, J = 9.0 Hz, 1H), 7.17 (d, J = 8.1 Hz, 2H), 7.07-6.99 (m, 
2H), 6.98-6.91 (m, 1H), 6.82 (d, J = 8.1 Hz, 2H), 3.92 (t, J = 7.2 Hz, 
2H), 3.68 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H); 13C NMR (75MHz, 
DMSO-d6): δ= 168.7, 167.0,158.0, 147.9, 144.7, 144.5, 133.8, 133.4, 
132.91, 132.85, 131.5, 131.3, 130.3, 130.0, 129.4, 125.3, 124.36, 124.32, 122.0, 121.63, 
121.55, 120.7, 119.3, 119.1, 114.0, 109.0, 55.1, 41.3, 32.1; MS(APCI) m/z: 415.0 [(M+H+) 
calculated for C25H19N2O3F, 415.14]. HPLC: found 96.8% (retention time = 10.3 min, 80 
MeOH : 20 H2O) and 96.4% (retention time = 7.4 min, 70 ACN: 30 H2O).  
 
[5-19] (E)-7’-chloro-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-19 was prepared from B-6 (0.5mmol) and 7-chloro-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. The product was filtered 
under reduced pressure and rinsed with AcOH. Dark solid. Yield: 
91% 
mp: 280-281°C. 1H NMR (300MHz, DMSO-d6): δ= 11.31 (s, 1H), 
9.07 (d, J = 7.8 Hz, 1H), 8.94 (d, J = 8.1 Hz, 1H), 7.46-7.41 (m, 2H), 
7.18 (d, J = 8.7 Hz, 2H), 7.10-6.96 (m, 3H), 6.84 (d, J = 8.7 Hz, 2H), 
3.94 (t, J = 7.5 Hz, 2H), 3.68 (s, 3H), 2.86 (t, J = 7.5 Hz, 2H); 13C 
NMR (75MHz, DMSO-d6): Not performed due to poor solubility. 
MS(APCI) m/z: 431.0 [(M+H+) calculated for C25H19N2O3Cl, 




















5-20 was prepared from B-6 (0.5mmol) and 7-bromo-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. The product was filtered 
under reduced pressure and rinsed with AcOH. Dark solid. Yield: 
90% 
mp: 290-291°C. 1H NMR (300MHz, DMSO-d6): δ= 11.15 (s, 1H), 
9.05 (d, J = 6.0 Hz, 1H), 8.96 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.1 
Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.10-7.02 
(m, 2H), 6.93 (t, J = 8.1 Hz, 1H), 6.82 (d, J = 8.7 Hz, 2H), 3.94 (t, J 
= 7.5 Hz, 2H), 3.68 (s, 3H), 2.86 (t, J = 7.2 Hz, 2H); 13C NMR 
(75MHz, DMSO-d6): Not performed due to poor solubility.  MS(APCI) m/z: 475.3, 477.3 
[(M+H+) calculated for C25H19N2O3Br, 475.3, 477.3]. HPLC: found 96.7% (retention time = 
14.0 min, 80 MeOH : 20 H2O) and 96.0% (retention time = 10.3 min, 70 ACN: 30 H2O). Anal. 
Calcd.for C25H19N2O3Br (475.33): C, 63.30; H, 4.09 Found: C, 63.15; H, 4.17. 
 
[5-21] (E)-6’-(dimethylamino)-1-(4-methoxyphenethyl)-[3,3'-biindolinylidene]-2,2'-dione 
5-21 was prepared from B-6 (0.5mmol) and C-26 (0.55mmol) as 
described in section 3.5.6.3. Extraction was carried out using 
EA/brine and purification by flash chromatography (DCM+ 1% 
EtOH) gave the desired product as a dark solid. Yield: 18% 
mp: 260-261°C. 1H NMR (300MHz, DMSO-d6): δ= 10.63 (s, 1H), 
8.92 (t, J = 8.1 Hz, 2H), 7.27 (t, J = 7.2 Hz, 1H), 7.19 (d, J = 8.4 
Hz, 2H), 7.02 (d, J = 8.1 Hz, 1H), 6.95 (t, J = 7.8 Hz, 1H), 6.84 (d, 
J = 8.4 Hz, 2H), 6.28 (dd, J1 = 9.3 Hz, J2 = 2.4 Hz, 1H), 6.08 (d, J 
= 2.4 Hz, 1H), 3.94 (t, J = 7.5 Hz, 2H), 3.70 (s, 3H), 3.07 (s, 6H), 
2.84 (t, J = 7.8 Hz, 2H); 13C NMR (75MHz, DMSO-d6): Not performed due to poor solubility. 
MS(APCI) m/z: 440.2 [(M+H+) calculated for C27H25N3O3, 440.19]. HPLC: found 97.3% 
(retention time = 9.0 min, 80 MeOH +0.1% TEA : 20 H2O) and 97.6% (retention time = 3.8 


















5-22 was prepared from B-6 (0.4mmol) and 6-trifluoromethyl -2-
oxindole (0.44mmol) as described in section 3.5.6.3. The product 
was filtered under reduced pressure and rinsed with EtOH. Dark 
solid. Yield: 69% 
mp: 239-240°C. 1H NMR (300MHz, DMSO-d6): δ= 11.17 (s, 1H), 
9.10 (t, J = 8.4 Hz, 2H), 7.43 (t, J = 7.5 Hz, 1H), 7.29 (d, J = 8.4 
Hz, 1H), 7.17 (d, J = 8.1 Hz, 2H), 7.07-7.00 (m, 3H), 6.82 (d, J = 
8.4 Hz, 2H), 3.92 (t, J = 6.9 Hz, 2H), 3.67 (s, 3H), 2.85 (t, J = 7.2 
Hz, 2H) ; 13C NMR (75MHz, DMSO-d6): δ= 168.4, 166.7, 157.9, 
144.6, 144.2, 134.8, 133.5, 131.7, 131.5, 131.1, 130.1, 129.8, 129.65, 129.57, 125.5, 124.8, 
121.9, 121.8, 120.5, 117.62, 117.57, 113.8, 108.8, 105.53, 105.48, 54.9, 41.1, 31.9; MS(APCI) 
m/z: 465.1 [(M+H+) calculated for C26H19N2O3F3, 465.13]. HPLC: found 100% (retention 




5-23 was prepared from B-6 (0.5mmol) and 6-cyano-2-oxindole 
(0.55mmol) as described in section 3.5.6.3. The product was 
filtered under reduced pressure and rinsed with EtOH. Dark solid. 
Yield: 78% 
mp: 268-270°C. 1H NMR (300MHz, DMSO-d6): δ= 11.24 (s, 1H), 
9.08 (d, J = 8.1 Hz, 2H), 7.47-7.39 (m, 2H), 7.19-7.17 (m, 3H), 
7.09-7.01 (m, 2H), 6.82 (d, J = 8.4 Hz, 2H), 3.93 (t, J = 6.9 Hz, 
2H), 3.68 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H); 13C NMR (75MHz, 
DMSO-d6): δ= 168.2, 166.7, 157.9, 144.9, 144.0, 135.5, 133.9, 
131.5, 130.1, 129.9, 129.7, 129.4, 125.5, 125.2, 121.9, 120.6, 118.7, 113.8, 113.2, 111.9, 
109.0, 55.0, 41.2, 31.9; MS(APCI) m/z: 422.2 [(M+H+) calculated for C26H19N3O3, 422.14]. 
HPLC: found 94.5% (retention time = 8.5 min, 80 MeOH : 20 H2O) and 96.4% (retention 
time = 6.2 min, 70 ACN: 30 H2O). Anal. Calcd.for C26H19N3O3 (421.45): C, 74.1 H, 4.54. 


















5-24 was prepared from B-6 (0.4mmol) and 6-mesyl-2-oxindole 
(0.44mmol) as described in section 3.5.6.3. Extraction was 
performed using EA/brine and purification by flash 
chromatography (gradient DCM to DCM +1.5% MeOH). Dark 
solid. Yield: 78% 
mp: 261-262°C. 1H NMR (300MHz, DMSO-d6): δ= 11.28 (s, 1H), 
9.15-9.08 (m, 2H), 7.50 (d, J = 8.7 Hz, 1H), 7.45 (t, J = 7.8 Hz, 
1H), 7.27 (s, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.10-7.02 (m, 2H), 6.82 
(d, J = 8.4 Hz, 2H), 3.94 (t, J = 6.9 Hz, 2H), 3.67 (s, 3H), 2.86 (t, J 
= 7.2 Hz, 2H) ; 13C NMR (75MHz, DMSO-d6): δ= 168.7, 166.9, 158.1, 145.0, 144.3, 143.1, 
135.7, 134.1, 131.7, 130.3, 130.1, 129.8, 129.7, 125.8, 122.2, 120.7, 119.8, 114.0, 109.2, 
107.5, 55.1, 43.5, 40.5, 32.1; MS(APCI) m/z: 475.2 [(M+H+) calculated for C26H22N2O5S, 
475.12]. HPLC: found 100% (retention time = 5.1 min, 80 MeOH : 20 H2O) and 100% 
(retention time = 4.3 min, 70 ACN: 30 H2O).  
 
[5-25] (E)-N-(1'-(4-methoxyphenethyl)-2,2'-dioxo-[3,3'-biindolinylidene]-6-yl)acetamide 
5-25 was prepared from B-6 (0.4mmol) and C-29 (0.44mmol) as 
described in section 3.5.6.3. Extraction was performed using 
EA/brine and purification by flash chromatography (DCM + 5% 
EtOH). Dark solid. Yield: 15% 
mp: 290-292°C. 1H NMR (300MHz, DMSO-d6): δ= 10.86 (s, 
1H), 10.28 (s, 1H), 9.03 (d, J = 7.8 Hz, 1H), 8.90 (d, J = 8.7 Hz, 
1H), 7.49 (s, 1H), 7.36 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8.7 Hz, 
2H), 7.06 (d, J = 8.1 Hz, 1H), 7.00 (t, J = 7.8 Hz, 1H), 6.92 (dd, 
J1 = 9.0 Hz, J2 = 1.8 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 3.94 (t, J 
= 6.9 Hz, 2H), 3.61 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H), 2.08 (s, 3H) ;  
13C NMR (75MHz, DMSO-d6): δ= 169.4, 169.0, 167.2, 157.9, 145.6, 143.5, 143.4, 133.5, 
131.8, 130.4, 130.2, 129.8, 129.2, 128.5, 121.5, 121.0, 116.5, 113.8, 110.9, 108.5, 99.9, 55.0, 
41.1, 32.1, 24.2 ; MS(APCI) m/z: 454.2 [(M+H+) calculated for C27H23N3O4, 454.17]. HPLC: 
found 99.2% (retention time = 5.8 min, 80 (MeOH + 0.1% TEA) : 20 H2O) and 98.7% 





















6-1 was prepared from F-5 (0.4mmol) and 2-oxindole (0.44mmol) as 
described in section 3.5.7.3. Extraction was performed using 
EA/brine at pH 10 and purification by flash chromatography (DCM 
+ 2% EtOH) gave the desired product as a dark solid. Yield: 57% 
mp: 206-207°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.06 (d, J = 8.1 Hz, 1H), 9.03 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 7.5 Hz, 
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.08-6.94 (m, 3H), 6.85 (d, J = 7.8 Hz, 
2H), 3.89 (t, J = 6.3 Hz, 2H), 2.56 (t, J = 5.7 Hz, 2H), 2.50-2.46 (m, 
4H), [4H embedded in water peak]; 1H NMR (300MHz, CDCl3): δ= 9.16-9.10 (m, 2H), 7.39-
7.29 (m, 2H), 7.05 (t, J = 7.8 Hz, 2H), 6.82 (d, J = 8.1 Hz, 2H), 3.93 (t, J = 7.2 Hz, 2H), 3.70 
(t, J = 4.2 Hz, 4H), 2.66 (t, J = 6.9 Hz, 2H), 2.57 (t, J = 4.2 Hz, 4H); 13C NMR (75MHz, 
DMSO-d6): δ= 168.8, 167.2, 144.2, 133.8, 132.9, 132.5, 132.2, 129.3, 129.0, 121.6, 121.2, 
120.9, 109.6, 108.6, 66.2, 54.9, 53.2, 36.7; MS(APCI) m/z: 376.3 [(M+H+) calculated for 
C22H21N3O3, 376.16]. HPLC: found 98.0% (retention time = 4.0 min, 80 MeOH : 20 H2O) and 
97.6% (retention time = 3.6 min, 70 ACN: 30 H2O).  
 
[6-2] (E)-1-(2-thiomorpholinoethyl)-[3,3'-biindolinylidene]-2,2'-dione 
6-2 was prepared from 1-1 (3mmol) and F-2 (3.6mmol) as described 
in section 3.5.7.5. Extraction was performed using DCM/brine at pH 
14 and purification by flash chromatography (4:1 Hex/EA + 5% 
triethylamine) gave the desired product as a dark solid. Yield: 20% 
mp: 192-193°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.06 (d, J = 6.9 Hz, 2H), 7.40 (t, J = 7.5 Hz, 1H), 7.34 (t, J = 7.5 Hz, 
1H), 7.06-6.93 (m, 3H), 6.84 (d, J = 7.8 Hz, 1H), 3.86 (t, J = 6.3 Hz, 
2H), 2.71-2.70 (m, 4H), 2.58 (t, J = 6.3 Hz, 2H), [4H embedded in 
DMSO peak]; 1H NMR (300MHz, CDCl3): δ= 9.09-9.02 (m, 2H), 7.31-7.20 (m, 2H), 6.97 (dt, 
J1 = 7.8 Hz, J2 = 2.4 Hz, 2H), 6.76-6.72 (m, 2H), 3.84 (t, J = 6.9 Hz, 2H), 2.79-2.76 (m, 4H), 
2.61-2.57 (m, 6H); 13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.3, 144.3, 144.2, 133.8, 
132.9, 132.6, 1322, 129.4, 129.0, 121.7, 121.2, 120.9, 109.7, 108.7, 55.1, 54.6, 36.9, 27.2; 
MS(APCI) m/z: 392.2 [(M+H+) calculated for C22H21N3O2S, 392.14]. HPLC: found 100% 
(retention time = 6.0 min, 80 (MeOH + 0.1%TEA) : 20 H2O) and 96.0% (retention time = 5.3 


















6-3 was prepared from 1-1 (1mmol) and F-3 (1.2mmol) as described 
in section 3.5.7.5. Extraction was performed using DCM/brine at pH 
14 and purification by flash chromatography (3:1 Hex/EA + 5% 
triethylamine) gave the desired product as a dark solid. Yield: 16% 
mp: 185-187°C. 1H NMR (300MHz, DMSO-d6): δ= 10.90 (s, 1H), 
9.07 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 1H), 7.35 (t, J = 7.8 Hz, 
1H), 7.06-6.97 (m, 3H), 6.84 (d, J = 7.5 Hz, 1H), 3.87 (t, J = 6.6 Hz, 
2H), 2.41 (brs, 4H), 1.43 (brs, 4H), 1.35 (brs, 2H); 13C NMR 
(75MHz, DMSO-d6): δ= 169.0, 167.3, 144.4, 144.3, 133.9, 133.0, 132.7, 132.4, 129.4, 129.1, 
121.7, 121.3, 120.9, 109.8, 108.8, 55.3, 54.2, 37.2, 25.6, 24.0; MS(APCI) m/z: 374.3 [(M+H+) 
calculated for C23H23N3O2, 374.18]. HPLC: found 98.7% (retention time = 8.1 min, 80 
(MeOH + 0.1%TEA) : 20 H2O) and 100% (retention time = 6.0 min, 70 (ACN + 0.1%TEA) : 
30 H2O).  
 
[6-4] (E)-1-(2-(4-methylpiperazin-1-yl)ethyl)-[3,3'-biindolinylidene]-2,2'-dione 
6-4 was prepared either from F-6 (0.3mmol) and 2-oxindole 
(0.33mmol) as described in section 3.5.7.3 or from F-8 (1mmol) and 
N-methylpiperazine (2mmol) as described in section 3.5.7.8. 
Extraction was performed using EA/brine at pH 10 and purification 
by flash chromatography (3:1 Hex/EA) to give the desired product as 
a dark solid. Yield: Both 52% 
mp: 204-206°C. 1H NMR (300MHz, DMSO-d6): δ= 10.91 (s, 1H), 
9.07 (d, J = 8.4 Hz, 2H), 7.41 (t, J = 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz, 
1H), 7.07-6.94 (m, 3H), 6.93 (d, J = 7.8 Hz, 1H), 3.88 (t, J = 6.3 Hz, 
2H), 2.55 (t, J = 6.6 Hz, 2H), 2.26 (brs, 4H), 2.11 (s, 3H), [4H embedded in DMSO peak]; 1H 
NMR (300MHz, CDCl3): δ= 9.16 (d, J = 8.1 Hz, 1H), 9.10 (d, J = 8.4 Hz, 1H), 7.38-7.27 (m, 
2H), 7.05 (t, J = 7.8 Hz, 2H), 6.82 (d, J = 8.1 Hz, 2H), 3.93 (t, J = 7.2 Hz, 2H), 2.69-2.64 (m, 
6H), 2.47 (brs, 4H), 2.28 (s, 3H) ; 13C NMR (75MHz, DMSO-d6): δ= 168.9, 167.2, 144.3, 
144.2, 133.9, 133.0, 132.7, 132.3, 129.4, 129.0, 121.72, 121.68, 121.3, 120.9, 109.7, 108.8, 
54.7, 54.6, 52.6, 45.6, 37.1 ; MS(APCI) m/z: 389.3 [(M+H+) calculated for C23H24N4O2, 
389.19]. HPLC: found 100% (retention time = 4.1 min, 80 (MeOH + 0.1%TEA) : 20 H2O) 
and 100% (retention time = 2.9 min, 70 (ACN + 0.1%TEA) : 30 H2O). Anal. Calcd.for 

















6-5 was prepared from F-5 (0.4mmol) and 6-methoxy-2-oxindole 
(0.44mmol) as described in section 3.5.7.4. Extraction was 
performed using EA/brine at pH 10 and purification by flash 
chromatography (DCM + 2% EtOH) gave the desired product as a 
dark solid. Yield: 27% 
mp: 182-184°C. 1H NMR (300MHz, DMSO-d6): δ= 10.88 (s, 1H), 
9.06-9.02 (m, 2H), 7.37 (d, J = 7.5 Hz, 1H), 7.07-6.98 (m, 2H), 
6.53 (dd, J1 = 9.0 Hz, J2 = 2.4 Hz, 1H), .6.38 (d, J = 2.1 Hz, 1H), 
3.90 (t, J = 5.7 Hz, 2H), 3.83 (s, 3H), 3.52 (brs, 4H), 2.56 (brs, 2H), [4H embedded in water 
peak]; 1H NMR (300MHz, CDCl3): δ= 9.14 (d, J = 9.0 Hz, 1H), 9.05 (d, J = 8.1 Hz, 1H), 7.33 
(t, J = 7.5 Hz, 1H), 7.07 (t, J = 7.8 Hz, 1H), 6.87 (d, J = 6.9 Hz, 1H), 6.56 (dd, J1 = 9.0 Hz, J2 
= 2.1 Hz, 1H), 6.35 (d, J = 2.4 Hz, 1H), 3.98 (brs, 2H), 3.87 (s, 3H), 3.73 (brs, 4H), 2.70 (brs, 
2H), 2.62 (brs, 4H); 13C NMR (75MHz, DMSO-d6): δ= 169.6, 167.5, 163.3, 146.6, 143.5, 
133.6, 131.5, 128.5, 128.4, 121.5, 121.1, 114.8, 108.4, 106.9, 95.6, 66.0, 55.6, 54.9, 53.1, 36.5; 
MS(APCI) m/z: 406.1 [(M+H+) calculated for C23H23N3O4, 406.17]. HPLC: found 98.1% 
(retention time = 4.1 min, 80 (MeOH + 0.1%TEA) : 20 H2O) and 95.8% (retention time = 3.2 
min, 70 (ACN +0.1%TEA) : 30 H2O).  
 
[6-6] (E)-6'-methoxy-1-(2-(4-methylpiperazin-1-yl)ethyl)-[3,3'-biindolinylidene]-2,2'-dione 
6-6 was prepared from F-9 (0.2mmol) and N-methylpiperazine 
(0.4mmol) as described in section 3.5.7.8. Extraction was 
performed using DCM/brine at pH 10 and purification by flash 
chromatography (3:1 Hex/EA) gave the desired product as a dark 
solid. Yield: 27% 
mp: 128-130°C. 1H NMR (300MHz, CDCl3): δ= 9.11 (d, J = 9.0 
Hz, 1H), 9.00 (d, J = 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 6.99 (t, 
J = 7.8 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 6.48 (d, J = 9.0 Hz, 1H), 
6.26 (s, 1H), 3.92 (t, J = 6.9 Hz, 2H), 3.80 (s, 3H), 2.69-2.62 (m, 
6H), 2.46 (brs, 4H), 2.27 (s, 3H); 13C NMR (75MHz, CDCl3): δ= 170.2, 168.2, 163.4, 145.1, 
143.8, 133.3, 132.1, 131.3, 129.9, 129.2, 122.0, 121.9, 115.9, 107.6, 106.9, 96.0, 55.5, 54.9, 
53.2, 45.9, 37.5 ; MS(APCI) m/z: 419.1 [(M+H+) calculated for C25H26N4O3, 419.2]. Anal. 




















6-7 was prepared from A-2 (0.5mmol) and F-11 (0.55mmol) as 
described in section 3.5.6.3 using EtOH as solvent in place of AcOH 
The precipitate was filtered under reduced pressure and rinsed with 
chilled EtOH. Dark solid. Yield: 40% 
mp: 297-299°C. 1H NMR (300MHz, DMSO-d6): δ= 11.54 (s, 1H), 
9.33 (d, J = 7.8 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 8.18 (d, J = 4.2 Hz, 
1H), 7.46 (t, J = 7.8 Hz, 1H), 7.09-7.02 (m, 3H), 3.22 (s, 3H);  13C 
NMR (75MHz, DMSO-d6): 168.3, 167.1, 157.4, 149.6, 145.3, 136.7, 133.6, 133.12, 133.15, 
129.2, 121.9, 120.4, 117.6, 116.2, 108.5, 26.0 ;MS(APCI) m/z: 278.1 [(M+H+) calculated for 
C16H11N3O2, 278.1]. HPLC: found 96.4% (retention time = 4.3 min, 80 MeOH : 20 H2O) and 




6-8 was prepared from B-6 (0.5mmol) and F-11 (0.55mmol) as 
described in section 3.5.6.3 using EtOH as solvent in place of AcOH. 
The product was filtered under reduced pressure and rinsed with EtOH. 
Dark solid. Yield: 62% 
mp: 256-257°C. 1H NMR (300MHz, DMSO-d6): δ= 11.54 (s, 1H), 9.20 
(d, J = 7.5 Hz, 1H), 9.09 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 4.5 Hz, 1H), 
7.43 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.08-7.02 (m, 3H), 
6.81 (d, J = 8.4 Hz, 2H), 3.93 (t, J = 6.0 Hz, 2H), 3.66 (s, 3H), 2.85 (t, 
J = 7.5 Hz, 2H); 13C NMR (75MHz, DMSO-d6): Not performed due to poor solubility. 
MS(APCI) m/z: 398.2 [(M+H+) calculated for C24H19N3O3, 398.14]. HPLC: found 99.3% 
(retention time = 7.1 min, 80 MeOH : 20 H2O) and 97.0% (retention time = 4.3 min, 70 ACN: 
30 H2O). Anal. Calcd.for C24H19N3O3 (397.43): C, 72.53; H, 4.82 Found: C, 72.35; H, 4.91. 
 
[7-1] 1H,1'H-[2,3']Biindolylidene-3,2'-dione 
7-1 was prepared as described in section 3.5.8 from isatin. Yield: 
81% 
mp: 341-342°C. 1H NMR (300MHz, DMSO-d6): δ= 11.01 (s, 
1H), 10.89 (s, 1H), 8.76 (d, J = 7.8 Hz, 1H), 7.65 (d, J = 7.5 Hz, 
1H), 7.58 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.26 (t, J 
= 7.5 Hz, 1H), 7.02 (t, J = 7.5 Hz, 2H), 6.91 (d, J = 7.8 Hz, 1H);  13C NMR (75MHz, DMSO-


















114.5, 110.7, 107.6; MS(APCI) m/z: 263.1 [(M+H+) calculated for C16H10N2O2, 263.07]. Anal. 
Calcd.for C16H10N2O2 (262.26): C, 73.27; H, 3.84. Found: C, 73.03; H, 3.95. 
 
[7-2] 1'-Methyl-1H,1'H-[2,3']biindolylidene-3,2'-dione 
7-2 was prepared as described in section 3.5.8 from A-2. Yield: 
80% 
mp: 295-297°C. 1H NMR (300MHz, DMSO-d6): δ= 11.06 (s, 
1H), 8.80 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 7.5 Hz, 1H), 7.59 (t, J 
= 7.8 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 7.12-7.01 (m, 3H), 3.28 (s, 
3H); 13C NMR (75MHz, DMSO-d6): δ= Not performed due to poor solubility. MS(APCI) m/z: 
277.7 [(M+H+) calculated for C17H12N2O2, 277.09]. HPLC: found 98.9% (retention time = 8.6 





A-2 was prepared as described in section 3.5.2.2.  
mp: 128-130 °C. 1H NMR (300MHz, DMSO-d6): δ= 7.68 (t, J= 8.1Hz, 
1H), 7.54 (d, J= 6.9Hz, 1H), 7.16-7.11 (m, 2H), 3.14 (s, 3H); 13C NMR 
(75 MHz, DMSO-d6): δ= 183.4, 158.1, 151.3, 138.1, 124.2, 123.1, 
117.3, 110.5, 25.9; MS(APCI) m/z: 161.8 [(M+H+) calculated for C9H7NO2, 162.05].  
 
[B-2] 1-benzylindoline-2,3-dione  
B-2 was prepared from isatin (10mmol) and benzyl chloride 
(12mmol) as described in section 3.5.3.1. The desired product was 
filtered and rinsed with deionized water and dried in the oven. 
Recrystallization in ethanol gave product as red wool. Yield: 98% 
1H NMR (300MHz, CDCl3): δ= 7.55 (d, J= 7.2Hz, 1H), 7.41 (t, J= 
7.8Hz, 1H), 7.27-7.19 (m, 5H), 7.03 (t, J= 7.5Hz, 1H), 6.71 (d, J= 7.8Hz, 1H); 13C NMR (125 
MHz, DMSO-d6): δ= 183.1, 158.3, 150.3, 138.0, 135.5, 128.6, 127.5, 127.3, 124.5, 123.3, 
117.7, 111.0, 42.9. 
 
[B-3] 1-phenethylindoline-2,3-dione  
B-3 was prepared from isatin (2mmol) and phenethyl bromide 
















filtered and rinsed with deionized water and dried in the oven. Recrystallization in ethanol 
gave product as red wool. Yield: 91%  
1H NMR 1H NMR (300MHz, DMSO-d6): δ= 7.63 (t, J= 7.8Hz, 1H), 7.53 (d, J= 7.5Hz, 1H), 
7.28-7.20 (m, 5H), 7.16 (d, J= 8.1Hz, 1H), 7.11 (t, J= 7.5Hz, 1H), 3.89 (t, J= 7.2Hz, 2H), 2.91 
(t, J= 7.5Hz, 2H); 13C NMR (125 MHz, DMSO-d6): δ= 183.4, 157.8, 150.5, 138.2, 128.8, 
128.4, 126.4, 124.5, 123.1, 117.2, 110.8, 41.0, 32.7. 
 
[B-4] 1-(2-methoxyphenethyl)indoline-2,3-dione  
B-4 was prepared from isatin (2mmol) and 2-methoxyphenethyl 
bromide (2.2mmol) as described in section 3.5.3.1. Extraction was 
performed using DCM/brine. Purification by flash chromatography 
with gradient 5:1 to 3:1 Hex/EA eluting system gave the desired 
product as red solid.  Yield: 62%  
1H NMR (300MHz, DMSO-d6): δ= 7.65 (t, J= 7.8Hz, 1H), 7.53 (d, 
J= 7.5Hz, 1H), 7.21-7.03 (m, 3H), 6.91 (d, J= 8.1Hz, 1H), 6.83 (d, J= 7.2Hz, 1H)), 3.84 (t, J= 
7.2Hz, 2H), 3.73 (s, 3H), 2.88 (t, J= 7.2Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.4, 
157.7, 157.2, 150.7, 138.1, 130.3, 128.0, 125.9, 124.3, 122.9, 120.3, 117.1, 110.5, 55.2, 
27.6 ;MS(APCI) m/z: 282.0 [(M+H+) calculated for C17H15NO3, 282.11].  
 
[B-5] 1-(3-methoxyphenethyl)indoline-2,3-dione  
B-5 was prepared from isatin (1.5mmol) and 3-methoxyphenethyl 
bromide (1.65mmol) as described in section 3.5.3.1. Extraction 
was performed using DCM/brine. Purification by flash 
chromatography with 5:1 Hex/EA eluting system gave the desired 
product as orange/red solid.  Yield: 62%  
1H NMR (300MHz, DMSO-d6): δ= 7.63 (t, J= 7.8Hz, 1H), 7.54 (d, 
J= 7.5Hz, 1H), 7.20-7.09 (m, 3H), 6.89-6.75 (m, 3H), 3.89 (t, J= 7.2Hz, 2H), 3.70 (s, 3H), 
2.89 (t, J= 7.5Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.3, 159.2, 157.8, 150.5, 139.7, 
138.1, 129.4, 124.4, 123.1, 121.0, 117.2, 114.3, 112.0, 110.9; MS(APCI) m/z: 282.0 [(M+H+) 











[B-6] 1-(4-methoxyphenethyl)indoline-2,3-dione  
B-6 was prepared from isatin (5mmol) and 4-methoxyphenethyl 
bromide (6mmol) as described in section 3.5.3.1. Extraction was 
performed using DCM/brine. Purification by flash chromatography 
with 5:1 Hex/EA eluting system gave the desired product as orange 
solid.  Yield: 61%  
mp: 131-133°C. 1H NMR (300MHz, DMSO-d6): δ= 7.64 (t, J= 
8.1Hz, 1H), 7.54 (d, J= 7.2Hz, 1H), 7.18 (d, J= 8.4Hz, 2H), 7.17 (d, 
J= 7.8Hz, 1H), 7.12 (t, J= 7.5Hz, 1H), 6.83 (d, J= 8.7Hz), 3.85 (t, J= 7.2Hz, 2H), 3.71 (s, 3H), 
2.85 (t, J= 7.5Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.3, 157.8, 157.7, 150.5, 138.1, 
129.9, 129.8, 124.4, 123.0, 117.2, 113.7, 110.8, 54.9, 41.1, 31.7; MS(APCI) m/z: 282.0 
[(M+H+) calculated for C17H15NO3, 282.11].  
 
[B-7] 1-(4-methylphenethyl)indoline-2,3-dione  
B-7 was prepared from isatin (2mmol) and 4-methylphenethyl 
bromide (2.2mmol) as described in section 3.5.3.1. The desired 
product was filtered and rinsed with deionized water and dried in the 
oven. Recrystallization in ethanol gave product as red wool. Yield: 
86% 
1H NMR (300MHz, DMSO-d6): δ= 7.64 (t, J= 7.8Hz, 1H), 7.54 (d, 
J= 7.2Hz), 7.20-7.07 (m, 6H), 3.86 (t, J= 7.2Hz, 2H), 2.86 (t, J= 
7.5Hz), 2.25 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ= 183.4, 157.8, 150.5, 138.3, 135.4, 
135.0, 128.9, 128.7, 124.5, 123.1, 117.2, 110.9, 41.0, 32.2, 20.6.  
 
[B-10] 1-(4-fluorophenethyl)indoline-2,3-dione  
B-10 was prepared from isatin (3mmol) and 4-fluorophenethyl 
bromide (3.6mmol) as described in section 3.5.3.2. Extraction was 
performed using EA/brine. Purification by flash chromatography 
with 5:1 Hex/EA eluting system gave the desired product as orange 
solid. Yield: 57% 
1H NMR (300MHz, DMSO-d6): δ= 7.63 (t, J= 7.2Hz, 1H), 7.53 (d, 
J= 7.5Hz, 1H), 7.32-7.28 (m, 2H), 7.16-7.05 (m, 4H), 3.88 (t, J= 
7.2Hz, 2H), 2.91 (t, J= 7.5Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.3, 162.6, 159.4, 
157.8, 150.5, 138.2, 134.4, 130.8, 130.7, 124.5, 123.1, 117.2, 115.2, 114.9, 110.8, 41.0, 31.8; 














[B-11] N-(4-(2-chloroethyl)phenyl)acetamide  
B-11 was prepared as described in section 3.5.3.3.  
1H NMR (300MHz, CDCl3): δ= 7.45 (d, J= 8.4Hz, 2H), 7.26 (s, 
1H), 7.16 (d, J= 8.1Hz, 2H), 3.54 (t, J= 7.5Hz, 2H), 3.12 (t, J= 
7.5Hz, 2H), 2.17 (s, 3H); 13C NMR (125 MHz, CDCl3): δ= 168.7, 




[B-12] 1-(2-cyclohexylethyl)indoline-2,3-dione  
B-12 was prepared from isatin (2mmol) and cyclohexyethyl bromide 
(2.2mmol) as described in section 3.5.3.1. Extraction was performed 
using EA/brine. Purification by flash chromatography with 10:1 
Hex/EA eluting system gave the desired product as red solid.  Yield: 
68%  
1H NMR (300MHz, DMSO-d6): δ= 7.66 (t, J= 7.5Hz, 1H), 7.54 (d, 
J= 7.2Hz, 1H), 7.15-7.10 (m, 2H), 3.67 (t, J= 7.2Hz, 2H), 1.76 (d, J= 
12.6Hz, 2H), 1.67-1.63 (m, 3H), 1.48 (q, J= 7.5Hz, 2H), 1.38-1.22 (m, 1H), 1.21-0.97 (m, 
3H), 0.94-0.86 (m, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.5, 157.9, 150.5, 138.2, 124.5, 
123.1, 117.5, 110.6, 37.4, 34.5, 33.9, 32.5, 26.0, 25.6; MS(APCI) m/z: 258.3 [(M+H+) 
calculated for C16H19NO2, 258.14].  
 
[B-13] 1-(3-phenylpropyl)indoline-2,3-dione  
B-13 was prepared from isatin (5mmol) and phenpropyl bromide 
(5.5mmol) as described in section 3.5.3.1. Extraction was 
performed using DCM/brine. Purification by flash 
chromatography with 3:1 Hex/EA eluting system gave the 
desired product as red solid.  Yield: 65%  
1H NMR (300MHz, DMSO-d6): δ= 7.63 (t, J= 7.8Hz, 1H), 7.53 (d, J= 7.5Hz, 1H), 7.28-7.20 
(m, 5H), 7.16 (d, J= 8.1Hz, 1H), 7.11 (t, J= 7.5Hz, 1H), 3.80 (t, J= 6.9Hz, 2H),  2.67 (t, J= 
7.5Hz, 2H), 1.93 (p, J= 7.5Hz, 2H); 13C NMR (125 MHz, DMSO-d6): δ= 183.5, 157.8, 150.5, 














[B-14] 1-cinnamylindoline-2,3-dione  
B-14 was prepared from isatin (3mmol) and cinnamyl bromide 
(3.6mmol) as described in section 3.5.3.2. Extraction was 
performed using EA/brine. Purification by flash chromatography 
with DCM eluting system gave the desired product as orange 
solid Yield: 97% 
1H NMR (300MHz, DMSO-d6): δ= 7.63 (t, J= 7.8Hz, 1H), 7.57 
(d, J= 7.2Hz, 1H), 7.41 (d, J= 7.2Hz, 2H), 7.31 (t, J= 7.2Hz, 2H), 7.25-7.20 (m, 1H), 7.15-
7.10 (m, 2H), 6.75 (d, J= 16.2Hz, 1H), 6.30 (td, J1= 15.9Hz, J2= 5.7Hz, 1H), 4.47 (d, J= 
5.4Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.2, 158.0, 150.5, 138.1, 136.1, 132.0, 
128.6, 127.8, 126.3, 124.4, 123.2, 122.8, 117.7, 111.1, 41.3; MS(APCI) m/z: 264.3 [(M+H+) 
calculated for C17H13NO2, 264.09].  
 
[B-15] 1-(3-phenylprop-2-yn-1-yl)indoline-2,3-dione  
B-15 was prepared from isatin (4mmol) and 3-phenprop-2-yn-1-
yl bromide (4.8mmol) as described in section 3.5.3.2. Extraction 
was performed using EA/brine. Purification by flash 
chromatography with 5:1 Hex/EA eluting system gave the 
desired product as orange solid Yield: 97% 
1H NMR (300MHz, DMSO-d6): δ= 7.74 (t, J= 7.8Hz, 1H), 7.60 (d, J= 7.5Hz, 1H), 7.44-7.32 
(m, 6H), 7.19 (t, J= 7.5Hz, 1H), 4.81 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.5, 157.3, 
149.5, 138.1, 131.5, 128.9, 128.6, 124.5, 123.5, 121.5, 117.7, 111.2, 83.1, 83.0, 29.7 ; 
MS(APCI) m/z: 262.2 [(M+H+) calculated for C17H11NO22, 262.08].  
 
[B-16] (2-chloroethoxy)benzene  
B-16 was prepared as described in section 3.5.3.4.  
1H NMR (300MHz, CDCl3): δ= 7.21 (t, J= 8.1Hz, 2H), 6.89 (t, J= 7.5Hz, 
2H), 6.83 (d, J= 8.4Hz, 2H), 4.13 (t, J= 5.7Hz, 2H), 3.71 (t, J= 5.7Hz, 2H); 
13C NMR (75 MHz, DMSO-d6): δ= 158.1, 129.5, 121.4, 114.7, 77.4, 77.0, 











[B-17] 1-(3-(4-methoxyphenyl)propyl)indoline-2,3-dione  
B-17 was prepared from isatin (2mmol) and 4-
methoxyphenpropyl bromide (2.2mmol) as described in 
section 3.5.3.1. Extraction was performed using 
DCM/brine. Purification by flash chromatography with 4:1 
Hex/EA eluting system gave the desired product as orange 
solid.  Yield: 76% 
1H NMR (300MHz, DMSO-d6): δ= 7.64 (t, J= 8.1Hz, 1H), 7.53 (d, J= 7.2Hz, 1H), 7.14-7.08 
(m, 4H), 6.81 (d, J= 8.4Hz, 2H), 3.70-3.65 (m, 5H), 2.60 (t, J= 7.5Hz, 2H), 1.87 (p, J= 7.5Hz, 
2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.6, 158.2, 157.5, 150.7, 138.2, 133.1, 129.2, 
124.5, 123.2, 117.5, 113.7, 110.7, 55.0, 39.3 (from DEPT135), 31.5, 28.6; MS(APCI) m/z: 
296.0 [(M+H+) calculated for C18H17NO3, 296.12].  
 
[B-18] 3-(2,3-dioxoindolin-1-yl)propanenitrile  
B-18 was prepared from isatin (3mmol) and 3-bromo-propanenitrile 
(3.6mmol) as described in section 3.5.3.2. Extraction was performed 
using EA/brine. Purification by flash chromatography with 2:1 Hex/EA 
eluting system gave the desired product as orange solid.  Yield: 34% 
1H NMR (300MHz, DMSO-d6): δ= 7.68 (t, J= 7.5Hz, 1H), 7.58 (d, J= 
7.5Hz, 1H), 7.32 (d, J= 7.8Hz, 1H), 7.16 (t, J= 7.5Hz, 1H), 3.99 (t, J= 
6.6Hz, 2H), 2.89 (t, J= 6.6Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.9, 158.1, 149.9, 
138.2, 124.6, 123.5, 118.7, 117.5, 110.9, 35.5, 15.8; MS(APCI) m/z: 201.2 [(M+H+) 
calculated for C11H8N2O2, 201.06].  
 
[B-19] 4-(2,3-dioxoindolin-1-yl)butanenitrile  
B-19 was prepared from isatin (6mmol) and 4-bromo-butanenitrile 
(3.6mmol) as described in section 3.5.3.2. Extraction was 
performed using EA/brine. Purification by flash chromatography 
with 2:1 Hex/EA eluting system gave the desired product as orange 
solid.  Yield: 80% 
1H NMR (300MHz, DMSO-d6): δ= 7.66 (t, J= 7.5Hz, 1H), 7.55 (d, J= 7.5Hz, 1H), 7.19 (d, J= 
8.1Hz, 1H), 7.13 (t, J= 7.5Hz, 1H), 3.75 (t, J= 6.6Hz, 2H), 2.60 (t, J= 7.2Hz, 2H), 1.92 (q, J= 
6.9Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.2, 158.4, 150.3, 138.0, 124.4, 123.1, 
120.3, 117.7, 110.4, 38.4, 22.9, 13.9; MS(APCI) m/z: 215.0 [(M+H+) calculated for 















[B-20] 1-(2-hydroxyethyl)indoline-2,3-dione  
B-20 was prepared from isatin (5mmol) and 2-bromoethanol (5.5mmol) 
as described in section 3.5.3.1. Extraction was performed using 
DCM/brine. Purification by flash chromatography with 3:1 Hex/EA 
eluting system gave the desired product as red solid.  Yield: 45% 
1H NMR (300MHz, DMSO-d6): δ= 7.64 (t, J= 7.5Hz, 1H), 7.54 (d, J= 
7.2Hz, 1H), 7.19 (d, J= 8.1Hz, 1H), 7.11 (t, J= 7.5Hz, 1H), 4.88 (t, J= 6.0Hz, 1H), 3.74 (t, J= 
5.7Hz, 2H), 3.65-3.59 (m, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 183.7, 158.3, 151.3, 138.1, 
124.3, 123.0, 117.4, 111.1, 57.7, 42.5, MS(APCI) m/z: 192.1 [(M+H+) calculated for 
C10H9NO3, 192.06].  
 
[C-1] 5-fluoro-1-methylindoline-2,3-dione  
C-1 was prepared from 5-fluoroisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using DCM/brine. Purification by flash chromatography with 3:1 
Hex/EA eluting system gave the desired product as orange solid. 
Yield: 94% 
m.p. 160-162 °C. 1H NMR (300 MHz, DMSO-d6): δ= 7.53 (td, J = 9.0, 2.7 Hz, 1H), 7.42 (dd, 
J = 6.9, 2.4 Hz, 1H), 7.15 (dd, J = 8.55, 3.75 Hz, 1H), 3.08 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6): δ= 182.8, 160.1, 158.1, 156.9, 147.6, 124.1, 123.8, 118.2, 118.1, 111.9, 111.8, 
111.4, 111.1, 26.1; MS(APCI) m/z: 179.8 [(M+H+) calculated for C9H6NO2F, 180.04].  
 
[C-2] 5-chloro-1-methylindoline-2,3-dione  
C-2 was prepared from 5-chloroisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using DCM/brine. Purification by flash chromatography with DCM 
eluting system gave the desired product as orange solid. Yield: 87% 
m.p. 178-180 °C. 1H NMR (300 MHz, DMSO-d6): δ= 7.71 (dd, J = 8.4, 2.1 Hz, 1H), 7.58 (d, 
J = 2.1 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 3.13 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 
182.4, 158.0, 149.9, 137.0, 127.4, 123.8, 118.7, 112.3, 26.1; MS(APCI) m/z: 196.2 [(M+H+) 
calculated for C9H6NO2Cl, 196.01].  
 
[C-3] 5-bromo-1-methylindoline-2,3-dione  
C-3 was prepared from 5-bromoisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 


















Hex/EA eluting system gave the desired product as orange solid. Yield: 98% 
m.p. 170-171 °C. 1H NMR (300 MHz, DMSO-d6): δ= 7.84 (dd, J = 8.4, 1.8 Hz, 1H), 7.68 (d, 
J = 1.8 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 3.13 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 
182.1, 157.7, 150.2, 139.7, 126.4, 119.0, 114.8, 112.6, 26.0; MS(APCI) m/z: 240.0 and 241.9 
[(M+H+) calculated for C9H6NO2Br, 239.96 and 241.96].  
 
[C-4] 5-methoxy-1-methylindoline-2,3-dione  
C-4 was prepared from 5-methoxyisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using EA/brine. Purification by flash chromatography with 3:1 
Hex/EA eluting system gave the desired product as orange solid. Yield: 92% 
1H NMR (300MHz, DMSO-d6): δ= 7.25 (dd, J1= 8.4Hz, J2= 2.7Hz, 1H), 7.11 (d, J= 2.7Hz, 
1H), 7.06 (d, J= 8.4Hz, 1H), 3.76 (s, 3H), 3.10 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 
183.7, 158.1, 155.7, 145.1, 123.8, 117.7, 111.5, 109.1, 55.8, 26.0; MS(APCI) m/z: 192.3 
[(M+H+) calculated for C10H9NO3, 192.06].  
 
[C-5] 6-fluoro-1-methylindoline-2,3-dione  
C-5 was prepared from 6-fluoroisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using EA/brine. Organic fraction was dried and concentrated to give 
the desired product as orange solid. Yield: 99% 
1H NMR (300MHz, DMSO-d6): δ= 7.62 (dd, J1= 8.1Hz, J2= 5.7Hz, 
1H), 7.13 (dd, J1= 9.6Hz, J2= 2.1Hz, 1H), 6.91 (dt, J1= 9.9Hz, J2= 2.1Hz, 1H), 3.13 (s, 3H); 
13C NMR (75 MHz, DMSO-d6): δ= 181.4, 169.9, 166.5, 158.5, 154.3, 154.1, 127.2, 127.1, 
114.2, 109.8, 109.4, 99.6, 99.2, 26.2; MS(APCI) m/z: 180.0 [(M+H+) calculated for 
C9H6NO2F, 180.04].  
 
[C-6] 6-chloro-1-methylindoline-2,3-dione  
C-6 was prepared from 6-chloroisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using EA/brine. Organic fraction was dried and concentrated to give 
the desired product as orange solid. Yield: 99% 
1H NMR (300MHz, DMSO-d6): δ= 7.54 (d, J= 8.1Hz, 1H), 7.32 (s,1H), 7.16 (d, J= 7.8Hz, 
1H), 3.13 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 182.0, 158.3, 152.5, 142.4, 125.6, 122.9, 















[C-7] 6-bromo-1-methylindoline-2,3-dione  
C-7 was prepared from 6-bromoisatin via the reflux method 
described in section 3.5.2.2 using CaH2. Extraction was performed 
using EA/brine. Organic fraction was dried and concentrated to give 
the desired product as orange solid. Yield: 99% 
1H NMR (300MHz, DMSO-d6): δ= 7.47-7.44 (m, 2H), 7.32 (d, J= 
7.8Hz, 1H), 3.13 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 182.3, 158.2, 152.3, 131.7, 
125.9, 125.5, 116.5, 113.8, 26.2 ; MS(APCI) m/z: 240.2, 242.2 [(M+H+) calculated for 
C9H6NO2Br, 239.96, 241.96].  
 
[C-8] 6-methoxy-1-methylindolin-2-one  
C-8 was prepared from 6-methoxy-2-oxindole as described in 
section 3.5.4.2. Extraction was performed using EA/brine. 
Purification by flash chromatography with 4:1 Hex/EA eluting 
system gave the desired product as light brown solid. Yield: 62% 
1H NMR (300MHz, CDCl3): δ= 7.13 (d, J= 8.1Hz, 1H ), 6.60 (s, 1H), 6.54 (dd, J1= 8.1Hz, J2= 
2.1Hz, 1H), 3.76 (s, 3H), 3.43 (s, 2H), 3.09 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 174.9, 
159.4, 146.1, 124.5, 116.1, 106.1, 95.9, 55.2, 34.4, 25.8; MS(APCI) m/z: 178.3 [(M+H+) 
calculated for C10H11NO2, 178.1].  
 
[C-9] 7-fluoro-1-methylindoline-2,3-dione  
C-9 was prepared from 7-fluoroisatin via the reflux method described in 
section 3.5.2.2 using CaH2. Extraction was performed using DCM/brine. 
Purification by flash chromatography with gradient 8:1 to 6:1 Hex/EA 
eluting system gave the desired product as orange solid. Yield: 95% 
m.p. 154-156 °C. 1H NMR (300 MHz, CDCl3): δ= 7.43-7.34 (m, 2H), 
7.10 (td, J = 7.8, 3.9 Hz, 1H), 3.47 (d, J = 3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ= 182.3, 
182.2, 157.7, 149.7, 146.4, 137.4, 137.2, 126.5, 126.2, 124.6, 124.5, 121.1, 121.0, 119.8, 28.9, 
28.9; MS(APCI) m/z: 179.8 [(M+H+) calculated for C9H6NO2F, 180.04].  
 
[C-10] 7-chloro-1-methylindoline-2,3-dione  
C-10 was prepared from 7-chloroisatin via the reflux method described 
in section 3.5.2.2 using CaH2. Extraction was performed using 
DCM/brine. Purification by flash chromatography with 6:1 Hex/EA 
eluting system gave the desired product as orange solid. Yield: 99% 
m.p. 157-159 °C. 1H NMR (300 MHz, CDCl3): δ= 7.55-7.52 (m, 2H), 

















139.5, 124.6, 123.3, 120.7, 116.1, 29.2; MS(APCI) m/z: 196.1 [(M+H+) calculated for 
C9H6NO2Cl , 196.01].  
 
[C-11] 7-bromo-1-methylindoline-2,3-dione  
C-11 was prepared from 7-bromoisatin via the reflux method described 
in section 3.5.2.2 using CaH2. Extraction was performed using 
DCM/brine. Purification by flash chromatography with 6:1 Hex/EA 
eluting system gave the desired product as orange solid. Yield: 87% 
m.p. 177-178 °C. 1H NMR (300 MHz, CDCl3): δ= 7.71 (d, J = 7.8 Hz, 
1H), 7.57 (d, J = 7.2 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 3.65 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ= 182.3, 158.5, 148.1, 143.7, 125.0, 124.4, 120.3, 104.2, 29.6; MS(APCI) m/z: 
240.0 and 242.0 [(M+H+) calculated for C9H6NO2Br , 239.96 and 241.96].  
 
[C-12] 7-methoxy-1-methylindolin-2-one  
C-12 was prepared from 7-methoxy-2-oxindole as described in section 
3.5.4.2. Extraction was performed using EA/brine. Purification by flash 
chromatography with 5:1 Hex/EA eluting system gave the desired 
product as light brown solid. Yield: 73% 
1H NMR (300MHz, DMSO-d6): δ= 6.97-6.92 (m, 2H), 6.90-6.85 (m, 1H), 3.81 (s, 3H), 3.51 
(s, 2H), 3.33 (s, 3H); 13C NMR (75 MHz, DMSO-d6): δ= 174.4, 144.6, 132.4, 126.0, 122.5, 
117.1, 112.1, 56.2, 35.3, 28.9; MS(APCI) m/z: 178.1 [(M+H+) calculated for C10H11NO2 , 
178.08].  
 
[C-25] 6-aminoindolin-2-one  
C-25 was prepared as described in section 3.5.4.3. 
mp 193-195°C. (lit. 194°C.) 1H NMR (300MHz, DMSO-d6): δ= 
10.08 (s, 1H), 6.80 (d, J= 8.1Hz, 1H ), 6.13-6.10 (m, 2H), 5.00 (s, 
2H), 3.23 (s, 2H); 13C NMR (75 MHz, CDCl3): δ= 177.3, 148.4, 
144.2, 124.5, 112.0, 106.6, 96.0, 35.1; MS(APCI) m/z: 148.9 [(M+H+) calculated for 














[C-26] 6-(dimethylamino)indolin-2-one  
C-26 was prepared as described in section 3.5.4.4. 
1H NMR (300MHz, DMSO-d6): δ= 10.17 (s, 1H), 6.97 (d, J= 
8.1Hz, 1H ), 6.26 (dd, J1= 8.1Hz, J2= 2.1Hz, 1H ), 6.19 (d, J= 
2.1Hz, 1H ), 3.31 (s, 2H), 2.85 (s, 6H); 13C NMR (75 MHz, 
CDCl3): δ= 177.1, 150.4, 144.5, 124.5, 112.7, 105.2, 94.3, 40.3, 35.0; MS(APCI) m/z: 177.1 
[(M+H+) calculated for C10H12N2O , 177.09].  
 
[C-29] N-(2-oxoindolin-6-yl)acetamide  
C-29 was prepared as described in section 3.5.4.5. 
1H NMR (300MHz, DMSO-d6): δ= 10.33 (s, 1H), 9.88 (s, 1H), 
7.35 (s, 1H), 7.08 (d, J= 7.8Hz, 1H ), 6.97 (d, J= 8.1Hz, 1H ), 
3.23 (s, 2H), 2.02 (s, 3H); MS(APCI) m/z: 191.1 [(M+H+) 
calculated for C10H10N2O2 , 191.07].  
 
[C-30] N-(2-oxoindolin-6-yl)methanesulfonamide  
C-30 was prepared as described in section 3.5.4.6. 
1H NMR (300MHz, DMSO-d6): δ= 10.34 (s, 1H), 9.64 (s, 1H), 
7.13 (d, J= 8.4Hz, 1H ), 6.77-6.75 (m, 2H), 3.41 (s, 2H), 2.94 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ= 176.7, 144.5, 137.8, 124.9, 
121.2, 112.5, 101.5, 45.5, 35.2; MS(APCI) m/z: 277.0 [(M+H+) calculated for C9H10N2O3S , 
227.04].  
 
[E-1] 5-fluoro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-1 was prepared from 5-fluoroisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. Purification 
by flash chromatography with 3:1 Hex/EA eluting system gave 
the desired product as orange solid. Yield: 58% 
m.p. 128-130 °C. 1H NMR (300 MHz, DMSO-d6): δ= 7.50 (td, J 
= 9.0, 2.4 Hz, 1H), 7.44 (dd, J = 7.2, 2.7 Hz, 1H), 7.18 (d, J = 
8.1 Hz, 3H), 6.82 (d, J = 8.4 Hz, 2H), 3.84 (t, J = 7.2 Hz, 2H), 
3.70 (s, 3H), 2.83 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.8, 160.0, 157.9, 
156.8, 146.8, 130.0, 129.9, 124.3, 124.0, 118.2, 118.1, 113.8, 112.4, 112.3, 111.6, 111.3, 55.0, 

























[E-2] 5-chloro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-2 was prepared from 5-chlorooisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. Purification 
by flash chromatography with 3:1 Hex/EA eluting system gave 
the desired product as orange solid. Yield: 50% 
m.p. 167-168°C. 1H NMR (300 MHz, DMSO-d6): δ= 7.67 (dd, J 
= 8.4, 2.1 Hz, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.18 (d, J = 8.4 Hz, 
3H), 6.83 (d, J = 8.4 Hz, 2H), 3.84 (t, J = 7.2 Hz, 2H), 3.70 (s, 
3H), 2.83 (t, J = 7.5 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.4, 157.9, 157.6, 149.1, 
137.0, 129.9, 129.9, 127.3, 124.0, 118.6, 113.8, 112.6, 55.0, 41.3, 31.7; MS(APCI) m/z: 315.9 
[(M+H+) calculated for C17H14NO3Cl, 316.07].  
 
[E-3] 5-bromo-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-3 was prepared from 5-bromoisatin (1mmol) and 4-
methoxyphenethyl bromide (1.1mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. 
Purification by flash chromatography with 4:1 DCM/Hex 
eluting system gave the desired product as orange solid. Yield: 
58% 
m.p. 173-174°C. 1H NMR (300 MHz, DMSO-d6): δ= 7.79 (dd, 
J = 8.4, 1.8 Hz, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.4 
Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 3.84 (t, J = 7.2 Hz, 2H), 3.71 (s, 
3H), 2.82 (t, J = 7.5 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.1, 157.8, 157.4, 149.4, 
139.7, 129.9, 129.8, 126.6, 119.0, 114.7, 113.7, 113.0, 54.9, 41.2, 31.7; MS(APCI) m/z: 359.8 
and 361.8 [(M+H+) calculated for C17H14NO3Br, 360.02 and 362.01].  
 
[E-4] 5-methoxy-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-4 was prepared from 5-methoxyisatin (1mmol) and 4-
methoxyphenethyl bromide (1.1mmol) as described in section 
3.5.6.1. Extraction was performed using EA/brine. Purification 
by flash chromatography with 3:1 Hex/EA eluting system gave 
the desired product as orange solid. Yield: 41%1H NMR 
(300MHz, DMSO-d6): δ= 7.22 (dd, J1= 8.7Hz, J2= 2.7Hz, 1H), 
7.18-7.10 (m, 4H),  6.82 (d, J= 8.4Hz, 2H), 3.82 (t, J= 7.2Hz, 
2H), 3.77 (s, 3H), 3.70 (s, 3H), 2.83 (t, J= 7.5Hz, 2H); MS(APCI) m/z: 312.0 [(M+H+) 


















[E-5] 6-fluoro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-5 was prepared from 6-fluoroisatin (1mmol) and 4-
methoxyphenethyl bromide (1.1mmol) as described in section 
3.5.6.1. Extraction was performed using EA/brine. Purification 
by flash chromatography with 3:1 Hex/EA eluting system gave 
the desired product as orange solid. Yield: 42% 
1H NMR (300MHz, DMSO-d6): δ= 7.64 (dd, J1= 8.4Hz, J2= 
6.0Hz,   1H), 7.19 (d, J= 8.4Hz, 2H),  7.09 (dd, J1= 9.9Hz, J2= 
2.1Hz, 1H), 6.82 (dt, J= 8.4Hz, J1= 9.6Hz, J2= 1.8Hz, 1H), 6.82 (d, J= 7.2Hz, 2H), 3.86 (d, J= 
7.2Hz, 2H), 3.70 (s, 3H), 2.83 (t, J= 7.2Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 181.5, 
166.6, 158.3, 158.0, 153.6, 153.4, 130.0, 127.6, 127.4, 114.1, 113.8, 109.9, 109.6, 99.9, 99.5, 
55.0, 41.5, 31.8; MS(APCI) m/z: 300.0 [(M+H+) calculated for C17H14NO3F, 300.10].  
 
[E-6] 6-chloro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-6 was prepared from 6-chloroisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. 
Purification by flash chromatography with DCM eluting 
system gave the desired product as orange solid. Yield: 47% 
1H NMR (300MHz, DMSO-d6): δ= 7.53 (d, J= 7,8Hz,  1H), 
7.21-7.18 (m, 3H),  7.13 (dd, J1= 8.1Hz, J2= 1.5Hz, 1H), 6.82 
(d, J= 8.4Hz, 2H), 3.85 (t, J= 7.2Hz, 2H), 3.70 (s, 3H), 2.83 (t, 
J= 7.2Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.1, 158.1, 158.0, 151.8, 142.6, 130.1, 
130.0, 125.8, 122.9, 116.0, 113.8, 111.3, 55.0, 41.5, 31.9; MS(APCI) m/z: 316.0 [(M+H+) 
calculated for C17H14NO3Cl, 316.07].  
 
[E-7] 6-bromo-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-7 was prepared from 6-bromoisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. 
Purification by flash chromatography with DCM eluting 
system gave the desired product as orange solid. Yield: 42% 
1H NMR (300MHz, DMSO-d6): δ= 7.44 (d, J= 8.1Hz,  1H), 
7.29-7.26 (m, 2H),  7.19 (d, J= 8.7Hz, 2H), 6.82 (d, J= 8.7Hz, 
2H), 3.85 (t, J= 6.9Hz, 2H), 3.70 (s, 3H), 2.82 (t, J= 7.2Hz, 

















125.8, 116.3, 114.1, 113.8, 55.0, 41.5, 32.0; MS(APCI) m/z: 359.9, 361.9 [(M+H+) calculated 
for C17H14NO3Br, 360.02, 362.01].  
 
[E-8] 6-methoxy-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-8 was prepared from 6-methoxyisatin (3mmol) and 4-
methoxyphenethyl bromide (3.6mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. 
Purification by flash chromatography with 3:1 Hex/EA eluting 
system gave the desired product as orange solid. Yield: 63% 
1H NMR (300MHz, CDCl3): δ= 7.49 (d, J= 8.4Hz,  1H), 7.07 
(d, J= 8.4Hz,  2H), 6.75 (d, J= 8.4Hz,  2H), 6.44 (dd, J1= 
8.4Hz, J2= 1.8Hz, 1H), 6.09 (d, J= 1.8Hz, 1H), 3.83-3.78 (m, 
5H), 3.70 (s, 3H), 2.85 (t, J= 7.5Hz, 2H); 13C NMR (75 MHz, CDCl3): δ= 179.8, 167.2, 158.5, 
157.5, 152.5, 128.8, 128.7, 126.9, 113.2, 110.1, 106.9, 96.2, 55.0, 54.2, 41.0, 32.0; MS(APCI) 
m/z: 312.2 [(M+H+) calculated for C18H17NO4, 312.12].  
 
[E-9] 7-fluoro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-9 was prepared from 7-fluoroisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. Purification 
by flash chromatography with 3:1 Hex/EA eluting system gave the 
desired product as orange solid. Yield: 60% 
m.p. 123-124 °C. 1H NMR (300 MHz, DMSO-d6): δ= 7.60 (dd, J = 
12.0, 8.4 Hz, 1H), 7.44 (d, J = 7.2 Hz, 1H), 7.22-7.12 (m, 3H), 
6.84 (d, J = 8.4 Hz, 2H), 3.90 (t, J = 7.2 Hz, 2H), 3.71 (s, 3H), 2.85 (t, J = 7.8 Hz, 2H); 13C 
NMR (75 MHz, DMSO-d6): δ 182.2, 182.2, 157.9, 157.7, 148.9, 145.6, 136.3, 136.2, 129.7, 
129.6, 126.1, 125.9, 124.4, 124.3, 120.9, 120.9, 120.5, 113.9, 54.9, 43.4, 33.2; MS(APCI) m/z: 













[E-10] 7-chloro-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-10 was prepared from 7-chloroisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. Purification 
by flash chromatography with 4:1 Hex/EA eluting system gave the 
desired product as orange solid. Yield: 47% 
m.p. 136-137°C. 1H NMR (300 MHz, DMSO-d6): δ= 7.71 (d, J = 
8.1 Hz, 1H), 7.56 (d, J = 6.9 Hz, 1H), 7.18-7.14 (m, 3H), 6.86 (d, J 
= 8.4 Hz, 2H), 4.12 (t, J = 7.8 Hz, 2H), 3.71 (s, 3H), 2.89 (t, J = 
8.1 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.0, 158.5, 157.9, 145.6, 139.7, 129.7, 
129.6, 124.7, 123.6, 120.9, 115.7, 114.0, 55.0, 42.7, 33.9; MS(APCI) m/z: 315.9 [(M+H+) 
calculated for C17H14NO3Cl, 316.07].  
 
[E-11] 7-bromo-1-(4-methoxyphenethyl)indoline-2,3-dione  
E-11 was prepared from 7-bromoisatin (1mmol) and 4-
methoxyphenethyl bromide (1.2mmol) as described in section 
3.5.6.1. Extraction was performed using DCM/brine. Purification 
by flash chromatography with 4:1 Hex/EA eluting system gave the 
desired product as orange solid. Yield: 60% 
m.p. 150-151°C. 1H NMR (300 MHz, DMSO-d6): δ= 7.86 (d, J = 
8.4 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.19 (d, J = 8.4 Hz, 2H), 
7.08 (t, J = 7.8 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 4.16 (t, J = 8.1 Hz, 2H), 3.72 (s, 3H), 2.90 (t, 
J = 8.4 Hz, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 182.0, 158.7, 157.9, 147.0, 142.9, 129.7, 
129.5, 124.9, 124.0, 121.2, 113.9, 103.2, 54.9, 42.2, 33.8; MS(APCI) m/z: 359.8 and 361.8 
[(M+H+) calculated for C17H14NO3Br, 360.02 and 362.01].  
 
[F-1] 4-(2-chloroethyl)morpholine  
F-1 was prepared from morpholine as described in section 3.5.7.1. 
Purification by flash chromatography with 4:1 Hex/EA eluting system gave 
the desired product as brown oil which solidified to a solid on standing. 
Yield: 68% 
1H NMR (300 MHz, DMSO-d6): δ= 3.67 (t, J = 6.9 Hz, 2H), 3.56 (t, J = 4.2 Hz, 4H), 2.64 (t, 
J = 6.6 Hz, 2H), 2.44 (t, J = 4.2 Hz, 4H); 1H NMR (300 MHz, CDCl3): δ= 3.65 (t, J = 4.2 Hz, 
4H), 3.52 (t, J = 6.9 Hz, 2H), 2.65 (t, J = 6.9 Hz, 2H), 2.44 (t, J = 4.5 Hz, 4H); 13C NMR (75 
MHz, DMSO-d6): δ= 66.0, 59.4, 53.0, 41.0; MS(APCI) m/z: 149.9, 152.0 [(M+H+) calculated 
















[F-2] 4-(2-chloroethyl)thiomorpholine  
F-2 was prepared from thiomorpholine as described in section 3.5.7.1. 
Purification by flash chromatography with DCM eluting system gave the 
desired product as brown oil which solidified to a solid on standing. Yield: 
52% 
1H NMR (300 MHz, DMSO-d6): δ= 3.64 (t, J = 6.9 Hz, 2H), 2.72-2.64 (m, 6H), 2.59-2.50 (m, 
4H); 13C NMR (75 MHz, DMSO-d6): δ= 59.7, 54.3, 41.3, 27.1; MS(APCI) m/z: 166.0, 166.8 
[(M+H+) calculated for C6H12NSCl, 166.04, 168.04].  
 
 [F-3] 1-(2-chloroethyl)piperidine  
F-3 was prepared from piperidine as described in section 3.5.7.1. Purification 
by flash chromatography with (3:1 Hex/EA + 0.5% TEA) eluting system 
gave the desired product as yellow oil which solidified to a solid on standing. 
Unstable. Yield: 34% 
1H NMR (300 MHz, DMSO-d6): δ= 3.64 (t, J = 6.6 Hz, 2H), 2.58 (t, J = 6.9 Hz, 2H), 2.38 
(brs, 4H), 1.47 (brs, 4H), 1.36 (brs, 2H); 13C NMR (75 MHz, DMSO-d6): δ= 59.9, 53.8, 41.5, 
25.4, 23.8; MS(APCI) m/z: 147.8 [(M+H+) calculated for C7H14NCl, 148.08].  
 
[F-4] 1-(2-chloroethyl)-4-methylpiperazine  
F-4 was prepared from N-methylpiperazine as described in section 3.5.7.1. 
Purification by flash chromatography with (3:1 Hex/EA + 3% TEA) eluting 
system gave the desired product as brown oil which solidified to a solid on 
standing. Yield: 78% 
1H NMR (300 MHz, CDCl3): δ= 3.67 (t, J = 6.9 Hz, 2H), 2.73 (t, J = 6.9 Hz, 2H), 2.55 (brs, 
4H), 2.46 (brs, 4H), 2.28 (s, 3H); 13C NMR (75 MHz, CDCl3): δ= 59.7, 54.9, 53.0, 46.0, 40.9; 
MS(APCI) m/z: 163.1 [(M+H+) calculated for C7H15N2Cl, 163.09]. m/z peak of 127.1 
corresponding to the aziridinium salt form detected as major peak. 
 
[F-5] 1-(2-morpholinoethyl)indoline-2,3-dione  
F-5 was prepared from F-1 as described in section 3.5.7.2. 
Purification by flash chromatography with 3:1 Hex/EA eluting 
system gave the desired product as orange solid. Yield: 74% 
1H NMR (300 MHz, CDCl3): δ= 7.63-7.59 (m, 2H), 7.12 (t, J = 7.8 
Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 3.86 (t, J = 6.6 Hz, 2H), 3.66 (t, J 
= 4.5 Hz, 4H), 2.64 (t, J = 6.6 Hz, 2H), 2.53 (t, J = 4.5 Hz, 4H); 13C 
NMR (75 MHz, DMSO-d6): δ= 183.6, 158.2, 150.8, 138.4, 124.5, 123.3, 117.4, 111.0, 66.2, 















 [F-6] 1-(2-(4-methylpiperazin-1-yl)ethyl)indoline-2,3-dione  
F-6 was prepared from F-4 as described in section 3.5.7.2. 
Purification by flash chromatography with gradient elution from 2:1 
Hex/EA to EA +2%EtOH gave the desired product as brown solid. 
Yield: 71% 
1H NMR (300 MHz, CDCl3): δ= 7.61-7.55 (m, 2H), 7.13 (t, J = 7.5 
Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 3.85 (t, J = 6.9 Hz, 2H), 2.64 (t, J 
= 6.9 Hz, 2H), 2.58 (brs, 4H), 2.43 (brs, 4H), 2.27 (s, 3H); MS(APCI) 
m/z: 274.0 [(M+H+) calculated for C15H19N3O2, 274.15]. 
 
[F-7] 1-(2-bromoethyl)indoline-2,3-dione  
F-7 was prepared as described in section 3.5.7.6. 
1H NMR (300MHz, CDCl3): δ= 7.64-7.53 (m, 2H), 7.14 (t, J = 7.5 Hz, 
1H), 7.00 (d, J = 8.1 Hz, 1H), 4.14 (t, J = 6.6 Hz, 2H), 3.61 (t, J = 6.6 
Hz, 2H); 13C NMR (75MHz, CDCl3): δ= 182.6, 158.2, 150.4, 138.4, 
125.7, 124.0, 117.6, 110.2, 41.9, 27.0; 
 
[F-8] (E)-1-(2-bromoethyl)-[3,3'-biindolinylidene]-2,2'-dione  
F-8 was prepared from F-7 and 2-oxindole as described in section 
3.5.7.7. Extraction was performed using DCM/brine. Purification by 
flash chromatography with gradient elution from 8:1 to 1:1 Hex/EA 
gave the desired product as dark solid. Yield: 35% 
1H NMR (300MHz, CDCl3): δ= 9.13 (d, J = 7.8 Hz, 1H), 7.67 (s, 
1H), 7.38-7.30 (m, 2H), 7.11-7.03 (m, 2H), 6.87 (d, J = 7.8 Hz, 1H), 
6.81 (d, J = 7.8 Hz, 1H), 4.20 (t, J = 7.2 Hz, 2H), 3.60 (t, J = 7.2 Hz, 
2H); 
 
[F-9] (E)-1-(2-bromoethyl)-6'-methoxy-[3,3'-biindolinylidene]-2,2'-dione  
F-9 was prepared from F-7 and 6-methoxy-2-oxindole as 
described in section 3.5.7.7. Extraction was performed using 
DCM/brine. Purification by flash chromatography with 
gradient elution from 8:1 to 2:1 Hex/EA gave the desired 
product as dark solid Yield: 7% 
1H NMR (300MHz, CDCl3): δ= 9.12 (d, J = 9.0 Hz, 1H), 9.07 
(d, J = 8.1 Hz, 1H), 7.98 (s, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.06 
























Hz, J2 = 1.8 Hz, 1H), 6.85 (d, J = 1.8 Hz, 1H),  4.20 (t, J = 7.2 Hz, 2H), 3.86 (s, 3H), 3.59 (t, J 
= 6.9 Hz, 2H); 
 
[F-10] 3,3-dibromo-1H-pyrrolo[2,3-b]pyridin-2(3H)-one  
F-10 was prepared as described in section 3.5.7.9. 
1H NMR (300MHz, DMSO-d6): δ= 12.0 (brs, 1H), 8.21 (d, J= 5.1Hz, 
1H ), 8.00 (d, J= 7.5Hz, 1H ), 7.18 (dd, J1= 7.5Hz, J2= 5.1Hz, 1H ); 
 
 
[F-11] 1H-pyrrolo[2,3-b]pyridin-2(3H)-one  
F-11 was prepared as described in section 3.5.7.10. 
1H NMR (300MHz, DMSO-d6): δ= 11.42 (brs, 1H), 8.06 (d, J= 5.4Hz, 
1H ), 7.71 (d, J= 7.2Hz, 1H ), 7.05 (t, J= 6.0Hz, 1H ), 3.60 (s, 2H); 13C 
NMR (75 MHz, CDCl3): δ= 175.7, 156.8, 142.7, 133.8, 122.0, 117.6, 35.1; MS(APCI) m/z: 







Appendix 3-2: Determination of purity by HPLC. 
 
For compounds analyzed by high performance liquid chromatography (HPLC), the 
peak area of the target compound should be 95% or more on both solvent systems. 
Determinations were carried out on either 1) Waters Delta 600 liquid chromatography system, 
or 2) Agilent Technologies system, with Agilent Zorbax Eclipse XDB-C18 column (4.6mm x 
150mm, 5µm). The isocratic mode was employed using two solvent systems: methanol-water 
and acetonitrile-water. Flow rate was fixed at 1ml/min and UV detection was determined at 
isoindigo’s λmax of 400nm. The area under the main peak was determined and expressed as a 
percentage of the total peak area during a 20min run. All compounds were purified to a 
minimum of 95%. The retention time (Rt) of the principal peak in both solvent systems was 
reported in minutes.  
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The wavelength of 396nm was chosen because all the compounds register reasonable 
absorbance readings between 390nm and 402nm. 
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Appendix 5-3: Representative figure showing FACS analysis of normal, apoptotic and 
necrotic K562 cells after 48 h incubation with vehicle (media + 0.4% v/v DMSO) and test 




Appendix 6-1: Changes in tumour size (mm3) (28 days) of xenograft-bearing mice treated 
with vehicle (Control) and test compounds (meisoindigo, 4-5, 6-4). * Indicates administration 
of test compound (100 µL, 10 µM) on day 0, 3 and 10. 
 
 
